data_1ueo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ueo _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 N-CA-C 110.966 -0.436 . . . . 0.0 110.966 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.4 t -62.84 -31.23 51.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.505 -0.747 . . . . 0.0 110.937 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.6 OUTLIER -69.22 -12.44 61.67 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.503 -0.748 . . . . 0.0 111.53 -179.677 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 35' ' ' SER . 78.8 m 61.78 27.75 16.99 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.409 -0.807 . . . . 0.0 110.575 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 35' ' ' SER . 17.1 mmm180 -107.02 146.34 31.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.397 -0.814 . . . . 0.0 110.19 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.93 22.45 52.79 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.5 pt -138.87 154.96 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.154 -1.204 . . . . 0.0 110.281 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.48 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 55.0 m -74.51 165.75 24.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.607 -0.683 . . . . 0.0 110.043 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.483 ' CE2' ' HD2' ' A' ' 45' ' ' ARG . 84.2 t80 -60.02 -48.76 80.4 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.616 -0.677 . . . . 0.0 109.816 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -65.82 -33.75 76.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.583 -0.698 . . . . 0.0 110.122 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.3 OUTLIER -63.47 -46.38 86.47 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.143 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.47 -37.69 88.28 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.891 -0.505 . . . . 0.0 109.956 179.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.483 ' HD2' ' CE2' ' A' ' 41' ' ' PHE . 1.0 OUTLIER -64.54 -40.86 96.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.628 -0.67 . . . . 0.0 109.761 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -61.55 -43.95 97.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.774 -0.579 . . . . 0.0 110.971 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.1 t -67.04 -31.2 71.56 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.315 -0.865 . . . . 0.0 111.17 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 t -58.69 -42.5 88.7 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.077 -1.014 . . . . 0.0 109.86 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -84.53 -22.08 30.28 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.412 -0.805 . . . . 0.0 110.697 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -80.97 -36.01 31.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.239 -0.913 . . . . 0.0 111.01 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.49 18.29 1.69 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.187 -0.946 . . . . 0.0 111.97 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.28 31.74 78.22 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.517 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 3.6 mmp_? -117.57 137.75 52.38 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.43 -1.041 . . . . 0.0 110.68 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 21.5 m 64.35 52.51 1.86 Allowed 'General case' 0 N--CA 1.502 2.128 0 CA-C-O 121.84 0.828 . . . . 0.0 109.476 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 27.3 m -92.02 -20.39 21.38 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.955 -0.466 . . . . 0.0 111.262 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -112.81 42.55 1.84 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.167 -0.958 . . . . 0.0 110.002 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 75.8 t . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.529 -0.732 . . . . 0.0 110.199 179.986 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo . . . . . 0 N--CA 1.489 1.244 0 N-CA-C 110.689 -0.543 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.41 -30.64 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 121.485 -0.759 . . . . 0.0 110.811 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.55 -16.62 62.89 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.334 -0.854 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 38.8 m 59.31 25.56 14.24 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.512 -0.742 . . . . 0.0 111.169 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.4 mmt-85 -108.39 143.5 37.22 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.24 -0.913 . . . . 0.0 110.127 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.86 22.2 53.64 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.3 pt -134.93 156.3 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.135 -1.215 . . . . 0.0 110.098 179.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 m -74.48 166.02 24.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.637 -0.664 . . . . 0.0 110.515 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -60.18 -49.04 79.18 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.744 -0.597 . . . . 0.0 109.627 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -62.73 -35.36 79.49 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.624 -0.673 . . . . 0.0 110.059 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -63.36 -46.01 88.52 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.253 -0.904 . . . . 0.0 109.205 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.71 -33.04 68.43 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.714 -0.616 . . . . 0.0 109.552 179.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.403 ' HB3' ' NH2' ' A' ' 45' ' ' ARG . 3.1 mtp-105 -68.84 -38.2 79.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.831 -0.543 . . . . 0.0 110.495 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -67.4 -40.33 85.59 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.421 -0.799 . . . . 0.0 110.73 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 43.8 t -69.38 -31.82 70.45 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.351 -0.843 . . . . 0.0 111.207 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 30.5 t -58.41 -42.19 86.64 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.224 -0.923 . . . . 0.0 110.305 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -84.15 -23.66 30.54 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.385 -0.822 . . . . 0.0 111.0 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 4.6 mmt-85 -85.76 -32.9 21.6 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 111.309 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -139.35 9.29 2.48 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.121 -0.987 . . . . 0.0 112.283 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.06 27.79 72.73 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.498 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.08 140.1 48.76 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.271 -1.135 . . . . 0.0 110.382 -179.561 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 98.2 m 63.59 53.12 2.12 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.877 0.846 . . . . 0.0 109.181 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 25.8 m -97.13 -14.55 21.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.828 -0.545 . . . . 0.0 111.783 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -122.85 42.25 3.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.972 -1.08 . . . . 0.0 110.858 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 72.4 t . . . . . 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.725 179.403 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo . . . . . 0 N--CA 1.485 1.018 0 N-CA-C 110.286 -0.698 . . . . 0.0 110.286 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.47 -28.44 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.457 -0.777 . . . . 0.0 110.845 -179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -71.07 -12.66 61.64 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.257 -0.902 . . . . 0.0 111.353 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.2 m 55.32 29.19 12.51 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.333 -0.855 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -125.92 152.58 45.42 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.236 -0.915 . . . . 0.0 110.204 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.35 36.2 59.66 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.429 HD11 HG22 ' A' ' 57' ' ' VAL . 14.0 pt -127.44 156.25 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.291 -1.123 . . . . 0.0 110.243 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -82.38 160.24 22.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.507 -0.746 . . . . 0.0 109.38 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -58.15 -41.64 84.18 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.533 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -67.53 -36.72 81.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.633 -0.667 . . . . 0.0 110.156 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -65.61 -41.94 92.15 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.416 -0.803 . . . . 0.0 109.704 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.29 -34.12 75.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.757 -0.59 . . . . 0.0 110.361 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.16 -33.8 73.97 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.458 -0.776 . . . . 0.0 110.12 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -69.03 -46.0 69.03 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.538 -0.726 . . . . 0.0 111.059 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 42.4 t -69.52 -32.5 71.39 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.334 -0.854 . . . . 0.0 111.219 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.1 t -64.73 -42.04 95.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.222 -0.924 . . . . 0.0 110.775 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -82.46 -25.25 33.74 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.359 -0.838 . . . . 0.0 111.496 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.24 -29.51 18.14 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.189 -0.944 . . . . 0.0 111.526 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.2 mt -137.03 3.43 2.66 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.049 -1.032 . . . . 0.0 112.648 -178.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.49 28.45 73.61 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.429 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -118.16 146.81 43.92 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.296 -1.12 . . . . 0.0 110.606 -179.446 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.41 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.2 m 59.46 48.93 9.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 122.041 0.924 . . . . 0.0 109.027 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.5 m -92.53 -16.8 25.29 Favored 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.713 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -114.9 41.79 2.31 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.062 -1.023 . . . . 0.0 110.62 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.429 HG22 HD11 ' A' ' 39' ' ' ILE . 95.5 t . . . . . 0 N--CA 1.499 2.003 0 O-C-N 121.478 -0.764 . . . . 0.0 110.002 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo . . . . . 0 N--CA 1.488 1.166 0 N-CA-C 110.578 -0.585 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.0 t -76.16 -33.04 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.356 -0.84 . . . . 0.0 110.719 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.428 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.5 OUTLIER -73.17 -13.87 61.25 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.449 -0.782 . . . . 0.0 111.355 -179.859 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 35' ' ' SER . 60.1 m 61.95 24.65 14.7 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.536 -0.728 . . . . 0.0 111.428 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -107.93 139.83 41.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.88 23.12 39.74 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.9 pt -135.35 160.32 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.08 -1.247 . . . . 0.0 110.246 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.9 m -81.47 164.54 21.95 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.58 -0.7 . . . . 0.0 110.388 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -58.38 -48.31 81.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.242 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.6 t -60.65 -37.86 82.94 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.692 -0.63 . . . . 0.0 110.181 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -65.92 -44.22 85.79 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.362 -0.836 . . . . 0.0 109.466 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.46 -35.52 70.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.775 -0.578 . . . . 0.0 109.899 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? -69.94 -37.51 75.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.563 -0.711 . . . . 0.0 109.931 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.0 t -64.59 -40.47 95.58 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.664 -0.647 . . . . 0.0 110.706 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.1 t -71.62 -33.38 68.92 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.456 -0.778 . . . . 0.0 111.596 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.5 t -57.63 -44.04 85.26 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 21.3 t -80.33 -24.42 39.91 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 111.087 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.65 -32.15 19.41 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.258 -0.901 . . . . 0.0 111.684 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.1 mt -137.37 2.11 2.46 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.067 -1.021 . . . . 0.0 112.671 -178.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 74.05 22.78 77.46 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.3 mmp_? -110.65 143.99 40.26 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.22 -1.165 . . . . 0.0 110.833 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 93.4 m 61.84 51.82 3.68 Favored 'General case' 0 N--CA 1.5 2.05 0 CA-C-O 121.949 0.88 . . . . 0.0 109.233 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 43.0 m -96.9 -14.28 21.89 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.882 -0.511 . . . . 0.0 111.872 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -124.97 42.68 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.978 -1.076 . . . . 0.0 111.025 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 52.9 t . . . . . 0 N--CA 1.494 1.741 0 O-C-N 121.295 -0.878 . . . . 0.0 109.695 179.325 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 CA-C-O 121.313 0.464 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.1 t -72.3 -29.28 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.41 -0.806 . . . . 0.0 110.748 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -74.09 -6.53 48.16 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.346 -0.846 . . . . 0.0 111.68 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 35' ' ' SER . 96.2 m 58.14 28.58 16.66 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.235 -0.916 . . . . 0.0 110.587 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -109.16 155.01 21.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 110.128 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.86 17.9 77.89 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.5 pt -136.47 162.13 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.188 -1.183 . . . . 0.0 110.066 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.6 t -87.92 169.11 12.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.404 -0.81 . . . . 0.0 110.023 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.408 ' O ' ' HB2' ' A' ' 45' ' ' ARG . 60.3 t80 -59.42 -44.66 92.82 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.655 -0.653 . . . . 0.0 109.455 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.0 t -65.47 -39.58 92.12 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.647 -0.658 . . . . 0.0 110.074 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -65.86 -42.24 90.68 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.388 -0.82 . . . . 0.0 109.697 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.59 -39.01 81.12 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.589 -0.695 . . . . 0.0 109.348 178.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . 0.408 ' HB2' ' O ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -64.86 -40.02 94.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.792 -0.567 . . . . 0.0 109.533 178.874 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 t -62.04 -43.95 97.75 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.862 -0.524 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 27.2 t -67.26 -31.2 71.38 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.301 -0.874 . . . . 0.0 111.339 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.4 t -59.73 -41.95 92.07 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.968 -1.083 . . . . 0.0 109.855 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.9 t -84.84 -22.96 29.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.35 -0.844 . . . . 0.0 110.913 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.4 mtp180 -85.44 -33.65 21.86 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.217 -0.927 . . . . 0.0 111.304 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -140.26 8.97 2.27 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.17 -0.956 . . . . 0.0 112.192 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.72 24.95 75.38 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.14 144.41 43.22 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.208 -1.172 . . . . 0.0 110.714 -179.907 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 31.6 m 61.98 48.93 4.89 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 121.942 0.877 . . . . 0.0 109.395 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 18.2 m -89.08 -25.17 22.05 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.863 -0.523 . . . . 0.0 110.914 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -106.21 38.51 2.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.207 -0.933 . . . . 0.0 109.895 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.497 1.882 0 O-C-N 121.564 -0.71 . . . . 0.0 109.838 179.816 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo . . . . . 0 N--CA 1.489 1.214 0 N-CA-C 110.574 -0.587 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 69.9 t -62.09 -30.84 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.147 0 O-C-N 121.478 -0.764 . . . . 0.0 110.63 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.426 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 7.6 t -68.47 -10.23 54.07 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.446 -0.784 . . . . 0.0 111.307 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 35' ' ' SER . 73.4 m 59.36 27.49 16.59 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.355 -0.84 . . . . 0.0 110.996 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -108.59 150.63 27.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.394 -0.816 . . . . 0.0 110.028 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.55 24.09 71.3 Favored Glycine 0 N--CA 1.496 2.645 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.9 pt -134.06 157.41 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.049 -1.265 . . . . 0.0 110.278 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.09 162.11 23.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.654 -0.654 . . . . 0.0 109.474 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 87.2 t80 -57.04 -49.74 74.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.399 -0.813 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -64.38 -33.12 75.11 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.589 -0.695 . . . . 0.0 110.146 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -65.6 -43.13 90.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.316 -0.865 . . . . 0.0 109.482 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.86 -36.26 75.37 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.636 . . . . 0.0 109.853 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.3 ttt180 -67.47 -40.16 85.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.67 -0.644 . . . . 0.0 110.149 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.3 t -66.07 -36.88 84.38 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.609 -0.682 . . . . 0.0 110.794 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 19.1 t -72.61 -31.32 65.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.25 -0.906 . . . . 0.0 111.325 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 29.9 t -58.9 -42.95 90.82 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.141 -0.974 . . . . 0.0 110.078 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.8 t -84.86 -24.45 28.54 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.396 -0.815 . . . . 0.0 110.948 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -83.29 -32.13 26.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.217 -0.927 . . . . 0.0 111.475 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.82 12.67 1.87 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.176 -0.952 . . . . 0.0 112.208 -179.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.29 31.05 79.42 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.466 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.7 mmt180 -118.42 139.88 50.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.389 -1.065 . . . . 0.0 110.458 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 10.5 m 62.46 55.14 2.33 Favored 'General case' 0 N--CA 1.498 1.951 0 CA-C-O 121.999 0.904 . . . . 0.0 109.327 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 19.1 m -96.3 -16.43 21.34 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.43 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -112.8 42.36 1.88 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.1 -1.0 . . . . 0.0 110.189 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.497 1.908 0 O-C-N 121.384 -0.823 . . . . 0.0 109.954 179.761 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 N--CA 1.49 1.295 0 N-CA-C 110.817 -0.493 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 t -61.39 -29.4 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.521 -0.737 . . . . 0.0 110.522 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.437 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.1 t -69.63 -8.05 44.22 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.434 -0.792 . . . . 0.0 111.147 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 35' ' ' SER . 81.6 m 59.14 25.22 13.68 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.353 -0.842 . . . . 0.0 111.255 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -112.39 158.05 20.29 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.288 -0.883 . . . . 0.0 110.012 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.16 22.08 76.95 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.1 pt -135.47 153.59 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.142 -1.211 . . . . 0.0 110.274 179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.2 t -80.3 169.25 18.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.632 -0.667 . . . . 0.0 109.952 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -60.31 -48.86 79.93 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.568 -0.708 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.2 t -61.83 -36.44 81.17 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.666 -0.647 . . . . 0.0 110.192 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -64.62 -44.8 89.39 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.565 -0.709 . . . . 0.0 109.886 179.51 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.6 -33.99 76.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.803 -0.561 . . . . 0.0 110.395 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.22 -39.57 78.49 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.466 -0.771 . . . . 0.0 110.122 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -64.95 -40.44 95.02 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.658 -0.652 . . . . 0.0 110.951 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.4 t -71.62 -32.03 67.54 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.282 -0.886 . . . . 0.0 111.443 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 33.1 t -58.64 -42.9 89.38 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.126 -0.984 . . . . 0.0 110.363 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 32.3 t -84.24 -25.98 29.02 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.352 -0.843 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.26 -31.96 24.7 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.286 -0.884 . . . . 0.0 111.453 -179.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.4 mt -138.87 6.55 2.43 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 112.556 -178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.02 28.32 73.75 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.489 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 6.9 mmt-85 -115.6 139.92 49.65 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.213 -1.169 . . . . 0.0 110.638 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.489 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 80.5 m 62.46 57.27 1.92 Allowed 'General case' 0 N--CA 1.499 2.003 0 CA-C-O 121.939 0.876 . . . . 0.0 109.42 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 34.9 m -100.12 -6.21 26.63 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.749 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -128.18 46.43 2.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.065 . . . . 0.0 110.517 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 94.8 t . . . . . 0 N--CA 1.496 1.861 0 O-C-N 121.261 -0.9 . . . . 0.0 110.09 179.885 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo . . . . . 0 N--CA 1.488 1.197 0 N-CA-C 110.608 -0.574 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.35 -27.4 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.302 -0.874 . . . . 0.0 110.399 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.431 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -67.18 -18.39 65.25 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.429 -0.795 . . . . 0.0 110.78 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 35' ' ' SER . 95.5 m 58.99 26.27 14.86 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.549 -0.719 . . . . 0.0 111.178 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -108.95 144.57 36.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.261 -0.9 . . . . 0.0 110.046 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.27 34.27 64.23 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.416 HD13 ' HA ' ' A' ' 36' ' ' CYS . 23.3 pt -125.78 155.15 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.2 -1.176 . . . . 0.0 110.123 179.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.84 159.27 21.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.668 -0.645 . . . . 0.0 109.475 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -57.66 -42.47 83.57 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.424 -0.797 . . . . 0.0 109.641 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.2 t -67.32 -34.45 77.38 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.583 -0.698 . . . . 0.0 109.95 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.39 -41.35 89.5 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.473 -0.767 . . . . 0.0 109.69 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.23 -27.5 60.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.748 -0.595 . . . . 0.0 110.34 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -35.96 61.01 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.53 -0.731 . . . . 0.0 110.389 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -70.88 -40.62 72.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.448 -0.783 . . . . 0.0 111.09 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.7 t -73.55 -30.44 63.07 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.237 -0.914 . . . . 0.0 111.299 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.4 -42.63 92.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.126 -0.984 . . . . 0.0 110.579 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 33.1 t -82.92 -25.28 32.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.816 . . . . 0.0 111.587 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.9 mmm180 -92.28 -27.02 17.87 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.215 -0.928 . . . . 0.0 111.636 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 mt -137.31 2.95 2.56 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.071 -1.018 . . . . 0.0 112.509 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.64 28.28 73.46 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.416 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.8 OUTLIER -118.04 143.19 46.63 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.26 -1.141 . . . . 0.0 110.415 -179.647 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 1.3 m 62.39 52.87 2.91 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.001 0.905 . . . . 0.0 109.097 -179.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 50.4 m -97.85 -3.71 38.19 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.339 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 35.8 t-80 -122.67 45.35 2.4 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.167 -0.958 . . . . 0.0 109.88 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.0 t . . . . . 0 N--CA 1.497 1.885 0 O-C-N 121.373 -0.83 . . . . 0.0 110.194 -179.814 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 N--CA 1.489 1.215 0 N-CA-C 110.839 -0.485 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.4 t -65.0 -28.79 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.535 -0.728 . . . . 0.0 110.429 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.441 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.2 t -67.12 -21.38 65.84 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.484 -0.76 . . . . 0.0 110.896 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 35' ' ' SER . 74.1 m 59.62 28.68 18.16 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.557 -0.715 . . . . 0.0 110.892 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -104.41 146.09 29.34 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.271 -0.893 . . . . 0.0 110.273 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.99 26.69 43.88 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.8 pt -137.01 160.0 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.221 -1.164 . . . . 0.0 110.259 179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.8 m -85.53 168.27 14.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.556 -0.715 . . . . 0.0 110.06 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.65 -45.27 94.73 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.598 -0.689 . . . . 0.0 109.376 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.1 t -65.42 -38.53 90.19 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.611 -0.681 . . . . 0.0 110.026 179.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -63.25 -43.04 99.12 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.809 . . . . 0.0 109.71 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.98 -38.48 86.12 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.685 -0.634 . . . . 0.0 109.846 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.96 -38.27 85.8 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-O 121.551 0.691 . . . . 0.0 109.69 178.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 t -62.79 -40.94 98.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.726 -0.609 . . . . 0.0 111.598 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.0 t -76.83 -28.42 55.51 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.997 -1.064 . . . . 0.0 111.599 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.4 t -59.28 -41.14 88.21 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.068 -1.02 . . . . 0.0 109.606 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.7 t -86.81 -24.32 25.06 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 3.1 tmm_? -77.94 -36.7 48.99 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.364 -0.835 . . . . 0.0 111.066 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -144.07 16.97 1.74 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.231 -0.918 . . . . 0.0 111.946 -179.284 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.89 33.42 83.38 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.405 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.9 mmt-85 -119.6 144.27 47.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.418 -1.048 . . . . 0.0 110.598 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.7 m 60.2 54.7 3.93 Favored 'General case' 0 N--CA 1.498 1.965 0 CA-C-O 122.019 0.914 . . . . 0.0 109.095 -179.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.3 m -97.29 -17.15 19.96 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.399 -179.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -110.17 41.79 1.67 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.113 -0.992 . . . . 0.0 110.076 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 47.4 t . . . . . 0 N--CA 1.498 1.941 0 O-C-N 121.383 -0.823 . . . . 0.0 110.409 -179.663 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo . . . . . 0 N--CA 1.494 1.505 0 CA-C-O 121.369 0.487 . . . . 0.0 111.621 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 54.3 t -79.85 -36.29 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.967 0 O-C-N 121.507 -0.746 . . . . 0.0 110.487 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.419 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -68.8 -15.02 63.39 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.541 -0.724 . . . . 0.0 111.383 -179.606 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 35' ' ' SER . 33.0 m 57.8 27.97 15.27 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.4 -0.812 . . . . 0.0 110.84 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 7.4 mtt-85 -111.09 149.94 30.1 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.354 -0.841 . . . . 0.0 109.982 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.01 34.18 43.03 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.6 pt -129.77 154.15 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.135 . . . . 0.0 110.177 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 m -83.83 161.47 20.9 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.599 -0.688 . . . . 0.0 109.741 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.92 -41.39 82.58 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.432 -0.793 . . . . 0.0 109.574 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -67.97 -36.44 80.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 0.0 110.093 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -67.43 -40.19 85.47 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.429 -0.794 . . . . 0.0 109.911 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.92 -34.52 73.6 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 0.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.6 ttp180 -70.12 -31.3 68.79 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.434 -0.791 . . . . 0.0 110.232 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.0 t -71.35 -44.24 65.41 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.542 -0.724 . . . . 0.0 111.314 -179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.7 t -75.41 -29.18 59.68 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.19 -0.944 . . . . 0.0 111.467 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.5 t -62.25 -42.67 99.54 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.165 -0.959 . . . . 0.0 110.078 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 10.2 t -84.97 -25.12 27.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.329 -0.857 . . . . 0.0 110.685 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 -81.7 -33.71 31.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.414 -0.804 . . . . 0.0 111.312 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -142.12 9.57 1.9 Allowed 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.167 -0.958 . . . . 0.0 112.328 -179.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 66.99 27.72 73.53 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.464 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -115.73 144.82 43.42 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.172 -1.193 . . . . 0.0 110.812 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 44.9 m 62.08 51.78 3.5 Favored 'General case' 0 N--CA 1.499 1.985 0 CA-C-O 122.013 0.911 . . . . 0.0 109.438 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.36 -4.53 38.29 Favored 'General case' 0 N--CA 1.487 1.395 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.317 -179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.3 t-160 -126.02 47.74 2.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.048 -1.032 . . . . 0.0 109.944 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 64.2 t . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.511 -0.743 . . . . 0.0 110.379 -179.832 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 N--CA 1.487 1.104 0 N-CA-C 110.528 -0.605 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.2 t -79.83 -28.06 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.325 -0.859 . . . . 0.0 110.466 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -74.19 -11.8 60.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.228 -0.92 . . . . 0.0 111.179 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.8 m 58.27 25.69 12.99 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.399 -0.813 . . . . 0.0 111.006 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.8 mmt-85 -110.58 156.09 21.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.352 -0.843 . . . . 0.0 109.943 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.97 30.57 69.99 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.5 pt -131.69 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.266 -1.138 . . . . 0.0 109.981 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 1.6 m -82.27 158.52 23.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.715 -0.616 . . . . 0.0 109.446 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -56.62 -44.39 81.16 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.405 -0.809 . . . . 0.0 109.732 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.6 t -68.14 -35.74 78.58 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.598 -0.689 . . . . 0.0 109.971 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.404 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.0 OUTLIER -64.29 -41.92 96.63 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.638 -0.664 . . . . 0.0 109.925 179.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.82 83.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.576 -0.703 . . . . 0.0 109.993 179.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.8 mtm180 -65.62 -40.77 92.94 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.656 -0.653 . . . . 0.0 110.062 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.04 -45.12 96.08 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.832 -0.543 . . . . 0.0 111.363 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 51.8 t -68.56 -33.37 73.96 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.163 -0.961 . . . . 0.0 111.11 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.9 t -60.29 -41.86 94.27 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.167 -0.958 . . . . 0.0 110.465 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 23.0 t -83.43 -22.47 32.65 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.372 -0.83 . . . . 0.0 111.538 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -95.55 -26.68 15.69 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.032 -1.043 . . . . 0.0 111.584 -179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.1 mt -135.84 1.76 2.81 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.166 -0.959 . . . . 0.0 112.478 -178.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.79 26.94 73.7 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.532 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.78 146.31 42.93 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.304 -1.115 . . . . 0.0 110.418 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 92.6 m 60.76 53.52 3.9 Favored 'General case' 0 N--CA 1.499 1.978 0 CA-C-O 121.885 0.85 . . . . 0.0 109.136 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 53.6 m -100.15 -4.06 30.44 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.551 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -127.39 45.89 2.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.04 -1.038 . . . . 0.0 110.288 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 60.1 t . . . . . 0 N--CA 1.496 1.874 0 O-C-N 121.315 -0.866 . . . . 0.0 110.317 -179.934 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 N--CA 1.487 1.099 0 N-CA-C 110.577 -0.586 . . . . 0.0 110.577 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -69.14 -26.24 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 O-C-N 121.437 -0.789 . . . . 0.0 110.859 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.36 -11.13 59.99 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.15 -0.969 . . . . 0.0 111.411 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 79.7 m 57.44 26.79 13.02 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.391 -0.818 . . . . 0.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -108.45 150.32 27.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.304 -0.872 . . . . 0.0 110.565 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.86 28.23 65.28 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.9 pt -132.48 158.29 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.178 -1.189 . . . . 0.0 110.114 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.32 161.08 25.25 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.636 . . . . 0.0 109.684 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.25 -48.46 78.8 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.439 -0.788 . . . . 0.0 109.8 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.01 -33.91 76.88 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.605 -0.685 . . . . 0.0 110.094 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -63.64 -43.87 95.54 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.486 -0.759 . . . . 0.0 109.678 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.01 -36.14 79.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.638 -0.664 . . . . 0.0 109.545 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -64.53 -40.01 94.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.701 -0.624 . . . . 0.0 110.225 179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.9 t -62.91 -44.91 94.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.627 -0.67 . . . . 0.0 111.041 -179.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.525 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 41.4 t -65.71 -34.05 77.3 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.231 -0.918 . . . . 0.0 110.945 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 40.3 t -59.54 -42.66 92.83 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.144 -0.973 . . . . 0.0 110.572 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -87.84 -26.77 22.63 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.335 -0.853 . . . . 0.0 111.164 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -85.62 -30.67 23.08 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.291 -0.881 . . . . 0.0 111.368 -179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -134.52 4.58 3.39 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.29 -0.881 . . . . 0.0 112.21 -178.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.35 31.27 80.18 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.525 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 5.0 mmp_? -125.81 148.96 48.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.459 -1.024 . . . . 0.0 110.074 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.2 m 61.17 45.84 8.62 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.022 0.915 . . . . 0.0 108.611 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 9.0 m -90.12 -10.14 45.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.808 -0.557 . . . . 0.0 111.325 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -117.75 43.51 2.38 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.21 -0.931 . . . . 0.0 109.861 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 61.4 t . . . . . 0 N--CA 1.499 1.99 0 O-C-N 121.444 -0.785 . . . . 0.0 110.363 -179.609 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo . . . . . 0 N--CA 1.488 1.193 0 N-CA-C 110.386 -0.659 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.2 t -78.2 -32.07 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.409 -0.807 . . . . 0.0 110.733 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.43 -16.61 60.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.172 -0.955 . . . . 0.0 110.952 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.1 m 57.99 30.39 19.12 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.372 -0.83 . . . . 0.0 110.239 -179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.5 mtp180 -113.01 154.07 27.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.508 -0.745 . . . . 0.0 110.128 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.55 34.69 59.91 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.9 pt -139.83 161.81 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.403 -1.057 . . . . 0.0 109.855 179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 7.8 m -80.44 161.08 25.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.534 -0.728 . . . . 0.0 109.963 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.9 t80 -58.54 -43.72 89.36 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.512 -0.743 . . . . 0.0 109.39 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.9 t -65.0 -38.63 91.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.641 -0.662 . . . . 0.0 109.827 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 28.5 tp60 -64.21 -44.76 90.94 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.611 -0.68 . . . . 0.0 109.593 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.93 79.2 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -65.69 -36.26 83.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.815 -0.553 . . . . 0.0 109.793 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -63.42 -47.77 80.57 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.797 -0.564 . . . . 0.0 111.197 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 53.1 t -66.45 -33.69 76.26 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.241 -0.912 . . . . 0.0 111.091 -179.543 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.0 t -57.81 -41.67 82.69 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.163 -0.961 . . . . 0.0 110.169 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -84.59 -25.59 28.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.272 -0.892 . . . . 0.0 110.367 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.8 ttm180 -79.39 -36.18 39.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.327 -0.858 . . . . 0.0 111.195 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.32 11.39 2.14 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.116 -0.99 . . . . 0.0 112.353 -178.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.04 26.93 73.29 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.74 141.61 47.61 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.243 -1.151 . . . . 0.0 110.571 -179.921 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 54.1 m 66.25 54.61 0.93 Allowed 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.799 0.809 . . . . 0.0 108.917 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 67.5 m -102.92 -0.62 30.82 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.845 -0.535 . . . . 0.0 111.75 -178.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -137.03 50.24 2.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.935 -1.103 . . . . 0.0 110.645 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.2 t . . . . . 0 N--CA 1.497 1.91 0 O-C-N 121.115 -0.99 . . . . 0.0 110.245 179.649 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.489 1.254 0 N-CA-C 110.719 -0.531 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.6 t -77.38 -29.93 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.475 -0.766 . . . . 0.0 110.861 -179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.421 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -73.33 -12.68 60.92 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.24 -0.912 . . . . 0.0 111.27 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 35' ' ' SER . 68.5 m 58.15 25.55 12.64 Favored 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.45 -0.781 . . . . 0.0 111.155 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.0 mtt180 -115.9 158.55 22.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.317 -0.865 . . . . 0.0 110.032 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.83 28.74 73.91 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.427 ' CD1' ' HB3' ' A' ' 44' ' ' ALA . 16.2 pt -125.71 152.0 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.325 -1.103 . . . . 0.0 109.937 179.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -77.32 160.17 29.01 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.77 -44.56 86.25 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.346 -0.846 . . . . 0.0 109.724 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.0 -35.57 80.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.513 -0.742 . . . . 0.0 109.914 179.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.4 -44.22 96.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.396 -0.815 . . . . 0.0 109.117 178.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.427 ' HB3' ' CD1' ' A' ' 39' ' ' ILE . . . -70.56 -34.83 72.67 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.814 -0.554 . . . . 0.0 109.571 178.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -34.96 77.0 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.696 -0.627 . . . . 0.0 110.283 179.388 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -69.65 -41.44 75.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.497 -0.752 . . . . 0.0 110.839 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.8 t -71.96 -32.83 67.66 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.408 -0.808 . . . . 0.0 111.061 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.5 t -65.36 -43.17 91.65 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.246 -0.909 . . . . 0.0 110.917 -179.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.6 t -80.94 -21.36 40.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.451 -0.781 . . . . 0.0 112.126 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -101.79 -23.24 14.22 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.009 -1.057 . . . . 0.0 111.724 -179.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -134.14 -8.73 2.64 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.967 -1.083 . . . . 0.0 112.541 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.02 26.51 66.45 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.405 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.3 OUTLIER -120.23 148.72 43.33 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.246 -1.149 . . . . 0.0 110.689 -179.596 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 11.8 m 58.95 46.08 14.15 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 122.033 0.92 . . . . 0.0 108.885 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 20.7 m -88.76 -12.78 41.18 Favored 'General case' 0 N--CA 1.488 1.428 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.185 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -116.89 45.17 1.91 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.219 -0.926 . . . . 0.0 109.974 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.421 HG22 ' CB ' ' A' ' 44' ' ' ALA . 94.2 t . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.429 -0.795 . . . . 0.0 110.229 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 N-CA-C 110.455 -0.633 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.56 -32.07 54.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.474 -0.767 . . . . 0.0 110.438 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.9 -14.17 61.86 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.492 -0.755 . . . . 0.0 111.08 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.2 m 57.75 30.53 19.09 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.511 -0.743 . . . . 0.0 111.09 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.1 mtt85 -105.53 139.95 39.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.267 -0.895 . . . . 0.0 109.999 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.56 0.68 81.73 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 27.0 pt -116.28 158.48 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.063 -1.257 . . . . 0.0 110.125 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -80.08 165.11 22.83 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.699 -0.626 . . . . 0.0 110.639 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -57.82 -48.81 78.66 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.61 -0.681 . . . . 0.0 109.288 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -61.45 -37.51 83.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.668 -0.645 . . . . 0.0 109.781 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -64.82 -44.0 91.3 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.425 -0.797 . . . . 0.0 109.56 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.49 78.42 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.69 -0.631 . . . . 0.0 109.66 179.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -36.89 80.57 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.716 -0.615 . . . . 0.0 109.76 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.6 t -64.45 -42.16 96.13 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.756 -0.59 . . . . 0.0 110.946 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 42.3 t -70.26 -34.99 73.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.113 -0.992 . . . . 0.0 111.176 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.3 t -58.15 -40.55 81.67 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.121 -0.987 . . . . 0.0 110.212 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.09 -14.32 50.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 111.297 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -101.62 -31.02 11.03 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.103 -0.998 . . . . 0.0 111.209 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -134.23 -1.69 2.89 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.207 -0.933 . . . . 0.0 112.306 -179.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.98 72.33 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.444 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.3 OUTLIER -113.49 152.0 30.73 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.07 -1.253 . . . . 0.0 110.521 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.5 m 59.79 53.55 4.79 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.887 0.851 . . . . 0.0 108.721 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 69.3 m -104.94 9.57 34.55 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.475 -178.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -146.01 46.04 1.25 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 110.523 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.496 1.87 0 O-C-N 121.17 -0.956 . . . . 0.0 110.35 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo . . . . . 0 N--CA 1.49 1.313 0 N-CA-C 110.758 -0.516 . . . . 0.0 110.758 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 87.4 t -60.03 -31.27 47.42 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.584 -0.697 . . . . 0.0 110.936 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 t -72.86 -4.49 32.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.234 -0.916 . . . . 0.0 111.767 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 55.6 28.58 12.14 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.291 -0.881 . . . . 0.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.3 mtt85 -123.63 161.47 24.97 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.307 -0.87 . . . . 0.0 110.213 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.59 30.81 65.99 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.0 pt -141.61 159.47 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.496 -1.002 . . . . 0.0 109.896 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 11.6 m -80.84 161.41 24.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.515 -0.74 . . . . 0.0 109.824 179.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -57.4 -45.68 84.29 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.553 -0.717 . . . . 0.0 109.389 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.1 t -64.04 -36.6 84.52 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.658 -0.651 . . . . 0.0 109.864 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.44 -44.87 89.81 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.649 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -70.1 -36.44 74.88 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.727 -0.608 . . . . 0.0 109.901 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.6 tpp85 -67.82 -38.0 82.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.675 -0.64 . . . . 0.0 109.508 179.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -64.05 -44.11 93.47 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.816 -0.552 . . . . 0.0 110.686 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.4 t -64.87 -30.18 71.16 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.935 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.8 t -70.3 -43.21 70.82 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.214 -0.929 . . . . 0.0 110.558 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -81.85 -21.05 37.76 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.272 -0.893 . . . . 0.0 112.016 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.59 -19.7 13.69 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.035 -1.04 . . . . 0.0 111.714 -179.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -6.33 2.87 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.108 -0.995 . . . . 0.0 112.446 -179.168 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.52 25.99 74.82 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.451 ' HA ' ' HD2' ' A' ' 53' ' ' ARG . 13.9 mmm180 -121.22 148.76 43.82 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.227 -1.161 . . . . 0.0 110.439 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 5.3 m 59.26 48.32 10.42 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-O 121.97 0.89 . . . . 0.0 108.824 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 14.8 m -91.43 -6.42 52.8 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.373 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -120.63 45.38 2.24 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.146 -0.971 . . . . 0.0 109.888 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 39.1 t . . . . . 0 N--CA 1.497 1.905 0 O-C-N 121.391 -0.818 . . . . 0.0 110.563 -179.585 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo . . . . . 0 N--CA 1.49 1.274 0 N-CA-C 110.832 -0.488 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.4 t -65.92 -27.86 42.31 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.384 -0.822 . . . . 0.0 110.31 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' SER . . . . . 0.422 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -65.38 -18.04 65.0 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.403 -0.811 . . . . 0.0 111.034 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.445 ' HA ' HD13 ' A' ' 39' ' ' ILE . 84.1 m 58.29 27.23 14.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.479 -0.763 . . . . 0.0 111.211 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -114.21 147.72 38.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.397 -0.814 . . . . 0.0 109.848 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.11 30.24 65.57 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.445 HD13 ' HA ' ' A' ' 36' ' ' CYS . 23.4 pt -124.67 155.77 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.381 -1.07 . . . . 0.0 109.854 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -82.13 157.32 24.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.647 . . . . 0.0 109.413 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.61 -39.95 78.03 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.419 -0.801 . . . . 0.0 109.69 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -69.91 -35.63 74.74 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.632 -0.668 . . . . 0.0 110.084 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -65.38 -40.16 93.17 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.433 ' HB3' ' CD1' ' A' ' 39' ' ' ILE . . . -70.59 -35.88 73.25 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.669 -0.644 . . . . 0.0 110.285 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.27 -32.36 70.14 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 179.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.498 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 8.5 t -71.44 -41.6 69.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.555 -0.716 . . . . 0.0 110.948 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 t -74.0 -29.07 61.76 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.242 -0.911 . . . . 0.0 111.743 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.7 t -59.48 -43.3 93.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.987 -1.07 . . . . 0.0 109.996 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 12.3 t -89.27 -25.21 21.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.381 -0.824 . . . . 0.0 110.629 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.498 ' HB2' ' O ' ' A' ' 46' ' ' SER . 2.3 ttp85 -79.72 -34.66 39.89 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.407 -0.808 . . . . 0.0 111.181 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -141.08 10.68 2.16 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.162 -0.961 . . . . 0.0 112.289 -179.026 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.81 33.38 82.82 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -123.68 142.52 50.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.584 -0.95 . . . . 0.0 110.097 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 1.8 m 59.76 56.29 3.6 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 121.985 0.898 . . . . 0.0 108.974 -179.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 4.4 m -94.98 -11.5 28.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.883 -0.511 . . . . 0.0 111.312 -178.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -122.69 44.14 2.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.149 -0.969 . . . . 0.0 110.078 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 38.1 t . . . . . 0 N--CA 1.5 2.026 0 O-C-N 121.494 -0.754 . . . . 0.0 110.363 -179.746 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo . . . . . 0 N--CA 1.49 1.292 0 N-CA-C 110.692 -0.542 . . . . 0.0 110.692 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 96.2 t -66.22 -29.6 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.363 -0.836 . . . . 0.0 110.669 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.2 t -68.51 -19.31 64.52 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.353 -0.842 . . . . 0.0 111.092 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.3 m 60.69 30.18 19.53 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.495 -0.753 . . . . 0.0 110.627 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -107.41 146.47 31.63 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.27 -0.894 . . . . 0.0 110.373 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.83 29.22 55.23 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 28.4 pt -137.55 163.13 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.198 -1.178 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.423 ' HB3' ' HB2' ' A' ' 43' ' ' GLN . 13.5 t -80.7 166.56 20.92 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.564 -0.71 . . . . 0.0 110.082 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -62.58 -49.34 75.64 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 46' ' ' SER . 2.7 t -63.57 -35.32 80.1 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.696 -0.627 . . . . 0.0 109.985 179.245 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.423 ' HB2' ' HB3' ' A' ' 40' ' ' SER . 4.8 tt0 -64.74 -43.39 93.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.45 -0.781 . . . . 0.0 109.645 179.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -70.73 -36.65 73.29 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.56 -0.713 . . . . 0.0 109.492 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 5.6 ttt-85 -68.36 -33.44 74.28 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.758 -0.589 . . . . 0.0 109.7 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 42' ' ' SER . 0.1 OUTLIER -66.33 -46.81 75.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.801 -0.562 . . . . 0.0 110.93 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.4 t -66.02 -30.13 70.61 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.321 -0.862 . . . . 0.0 111.248 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 35.4 t -58.84 -41.06 86.04 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.942 -1.099 . . . . 0.0 109.941 179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 19.4 t -87.26 -25.3 24.04 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.668 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.83 -34.41 26.9 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.314 -0.866 . . . . 0.0 111.316 -179.513 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -137.56 6.79 2.76 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.178 -0.951 . . . . 0.0 112.374 -179.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.08 27.08 74.18 Favored Glycine 0 N--CA 1.497 2.749 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.502 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.4 OUTLIER -117.53 145.65 44.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.21 -1.17 . . . . 0.0 110.293 179.941 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.502 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 83.3 m 63.23 53.7 2.19 Favored 'General case' 0 N--CA 1.501 2.108 0 CA-C-O 121.903 0.858 . . . . 0.0 108.806 -178.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.2 m -101.27 8.56 42.4 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.904 -0.497 . . . . 0.0 111.689 -178.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.7 t60 -141.69 42.39 1.72 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 N--CA 1.495 1.809 0 O-C-N 121.276 -0.89 . . . . 0.0 110.061 179.871 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 CA-C-O 121.266 0.444 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 50.8 t -68.24 -31.1 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.409 -0.807 . . . . 0.0 110.348 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.8 t -68.48 -16.02 63.75 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.407 -0.808 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 57.42 30.33 18.43 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.358 -0.838 . . . . 0.0 110.775 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.3 mtt180 -102.14 152.65 20.76 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.337 -0.852 . . . . 0.0 110.444 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.38 17.22 76.58 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.3 pt -133.18 159.81 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.057 -1.26 . . . . 0.0 110.241 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.6 161.74 23.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.653 -0.655 . . . . 0.0 109.696 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 86.3 t80 -56.36 -50.12 72.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.498 -0.751 . . . . 0.0 109.567 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.5 t -63.07 -35.86 81.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.689 -0.632 . . . . 0.0 110.196 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -64.22 -42.47 96.58 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.43 -0.794 . . . . 0.0 109.801 179.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -36.06 77.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.552 -0.718 . . . . 0.0 109.9 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.38 -40.83 93.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.772 -0.58 . . . . 0.0 110.084 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.6 t -62.8 -43.47 98.73 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.558 -0.714 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.3 t -64.81 -34.26 77.95 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.253 -0.904 . . . . 0.0 110.776 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 37.3 t -61.28 -43.09 99.45 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.309 -0.869 . . . . 0.0 110.045 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.0 m -80.06 -13.07 59.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.51 -0.744 . . . . 0.0 111.265 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.92 -28.56 12.33 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.207 -0.933 . . . . 0.0 111.186 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.95 7.84 1.86 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.058 -1.026 . . . . 0.0 112.515 -179.129 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.76 27.17 74.06 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 120.857 -1.152 . . . . 0.0 110.312 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.4 mmp_? -114.83 143.5 45.01 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.078 -1.248 . . . . 0.0 110.562 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 27.5 m 61.7 56.02 2.56 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-O 121.879 0.847 . . . . 0.0 108.973 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 63.8 m -101.85 -3.14 28.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.925 -0.485 . . . . 0.0 112.01 -178.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -136.42 47.98 2.16 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.983 -1.073 . . . . 0.0 111.006 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 95.5 t . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.1 -1.0 . . . . 0.0 109.742 179.348 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.404 ' HG3' HG23 ' A' ' 39' ' ' ILE . 46.3 Cg_endo . . . . . 0 N--CA 1.485 0.989 0 N-CA-C 109.879 -0.854 . . . . 0.0 109.879 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 43.5 t -73.82 -30.33 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.21 -0.931 . . . . 0.0 110.937 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.5 t -73.65 -10.88 60.15 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.275 -0.891 . . . . 0.0 111.825 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 74.8 m 57.43 29.28 16.72 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.232 -0.917 . . . . 0.0 110.878 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -128.51 158.94 36.99 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.306 -0.871 . . . . 0.0 110.636 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.24 37.25 71.45 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.404 HG23 ' HG3' ' A' ' 33' ' ' PRO . 14.1 pt -143.99 159.5 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.423 -1.045 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.5 m -76.06 160.28 29.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.642 -0.661 . . . . 0.0 109.701 179.369 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -58.17 -44.67 88.08 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 109.478 179.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -62.61 -37.86 87.92 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.619 -0.676 . . . . 0.0 109.903 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -64.51 -45.82 85.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.546 -0.721 . . . . 0.0 109.668 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.93 -36.7 80.59 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.813 -0.555 . . . . 0.0 109.932 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 33.4 ttp85 -69.95 -36.96 75.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.538 -0.726 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.1 t -63.27 -40.09 96.43 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.687 -0.633 . . . . 0.0 110.845 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 29.6 t -67.77 -40.05 84.05 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.352 -0.843 . . . . 0.0 110.745 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.5 t -59.07 -42.74 91.1 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.392 -0.817 . . . . 0.0 110.747 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.9 -18.89 49.45 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.427 -0.795 . . . . 0.0 111.902 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.83 -25.18 13.6 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.084 -1.01 . . . . 0.0 111.806 -179.229 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -135.1 -5.86 2.36 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.065 -1.022 . . . . 0.0 112.669 -178.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.5 22.92 71.75 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ARG . . . . . 0.479 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.74 148.01 41.51 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.238 -1.154 . . . . 0.0 110.548 -179.847 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 84.7 m 61.37 47.42 6.84 Favored 'General case' 0 N--CA 1.498 1.931 0 CA-C-O 121.974 0.892 . . . . 0.0 109.086 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 36.5 m -91.2 -7.96 49.88 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.904 -0.497 . . . . 0.0 111.228 -179.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.8 t60 -124.11 45.73 2.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.145 -0.972 . . . . 0.0 109.908 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.497 1.917 0 O-C-N 121.423 -0.798 . . . . 0.0 110.454 -179.825 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 N--CA 1.497 1.917 0 CA-C-O 121.373 0.606 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.47 158.29 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.655 -0.653 . . . . 0.0 110.33 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.8 m-85 -82.76 118.75 23.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.361 -0.837 . . . . 0.0 110.496 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -105.92 99.51 9.1 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.404 -0.81 . . . . 0.0 110.208 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.29 58.67 3.1 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 174.09 56.59 0.05 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -69.26 106.51 2.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.527 -0.984 . . . . 0.0 109.668 179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 70.16 -58.65 0.53 Allowed 'General case' 0 N--CA 1.504 2.245 0 O-C-N 122.043 -0.411 . . . . 0.0 110.61 -179.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -85.9 127.39 62.46 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.201 -0.937 . . . . 0.0 110.4 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.01 127.79 12.49 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.901 1.474 . . . . 0.0 110.226 179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.7 mt 52.07 65.15 6.62 Favored Pre-proline 0 N--CA 1.503 2.215 0 O-C-N 121.751 -0.593 . . . . 0.0 110.153 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -79.68 71.88 6.81 Favored 'Trans proline' 0 C--N 1.314 -1.238 0 O-C-N 123.771 1.406 . . . . 0.0 110.551 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.48 123.28 82.44 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.33 -0.856 . . . . 0.0 110.203 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.93 148.8 58.29 Favored 'Trans proline' 0 C--N 1.315 -1.236 0 O-C-N 123.895 1.471 . . . . 0.0 110.681 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.05 160.6 47.09 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.908 1.478 . . . . 0.0 110.828 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -76.11 -173.21 1.6 Allowed 'Trans proline' 0 C--N 1.313 -1.299 0 O-C-N 123.967 1.509 . . . . 0.0 110.774 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -67.22 148.69 51.43 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.487 -0.758 . . . . 0.0 110.598 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.3 145.29 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.697 -0.627 . . . . 0.0 109.975 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -66.52 116.55 35.38 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.458 -0.776 . . . . 0.0 110.13 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -72.71 178.0 6.87 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.79 1.416 . . . . 0.0 110.792 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -134.37 101.89 11.99 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.621 -0.674 . . . . 0.0 110.112 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.05 138.24 27.84 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.759 1.399 . . . . 0.0 110.57 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.99 -61.91 0.98 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.33 169.21 43.07 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.69 152.1 64.25 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.876 1.461 . . . . 0.0 110.804 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.432 HG22 HD12 ' A' ' 26' ' ' ILE . 14.0 mm -85.37 152.57 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.43 -0.794 . . . . 0.0 110.306 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 62.02 72.97 0.56 Allowed Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -78.26 -34.51 1.55 Allowed 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.888 1.468 . . . . 0.0 110.998 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -82.67 67.78 8.87 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -0.884 . . . . 0.0 110.159 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -132.41 41.18 3.23 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.259 -0.901 . . . . 0.0 110.655 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.97 47.1 0.04 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.583 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.8 t -176.21 78.6 0.28 Allowed Pre-proline 0 N--CA 1.5 2.071 0 O-C-N 121.351 -1.088 . . . . 0.0 110.299 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.94 151.11 78.29 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 O-C-N 123.895 1.471 . . . . 0.0 110.966 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.4 t -62.84 -31.23 51.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.505 -0.747 . . . . 0.0 110.937 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.6 OUTLIER -69.22 -12.44 61.67 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.503 -0.748 . . . . 0.0 111.53 -179.677 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 35' ' ' SER . 78.8 m 61.78 27.75 16.99 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.409 -0.807 . . . . 0.0 110.575 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 35' ' ' SER . 17.1 mmm180 -107.02 146.34 31.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.397 -0.814 . . . . 0.0 110.19 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.93 22.45 52.79 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.5 pt -138.87 154.96 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.154 -1.204 . . . . 0.0 110.281 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.48 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 55.0 m -74.51 165.75 24.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.607 -0.683 . . . . 0.0 110.043 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.483 ' CE2' ' HD2' ' A' ' 45' ' ' ARG . 84.2 t80 -60.02 -48.76 80.4 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.616 -0.677 . . . . 0.0 109.816 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -65.82 -33.75 76.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.583 -0.698 . . . . 0.0 110.122 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.3 OUTLIER -63.47 -46.38 86.47 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.143 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.47 -37.69 88.28 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.891 -0.505 . . . . 0.0 109.956 179.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.483 ' HD2' ' CE2' ' A' ' 41' ' ' PHE . 1.0 OUTLIER -64.54 -40.86 96.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.628 -0.67 . . . . 0.0 109.761 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -61.55 -43.95 97.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.774 -0.579 . . . . 0.0 110.971 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.1 t -67.04 -31.2 71.56 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.315 -0.865 . . . . 0.0 111.17 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 t -58.69 -42.5 88.7 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.077 -1.014 . . . . 0.0 109.86 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -84.53 -22.08 30.28 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.412 -0.805 . . . . 0.0 110.697 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -80.97 -36.01 31.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.239 -0.913 . . . . 0.0 111.01 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.49 18.29 1.69 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.187 -0.946 . . . . 0.0 111.97 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.28 31.74 78.22 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.517 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 3.6 mmp_? -117.57 137.75 52.38 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.43 -1.041 . . . . 0.0 110.68 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 21.5 m 64.35 52.51 1.86 Allowed 'General case' 0 N--CA 1.502 2.128 0 CA-C-O 121.84 0.828 . . . . 0.0 109.476 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 27.3 m -92.02 -20.39 21.38 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.955 -0.466 . . . . 0.0 111.262 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -112.81 42.55 1.84 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.167 -0.958 . . . . 0.0 110.002 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 75.8 t -71.22 125.49 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.529 -0.732 . . . . 0.0 110.199 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.17 125.49 3.28 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -160.97 141.81 11.5 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.592 -0.946 . . . . 0.0 110.324 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.73 -176.63 48.45 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 t80 -76.22 152.29 36.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.314 -1.109 . . . . 0.0 110.248 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -143.7 154.82 43.88 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.625 -0.672 . . . . 0.0 110.348 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.47 0 CA-C-O 118.118 -1.379 . . . . 0.0 109.679 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 . . . . . 0 N--CA 1.496 1.852 0 CA-C-O 121.316 0.579 . . . . 0.0 110.774 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 94.9 t -76.14 148.01 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.644 -0.66 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -90.4 153.88 20.09 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.507 -0.745 . . . . 0.0 110.239 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -108.3 117.69 34.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.443 -0.786 . . . . 0.0 110.284 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -147.82 -94.81 0.15 Allowed Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.1 138.25 6.01 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 5.0 m-85 -69.27 135.44 50.49 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.561 -0.964 . . . . 0.0 110.604 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -96.93 118.02 32.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.515 -0.741 . . . . 0.0 110.292 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.71 127.67 59.4 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.428 -0.795 . . . . 0.0 110.367 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.86 152.82 63.95 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.921 1.485 . . . . 0.0 110.482 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.3 mp 54.74 75.92 0.56 Allowed Pre-proline 0 N--CA 1.502 2.144 0 O-C-N 121.763 -0.586 . . . . 0.0 110.0 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.32 85.17 1.08 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.851 1.448 . . . . 0.0 110.622 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.23 127.84 57.6 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.452 -0.78 . . . . 0.0 110.203 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.34 169.73 20.94 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.959 1.505 . . . . 0.0 110.688 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.56 119.89 6.55 Favored 'Trans proline' 0 C--N 1.315 -1.201 0 O-C-N 123.783 1.412 . . . . 0.0 110.483 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.57 91.56 0.78 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.935 1.492 . . . . 0.0 110.527 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -91.53 155.9 18.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.42 -0.8 . . . . 0.0 110.426 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t -125.62 146.65 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.618 -0.676 . . . . 0.0 110.159 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -76.57 129.73 78.72 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.387 -0.82 . . . . 0.0 110.077 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.69 -174.6 1.74 Allowed 'Trans proline' 0 C--N 1.314 -1.248 0 O-C-N 123.88 1.463 . . . . 0.0 110.777 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 2.2 tp -69.56 132.29 89.38 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.43 -0.794 . . . . 0.0 110.312 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.08 120.06 5.88 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 O-C-N 123.899 1.473 . . . . 0.0 110.764 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -76.68 85.28 0.97 Allowed Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.82 84.19 0.92 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.63 148.39 47.25 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.95 1.5 . . . . 0.0 110.756 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 13.0 mt -94.14 147.67 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.465 -0.772 . . . . 0.0 110.194 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.27 82.98 1.43 Allowed Glycine 0 N--CA 1.496 2.633 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -76.42 -174.69 2.21 Favored 'Trans proline' 0 C--N 1.315 -1.214 0 O-C-N 123.974 1.513 . . . . 0.0 110.764 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -79.33 69.32 5.54 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.397 -0.814 . . . . 0.0 110.207 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -151.09 41.36 0.74 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.378 -0.826 . . . . 0.0 110.669 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.21 43.02 0.25 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 52.8 t -175.03 89.08 0.31 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.587 -0.949 . . . . 0.0 110.023 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.86 141.95 60.98 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.756 1.398 . . . . 0.0 110.689 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.41 -30.64 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 121.485 -0.759 . . . . 0.0 110.811 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.55 -16.62 62.89 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.334 -0.854 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 38.8 m 59.31 25.56 14.24 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.512 -0.742 . . . . 0.0 111.169 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.4 mmt-85 -108.39 143.5 37.22 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.24 -0.913 . . . . 0.0 110.127 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.86 22.2 53.64 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.3 pt -134.93 156.3 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.135 -1.215 . . . . 0.0 110.098 179.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 m -74.48 166.02 24.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.637 -0.664 . . . . 0.0 110.515 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -60.18 -49.04 79.18 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.744 -0.597 . . . . 0.0 109.627 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -62.73 -35.36 79.49 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.624 -0.673 . . . . 0.0 110.059 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -63.36 -46.01 88.52 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.253 -0.904 . . . . 0.0 109.205 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.71 -33.04 68.43 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.714 -0.616 . . . . 0.0 109.552 179.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.403 ' HB3' ' NH2' ' A' ' 45' ' ' ARG . 3.1 mtp-105 -68.84 -38.2 79.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.831 -0.543 . . . . 0.0 110.495 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -67.4 -40.33 85.59 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.421 -0.799 . . . . 0.0 110.73 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 43.8 t -69.38 -31.82 70.45 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.351 -0.843 . . . . 0.0 111.207 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 30.5 t -58.41 -42.19 86.64 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.224 -0.923 . . . . 0.0 110.305 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -84.15 -23.66 30.54 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.385 -0.822 . . . . 0.0 111.0 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 4.6 mmt-85 -85.76 -32.9 21.6 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 111.309 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -139.35 9.29 2.48 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.121 -0.987 . . . . 0.0 112.283 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.06 27.79 72.73 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.498 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.08 140.1 48.76 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.271 -1.135 . . . . 0.0 110.382 -179.561 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 98.2 m 63.59 53.12 2.12 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.877 0.846 . . . . 0.0 109.181 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 25.8 m -97.13 -14.55 21.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.828 -0.545 . . . . 0.0 111.783 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -122.85 42.25 3.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.972 -1.08 . . . . 0.0 110.858 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 72.4 t -109.47 109.68 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.725 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.57 89.43 0.17 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 6.6 mmmt -64.92 109.72 2.2 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.578 -0.954 . . . . 0.0 110.094 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.52 -177.14 47.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 74.7 t80 -78.6 150.34 32.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.277 -1.131 . . . . 0.0 110.085 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p -145.06 156.51 43.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.644 -0.66 . . . . 0.0 110.275 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.527 0 CA-C-O 118.05 -1.417 . . . . 0.0 109.626 -179.95 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 121.322 0.582 . . . . 0.0 110.667 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.9 t -81.17 153.34 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.71 -0.619 . . . . 0.0 109.773 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -73.07 127.64 33.17 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.475 -0.766 . . . . 0.0 110.186 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.12 116.68 31.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.439 -0.788 . . . . 0.0 110.48 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.54 71.7 0.33 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 154.84 128.07 1.14 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 5.9 m-85 -69.88 147.71 49.95 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.499 -1.0 . . . . 0.0 110.348 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.46 -30.58 69.76 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.491 -0.756 . . . . 0.0 110.55 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.44 133.49 67.5 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.48 -0.762 . . . . 0.0 110.04 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.49 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.0 Cg_endo -72.95 136.91 25.81 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.933 1.491 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.49 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 44.8 mt 65.84 131.22 0.03 OUTLIER Pre-proline 0 N--CA 1.505 2.317 0 O-C-N 122.163 -0.335 . . . . 0.0 110.776 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.32 74.6 3.59 Favored 'Trans proline' 0 C--N 1.315 -1.186 0 O-C-N 123.683 1.36 . . . . 0.0 110.523 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.55 131.47 45.63 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.38 -0.825 . . . . 0.0 110.27 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -71.92 146.96 48.62 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 123.876 1.461 . . . . 0.0 110.84 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.71 147.24 39.7 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.875 1.461 . . . . 0.0 110.675 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.04 90.19 0.87 Allowed 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.866 1.456 . . . . 0.0 110.617 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -76.23 153.48 36.02 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.365 -0.835 . . . . 0.0 110.537 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.8 t -79.66 144.1 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.67 . . . . 0.0 110.154 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.1 tpm_? -110.83 99.54 42.62 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.515 -0.74 . . . . 0.0 110.012 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.07 -178.7 3.36 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 O-C-N 123.853 1.449 . . . . 0.0 110.904 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.04 100.14 8.0 Favored Pre-proline 0 N--CA 1.495 1.779 0 O-C-N 121.388 -0.82 . . . . 0.0 110.187 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.34 158.79 40.7 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.841 1.443 . . . . 0.0 110.743 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.46 -91.03 1.58 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.33 99.35 1.15 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 148.15 47.98 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 O-C-N 123.889 1.468 . . . . 0.0 110.611 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 4.2 mt -106.74 135.57 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.392 -0.817 . . . . 0.0 110.23 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 81.48 83.36 0.79 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -72.91 -44.12 0.67 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.96 1.505 . . . . 0.0 110.654 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -93.36 49.3 1.38 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.25 38.62 2.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 110.428 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.35 41.47 0.89 Allowed Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 15.3 t -173.25 112.49 0.34 Allowed Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.414 -1.051 . . . . 0.0 110.092 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -72.5 129.52 14.85 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.599 1.315 . . . . 0.0 110.286 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.47 -28.44 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.457 -0.777 . . . . 0.0 110.845 -179.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -71.07 -12.66 61.64 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.257 -0.902 . . . . 0.0 111.353 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.2 m 55.32 29.19 12.51 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.333 -0.855 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -125.92 152.58 45.42 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.236 -0.915 . . . . 0.0 110.204 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.35 36.2 59.66 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.429 HD11 HG22 ' A' ' 57' ' ' VAL . 14.0 pt -127.44 156.25 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.291 -1.123 . . . . 0.0 110.243 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -82.38 160.24 22.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.507 -0.746 . . . . 0.0 109.38 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -58.15 -41.64 84.18 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.533 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -67.53 -36.72 81.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.633 -0.667 . . . . 0.0 110.156 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -65.61 -41.94 92.15 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.416 -0.803 . . . . 0.0 109.704 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.29 -34.12 75.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.757 -0.59 . . . . 0.0 110.361 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.16 -33.8 73.97 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.458 -0.776 . . . . 0.0 110.12 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -69.03 -46.0 69.03 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.538 -0.726 . . . . 0.0 111.059 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 42.4 t -69.52 -32.5 71.39 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.334 -0.854 . . . . 0.0 111.219 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.1 t -64.73 -42.04 95.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.222 -0.924 . . . . 0.0 110.775 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -82.46 -25.25 33.74 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.359 -0.838 . . . . 0.0 111.496 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.24 -29.51 18.14 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.189 -0.944 . . . . 0.0 111.526 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.2 mt -137.03 3.43 2.66 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.049 -1.032 . . . . 0.0 112.648 -178.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.49 28.45 73.61 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.429 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -118.16 146.81 43.92 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.296 -1.12 . . . . 0.0 110.606 -179.446 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.41 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.2 m 59.46 48.93 9.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 122.041 0.924 . . . . 0.0 109.027 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.5 m -92.53 -16.8 25.29 Favored 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.713 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -114.9 41.79 2.31 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.062 -1.023 . . . . 0.0 110.62 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.429 HG22 HD11 ' A' ' 39' ' ' ILE . 95.5 t -76.36 143.23 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.478 -0.764 . . . . 0.0 110.002 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.27 162.72 38.53 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -105.23 121.51 44.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.295 -1.121 . . . . 0.0 110.072 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.15 173.66 42.11 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.2 t80 -74.13 154.86 38.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.319 -1.107 . . . . 0.0 110.512 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.9 p -144.23 161.94 37.62 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.545 -0.722 . . . . 0.0 110.228 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.421 0 CA-C-O 118.178 -1.346 . . . . 0.0 109.823 -179.965 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.445 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 3.4 mp0 . . . . . 0 N--CA 1.496 1.828 0 CA-C-O 121.04 0.447 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 39.2 t 63.79 161.49 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 CA-C-O 121.438 0.637 . . . . 0.0 110.825 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -82.93 141.1 32.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.227 -0.92 . . . . 0.0 110.134 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.37 149.66 44.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 110.639 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.59 -157.27 24.61 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.62 108.3 1.23 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -64.65 121.4 14.39 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.541 -0.976 . . . . 0.0 110.176 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 53.65 31.64 13.04 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.851 -0.531 . . . . 0.0 110.694 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.95 93.4 27.21 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.255 -0.903 . . . . 0.0 110.252 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.41 148.81 49.32 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 O-C-N 124.002 1.527 . . . . 0.0 110.974 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.6 pt -89.86 121.34 69.03 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.496 -0.752 . . . . 0.0 110.332 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.44 77.16 2.58 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.8 1.421 . . . . 0.0 110.697 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.61 142.0 73.42 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.296 -0.878 . . . . 0.0 110.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.61 113.37 3.72 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 124.026 1.54 . . . . 0.0 110.767 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.91 148.82 36.24 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.826 1.435 . . . . 0.0 110.653 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.0 76.46 3.77 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.963 1.507 . . . . 0.0 110.286 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -81.35 147.59 29.77 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.388 -0.82 . . . . 0.0 110.615 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -109.25 150.84 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.811 -0.556 . . . . 0.0 109.815 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 115.95 30.98 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.473 -0.767 . . . . 0.0 110.374 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -76.1 -173.23 1.6 Allowed 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.934 1.491 . . . . 0.0 110.793 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 1.9 pp -75.04 159.44 82.77 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 121.549 -0.719 . . . . 0.0 110.345 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.08 121.58 7.68 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.822 1.432 . . . . 0.0 110.615 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -131.75 97.86 0.36 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.82 91.03 1.32 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.77 145.93 41.95 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.912 1.48 . . . . 0.0 110.746 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.0 mt -115.46 158.23 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.502 -0.749 . . . . 0.0 110.08 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.52 136.05 7.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -76.28 -159.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.993 1.522 . . . . 0.0 110.615 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -69.36 79.36 0.38 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.414 -0.804 . . . . 0.0 110.228 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -159.49 42.94 0.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.393 -0.817 . . . . 0.0 110.49 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -160.23 42.31 0.44 Allowed Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 43.3 t -174.31 95.43 0.31 Allowed Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.478 -1.013 . . . . 0.0 110.091 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -67.34 153.06 78.09 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.579 1.305 . . . . 0.0 110.578 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.0 t -76.16 -33.04 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.356 -0.84 . . . . 0.0 110.719 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.428 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.5 OUTLIER -73.17 -13.87 61.25 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.449 -0.782 . . . . 0.0 111.355 -179.859 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.428 ' HB2' ' O ' ' A' ' 35' ' ' SER . 60.1 m 61.95 24.65 14.7 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.536 -0.728 . . . . 0.0 111.428 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -107.93 139.83 41.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.88 23.12 39.74 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.9 pt -135.35 160.32 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.08 -1.247 . . . . 0.0 110.246 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.9 m -81.47 164.54 21.95 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.58 -0.7 . . . . 0.0 110.388 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -58.38 -48.31 81.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.242 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.6 t -60.65 -37.86 82.94 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.692 -0.63 . . . . 0.0 110.181 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -65.92 -44.22 85.79 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.362 -0.836 . . . . 0.0 109.466 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.46 -35.52 70.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.775 -0.578 . . . . 0.0 109.899 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? -69.94 -37.51 75.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.563 -0.711 . . . . 0.0 109.931 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.0 t -64.59 -40.47 95.58 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.664 -0.647 . . . . 0.0 110.706 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.1 t -71.62 -33.38 68.92 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.456 -0.778 . . . . 0.0 111.596 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.5 t -57.63 -44.04 85.26 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 21.3 t -80.33 -24.42 39.91 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 111.087 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.65 -32.15 19.41 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.258 -0.901 . . . . 0.0 111.684 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.1 mt -137.37 2.11 2.46 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.067 -1.021 . . . . 0.0 112.671 -178.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 74.05 22.78 77.46 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.457 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.3 mmp_? -110.65 143.99 40.26 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.22 -1.165 . . . . 0.0 110.833 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 93.4 m 61.84 51.82 3.68 Favored 'General case' 0 N--CA 1.5 2.05 0 CA-C-O 121.949 0.88 . . . . 0.0 109.233 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 43.0 m -96.9 -14.28 21.89 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.882 -0.511 . . . . 0.0 111.872 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -124.97 42.68 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.978 -1.076 . . . . 0.0 111.025 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 52.9 t -106.61 117.43 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.295 -0.878 . . . . 0.0 109.695 179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.33 99.97 0.31 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.89 107.12 18.83 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.406 -1.055 . . . . 0.0 110.176 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.01 142.18 9.35 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -72.56 160.58 32.04 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.43 -1.041 . . . . 0.0 110.516 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.5 t -99.14 179.62 4.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.606 -0.684 . . . . 0.0 110.69 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 CA-C-O 117.937 -1.479 . . . . 0.0 109.549 179.891 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 . . . . . 0 N--CA 1.496 1.837 0 CA-C-O 121.289 0.566 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 28.1 m -77.81 150.69 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.644 -0.66 . . . . 0.0 110.285 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -160.96 170.0 21.45 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.474 -0.766 . . . . 0.0 110.509 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 75.4 mttt -105.82 131.74 52.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.384 -0.823 . . . . 0.0 110.243 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.12 -131.33 1.42 Allowed Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -98.0 105.82 3.19 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -80.14 96.2 6.46 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.388 -1.066 . . . . 0.0 110.299 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 56.34 -90.23 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.855 -0.528 . . . . 0.0 110.851 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -96.01 122.92 57.06 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.004 -1.06 . . . . 0.0 110.131 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.25 127.7 12.98 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.831 1.438 . . . . 0.0 110.583 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.6 pt -134.95 119.53 13.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.507 -0.746 . . . . 0.0 110.423 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.06 90.49 0.97 Allowed 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.869 1.457 . . . . 0.0 110.425 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.51 135.59 90.69 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.419 -0.801 . . . . 0.0 110.471 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.31 130.95 15.77 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 124.083 1.57 . . . . 0.0 110.902 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.17 142.1 26.94 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 O-C-N 123.917 1.482 . . . . 0.0 110.751 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -73.65 82.9 1.62 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.862 1.454 . . . . 0.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -80.5 154.8 27.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.281 -0.887 . . . . 0.0 110.647 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -83.78 150.33 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.63 -0.669 . . . . 0.0 110.081 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.4 ttp85 -70.66 131.54 87.82 Favored Pre-proline 0 N--CA 1.497 1.904 0 O-C-N 121.539 -0.725 . . . . 0.0 110.027 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.68 126.93 12.52 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.869 1.457 . . . . 0.0 110.925 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.414 ' HG ' ' HD2' ' A' ' 22' ' ' PRO . 7.1 tt -91.63 131.31 36.25 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.674 -0.641 . . . . 0.0 110.373 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' HG ' ' A' ' 21' ' ' LEU . 44.5 Cg_endo -72.24 105.43 1.85 Allowed 'Trans proline' 0 C--N 1.314 -1.253 0 O-C-N 123.911 1.479 . . . . 0.0 110.447 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -135.99 -50.82 0.07 OUTLIER Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.68 160.75 35.97 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.36 145.71 43.63 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.897 1.472 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.9 tt -147.06 160.67 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 110.471 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.33 166.14 41.01 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -74.8 -1.37 11.07 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.955 1.503 . . . . 0.0 111.792 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -70.84 80.1 0.63 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.088 -1.008 . . . . 0.0 110.708 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -147.43 46.75 1.13 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.461 -0.775 . . . . 0.0 110.442 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 32' ' ' CYS . . . 165.08 50.48 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 31' ' ' GLY . 51.9 t 178.91 81.01 0.16 Allowed Pre-proline 0 N--CA 1.501 2.078 0 O-C-N 121.566 -0.961 . . . . 0.0 109.978 179.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.46 159.98 49.95 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.761 1.4 . . . . 0.0 111.168 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.1 t -72.3 -29.28 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.41 -0.806 . . . . 0.0 110.748 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -74.09 -6.53 48.16 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.346 -0.846 . . . . 0.0 111.68 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.412 ' HB2' ' O ' ' A' ' 35' ' ' SER . 96.2 m 58.14 28.58 16.66 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.235 -0.916 . . . . 0.0 110.587 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -109.16 155.01 21.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 110.128 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.86 17.9 77.89 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.5 pt -136.47 162.13 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.188 -1.183 . . . . 0.0 110.066 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.6 t -87.92 169.11 12.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.404 -0.81 . . . . 0.0 110.023 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.408 ' O ' ' HB2' ' A' ' 45' ' ' ARG . 60.3 t80 -59.42 -44.66 92.82 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.655 -0.653 . . . . 0.0 109.455 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.0 t -65.47 -39.58 92.12 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.647 -0.658 . . . . 0.0 110.074 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -65.86 -42.24 90.68 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.388 -0.82 . . . . 0.0 109.697 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.59 -39.01 81.12 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.589 -0.695 . . . . 0.0 109.348 178.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.408 ' HB2' ' O ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -64.86 -40.02 94.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.792 -0.567 . . . . 0.0 109.533 178.874 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 t -62.04 -43.95 97.75 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.862 -0.524 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 27.2 t -67.26 -31.2 71.38 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.301 -0.874 . . . . 0.0 111.339 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.4 t -59.73 -41.95 92.07 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.968 -1.083 . . . . 0.0 109.855 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.9 t -84.84 -22.96 29.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.35 -0.844 . . . . 0.0 110.913 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.4 mtp180 -85.44 -33.65 21.86 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.217 -0.927 . . . . 0.0 111.304 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -140.26 8.97 2.27 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.17 -0.956 . . . . 0.0 112.192 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.72 24.95 75.38 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.14 144.41 43.22 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.208 -1.172 . . . . 0.0 110.714 -179.907 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 31.6 m 61.98 48.93 4.89 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 121.942 0.877 . . . . 0.0 109.395 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 18.2 m -89.08 -25.17 22.05 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.863 -0.523 . . . . 0.0 110.914 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -106.21 38.51 2.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.207 -0.933 . . . . 0.0 109.895 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 20.3 t -63.2 124.54 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.564 -0.71 . . . . 0.0 109.838 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.08 164.18 39.71 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 -179.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 5.0 mptt -85.54 76.77 9.99 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.252 -1.146 . . . . 0.0 110.396 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.69 141.09 3.88 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -72.85 153.97 40.81 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 110.159 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.1 t -154.33 -178.28 7.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.505 -0.747 . . . . 0.0 110.852 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.443 0 CA-C-O 117.963 -1.465 . . . . 0.0 109.567 179.928 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.498 1.932 0 CA-C-O 121.308 0.575 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 3' ' ' TYR . 8.0 p -139.58 127.91 26.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.743 -0.598 . . . . 0.0 109.879 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' A' ' 2' ' ' VAL . 57.0 m-85 60.02 174.79 0.09 Allowed 'General case' 0 N--CA 1.505 2.287 0 CA-C-O 121.517 0.675 . . . . 0.0 111.013 -179.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.3 mmtt -109.24 90.62 3.35 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 109.895 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.14 157.2 23.87 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.02 40.22 88.72 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -101.15 125.23 47.75 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.48 -1.012 . . . . 0.0 110.46 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.22 71.06 1.37 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.611 -0.68 . . . . 0.0 110.119 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 18.8 ttp180 48.89 65.14 7.51 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.727 -0.608 . . . . 0.0 110.958 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -82.5 120.68 3.24 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.646 1.34 . . . . 0.0 110.733 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 11.6 mt -127.57 79.17 73.84 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.411 -0.805 . . . . 0.0 109.949 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.32 -164.96 0.3 Allowed 'Trans proline' 0 C--N 1.313 -1.299 0 O-C-N 123.773 1.407 . . . . 0.0 110.723 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.93 153.68 86.81 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.57 -0.706 . . . . 0.0 110.366 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.2 141.42 29.18 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 124.045 1.55 . . . . 0.0 110.67 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.68 137.05 21.97 Favored 'Trans proline' 0 C--N 1.316 -1.155 0 O-C-N 123.879 1.463 . . . . 0.0 110.878 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.33 149.64 31.68 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.862 1.454 . . . . 0.0 110.567 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -77.71 147.02 35.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.572 -0.705 . . . . 0.0 110.155 179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.0 t 60.37 165.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.119 0 CA-C-O 121.562 0.696 . . . . 0.0 110.846 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.6 90.57 8.98 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.154 -0.966 . . . . 0.0 109.939 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.77 177.97 6.95 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 O-C-N 123.802 1.422 . . . . 0.0 110.626 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.416 ' CD2' ' HA ' ' A' ' 25' ' ' PRO . 50.8 mt -122.83 101.57 39.22 Favored Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.601 -0.687 . . . . 0.0 110.105 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.35 111.53 3.31 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.858 1.452 . . . . 0.0 111.023 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.53 50.02 16.96 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.41 174.05 48.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.416 ' HA ' ' CD2' ' A' ' 21' ' ' LEU . 44.2 Cg_endo -70.25 129.15 16.6 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 O-C-N 123.973 1.512 . . . . 0.0 110.575 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mt -57.45 141.56 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.571 -0.705 . . . . 0.0 109.949 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.07 132.65 5.44 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.95 -26.93 18.08 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.874 1.46 . . . . 0.0 111.291 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -80.26 65.61 5.47 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.287 -0.883 . . . . 0.0 110.352 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -133.09 40.06 3.24 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.291 -0.881 . . . . 0.0 110.798 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.57 45.0 0.06 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 120.089 -1.053 . . . . 0.0 110.623 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 51.0 t -172.4 78.67 0.45 Allowed Pre-proline 0 N--CA 1.497 1.904 0 O-C-N 121.281 -1.129 . . . . 0.0 110.467 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -68.78 145.38 62.67 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.931 1.49 . . . . 0.0 110.574 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 69.9 t -62.09 -30.84 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.147 0 O-C-N 121.478 -0.764 . . . . 0.0 110.63 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.426 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 7.6 t -68.47 -10.23 54.07 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.446 -0.784 . . . . 0.0 111.307 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.426 ' HB2' ' O ' ' A' ' 35' ' ' SER . 73.4 m 59.36 27.49 16.59 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.355 -0.84 . . . . 0.0 110.996 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -108.59 150.63 27.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.394 -0.816 . . . . 0.0 110.028 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.55 24.09 71.3 Favored Glycine 0 N--CA 1.496 2.645 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.9 pt -134.06 157.41 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.049 -1.265 . . . . 0.0 110.278 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.09 162.11 23.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.654 -0.654 . . . . 0.0 109.474 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 87.2 t80 -57.04 -49.74 74.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.399 -0.813 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -64.38 -33.12 75.11 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.589 -0.695 . . . . 0.0 110.146 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -65.6 -43.13 90.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.316 -0.865 . . . . 0.0 109.482 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.86 -36.26 75.37 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.636 . . . . 0.0 109.853 179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.3 ttt180 -67.47 -40.16 85.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.67 -0.644 . . . . 0.0 110.149 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.3 t -66.07 -36.88 84.38 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.609 -0.682 . . . . 0.0 110.794 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 19.1 t -72.61 -31.32 65.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.25 -0.906 . . . . 0.0 111.325 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 29.9 t -58.9 -42.95 90.82 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.141 -0.974 . . . . 0.0 110.078 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.8 t -84.86 -24.45 28.54 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.396 -0.815 . . . . 0.0 110.948 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -83.29 -32.13 26.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.217 -0.927 . . . . 0.0 111.475 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.82 12.67 1.87 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.176 -0.952 . . . . 0.0 112.208 -179.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.29 31.05 79.42 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.466 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.7 mmt180 -118.42 139.88 50.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.389 -1.065 . . . . 0.0 110.458 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 10.5 m 62.46 55.14 2.33 Favored 'General case' 0 N--CA 1.498 1.951 0 CA-C-O 121.999 0.904 . . . . 0.0 109.327 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 19.1 m -96.3 -16.43 21.34 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.43 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -112.8 42.36 1.88 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.1 -1.0 . . . . 0.0 110.189 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 74.0 t -83.01 121.43 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.384 -0.823 . . . . 0.0 109.954 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.0 134.12 5.44 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 8.4 tttm 62.58 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 O-C-N 121.88 -0.776 . . . . 0.0 110.262 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.6 -176.12 41.15 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -76.43 160.9 29.12 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.4 -1.059 . . . . 0.0 110.516 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.4 m -64.78 154.2 37.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.514 -0.741 . . . . 0.0 110.619 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 117.905 -1.497 . . . . 0.0 109.478 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.4 mp0 . . . . . 0 N--CA 1.497 1.9 0 CA-C-O 121.18 0.514 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.8 t 52.68 73.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 CA-C-O 121.157 0.503 . . . . 0.0 110.222 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 2.3 t80 68.23 144.0 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.165 0 CA-C-O 121.238 0.542 . . . . 0.0 110.56 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 56.77 81.18 0.14 Allowed 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.57 -0.706 . . . . 0.0 110.707 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -161.98 124.98 1.36 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.09 77.45 2.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -136.24 107.15 6.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.474 -1.015 . . . . 0.0 110.053 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -71.44 -54.18 11.53 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.522 -0.736 . . . . 0.0 110.286 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.86 75.49 48.81 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 110.106 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.65 87.34 1.12 Allowed 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.846 1.445 . . . . 0.0 110.152 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.6 mm 57.04 75.94 0.53 Allowed Pre-proline 0 N--CA 1.501 2.085 0 O-C-N 121.719 -0.613 . . . . 0.0 110.119 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.07 80.18 1.9 Allowed 'Trans proline' 0 C--N 1.316 -1.17 0 O-C-N 123.771 1.406 . . . . 0.0 110.775 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.32 154.05 27.83 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.737 . . . . 0.0 109.982 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.29 132.7 21.37 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.845 1.445 . . . . 0.0 110.746 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.7 143.71 30.5 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 O-C-N 123.928 1.489 . . . . 0.0 110.762 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.66 175.71 10.94 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.864 1.455 . . . . 0.0 110.901 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -78.61 162.88 25.94 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.55 -0.719 . . . . 0.0 110.587 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -81.56 152.75 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.797 -0.564 . . . . 0.0 110.179 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -68.4 130.94 91.92 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.527 -0.733 . . . . 0.0 110.05 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -71.13 -178.67 2.99 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 O-C-N 123.97 1.511 . . . . 0.0 110.67 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.44 ' HB3' ' HD2' ' A' ' 22' ' ' PRO . 35.2 mt -125.86 165.79 25.08 Favored Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.516 -0.74 . . . . 0.0 110.258 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' HB3' ' A' ' 21' ' ' LEU . 43.6 Cg_endo -69.94 118.97 5.99 Favored 'Trans proline' 0 C--N 1.315 -1.226 0 O-C-N 123.747 1.393 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.24 -96.97 1.84 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.83 88.11 0.39 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.28 129.39 13.91 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.96 1.505 . . . . 0.0 110.448 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.404 HG23 HD12 ' A' ' 26' ' ' ILE . 23.1 mm -127.82 158.02 39.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.462 -0.774 . . . . 0.0 110.372 -179.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.99 84.84 1.35 Allowed Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.04 -169.74 0.61 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.967 1.509 . . . . 0.0 110.731 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -79.85 65.91 5.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.359 -0.838 . . . . 0.0 109.971 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 16.9 m-80 -133.06 40.72 3.19 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.519 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.18 44.58 0.06 OUTLIER Glycine 0 N--CA 1.493 2.485 0 C-N-CA 120.095 -1.05 . . . . 0.0 110.611 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.4 t -175.01 81.74 0.32 Allowed Pre-proline 0 N--CA 1.5 2.055 0 O-C-N 121.289 -1.124 . . . . 0.0 110.356 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.94 144.23 57.69 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 O-C-N 123.907 1.478 . . . . 0.0 110.817 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 t -61.39 -29.4 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.521 -0.737 . . . . 0.0 110.522 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.437 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.1 t -69.63 -8.05 44.22 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.434 -0.792 . . . . 0.0 111.147 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 35' ' ' SER . 81.6 m 59.14 25.22 13.68 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.353 -0.842 . . . . 0.0 111.255 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -112.39 158.05 20.29 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.288 -0.883 . . . . 0.0 110.012 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.16 22.08 76.95 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.1 pt -135.47 153.59 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.142 -1.211 . . . . 0.0 110.274 179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.2 t -80.3 169.25 18.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.632 -0.667 . . . . 0.0 109.952 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -60.31 -48.86 79.93 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.568 -0.708 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.2 t -61.83 -36.44 81.17 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.666 -0.647 . . . . 0.0 110.192 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -64.62 -44.8 89.39 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.565 -0.709 . . . . 0.0 109.886 179.51 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.6 -33.99 76.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.803 -0.561 . . . . 0.0 110.395 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.22 -39.57 78.49 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.466 -0.771 . . . . 0.0 110.122 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 t -64.95 -40.44 95.02 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.658 -0.652 . . . . 0.0 110.951 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.4 t -71.62 -32.03 67.54 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.282 -0.886 . . . . 0.0 111.443 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 33.1 t -58.64 -42.9 89.38 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.126 -0.984 . . . . 0.0 110.363 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 32.3 t -84.24 -25.98 29.02 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.352 -0.843 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -84.26 -31.96 24.7 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.286 -0.884 . . . . 0.0 111.453 -179.394 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.4 mt -138.87 6.55 2.43 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 112.556 -178.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.02 28.32 73.75 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.489 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 6.9 mmt-85 -115.6 139.92 49.65 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.213 -1.169 . . . . 0.0 110.638 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.489 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 80.5 m 62.46 57.27 1.92 Allowed 'General case' 0 N--CA 1.499 2.003 0 CA-C-O 121.939 0.876 . . . . 0.0 109.42 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 34.9 m -100.12 -6.21 26.63 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.749 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -128.18 46.43 2.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.065 . . . . 0.0 110.517 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 94.8 t -92.68 115.85 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.261 -0.9 . . . . 0.0 110.09 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.32 118.04 1.91 Allowed Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.81 116.47 17.99 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.439 -1.036 . . . . 0.0 110.346 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.23 -178.05 43.03 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -77.26 163.47 26.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.391 -1.064 . . . . 0.0 110.465 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.8 m -76.44 163.58 26.81 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.498 -0.751 . . . . 0.0 110.444 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.925 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 . . . . . 0 N--CA 1.497 1.884 0 CA-C-O 121.336 0.589 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.97 104.06 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.614 -0.679 . . . . 0.0 109.79 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -147.67 143.41 27.63 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.512 -0.743 . . . . 0.0 110.357 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 23.8 tttm -156.82 134.88 11.13 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.464 -0.772 . . . . 0.0 110.406 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.1 -164.19 33.66 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -101.37 -73.13 1.0 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 3.5 t80 -105.0 127.49 52.89 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.532 -0.981 . . . . 0.0 110.247 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -159.1 79.65 0.76 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.469 -0.769 . . . . 0.0 110.367 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.43 105.49 47.12 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.348 -0.845 . . . . 0.0 110.029 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.401 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.2 Cg_endo -71.71 134.86 24.8 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 O-C-N 123.843 1.444 . . . . 0.0 110.759 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.401 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 51.3 mt 60.04 99.61 0.04 OUTLIER Pre-proline 0 N--CA 1.503 2.223 0 O-C-N 121.94 -0.475 . . . . 0.0 110.732 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.79 -160.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.659 1.347 . . . . 0.0 110.299 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.78 115.84 21.93 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.475 -0.766 . . . . 0.0 110.095 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.55 158.93 50.1 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.888 1.467 . . . . 0.0 110.624 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.32 150.04 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.93 1.49 . . . . 0.0 110.618 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.92 169.92 21.55 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 O-C-N 123.791 1.416 . . . . 0.0 110.591 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -160.41 160.06 31.77 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.62 -0.675 . . . . 0.0 110.489 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.6 t -74.39 140.15 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.566 -0.709 . . . . 0.0 110.045 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.54 100.21 52.71 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.414 -0.803 . . . . 0.0 110.096 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.05 177.05 8.26 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.774 1.408 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 2.0 pp -88.37 150.47 46.84 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.449 -0.782 . . . . 0.0 110.496 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.15 136.2 19.78 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.847 1.446 . . . . 0.0 110.472 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.64 -103.19 0.63 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.32 163.89 39.4 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.32 151.13 53.88 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.857 1.451 . . . . 0.0 110.69 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 18.5 mm -125.26 153.48 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.19 80.32 0.5 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -75.98 -42.16 0.44 Allowed 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.916 1.482 . . . . 0.0 111.071 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -82.61 70.4 9.57 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.24 -0.912 . . . . 0.0 110.234 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -144.98 43.44 1.33 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.374 -0.829 . . . . 0.0 110.565 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -177.85 46.37 0.1 OUTLIER Glycine 0 N--CA 1.494 2.539 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.1 t -168.87 91.01 0.6 Allowed Pre-proline 0 N--CA 1.498 1.941 0 O-C-N 121.326 -1.102 . . . . 0.0 110.331 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.33 139.77 32.51 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 O-C-N 123.762 1.401 . . . . 0.0 110.608 179.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.35 -27.4 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.302 -0.874 . . . . 0.0 110.399 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.431 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -67.18 -18.39 65.25 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.429 -0.795 . . . . 0.0 110.78 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 35' ' ' SER . 95.5 m 58.99 26.27 14.86 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.549 -0.719 . . . . 0.0 111.178 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -108.95 144.57 36.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.261 -0.9 . . . . 0.0 110.046 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.27 34.27 64.23 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.416 HD13 ' HA ' ' A' ' 36' ' ' CYS . 23.3 pt -125.78 155.15 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.2 -1.176 . . . . 0.0 110.123 179.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.84 159.27 21.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.668 -0.645 . . . . 0.0 109.475 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -57.66 -42.47 83.57 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.424 -0.797 . . . . 0.0 109.641 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.2 t -67.32 -34.45 77.38 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.583 -0.698 . . . . 0.0 109.95 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.39 -41.35 89.5 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.473 -0.767 . . . . 0.0 109.69 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.23 -27.5 60.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.748 -0.595 . . . . 0.0 110.34 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -35.96 61.01 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.53 -0.731 . . . . 0.0 110.389 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -70.88 -40.62 72.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.448 -0.783 . . . . 0.0 111.09 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.7 t -73.55 -30.44 63.07 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.237 -0.914 . . . . 0.0 111.299 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.4 -42.63 92.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.126 -0.984 . . . . 0.0 110.579 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 33.1 t -82.92 -25.28 32.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.816 . . . . 0.0 111.587 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.9 mmm180 -92.28 -27.02 17.87 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.215 -0.928 . . . . 0.0 111.636 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 mt -137.31 2.95 2.56 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.071 -1.018 . . . . 0.0 112.509 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.64 28.28 73.46 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.416 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.8 OUTLIER -118.04 143.19 46.63 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.26 -1.141 . . . . 0.0 110.415 -179.647 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 1.3 m 62.39 52.87 2.91 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.001 0.905 . . . . 0.0 109.097 -179.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 50.4 m -97.85 -3.71 38.19 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.339 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 35.8 t-80 -122.67 45.35 2.4 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.167 -0.958 . . . . 0.0 109.88 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 17.0 t -92.76 112.16 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.373 -0.83 . . . . 0.0 110.194 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.39 88.72 0.54 Allowed Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -158.9 139.68 12.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.514 -0.992 . . . . 0.0 110.643 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.53 125.32 1.81 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 t80 -79.33 163.94 24.47 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.476 -1.014 . . . . 0.0 110.301 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.0 m -77.97 166.29 23.03 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.604 -0.685 . . . . 0.0 110.381 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 CA-C-O 117.985 -1.453 . . . . 0.0 109.535 179.906 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.477 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 5.7 pm0 . . . . . 0 N--CA 1.497 1.904 0 CA-C-O 121.016 0.436 . . . . 0.0 110.648 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.477 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 46.9 t 65.8 144.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.308 0.575 . . . . 0.0 110.698 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 62.49 174.3 0.14 Allowed 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.473 -0.767 . . . . 0.0 110.75 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.4 pttm -86.09 129.06 34.96 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.317 -0.864 . . . . 0.0 110.312 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.42 -165.81 37.5 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -79.46 102.76 2.0 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -63.13 119.43 9.53 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.615 -0.932 . . . . 0.0 109.859 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 52.39 47.36 24.89 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.373 0.606 . . . . 0.0 110.178 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.7 ttt-85 -120.55 142.18 33.61 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.418 -0.801 . . . . 0.0 110.327 -179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -72.66 89.16 0.86 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 O-C-N 123.909 1.478 . . . . 0.0 110.309 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.1 pt -77.98 149.3 76.65 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.476 -0.765 . . . . 0.0 110.373 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.86 88.92 0.89 Allowed 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 124.063 1.559 . . . . 0.0 110.499 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 3.9 mtm105 -73.86 131.94 80.99 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.515 -0.74 . . . . 0.0 110.445 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.94 128.83 13.56 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 124.008 1.53 . . . . 0.0 110.755 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.2 129.22 11.97 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.794 1.418 . . . . 0.0 110.77 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -74.26 97.43 1.02 Allowed 'Trans proline' 0 C--N 1.316 -1.158 0 O-C-N 123.796 1.419 . . . . 0.0 110.52 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -154.11 152.71 30.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.325 -0.86 . . . . 0.0 110.545 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.4 t -82.55 145.27 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.676 -0.64 . . . . 0.0 109.701 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 -63.89 112.45 7.41 Favored Pre-proline 0 N--CA 1.497 1.896 0 O-C-N 121.575 -0.703 . . . . 0.0 110.417 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -78.01 -173.37 1.8 Allowed 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.836 1.44 . . . . 0.0 110.512 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.16 76.34 57.78 Favored Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.453 -0.779 . . . . 0.0 110.034 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.93 126.73 10.2 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 123.85 1.448 . . . . 0.0 110.74 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -127.18 -111.96 1.72 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.2 164.13 39.07 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.5 151.31 52.98 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.867 1.457 . . . . 0.0 110.684 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.6 tt -84.3 151.01 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.415 -0.803 . . . . 0.0 110.373 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.11 84.3 0.49 Allowed Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -74.48 -51.59 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.967 1.509 . . . . 0.0 111.042 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -110.97 45.05 1.2 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.171 -0.956 . . . . 0.0 110.095 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -131.08 34.81 3.99 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.519 -0.738 . . . . 0.0 110.569 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.83 38.7 0.75 Allowed Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.434 ' SG ' ' HB3' ' A' ' 53' ' ' ARG . 2.2 t -173.08 87.86 0.39 Allowed Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.597 -0.943 . . . . 0.0 110.183 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.89 139.83 44.39 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 124.007 1.53 . . . . 0.0 110.839 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.4 t -65.0 -28.79 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.535 -0.728 . . . . 0.0 110.429 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.441 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.2 t -67.12 -21.38 65.84 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.484 -0.76 . . . . 0.0 110.896 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 35' ' ' SER . 74.1 m 59.62 28.68 18.16 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.557 -0.715 . . . . 0.0 110.892 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -104.41 146.09 29.34 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.271 -0.893 . . . . 0.0 110.273 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.99 26.69 43.88 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.8 pt -137.01 160.0 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.221 -1.164 . . . . 0.0 110.259 179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.8 m -85.53 168.27 14.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.556 -0.715 . . . . 0.0 110.06 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.65 -45.27 94.73 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.598 -0.689 . . . . 0.0 109.376 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.1 t -65.42 -38.53 90.19 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.611 -0.681 . . . . 0.0 110.026 179.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -63.25 -43.04 99.12 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.809 . . . . 0.0 109.71 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.98 -38.48 86.12 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.685 -0.634 . . . . 0.0 109.846 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.96 -38.27 85.8 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-O 121.551 0.691 . . . . 0.0 109.69 178.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 t -62.79 -40.94 98.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.726 -0.609 . . . . 0.0 111.598 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.0 t -76.83 -28.42 55.51 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.997 -1.064 . . . . 0.0 111.599 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.4 t -59.28 -41.14 88.21 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.068 -1.02 . . . . 0.0 109.606 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.7 t -86.81 -24.32 25.06 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 3.1 tmm_? -77.94 -36.7 48.99 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.364 -0.835 . . . . 0.0 111.066 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -144.07 16.97 1.74 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.231 -0.918 . . . . 0.0 111.946 -179.284 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.89 33.42 83.38 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.434 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 5.9 mmt-85 -119.6 144.27 47.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.418 -1.048 . . . . 0.0 110.598 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.7 m 60.2 54.7 3.93 Favored 'General case' 0 N--CA 1.498 1.965 0 CA-C-O 122.019 0.914 . . . . 0.0 109.095 -179.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.3 m -97.29 -17.15 19.96 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.399 -179.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -110.17 41.79 1.67 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.113 -0.992 . . . . 0.0 110.076 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 47.4 t -80.14 118.9 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.383 -0.823 . . . . 0.0 110.409 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.73 97.73 0.37 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -157.5 155.59 30.58 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.457 -1.025 . . . . 0.0 110.437 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.04 127.75 3.45 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.6 t80 -79.49 167.63 20.54 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.525 -0.985 . . . . 0.0 110.561 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 p -80.48 168.82 18.49 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.571 -0.706 . . . . 0.0 110.42 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.446 0 CA-C-O 118.034 -1.426 . . . . 0.0 109.732 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 35.4 mt-30 . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.301 0.572 . . . . 0.0 110.329 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.4 p -77.72 145.85 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.5 -0.75 . . . . 0.0 110.213 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -110.36 107.08 16.68 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.508 -0.745 . . . . 0.0 110.033 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.14 156.8 42.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.526 -0.734 . . . . 0.0 110.241 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.26 -73.65 0.05 OUTLIER Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 102.38 150.66 23.08 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -76.28 93.38 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.502 -0.999 . . . . 0.0 110.285 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -68.51 -32.82 73.05 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.522 -0.737 . . . . 0.0 110.796 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.98 118.14 55.53 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.387 -0.82 . . . . 0.0 110.267 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.92 128.56 11.65 Favored 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.855 1.45 . . . . 0.0 110.756 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.401 HG23 ' HB3' ' A' ' 14' ' ' PRO . 48.2 mt -86.23 115.0 60.34 Favored Pre-proline 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.824 . . . . 0.0 110.106 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.68 83.63 1.07 Allowed 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 123.924 1.486 . . . . 0.0 110.739 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.1 tpm_? 59.1 91.9 0.07 OUTLIER Pre-proline 0 N--CA 1.503 2.218 0 O-C-N 121.802 -0.561 . . . . 0.0 111.056 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.401 ' HB3' HG23 ' A' ' 11' ' ' ILE . 46.5 Cg_endo -74.45 127.96 11.53 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.857 1.451 . . . . 0.0 110.686 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.43 126.05 8.79 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.871 1.458 . . . . 0.0 110.595 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.505 ' O ' ' HB3' ' A' ' 17' ' ' PHE . 47.1 Cg_endo -73.1 95.77 0.85 Allowed 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.865 1.455 . . . . 0.0 110.707 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.505 ' HB3' ' O ' ' A' ' 16' ' ' PRO . 75.6 t80 63.22 151.04 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.256 0 CA-C-O 121.703 0.763 . . . . 0.0 111.433 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -114.65 136.16 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.346 -0.846 . . . . 0.0 109.955 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -111.09 121.43 40.65 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.499 -0.751 . . . . 0.0 110.417 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -73.17 -173.46 1.28 Allowed 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.916 1.482 . . . . 0.0 110.668 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -108.95 94.88 15.63 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.429 -0.794 . . . . 0.0 110.259 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.66 95.76 0.97 Allowed 'Trans proline' 0 C--N 1.315 -1.22 0 O-C-N 123.846 1.445 . . . . 0.0 110.509 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.36 60.55 0.28 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 147.08 16.02 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -73.49 157.98 48.38 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.759 1.4 . . . . 0.0 110.542 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.3 mm -123.57 153.04 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.374 -0.829 . . . . 0.0 110.383 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.39 75.52 0.5 Allowed Glycine 0 N--CA 1.495 2.615 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -79.71 -38.26 0.39 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.862 1.453 . . . . 0.0 111.014 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -83.55 70.99 10.36 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.382 -0.824 . . . . 0.0 110.182 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -136.14 45.61 2.36 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 164.65 49.42 0.02 OUTLIER Glycine 0 N--CA 1.492 2.415 0 C-N-CA 119.866 -1.159 . . . . 0.0 110.662 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.3 t -172.79 96.7 0.36 Allowed Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 121.32 -1.106 . . . . 0.0 110.542 179.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -69.02 160.34 50.3 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 123.852 1.448 . . . . 0.0 111.621 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 54.3 t -79.85 -36.29 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.967 0 O-C-N 121.507 -0.746 . . . . 0.0 110.487 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.419 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -68.8 -15.02 63.39 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.541 -0.724 . . . . 0.0 111.383 -179.606 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 35' ' ' SER . 33.0 m 57.8 27.97 15.27 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.4 -0.812 . . . . 0.0 110.84 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 7.4 mtt-85 -111.09 149.94 30.1 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.354 -0.841 . . . . 0.0 109.982 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.01 34.18 43.03 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.6 pt -129.77 154.15 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.135 . . . . 0.0 110.177 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 m -83.83 161.47 20.9 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.599 -0.688 . . . . 0.0 109.741 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.92 -41.39 82.58 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.432 -0.793 . . . . 0.0 109.574 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -67.97 -36.44 80.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 0.0 110.093 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -67.43 -40.19 85.47 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.429 -0.794 . . . . 0.0 109.911 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.92 -34.52 73.6 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 0.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.6 ttp180 -70.12 -31.3 68.79 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.434 -0.791 . . . . 0.0 110.232 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.0 t -71.35 -44.24 65.41 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.542 -0.724 . . . . 0.0 111.314 -179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.7 t -75.41 -29.18 59.68 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.19 -0.944 . . . . 0.0 111.467 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.5 t -62.25 -42.67 99.54 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.165 -0.959 . . . . 0.0 110.078 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 10.2 t -84.97 -25.12 27.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.329 -0.857 . . . . 0.0 110.685 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 -81.7 -33.71 31.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.414 -0.804 . . . . 0.0 111.312 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -142.12 9.57 1.9 Allowed 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.167 -0.958 . . . . 0.0 112.328 -179.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 66.99 27.72 73.53 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.464 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -115.73 144.82 43.42 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.172 -1.193 . . . . 0.0 110.812 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 44.9 m 62.08 51.78 3.5 Favored 'General case' 0 N--CA 1.499 1.985 0 CA-C-O 122.013 0.911 . . . . 0.0 109.438 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.36 -4.53 38.29 Favored 'General case' 0 N--CA 1.487 1.395 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.317 -179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.3 t-160 -126.02 47.74 2.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.048 -1.032 . . . . 0.0 109.944 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 64.2 t -90.68 144.7 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.511 -0.743 . . . . 0.0 110.379 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.33 139.01 7.6 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.971 -1.251 . . . . 0.0 109.971 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.6 106.86 3.64 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -1.043 . . . . 0.0 110.513 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.7 177.04 39.85 Favored Glycine 0 N--CA 1.494 2.554 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.419 ' O ' ' HB2' ' A' ' 62' ' ' SER . 39.6 t80 -74.69 153.16 39.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.378 -1.072 . . . . 0.0 110.331 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 61' ' ' TYR . 69.2 m 59.11 178.57 0.08 Allowed 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.554 0.693 . . . . 0.0 111.045 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.416 0 CA-C-O 118.003 -1.443 . . . . 0.0 109.528 -179.709 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.7 mm100 . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 121.35 0.595 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.0 t -84.89 130.86 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.543 -0.723 . . . . 0.0 109.877 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -110.23 108.73 18.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.372 -0.83 . . . . 0.0 110.329 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -132.85 81.38 1.94 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.501 -0.749 . . . . 0.0 109.935 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 74.15 -95.74 0.86 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 169.75 -77.82 0.1 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -94.71 94.06 7.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.546 -0.973 . . . . 0.0 109.796 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -155.32 -178.55 7.34 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.529 -0.732 . . . . 0.0 110.422 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.4 157.37 65.13 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.471 -0.768 . . . . 0.0 110.219 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 125.42 9.99 Favored 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.879 1.463 . . . . 0.0 110.659 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 13.7 tt -90.18 117.76 68.3 Favored Pre-proline 0 N--CA 1.494 1.773 0 O-C-N 121.379 -0.826 . . . . 0.0 110.513 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.55 74.29 3.81 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 123.85 1.447 . . . . 0.0 110.526 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.63 137.56 47.76 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.409 -0.807 . . . . 0.0 110.4 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.14 155.56 56.55 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 124.062 1.559 . . . . 0.0 110.776 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.6 120.9 6.99 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 O-C-N 123.878 1.462 . . . . 0.0 110.515 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -75.96 -171.88 1.19 Allowed 'Trans proline' 0 C--N 1.316 -1.18 0 O-C-N 123.858 1.452 . . . . 0.0 110.786 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -66.26 158.77 28.08 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.581 -0.699 . . . . 0.0 110.752 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -72.54 130.24 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.573 -0.704 . . . . 0.0 110.093 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.0 tpp180 -94.32 122.45 61.31 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.701 -0.624 . . . . 0.0 110.527 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.18 -172.38 1.13 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.96 1.505 . . . . 0.0 110.891 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.38 153.54 95.75 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.478 -0.764 . . . . 0.0 110.504 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.52 127.62 13.45 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.922 1.485 . . . . 0.0 110.58 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 154.79 -108.19 0.35 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.97 87.41 0.56 Allowed Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -73.49 140.03 29.41 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.879 1.463 . . . . 0.0 110.647 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.8 mp -121.24 163.06 19.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.487 -0.758 . . . . 0.0 110.173 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.29 171.33 39.74 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.89 -10.63 28.03 Favored 'Trans proline' 0 N--CA 1.491 1.372 0 O-C-N 124.12 1.59 . . . . 0.0 111.812 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.4 t80 -74.1 71.21 1.62 Allowed 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.117 -0.989 . . . . 0.0 110.371 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.96 43.72 0.15 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.312 -0.868 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.98 44.12 0.46 Allowed Glycine 0 N--CA 1.496 2.638 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 40.0 t -172.76 112.51 0.36 Allowed Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.423 -1.045 . . . . 0.0 110.227 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.54 150.01 50.62 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.579 1.305 . . . . 0.0 110.528 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.2 t -79.83 -28.06 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.325 -0.859 . . . . 0.0 110.466 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -74.19 -11.8 60.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.228 -0.92 . . . . 0.0 111.179 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.8 m 58.27 25.69 12.99 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.399 -0.813 . . . . 0.0 111.006 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.8 mmt-85 -110.58 156.09 21.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.352 -0.843 . . . . 0.0 109.943 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.97 30.57 69.99 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.5 pt -131.69 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.266 -1.138 . . . . 0.0 109.981 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.404 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 1.6 m -82.27 158.52 23.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.715 -0.616 . . . . 0.0 109.446 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -56.62 -44.39 81.16 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.405 -0.809 . . . . 0.0 109.732 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.6 t -68.14 -35.74 78.58 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.598 -0.689 . . . . 0.0 109.971 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.404 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.0 OUTLIER -64.29 -41.92 96.63 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.638 -0.664 . . . . 0.0 109.925 179.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.82 83.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.576 -0.703 . . . . 0.0 109.993 179.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.8 mtm180 -65.62 -40.77 92.94 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.656 -0.653 . . . . 0.0 110.062 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.04 -45.12 96.08 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.832 -0.543 . . . . 0.0 111.363 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 51.8 t -68.56 -33.37 73.96 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.163 -0.961 . . . . 0.0 111.11 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.9 t -60.29 -41.86 94.27 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.167 -0.958 . . . . 0.0 110.465 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 23.0 t -83.43 -22.47 32.65 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.372 -0.83 . . . . 0.0 111.538 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -95.55 -26.68 15.69 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.032 -1.043 . . . . 0.0 111.584 -179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.1 mt -135.84 1.76 2.81 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.166 -0.959 . . . . 0.0 112.478 -178.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.79 26.94 73.7 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.532 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.78 146.31 42.93 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.304 -1.115 . . . . 0.0 110.418 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 92.6 m 60.76 53.52 3.9 Favored 'General case' 0 N--CA 1.499 1.978 0 CA-C-O 121.885 0.85 . . . . 0.0 109.136 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 53.6 m -100.15 -4.06 30.44 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.551 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -127.39 45.89 2.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.04 -1.038 . . . . 0.0 110.288 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 60.1 t -90.09 145.02 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.315 -0.866 . . . . 0.0 110.317 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.38 81.91 1.09 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.3 tttp -166.8 120.84 1.05 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.706 -0.879 . . . . 0.0 110.293 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.7 135.22 6.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.5 t80 -70.52 155.29 40.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.311 -1.111 . . . . 0.0 110.362 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 p -130.26 164.24 25.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.578 -0.701 . . . . 0.0 110.682 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 CA-C-O 117.989 -1.45 . . . . 0.0 109.569 179.866 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.28 0.562 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.86 115.51 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.537 -0.727 . . . . 0.0 110.002 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -80.63 143.38 33.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.417 -0.802 . . . . 0.0 110.299 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.95 133.01 38.12 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.579 -0.701 . . . . 0.0 110.606 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.97 -56.7 1.0 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.425 ' O ' ' HB3' ' A' ' 7' ' ' TYR . . . 179.41 -63.93 0.08 OUTLIER Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.425 ' HB3' ' O ' ' A' ' 6' ' ' GLY . 70.1 t80 63.06 104.23 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 O-C-N 122.01 -0.7 . . . . 0.0 111.011 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -82.66 -171.71 3.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.266 -0.896 . . . . 0.0 110.197 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.0 126.33 89.43 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.347 -0.846 . . . . 0.0 110.409 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.19 121.75 7.48 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 O-C-N 123.907 1.477 . . . . 0.0 110.886 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.41 127.18 67.05 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.447 -0.783 . . . . 0.0 110.524 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -73.96 62.92 4.97 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.813 1.428 . . . . 0.0 110.549 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -163.9 72.74 1.76 Allowed Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.339 -0.851 . . . . 0.0 109.943 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.89 156.95 47.88 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.86 1.453 . . . . 0.0 110.867 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.18 143.08 28.08 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.993 1.522 . . . . 0.0 110.622 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -74.02 84.36 1.5 Allowed 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.868 1.457 . . . . 0.0 110.316 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -146.37 153.57 40.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.45 -0.781 . . . . 0.0 110.397 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.05 143.0 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.634 -0.666 . . . . 0.0 109.988 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -107.77 120.59 46.72 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 110.296 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.26 172.16 16.17 Favored 'Trans proline' 0 C--N 1.314 -1.241 0 O-C-N 123.876 1.461 . . . . 0.0 110.544 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -134.25 121.59 15.57 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.638 -0.664 . . . . 0.0 110.063 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -70.51 116.39 4.62 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.808 1.425 . . . . 0.0 110.494 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.38 -68.57 0.3 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.57 158.66 34.58 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.58 144.46 35.84 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.575 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 13.4 mm -71.19 150.42 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.413 -0.805 . . . . 0.0 110.176 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.17 74.77 0.42 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -76.31 -47.85 0.15 Allowed 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.933 1.491 . . . . 0.0 110.622 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -84.49 64.52 8.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.85 . . . . 0.0 109.525 179.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -155.44 41.51 0.42 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.356 -0.84 . . . . 0.0 110.586 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.01 41.57 0.76 Allowed Glycine 0 N--CA 1.496 2.646 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.6 t -172.64 106.07 0.34 Allowed Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.456 -1.026 . . . . 0.0 110.048 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.1 139.8 36.4 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.609 1.321 . . . . 0.0 110.577 179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -69.14 -26.24 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 O-C-N 121.437 -0.789 . . . . 0.0 110.859 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.36 -11.13 59.99 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.15 -0.969 . . . . 0.0 111.411 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 79.7 m 57.44 26.79 13.02 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.391 -0.818 . . . . 0.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -108.45 150.32 27.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.304 -0.872 . . . . 0.0 110.565 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.86 28.23 65.28 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 23.9 pt -132.48 158.29 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.178 -1.189 . . . . 0.0 110.114 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.32 161.08 25.25 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.636 . . . . 0.0 109.684 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.25 -48.46 78.8 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.439 -0.788 . . . . 0.0 109.8 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.01 -33.91 76.88 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.605 -0.685 . . . . 0.0 110.094 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -63.64 -43.87 95.54 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.486 -0.759 . . . . 0.0 109.678 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.01 -36.14 79.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.638 -0.664 . . . . 0.0 109.545 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -64.53 -40.01 94.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.701 -0.624 . . . . 0.0 110.225 179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.9 t -62.91 -44.91 94.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.627 -0.67 . . . . 0.0 111.041 -179.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.525 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 41.4 t -65.71 -34.05 77.3 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.231 -0.918 . . . . 0.0 110.945 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 40.3 t -59.54 -42.66 92.83 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.144 -0.973 . . . . 0.0 110.572 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -87.84 -26.77 22.63 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.335 -0.853 . . . . 0.0 111.164 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -85.62 -30.67 23.08 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.291 -0.881 . . . . 0.0 111.368 -179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -134.52 4.58 3.39 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.29 -0.881 . . . . 0.0 112.21 -178.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.35 31.27 80.18 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.525 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 5.0 mmp_? -125.81 148.96 48.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.459 -1.024 . . . . 0.0 110.074 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.2 m 61.17 45.84 8.62 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.022 0.915 . . . . 0.0 108.611 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 9.0 m -90.12 -10.14 45.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.808 -0.557 . . . . 0.0 111.325 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -117.75 43.51 2.38 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.21 -0.931 . . . . 0.0 109.861 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 61.4 t -79.63 117.57 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.444 -0.785 . . . . 0.0 110.363 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.34 143.25 10.5 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.79 124.15 2.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.51 -0.994 . . . . 0.0 110.352 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.65 -177.68 43.71 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 47.1 t80 -80.13 159.95 25.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.357 -1.084 . . . . 0.0 110.37 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 61.4 m -77.45 166.79 22.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.473 -0.767 . . . . 0.0 110.563 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.386 0 CA-C-O 118.031 -1.427 . . . . 0.0 109.662 -179.916 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.8 pm0 . . . . . 0 N--CA 1.497 1.907 0 CA-C-O 121.267 0.556 . . . . 0.0 110.646 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.9 p -132.42 149.73 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.704 -0.623 . . . . 0.0 110.329 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -108.95 79.76 1.25 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.442 -0.786 . . . . 0.0 109.826 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.0 107.91 3.55 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.459 -0.776 . . . . 0.0 110.168 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.45 -164.24 34.45 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -166.3 83.94 0.1 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -100.02 146.49 26.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.551 -0.97 . . . . 0.0 110.318 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 50.54 -134.12 1.59 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.735 -0.603 . . . . 0.0 110.486 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.3 122.0 7.3 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.098 -1.001 . . . . 0.0 110.06 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -70.93 142.54 43.01 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.87 1.458 . . . . 0.0 110.349 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.5 mp 55.54 72.84 0.95 Allowed Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.866 -0.521 . . . . 0.0 110.084 -179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.95 -169.13 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.718 1.378 . . . . 0.0 110.63 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.45 ' HA ' ' HD2' ' A' ' 13' ' ' ARG . 4.4 mmm180 -68.67 114.85 25.08 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.794 -0.566 . . . . 0.0 110.295 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.89 145.11 44.76 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.86 1.453 . . . . 0.0 110.826 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.8 138.15 18.56 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.949 1.5 . . . . 0.0 110.656 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.02 95.61 0.84 Allowed 'Trans proline' 0 C--N 1.315 -1.192 0 O-C-N 123.916 1.482 . . . . 0.0 110.658 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -75.9 146.11 39.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.817 . . . . 0.0 110.39 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.2 t -85.3 156.66 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.649 -0.657 . . . . 0.0 110.132 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.13 117.28 20.36 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.645 -0.659 . . . . 0.0 110.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.11 169.89 19.48 Favored 'Trans proline' 0 C--N 1.315 -1.208 0 O-C-N 123.942 1.496 . . . . 0.0 110.633 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 52.32 64.13 7.95 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.844 -0.535 . . . . 0.0 110.727 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -81.88 144.58 13.74 Favored 'Trans proline' 0 C--N 1.314 -1.264 0 O-C-N 123.707 1.372 . . . . 0.0 110.726 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.07 54.85 2.36 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.67 139.8 4.01 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -76.8 178.75 7.21 Favored 'Trans proline' 0 N--CA 1.488 1.189 0 O-C-N 123.981 1.516 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.407 HG23 HD12 ' A' ' 26' ' ' ILE . 14.0 mm -63.21 156.33 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.63 -0.669 . . . . 0.0 110.459 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.08 85.03 1.43 Allowed Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.78 -20.95 19.38 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.97 1.51 . . . . 0.0 111.437 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -85.15 49.3 1.72 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.14 -0.975 . . . . 0.0 110.585 -179.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 m-80 -138.06 41.86 2.27 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.309 -0.87 . . . . 0.0 110.445 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.5 38.1 1.1 Allowed Glycine 0 N--CA 1.497 2.702 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 47.2 t -177.49 113.94 0.24 Allowed Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.632 -0.922 . . . . 0.0 110.006 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.93 149.63 66.08 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 O-C-N 123.55 1.289 . . . . 0.0 110.386 179.228 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.2 t -78.2 -32.07 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.409 -0.807 . . . . 0.0 110.733 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.43 -16.61 60.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.172 -0.955 . . . . 0.0 110.952 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.1 m 57.99 30.39 19.12 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.372 -0.83 . . . . 0.0 110.239 -179.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.5 mtp180 -113.01 154.07 27.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.508 -0.745 . . . . 0.0 110.128 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.55 34.69 59.91 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.9 pt -139.83 161.81 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.403 -1.057 . . . . 0.0 109.855 179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 7.8 m -80.44 161.08 25.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.534 -0.728 . . . . 0.0 109.963 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.9 t80 -58.54 -43.72 89.36 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.512 -0.743 . . . . 0.0 109.39 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.9 t -65.0 -38.63 91.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.641 -0.662 . . . . 0.0 109.827 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 28.5 tp60 -64.21 -44.76 90.94 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.611 -0.68 . . . . 0.0 109.593 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.93 79.2 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -65.69 -36.26 83.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.815 -0.553 . . . . 0.0 109.793 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -63.42 -47.77 80.57 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.797 -0.564 . . . . 0.0 111.197 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.436 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 53.1 t -66.45 -33.69 76.26 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.241 -0.912 . . . . 0.0 111.091 -179.543 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.0 t -57.81 -41.67 82.69 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.163 -0.961 . . . . 0.0 110.169 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -84.59 -25.59 28.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.272 -0.892 . . . . 0.0 110.367 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.8 ttm180 -79.39 -36.18 39.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.327 -0.858 . . . . 0.0 111.195 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.32 11.39 2.14 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.116 -0.99 . . . . 0.0 112.353 -178.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.04 26.93 73.29 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.74 141.61 47.61 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.243 -1.151 . . . . 0.0 110.571 -179.921 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 54.1 m 66.25 54.61 0.93 Allowed 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.799 0.809 . . . . 0.0 108.917 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 67.5 m -102.92 -0.62 30.82 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.845 -0.535 . . . . 0.0 111.75 -178.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -137.03 50.24 2.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.935 -1.103 . . . . 0.0 110.645 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.2 t -95.64 137.3 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.115 -0.99 . . . . 0.0 110.245 179.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.52 168.38 41.21 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.93 99.88 5.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.444 -1.033 . . . . 0.0 110.022 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 76.27 98.39 0.15 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -91.7 160.46 15.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.512 -0.993 . . . . 0.0 110.563 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.1 p -73.06 174.36 8.02 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.535 -0.728 . . . . 0.0 110.762 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 CA-C-O 118.021 -1.433 . . . . 0.0 109.608 179.967 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 121.354 0.597 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 94.3 t -104.49 134.66 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.661 -0.649 . . . . 0.0 109.897 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 60.51 101.2 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.197 0 CA-C-O 121.451 0.643 . . . . 0.0 110.619 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.31 101.66 1.96 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.292 -0.88 . . . . 0.0 110.421 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.45 -159.37 29.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -171.06 148.72 11.48 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 42.5 m-85 -87.41 84.67 7.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.433 -1.039 . . . . 0.0 110.141 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -158.94 160.38 35.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.433 -0.792 . . . . 0.0 110.305 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.6 mtt-85 -109.67 104.18 54.78 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.404 -0.81 . . . . 0.0 110.185 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.57 129.72 16.1 Favored 'Trans proline' 0 C--N 1.316 -1.165 0 O-C-N 123.824 1.434 . . . . 0.0 110.433 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 32.0 mt 53.46 69.62 2.18 Favored Pre-proline 0 N--CA 1.501 2.117 0 O-C-N 121.788 -0.57 . . . . 0.0 110.151 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -75.69 69.15 6.15 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.827 1.435 . . . . 0.0 110.372 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 15.4 tpp180 -153.2 112.14 2.65 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.38 -0.825 . . . . 0.0 110.031 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.1 141.13 29.09 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.918 1.483 . . . . 0.0 110.728 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.69 144.17 31.13 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.91 1.479 . . . . 0.0 110.655 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.69 72.67 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 O-C-N 123.832 1.438 . . . . 0.0 110.332 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -161.37 155.58 22.6 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.372 -0.83 . . . . 0.0 110.524 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -125.3 144.87 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.714 -0.616 . . . . 0.0 109.965 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -88.84 114.85 61.67 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.591 -0.693 . . . . 0.0 110.337 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.493 ' O ' ' HB2' ' A' ' 21' ' ' LEU . 51.4 Cg_endo -77.04 179.6 6.37 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.854 1.45 . . . . 0.0 110.745 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . 0.493 ' HB2' ' O ' ' A' ' 20' ' ' PRO . 1.2 mt 63.63 157.61 0.12 Allowed Pre-proline 0 N--CA 1.506 2.361 0 O-C-N 122.028 -0.42 . . . . 0.0 111.456 179.597 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.48 105.66 2.12 Favored 'Trans proline' 0 C--N 1.314 -1.245 0 O-C-N 123.729 1.384 . . . . 0.0 110.517 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.28 90.01 0.62 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.52 89.6 1.32 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.33 156.0 55.27 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.89 1.468 . . . . 0.0 110.682 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.7 mp -105.84 143.78 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.404 -0.81 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.2 80.85 0.75 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.54 -171.09 1.01 Allowed 'Trans proline' 0 C--N 1.314 -1.272 0 O-C-N 123.887 1.467 . . . . 0.0 110.694 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.0 t80 -78.59 62.16 3.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.362 -0.836 . . . . 0.0 109.779 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -141.82 38.75 1.65 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.297 -0.877 . . . . 0.0 110.929 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -164.49 41.29 0.3 Allowed Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.955 -1.116 . . . . 0.0 110.418 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.1 t -170.31 98.71 0.45 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.367 -1.078 . . . . 0.0 110.372 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.79 152.9 69.26 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.833 1.438 . . . . 0.0 110.719 179.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.6 t -77.38 -29.93 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.475 -0.766 . . . . 0.0 110.861 -179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.421 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -73.33 -12.68 60.92 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.24 -0.912 . . . . 0.0 111.27 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.421 ' HB2' ' O ' ' A' ' 35' ' ' SER . 68.5 m 58.15 25.55 12.64 Favored 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.45 -0.781 . . . . 0.0 111.155 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.0 mtt180 -115.9 158.55 22.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.317 -0.865 . . . . 0.0 110.032 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.83 28.74 73.91 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.427 ' CD1' ' HB3' ' A' ' 44' ' ' ALA . 16.2 pt -125.71 152.0 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.325 -1.103 . . . . 0.0 109.937 179.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -77.32 160.17 29.01 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.77 -44.56 86.25 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.346 -0.846 . . . . 0.0 109.724 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.0 -35.57 80.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.513 -0.742 . . . . 0.0 109.914 179.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.4 -44.22 96.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.396 -0.815 . . . . 0.0 109.117 178.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.427 ' HB3' ' CD1' ' A' ' 39' ' ' ILE . . . -70.56 -34.83 72.67 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.814 -0.554 . . . . 0.0 109.571 178.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -34.96 77.0 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.696 -0.627 . . . . 0.0 110.283 179.388 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -69.65 -41.44 75.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.497 -0.752 . . . . 0.0 110.839 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.8 t -71.96 -32.83 67.66 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.408 -0.808 . . . . 0.0 111.061 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.5 t -65.36 -43.17 91.65 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.246 -0.909 . . . . 0.0 110.917 -179.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.6 t -80.94 -21.36 40.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.451 -0.781 . . . . 0.0 112.126 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -101.79 -23.24 14.22 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.009 -1.057 . . . . 0.0 111.724 -179.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -134.14 -8.73 2.64 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.967 -1.083 . . . . 0.0 112.541 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.02 26.51 66.45 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.405 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.3 OUTLIER -120.23 148.72 43.33 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.246 -1.149 . . . . 0.0 110.689 -179.596 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 11.8 m 58.95 46.08 14.15 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 122.033 0.92 . . . . 0.0 108.885 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 20.7 m -88.76 -12.78 41.18 Favored 'General case' 0 N--CA 1.488 1.428 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.185 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -116.89 45.17 1.91 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.219 -0.926 . . . . 0.0 109.974 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.421 HG22 ' CB ' ' A' ' 44' ' ' ALA . 94.2 t -80.33 116.81 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.429 -0.795 . . . . 0.0 110.229 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.18 125.31 3.24 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -68.3 92.99 0.44 Allowed 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.452 -1.028 . . . . 0.0 109.838 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.32 -165.1 32.42 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -178.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 63.9 t80 -57.5 139.65 52.75 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.369 -1.077 . . . . 0.0 110.275 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -156.08 -179.87 8.56 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.625 -0.672 . . . . 0.0 110.595 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.484 0 CA-C-O 118.02 -1.433 . . . . 0.0 109.582 -179.974 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.42 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 3.5 mp0 . . . . . 0 N--CA 1.496 1.856 0 CA-C-O 121.024 0.44 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.42 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 16.0 t 64.54 164.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.387 0 CA-C-O 121.414 0.626 . . . . 0.0 110.75 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -136.37 150.17 48.69 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.321 -0.862 . . . . 0.0 110.528 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.49 95.25 6.13 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.491 -0.755 . . . . 0.0 109.916 179.6 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.81 54.4 3.93 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -176.87 94.7 0.1 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -83.38 125.86 32.12 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.608 -0.936 . . . . 0.0 110.221 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -164.1 -57.16 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.505 -0.747 . . . . 0.0 110.402 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 5.7 mtp180 -76.08 157.91 82.74 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.413 -0.804 . . . . 0.0 110.456 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -71.87 138.03 30.69 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.821 1.432 . . . . 0.0 110.636 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.9 mt -92.3 134.2 28.7 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.469 -0.77 . . . . 0.0 110.008 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -71.26 73.16 2.14 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 124.045 1.55 . . . . 0.0 110.739 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 30.6 ttt85 -149.01 122.67 4.62 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.437 -0.79 . . . . 0.0 109.913 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.74 117.99 5.14 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.929 1.489 . . . . 0.0 110.557 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -76.09 143.92 26.24 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.825 1.434 . . . . 0.0 110.603 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.6 79.5 2.79 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.884 1.465 . . . . 0.0 110.388 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -91.31 149.48 21.72 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.26 -0.9 . . . . 0.0 110.468 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.65 145.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.742 -0.599 . . . . 0.0 109.892 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.14 112.33 54.51 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.564 -0.71 . . . . 0.0 110.199 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.18 179.3 5.93 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 O-C-N 123.802 1.422 . . . . 0.0 110.913 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 53.97 72.71 1.05 Allowed Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.913 -0.492 . . . . 0.0 110.905 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.86 142.84 28.84 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 123.76 1.4 . . . . 0.0 110.384 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.17 63.7 0.85 Allowed Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.1 166.0 41.71 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.92 153.19 58.28 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 O-C-N 123.851 1.448 . . . . 0.0 110.641 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 15.8 tt -83.1 150.13 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.418 -0.801 . . . . 0.0 110.466 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.69 83.84 0.59 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.33 -32.79 7.79 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 124.006 1.529 . . . . 0.0 110.867 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -79.98 63.59 4.55 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.356 -0.84 . . . . 0.0 110.102 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 -148.1 37.83 0.87 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.298 -0.876 . . . . 0.0 110.775 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.02 45.46 0.58 Allowed Glycine 0 N--CA 1.496 2.633 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 17.4 t -169.71 105.75 0.46 Allowed Pre-proline 0 N--CA 1.495 1.775 0 O-C-N 121.521 -0.988 . . . . 0.0 110.106 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.67 126.96 13.26 Favored 'Trans proline' 0 C--N 1.313 -1.315 0 O-C-N 123.624 1.328 . . . . 0.0 110.455 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 90.3 t -62.56 -32.07 54.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.474 -0.767 . . . . 0.0 110.438 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.9 -14.17 61.86 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.492 -0.755 . . . . 0.0 111.08 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.2 m 57.75 30.53 19.09 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.511 -0.743 . . . . 0.0 111.09 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.1 mtt85 -105.53 139.95 39.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.267 -0.895 . . . . 0.0 109.999 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.56 0.68 81.73 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 27.0 pt -116.28 158.48 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.063 -1.257 . . . . 0.0 110.125 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -80.08 165.11 22.83 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.699 -0.626 . . . . 0.0 110.639 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -57.82 -48.81 78.66 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.61 -0.681 . . . . 0.0 109.288 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -61.45 -37.51 83.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.668 -0.645 . . . . 0.0 109.781 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -64.82 -44.0 91.3 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.425 -0.797 . . . . 0.0 109.56 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.49 78.42 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.69 -0.631 . . . . 0.0 109.66 179.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -36.89 80.57 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.716 -0.615 . . . . 0.0 109.76 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.6 t -64.45 -42.16 96.13 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.756 -0.59 . . . . 0.0 110.946 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 42.3 t -70.26 -34.99 73.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.113 -0.992 . . . . 0.0 111.176 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.3 t -58.15 -40.55 81.67 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.121 -0.987 . . . . 0.0 110.212 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.09 -14.32 50.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 111.297 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -101.62 -31.02 11.03 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.103 -0.998 . . . . 0.0 111.209 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -134.23 -1.69 2.89 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.207 -0.933 . . . . 0.0 112.306 -179.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.98 72.33 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.444 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.3 OUTLIER -113.49 152.0 30.73 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.07 -1.253 . . . . 0.0 110.521 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.5 m 59.79 53.55 4.79 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.887 0.851 . . . . 0.0 108.721 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 69.3 m -104.94 9.57 34.55 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.475 -178.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -146.01 46.04 1.25 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 110.523 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 70.8 t -106.26 126.24 61.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.17 -0.956 . . . . 0.0 110.35 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.63 157.52 33.75 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.86 136.75 3.02 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.513 -0.992 . . . . 0.0 110.462 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.2 -172.79 49.52 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.0 t80 -69.61 140.82 53.77 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.368 -1.077 . . . . 0.0 110.083 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.7 p -161.72 167.05 25.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.553 -0.717 . . . . 0.0 110.643 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 CA-C-O 118.015 -1.436 . . . . 0.0 109.533 179.9 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 . . . . . 0 N--CA 1.496 1.844 0 CA-C-O 121.311 0.577 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.5 p -132.1 147.69 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.657 -0.652 . . . . 0.0 110.113 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 56.62 79.79 0.17 Allowed 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.345 0.593 . . . . 0.0 110.574 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 26.7 tttm -89.65 141.7 28.36 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.364 -0.835 . . . . 0.0 110.42 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -161.8 -111.63 0.27 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 175.31 65.07 0.06 OUTLIER Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 51.3 m-85 -97.18 110.78 23.26 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.543 -0.975 . . . . 0.0 109.92 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 56.07 45.18 24.06 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.747 -0.596 . . . . 0.0 110.466 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -135.68 87.47 25.88 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.094 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.65 171.28 16.71 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.861 1.453 . . . . 0.0 110.609 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 6.8 tt -57.71 115.57 11.41 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.532 -0.73 . . . . 0.0 110.572 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.429 ' O ' ' HB3' ' A' ' 13' ' ' ARG . 50.6 Cg_endo -76.14 72.2 5.42 Favored 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.869 1.457 . . . . 0.0 110.573 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HB3' ' O ' ' A' ' 12' ' ' PRO . 11.4 ttp-105 63.48 109.34 0.03 OUTLIER Pre-proline 0 N--CA 1.502 2.166 0 O-C-N 121.848 -0.533 . . . . 0.0 110.911 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.89 112.73 3.47 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.726 1.382 . . . . 0.0 110.27 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.95 162.01 42.11 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.777 1.409 . . . . 0.0 110.754 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.04 99.02 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.934 1.492 . . . . 0.0 110.631 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -73.69 161.54 30.15 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.509 -0.745 . . . . 0.0 110.639 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.92 151.16 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.74 -0.6 . . . . 0.0 110.248 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.444 ' HG3' ' HD2' ' A' ' 20' ' ' PRO . 3.7 tpp180 -72.92 132.46 82.88 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.454 -0.778 . . . . 0.0 110.367 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.444 ' HD2' ' HG3' ' A' ' 19' ' ' ARG . 49.2 Cg_endo -73.76 -171.08 0.78 Allowed 'Trans proline' 0 N--CA 1.488 1.177 0 O-C-N 123.906 1.477 . . . . 0.0 110.886 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 61.67 76.12 0.41 Allowed Pre-proline 0 N--CA 1.501 2.084 0 O-C-N 121.793 -0.567 . . . . 0.0 110.563 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.95 136.74 23.21 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.788 1.415 . . . . 0.0 110.727 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.71 110.2 3.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.6 92.08 1.28 Allowed Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.86 156.41 56.71 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 124.025 1.54 . . . . 0.0 110.892 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.7 tt -73.88 162.36 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.517 -0.739 . . . . 0.0 110.742 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.16 81.94 1.42 Allowed Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -77.23 -169.22 0.7 Allowed 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.894 1.47 . . . . 0.0 110.607 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -78.63 62.67 3.24 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.394 -0.816 . . . . 0.0 109.996 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -139.07 40.25 2.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 0.0 110.71 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -173.6 44.51 0.15 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 34.0 t -168.88 86.75 0.65 Allowed Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.364 -1.08 . . . . 0.0 110.327 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.52 140.05 50.95 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.851 1.448 . . . . 0.0 110.758 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 87.4 t -60.03 -31.27 47.42 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.584 -0.697 . . . . 0.0 110.936 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 t -72.86 -4.49 32.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.234 -0.916 . . . . 0.0 111.767 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 55.6 28.58 12.14 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.291 -0.881 . . . . 0.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.3 mtt85 -123.63 161.47 24.97 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.307 -0.87 . . . . 0.0 110.213 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.59 30.81 65.99 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.0 pt -141.61 159.47 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.496 -1.002 . . . . 0.0 109.896 179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 11.6 m -80.84 161.41 24.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.515 -0.74 . . . . 0.0 109.824 179.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -57.4 -45.68 84.29 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.553 -0.717 . . . . 0.0 109.389 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.1 t -64.04 -36.6 84.52 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.658 -0.651 . . . . 0.0 109.864 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.44 -44.87 89.81 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.649 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -70.1 -36.44 74.88 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.727 -0.608 . . . . 0.0 109.901 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.6 tpp85 -67.82 -38.0 82.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.675 -0.64 . . . . 0.0 109.508 179.088 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -64.05 -44.11 93.47 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.816 -0.552 . . . . 0.0 110.686 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.4 t -64.87 -30.18 71.16 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.935 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.8 t -70.3 -43.21 70.82 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.214 -0.929 . . . . 0.0 110.558 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -81.85 -21.05 37.76 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.272 -0.893 . . . . 0.0 112.016 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.59 -19.7 13.69 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.035 -1.04 . . . . 0.0 111.714 -179.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -6.33 2.87 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.108 -0.995 . . . . 0.0 112.446 -179.168 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.52 25.99 74.82 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.451 ' HA ' ' HD2' ' A' ' 53' ' ' ARG . 13.9 mmm180 -121.22 148.76 43.82 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.227 -1.161 . . . . 0.0 110.439 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 5.3 m 59.26 48.32 10.42 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-O 121.97 0.89 . . . . 0.0 108.824 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 14.8 m -91.43 -6.42 52.8 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.373 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -120.63 45.38 2.24 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.146 -0.971 . . . . 0.0 109.888 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 39.1 t -88.92 127.27 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.391 -0.818 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.98 116.99 1.98 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.1 mtmt -133.54 97.39 3.93 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.47 -1.017 . . . . 0.0 109.983 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.75 179.93 43.18 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -74.24 157.09 36.48 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.431 -1.041 . . . . 0.0 110.221 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.82 129.62 42.38 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.566 -0.709 . . . . 0.0 110.316 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 CA-C-O 117.918 -1.49 . . . . 0.0 109.636 -179.746 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 121.429 0.633 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 35.9 m -75.17 142.79 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.589 -0.695 . . . . 0.0 110.339 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -108.78 80.94 1.38 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.362 -0.836 . . . . 0.0 110.058 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 164.13 35.34 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.378 -0.826 . . . . 0.0 110.556 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -146.13 121.29 1.44 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -80.99 -76.52 1.04 Allowed Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -61.09 133.81 56.41 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.571 -0.958 . . . . 0.0 110.212 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 62.05 87.56 0.1 Allowed 'General case' 0 N--CA 1.5 2.047 0 CA-C-O 121.438 0.637 . . . . 0.0 110.504 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.442 ' HG3' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -88.06 130.68 45.42 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.348 -0.845 . . . . 0.0 110.319 179.963 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.442 ' HD2' ' HG3' ' A' ' 9' ' ' ARG . 46.4 Cg_endo -73.07 146.32 41.09 Favored 'Trans proline' 0 C--N 1.315 -1.236 0 O-C-N 123.898 1.473 . . . . 0.0 110.761 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.0 mm -87.12 137.14 33.11 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.408 -0.807 . . . . 0.0 109.955 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.42 89.92 0.59 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 O-C-N 124.097 1.577 . . . . 0.0 110.4 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.455 ' HD3' ' HD2' ' A' ' 14' ' ' PRO . 0.1 OUTLIER -135.17 153.96 78.59 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.555 -0.715 . . . . 0.0 110.175 -179.846 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.455 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 44.3 Cg_endo -71.76 141.37 37.32 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.968 1.509 . . . . 0.0 110.559 179.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.44 124.09 9.14 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.841 1.443 . . . . 0.0 110.894 -179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -74.35 105.04 1.97 Allowed 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.915 1.482 . . . . 0.0 110.363 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -70.18 160.43 32.14 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.557 -0.715 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -77.01 143.28 13.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.603 -0.685 . . . . 0.0 110.232 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . 0.573 ' HG2' ' HD2' ' A' ' 20' ' ' PRO . 6.7 ttp85 -123.23 140.26 33.38 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.47 -0.769 . . . . 0.0 110.036 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HD2' ' HG2' ' A' ' 19' ' ' ARG . 43.5 Cg_endo -69.47 162.47 41.79 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.767 1.404 . . . . 0.0 110.92 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.6 mt -109.26 104.38 54.96 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.66 -0.65 . . . . 0.0 110.109 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.67 136.55 21.28 Favored 'Trans proline' 0 C--N 1.315 -1.206 0 O-C-N 123.894 1.471 . . . . 0.0 110.708 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.43 -128.72 2.73 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.44 146.49 16.04 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.03 98.92 1.04 Allowed 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.765 1.402 . . . . 0.0 110.601 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -124.13 148.67 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.673 -0.642 . . . . 0.0 110.086 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.83 129.38 5.04 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -78.02 1.72 8.64 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 123.953 1.502 . . . . 0.0 111.754 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -77.83 67.31 3.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.075 -1.016 . . . . 0.0 110.258 -179.625 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -134.04 42.2 2.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.325 -0.859 . . . . 0.0 110.55 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.4 45.19 0.06 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.982 -1.104 . . . . 0.0 110.655 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.4 t -173.83 86.46 0.37 Allowed Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.437 -1.037 . . . . 0.0 110.426 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.61 141.49 34.52 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.845 1.445 . . . . 0.0 110.832 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.4 t -65.92 -27.86 42.31 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.384 -0.822 . . . . 0.0 110.31 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' SER . . . . . 0.422 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -65.38 -18.04 65.0 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.403 -0.811 . . . . 0.0 111.034 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.445 ' HA ' HD13 ' A' ' 39' ' ' ILE . 84.1 m 58.29 27.23 14.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.479 -0.763 . . . . 0.0 111.211 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -114.21 147.72 38.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.397 -0.814 . . . . 0.0 109.848 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.11 30.24 65.57 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.445 HD13 ' HA ' ' A' ' 36' ' ' CYS . 23.4 pt -124.67 155.77 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.381 -1.07 . . . . 0.0 109.854 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -82.13 157.32 24.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.647 . . . . 0.0 109.413 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.61 -39.95 78.03 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.419 -0.801 . . . . 0.0 109.69 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -69.91 -35.63 74.74 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.632 -0.668 . . . . 0.0 110.084 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -65.38 -40.16 93.17 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.433 ' HB3' ' CD1' ' A' ' 39' ' ' ILE . . . -70.59 -35.88 73.25 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.669 -0.644 . . . . 0.0 110.285 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.27 -32.36 70.14 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 179.428 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.498 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 8.5 t -71.44 -41.6 69.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.555 -0.716 . . . . 0.0 110.948 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.8 t -74.0 -29.07 61.76 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.242 -0.911 . . . . 0.0 111.743 -179.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.7 t -59.48 -43.3 93.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.987 -1.07 . . . . 0.0 109.996 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 12.3 t -89.27 -25.21 21.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.381 -0.824 . . . . 0.0 110.629 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.498 ' HB2' ' O ' ' A' ' 46' ' ' SER . 2.3 ttp85 -79.72 -34.66 39.89 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.407 -0.808 . . . . 0.0 111.181 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -141.08 10.68 2.16 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.162 -0.961 . . . . 0.0 112.289 -179.026 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.81 33.38 82.82 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -123.68 142.52 50.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.584 -0.95 . . . . 0.0 110.097 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 1.8 m 59.76 56.29 3.6 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 121.985 0.898 . . . . 0.0 108.974 -179.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 4.4 m -94.98 -11.5 28.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.883 -0.511 . . . . 0.0 111.312 -178.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -122.69 44.14 2.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.149 -0.969 . . . . 0.0 110.078 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 38.1 t -78.58 114.13 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.494 -0.754 . . . . 0.0 110.363 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.6 126.31 2.0 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -86.78 114.4 23.42 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.348 -1.09 . . . . 0.0 110.077 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.4 -179.82 43.59 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.69 163.05 24.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.47 -1.018 . . . . 0.0 110.473 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 m -79.07 167.55 20.9 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.573 -0.704 . . . . 0.0 110.444 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 CA-C-O 117.947 -1.474 . . . . 0.0 109.515 179.958 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 9.3 mm-40 . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.245 0.545 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 93.5 t -80.6 147.58 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.684 -0.635 . . . . 0.0 109.923 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -155.9 159.82 39.62 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.462 -0.773 . . . . 0.0 110.669 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 4.0 pttt -89.81 78.99 6.77 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.405 -0.809 . . . . 0.0 110.462 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.5 83.89 0.33 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.49 -74.43 1.77 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.8 118.61 37.05 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.44 -1.035 . . . . 0.0 110.278 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -146.64 63.14 1.2 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.344 -0.847 . . . . 0.0 110.408 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.44 78.35 72.01 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.85 118.74 5.7 Favored 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.891 1.469 . . . . 0.0 110.43 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 46.0 mm 56.08 80.45 0.29 Allowed Pre-proline 0 N--CA 1.502 2.139 0 O-C-N 121.785 -0.572 . . . . 0.0 110.178 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.14 78.01 1.92 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 123.794 1.418 . . . . 0.0 110.81 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.78 78.48 5.51 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.317 -0.864 . . . . 0.0 109.926 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.55 147.57 46.2 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.814 1.429 . . . . 0.0 111.013 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -74.78 148.3 36.18 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 124.045 1.55 . . . . 0.0 110.62 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -74.12 71.81 4.23 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.882 1.464 . . . . 0.0 110.447 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -153.65 151.12 29.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.324 -0.86 . . . . 0.0 110.394 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -86.42 145.82 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.339 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.8 106.89 52.49 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.637 -0.664 . . . . 0.0 110.052 179.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.96 178.22 6.75 Favored 'Trans proline' 0 C--N 1.315 -1.187 0 O-C-N 123.746 1.393 . . . . 0.0 110.839 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.23 99.75 19.25 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.486 -0.759 . . . . 0.0 110.186 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.29 92.99 0.98 Allowed 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.845 1.445 . . . . 0.0 110.701 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -163.79 78.04 0.15 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.74 86.84 0.84 Allowed Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.89 145.04 35.52 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.805 1.424 . . . . 0.0 110.78 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 57.4 mt -127.72 145.45 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.452 -0.78 . . . . 0.0 110.042 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.1 87.85 1.32 Allowed Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.08 -32.82 10.38 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.861 1.453 . . . . 0.0 110.996 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 33.4 t80 -76.59 69.89 3.06 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.333 -0.854 . . . . 0.0 110.15 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -149.92 36.72 0.7 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.376 -0.828 . . . . 0.0 110.75 -179.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.34 43.45 0.51 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 52.5 t -177.37 88.29 0.24 Allowed Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.609 -0.936 . . . . 0.0 109.828 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.24 143.35 58.51 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 O-C-N 123.775 1.408 . . . . 0.0 110.692 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 96.2 t -66.22 -29.6 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.363 -0.836 . . . . 0.0 110.669 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.2 t -68.51 -19.31 64.52 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.353 -0.842 . . . . 0.0 111.092 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.3 m 60.69 30.18 19.53 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.495 -0.753 . . . . 0.0 110.627 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -107.41 146.47 31.63 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.27 -0.894 . . . . 0.0 110.373 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.83 29.22 55.23 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 28.4 pt -137.55 163.13 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.198 -1.178 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.423 ' HB3' ' HB2' ' A' ' 43' ' ' GLN . 13.5 t -80.7 166.56 20.92 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.564 -0.71 . . . . 0.0 110.082 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -62.58 -49.34 75.64 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 46' ' ' SER . 2.7 t -63.57 -35.32 80.1 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.696 -0.627 . . . . 0.0 109.985 179.245 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.423 ' HB2' ' HB3' ' A' ' 40' ' ' SER . 4.8 tt0 -64.74 -43.39 93.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.45 -0.781 . . . . 0.0 109.645 179.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -70.73 -36.65 73.29 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.56 -0.713 . . . . 0.0 109.492 179.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 5.6 ttt-85 -68.36 -33.44 74.28 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.758 -0.589 . . . . 0.0 109.7 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 42' ' ' SER . 0.1 OUTLIER -66.33 -46.81 75.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.801 -0.562 . . . . 0.0 110.93 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.4 t -66.02 -30.13 70.61 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.321 -0.862 . . . . 0.0 111.248 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 35.4 t -58.84 -41.06 86.04 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.942 -1.099 . . . . 0.0 109.941 179.715 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 19.4 t -87.26 -25.3 24.04 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.668 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.83 -34.41 26.9 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.314 -0.866 . . . . 0.0 111.316 -179.513 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -137.56 6.79 2.76 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.178 -0.951 . . . . 0.0 112.374 -179.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.08 27.08 74.18 Favored Glycine 0 N--CA 1.497 2.749 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.502 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.4 OUTLIER -117.53 145.65 44.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.21 -1.17 . . . . 0.0 110.293 179.941 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.502 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 83.3 m 63.23 53.7 2.19 Favored 'General case' 0 N--CA 1.501 2.108 0 CA-C-O 121.903 0.858 . . . . 0.0 108.806 -178.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.2 m -101.27 8.56 42.4 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.904 -0.497 . . . . 0.0 111.689 -178.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.7 t60 -141.69 42.39 1.72 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 96.4 t -98.49 117.27 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.276 -0.89 . . . . 0.0 110.061 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.75 54.41 2.79 Favored Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -91.08 78.47 5.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.708 -0.878 . . . . 0.0 110.154 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.14 133.74 5.37 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 72.6 t80 -79.0 155.25 28.95 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.383 -1.069 . . . . 0.0 110.234 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.09 131.71 37.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.518 -0.739 . . . . 0.0 110.18 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 CA-C-O 117.968 -1.462 . . . . 0.0 109.593 -179.959 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 CA-C-O 121.317 0.579 . . . . 0.0 110.72 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.5 p -161.43 149.67 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.73 -0.606 . . . . 0.0 110.381 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -123.37 167.66 13.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.445 -0.784 . . . . 0.0 110.354 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 20.7 tttm 56.67 73.61 0.44 Allowed 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.404 0.621 . . . . 0.0 110.089 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 139.28 102.11 0.53 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.71 146.11 15.66 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -105.79 114.6 28.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.4 -1.059 . . . . 0.0 110.172 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -138.82 135.62 34.78 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.384 -0.823 . . . . 0.0 110.416 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -86.02 132.9 42.32 Favored Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 110.135 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.78 157.0 52.56 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 124.002 1.527 . . . . 0.0 111.086 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.427 HG23 ' HD2' ' A' ' 12' ' ' PRO . 6.1 mt -70.24 140.23 87.78 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 121.515 -0.741 . . . . 0.0 110.154 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . 0.427 ' HD2' HG23 ' A' ' 11' ' ' ILE . 46.4 Cg_endo -72.31 79.0 1.84 Allowed 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.996 1.524 . . . . 0.0 110.305 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.463 ' HG3' ' HD2' ' A' ' 14' ' ' PRO . 19.5 ttt-85 -135.56 144.36 48.91 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.533 -0.729 . . . . 0.0 109.96 -179.772 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.463 ' HD2' ' HG3' ' A' ' 13' ' ' ARG . 44.1 Cg_endo -70.07 144.35 52.13 Favored 'Trans proline' 0 C--N 1.313 -1.318 0 O-C-N 123.836 1.44 . . . . 0.0 110.501 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.9 147.17 43.48 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.885 1.466 . . . . 0.0 110.873 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -77.14 -169.5 0.75 Allowed 'Trans proline' 0 C--N 1.315 -1.22 0 O-C-N 123.979 1.515 . . . . 0.0 110.809 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -68.05 167.6 13.62 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.539 -0.726 . . . . 0.0 110.596 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.79 144.87 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.687 -0.633 . . . . 0.0 110.525 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -99.08 123.27 49.58 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.586 -0.696 . . . . 0.0 110.14 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.55 159.22 51.84 Favored 'Trans proline' 0 C--N 1.314 -1.289 0 O-C-N 123.757 1.398 . . . . 0.0 110.475 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.98 106.64 58.99 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.616 -0.678 . . . . 0.0 110.239 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.96 140.87 32.27 Favored 'Trans proline' 0 C--N 1.315 -1.2 0 O-C-N 123.851 1.448 . . . . 0.0 110.528 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -77.08 -41.47 22.12 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.67 102.47 0.98 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.33 115.01 4.16 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.89 1.468 . . . . 0.0 110.691 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 15.9 tt -73.14 165.67 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.592 -0.693 . . . . 0.0 110.145 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.24 -172.82 35.29 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -67.56 -11.13 31.07 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 O-C-N 124.101 1.579 . . . . 0.0 111.741 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -82.11 63.41 6.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.148 -0.97 . . . . 0.0 110.262 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -130.02 36.74 3.99 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.103 -0.998 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 172.89 46.59 0.04 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.54 179.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 5.0 t -168.93 81.95 0.7 Allowed Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.235 -1.156 . . . . 0.0 110.208 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -65.81 152.83 80.46 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 124.027 1.541 . . . . 0.0 111.074 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 50.8 t -68.24 -31.1 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.409 -0.807 . . . . 0.0 110.348 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.8 t -68.48 -16.02 63.75 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.407 -0.808 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 57.42 30.33 18.43 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.358 -0.838 . . . . 0.0 110.775 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.3 mtt180 -102.14 152.65 20.76 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.337 -0.852 . . . . 0.0 110.444 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.38 17.22 76.58 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.3 pt -133.18 159.81 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.057 -1.26 . . . . 0.0 110.241 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.6 161.74 23.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.653 -0.655 . . . . 0.0 109.696 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 86.3 t80 -56.36 -50.12 72.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.498 -0.751 . . . . 0.0 109.567 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.5 t -63.07 -35.86 81.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.689 -0.632 . . . . 0.0 110.196 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -64.22 -42.47 96.58 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.43 -0.794 . . . . 0.0 109.801 179.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -36.06 77.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.552 -0.718 . . . . 0.0 109.9 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.38 -40.83 93.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.772 -0.58 . . . . 0.0 110.084 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.6 t -62.8 -43.47 98.73 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.558 -0.714 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.3 t -64.81 -34.26 77.95 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.253 -0.904 . . . . 0.0 110.776 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 37.3 t -61.28 -43.09 99.45 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.309 -0.869 . . . . 0.0 110.045 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.0 m -80.06 -13.07 59.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.51 -0.744 . . . . 0.0 111.265 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.92 -28.56 12.33 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.207 -0.933 . . . . 0.0 111.186 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.95 7.84 1.86 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.058 -1.026 . . . . 0.0 112.515 -179.129 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.76 27.17 74.06 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 120.857 -1.152 . . . . 0.0 110.312 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.4 mmp_? -114.83 143.5 45.01 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.078 -1.248 . . . . 0.0 110.562 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 27.5 m 61.7 56.02 2.56 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-O 121.879 0.847 . . . . 0.0 108.973 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 63.8 m -101.85 -3.14 28.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.925 -0.485 . . . . 0.0 112.01 -178.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -136.42 47.98 2.16 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.983 -1.073 . . . . 0.0 111.006 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 95.5 t -106.35 109.49 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.1 -1.0 . . . . 0.0 109.742 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.7 93.62 0.3 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 6.6 tttm -99.9 102.16 13.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -1.007 . . . . 0.0 110.206 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.52 -176.68 40.13 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.9 t80 -73.46 157.15 37.36 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.468 -1.019 . . . . 0.0 110.521 -179.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.8 p -154.84 166.44 33.48 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.593 -0.692 . . . . 0.0 110.514 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 CA-C-O 118.011 -1.439 . . . . 0.0 109.59 179.974 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 . . . . . 0 N--CA 1.498 1.957 0 CA-C-O 121.365 0.602 . . . . 0.0 110.657 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 66.7 t -113.26 139.98 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.654 -0.654 . . . . 0.0 109.846 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER 65.96 166.54 0.2 Allowed 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.31 149.62 49.8 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.413 -0.804 . . . . 0.0 110.324 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.04 -86.85 0.23 Allowed Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.55 152.8 11.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 t80 -145.05 79.58 1.59 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.47 -1.018 . . . . 0.0 110.227 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -157.63 125.34 5.3 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.393 -0.817 . . . . 0.0 110.191 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 1.1 ttm-85 -139.65 86.84 13.54 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.238 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.475 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.5 Cg_endo -73.28 130.1 14.77 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.955 1.502 . . . . 0.0 110.343 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.475 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 48.5 mt 65.0 118.21 0.02 OUTLIER Pre-proline 0 N--CA 1.505 2.314 0 O-C-N 122.073 -0.392 . . . . 0.0 110.606 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -76.7 65.68 7.5 Favored 'Trans proline' 0 C--N 1.315 -1.201 0 O-C-N 123.571 1.3 . . . . 0.0 110.469 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.5 ttm-85 -164.01 140.04 5.1 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.399 -0.813 . . . . 0.0 109.95 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.23 136.88 25.11 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.88 1.463 . . . . 0.0 110.68 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.82 140.66 26.26 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.937 1.493 . . . . 0.0 110.737 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.69 80.87 2.24 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.842 1.443 . . . . 0.0 110.4 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -80.56 153.54 28.0 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.316 -0.865 . . . . 0.0 110.489 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -85.74 141.78 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.657 -0.652 . . . . 0.0 110.045 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.8 ttt-85 -110.61 126.53 28.62 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.448 -0.783 . . . . 0.0 110.159 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -72.86 177.91 7.08 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 O-C-N 123.868 1.457 . . . . 0.0 110.669 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.5 tp -148.88 74.85 10.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.47 -0.769 . . . . 0.0 110.18 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -73.79 115.58 4.38 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.792 1.417 . . . . 0.0 110.379 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 118.48 -66.81 0.37 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.73 95.84 0.54 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.84 142.41 35.22 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.875 1.461 . . . . 0.0 110.839 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 mt -97.75 141.82 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.491 -0.755 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.73 84.22 1.33 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.73 -33.11 8.57 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 124.049 1.552 . . . . 0.0 111.018 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.596 ' CE1' ' HB3' ' A' ' 32' ' ' CYS . 3.2 t80 -81.66 77.2 8.53 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.311 -0.868 . . . . 0.0 109.357 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -114.83 42.03 2.25 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.26 -0.9 . . . . 0.0 111.073 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.446 ' O ' ' HB2' ' A' ' 32' ' ' CYS . . . -156.32 32.64 0.59 Allowed Glycine 0 N--CA 1.494 2.519 0 C-N-CA 119.959 -1.115 . . . . 0.0 110.541 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.596 ' HB3' ' CE1' ' A' ' 29' ' ' TYR . 40.7 t 177.79 119.51 0.18 Allowed Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.6 -0.941 . . . . 0.0 110.569 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.404 ' HG3' HG23 ' A' ' 39' ' ' ILE . 46.3 Cg_endo -75.96 142.78 25.4 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.311 1.164 . . . . 0.0 109.879 178.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 43.5 t -73.82 -30.33 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.21 -0.931 . . . . 0.0 110.937 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.5 t -73.65 -10.88 60.15 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.275 -0.891 . . . . 0.0 111.825 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 74.8 m 57.43 29.28 16.72 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.232 -0.917 . . . . 0.0 110.878 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -128.51 158.94 36.99 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.306 -0.871 . . . . 0.0 110.636 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.24 37.25 71.45 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.404 HG23 ' HG3' ' A' ' 33' ' ' PRO . 14.1 pt -143.99 159.5 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.423 -1.045 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.5 m -76.06 160.28 29.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.642 -0.661 . . . . 0.0 109.701 179.369 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -58.17 -44.67 88.08 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 109.478 179.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -62.61 -37.86 87.92 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.619 -0.676 . . . . 0.0 109.903 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -64.51 -45.82 85.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.546 -0.721 . . . . 0.0 109.668 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.93 -36.7 80.59 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.813 -0.555 . . . . 0.0 109.932 179.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 33.4 ttp85 -69.95 -36.96 75.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.538 -0.726 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.1 t -63.27 -40.09 96.43 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.687 -0.633 . . . . 0.0 110.845 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 29.6 t -67.77 -40.05 84.05 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.352 -0.843 . . . . 0.0 110.745 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.5 t -59.07 -42.74 91.1 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.392 -0.817 . . . . 0.0 110.747 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.9 -18.89 49.45 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.427 -0.795 . . . . 0.0 111.902 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.83 -25.18 13.6 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.084 -1.01 . . . . 0.0 111.806 -179.229 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -135.1 -5.86 2.36 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.065 -1.022 . . . . 0.0 112.669 -178.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.5 22.92 71.75 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.479 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.74 148.01 41.51 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.238 -1.154 . . . . 0.0 110.548 -179.847 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 84.7 m 61.37 47.42 6.84 Favored 'General case' 0 N--CA 1.498 1.931 0 CA-C-O 121.974 0.892 . . . . 0.0 109.086 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 36.5 m -91.2 -7.96 49.88 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.904 -0.497 . . . . 0.0 111.228 -179.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.8 t60 -124.11 45.73 2.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.145 -0.972 . . . . 0.0 109.908 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 54.4 t -81.79 137.33 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.423 -0.798 . . . . 0.0 110.454 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.8 112.54 0.49 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.1 mtmt -114.23 98.76 7.14 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.419 -1.048 . . . . 0.0 110.081 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.85 126.52 3.42 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -70.42 157.01 38.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.458 -1.025 . . . . 0.0 110.331 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.2 p -131.32 164.1 26.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.526 -0.734 . . . . 0.0 110.685 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.906 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 N-CA-C 110.966 -0.436 . . . . 0.0 110.966 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.4 t -62.84 -31.23 51.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.505 -0.747 . . . . 0.0 110.937 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.6 OUTLIER -69.22 -12.44 61.67 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.503 -0.748 . . . . 0.0 111.53 -179.677 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 35' ' ' SER . 78.8 m 61.78 27.75 16.99 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.409 -0.807 . . . . 0.0 110.575 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HG2' ' O ' ' A' ' 35' ' ' SER . 17.1 mmm180 -107.02 146.34 31.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.397 -0.814 . . . . 0.0 110.19 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.93 22.45 52.79 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.5 pt -138.87 154.96 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.154 -1.204 . . . . 0.0 110.281 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.486 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 55.0 m -74.51 165.75 24.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.607 -0.683 . . . . 0.0 110.043 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.49 ' CE2' ' HD2' ' A' ' 45' ' ' ARG . 84.2 t80 -60.02 -48.76 80.4 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.616 -0.677 . . . . 0.0 109.816 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -65.82 -33.75 76.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.583 -0.698 . . . . 0.0 110.122 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.486 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.3 OUTLIER -63.47 -46.38 86.47 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.143 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.81 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -63.47 -37.69 88.28 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.891 -0.505 . . . . 0.0 109.956 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.49 ' HD2' ' CE2' ' A' ' 41' ' ' PHE . 1.0 OUTLIER -64.54 -40.86 96.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.628 -0.67 . . . . 0.0 109.761 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -61.55 -43.95 97.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.774 -0.579 . . . . 0.0 110.971 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.1 t -67.04 -31.2 71.56 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.315 -0.865 . . . . 0.0 111.17 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 t -58.69 -42.5 88.7 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.077 -1.014 . . . . 0.0 109.86 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -84.53 -22.08 30.28 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.412 -0.805 . . . . 0.0 110.697 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -80.97 -36.01 31.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.239 -0.913 . . . . 0.0 111.01 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.49 18.29 1.69 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.187 -0.946 . . . . 0.0 111.97 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.28 31.74 78.22 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.524 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 3.6 mmp_? -117.57 137.75 52.38 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.43 -1.041 . . . . 0.0 110.68 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.524 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 21.5 m 64.35 52.51 1.86 Allowed 'General case' 0 N--CA 1.502 2.128 0 CA-C-O 121.84 0.828 . . . . 0.0 109.476 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 27.3 m -92.02 -20.39 21.38 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.955 -0.466 . . . . 0.0 111.262 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -112.81 42.55 1.84 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.167 -0.958 . . . . 0.0 110.002 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.81 HG21 ' HB1' ' A' ' 44' ' ' ALA . 75.8 t . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.529 -0.732 . . . . 0.0 110.199 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo . . . . . 0 N--CA 1.489 1.244 0 N-CA-C 110.689 -0.543 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.41 -30.64 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 121.485 -0.759 . . . . 0.0 110.811 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.55 -16.62 62.89 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.334 -0.854 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.484 ' CB ' HG21 ' A' ' 57' ' ' VAL . 38.8 m 59.31 25.56 14.24 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.512 -0.742 . . . . 0.0 111.169 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.4 mmt-85 -108.39 143.5 37.22 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.24 -0.913 . . . . 0.0 110.127 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.86 22.2 53.64 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.407 HD13 HG21 ' A' ' 39' ' ' ILE . 26.3 pt -134.93 156.3 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.135 -1.215 . . . . 0.0 110.098 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 m -74.48 166.02 24.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.637 -0.664 . . . . 0.0 110.515 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -60.18 -49.04 79.18 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.744 -0.597 . . . . 0.0 109.627 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -62.73 -35.36 79.49 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.624 -0.673 . . . . 0.0 110.059 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -63.36 -46.01 88.52 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.253 -0.904 . . . . 0.0 109.205 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.71 -33.04 68.43 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.714 -0.616 . . . . 0.0 109.552 179.023 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.1 mtp-105 -68.84 -38.2 79.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.831 -0.543 . . . . 0.0 110.495 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -67.4 -40.33 85.59 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.421 -0.799 . . . . 0.0 110.73 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 43.8 t -69.38 -31.82 70.45 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.351 -0.843 . . . . 0.0 111.207 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 30.5 t -58.41 -42.19 86.64 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.224 -0.923 . . . . 0.0 110.305 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -84.15 -23.66 30.54 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.385 -0.822 . . . . 0.0 111.0 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 4.6 mmt-85 -85.76 -32.9 21.6 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 111.309 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -139.35 9.29 2.48 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.121 -0.987 . . . . 0.0 112.283 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.06 27.79 72.73 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.513 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.08 140.1 48.76 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.271 -1.135 . . . . 0.0 110.382 -179.561 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 98.2 m 63.59 53.12 2.12 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.877 0.846 . . . . 0.0 109.181 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 25.8 m -97.13 -14.55 21.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.828 -0.545 . . . . 0.0 111.783 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -122.85 42.25 3.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.972 -1.08 . . . . 0.0 110.858 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.484 HG21 ' CB ' ' A' ' 36' ' ' CYS . 72.4 t . . . . . 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.725 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo . . . . . 0 N--CA 1.485 1.018 0 N-CA-C 110.286 -0.698 . . . . 0.0 110.286 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.47 -28.44 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.457 -0.777 . . . . 0.0 110.845 -179.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -71.07 -12.66 61.64 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.257 -0.902 . . . . 0.0 111.353 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.2 m 55.32 29.19 12.51 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.333 -0.855 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -125.92 152.58 45.42 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.236 -0.915 . . . . 0.0 110.204 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.35 36.2 59.66 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -127.44 156.25 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.291 -1.123 . . . . 0.0 110.243 179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -82.38 160.24 22.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.507 -0.746 . . . . 0.0 109.38 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -58.15 -41.64 84.18 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.533 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -67.53 -36.72 81.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.633 -0.667 . . . . 0.0 110.156 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -65.61 -41.94 92.15 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.416 -0.803 . . . . 0.0 109.704 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.29 -34.12 75.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.757 -0.59 . . . . 0.0 110.361 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.16 -33.8 73.97 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.458 -0.776 . . . . 0.0 110.12 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -69.03 -46.0 69.03 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.538 -0.726 . . . . 0.0 111.059 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 42.4 t -69.52 -32.5 71.39 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.334 -0.854 . . . . 0.0 111.219 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.1 t -64.73 -42.04 95.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.222 -0.924 . . . . 0.0 110.775 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -82.46 -25.25 33.74 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.359 -0.838 . . . . 0.0 111.496 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.24 -29.51 18.14 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.189 -0.944 . . . . 0.0 111.526 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.2 mt -137.03 3.43 2.66 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.049 -1.032 . . . . 0.0 112.648 -178.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.49 28.45 73.61 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.453 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -118.16 146.81 43.92 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.296 -1.12 . . . . 0.0 110.606 -179.446 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.2 m 59.46 48.93 9.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 122.041 0.924 . . . . 0.0 109.027 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.5 m -92.53 -16.8 25.29 Favored 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.713 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -114.9 41.79 2.31 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.062 -1.023 . . . . 0.0 110.62 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 95.5 t . . . . . 0 N--CA 1.499 2.003 0 O-C-N 121.478 -0.764 . . . . 0.0 110.002 179.804 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo . . . . . 0 N--CA 1.488 1.166 0 N-CA-C 110.578 -0.585 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.0 t -76.16 -33.04 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.356 -0.84 . . . . 0.0 110.719 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.423 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.5 OUTLIER -73.17 -13.87 61.25 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.449 -0.782 . . . . 0.0 111.355 -179.859 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.435 ' HB3' HG21 ' A' ' 57' ' ' VAL . 60.1 m 61.95 24.65 14.7 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.536 -0.728 . . . . 0.0 111.428 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -107.93 139.83 41.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.88 23.12 39.74 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.9 pt -135.35 160.32 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.08 -1.247 . . . . 0.0 110.246 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.9 m -81.47 164.54 21.95 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.58 -0.7 . . . . 0.0 110.388 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -58.38 -48.31 81.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.242 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.6 t -60.65 -37.86 82.94 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.692 -0.63 . . . . 0.0 110.181 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -65.92 -44.22 85.79 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.362 -0.836 . . . . 0.0 109.466 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.46 -35.52 70.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.775 -0.578 . . . . 0.0 109.899 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? -69.94 -37.51 75.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.563 -0.711 . . . . 0.0 109.931 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.0 t -64.59 -40.47 95.58 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.664 -0.647 . . . . 0.0 110.706 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.1 t -71.62 -33.38 68.92 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.456 -0.778 . . . . 0.0 111.596 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.5 t -57.63 -44.04 85.26 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 21.3 t -80.33 -24.42 39.91 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 111.087 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.65 -32.15 19.41 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.258 -0.901 . . . . 0.0 111.684 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.1 mt -137.37 2.11 2.46 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.067 -1.021 . . . . 0.0 112.671 -178.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 74.05 22.78 77.46 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.3 mmp_? -110.65 143.99 40.26 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.22 -1.165 . . . . 0.0 110.833 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 93.4 m 61.84 51.82 3.68 Favored 'General case' 0 N--CA 1.5 2.05 0 CA-C-O 121.949 0.88 . . . . 0.0 109.233 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 43.0 m -96.9 -14.28 21.89 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.882 -0.511 . . . . 0.0 111.872 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -124.97 42.68 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.978 -1.076 . . . . 0.0 111.025 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 36' ' ' CYS . 52.9 t . . . . . 0 N--CA 1.494 1.741 0 O-C-N 121.295 -0.878 . . . . 0.0 109.695 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 CA-C-O 121.313 0.464 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.1 t -72.3 -29.28 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.41 -0.806 . . . . 0.0 110.748 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -74.09 -6.53 48.16 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.346 -0.846 . . . . 0.0 111.68 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 96.2 m 58.14 28.58 16.66 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.235 -0.916 . . . . 0.0 110.587 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -109.16 155.01 21.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 110.128 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.86 17.9 77.89 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.5 pt -136.47 162.13 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.188 -1.183 . . . . 0.0 110.066 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.6 t -87.92 169.11 12.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.404 -0.81 . . . . 0.0 110.023 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.421 ' O ' ' HB2' ' A' ' 45' ' ' ARG . 60.3 t80 -59.42 -44.66 92.82 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.655 -0.653 . . . . 0.0 109.455 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.0 t -65.47 -39.58 92.12 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.647 -0.658 . . . . 0.0 110.074 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -65.86 -42.24 90.68 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.388 -0.82 . . . . 0.0 109.697 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.865 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.59 -39.01 81.12 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.589 -0.695 . . . . 0.0 109.348 178.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -64.86 -40.02 94.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.792 -0.567 . . . . 0.0 109.533 178.874 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 t -62.04 -43.95 97.75 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.862 -0.524 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 27.2 t -67.26 -31.2 71.38 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.301 -0.874 . . . . 0.0 111.339 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.4 t -59.73 -41.95 92.07 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.968 -1.083 . . . . 0.0 109.855 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.9 t -84.84 -22.96 29.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.35 -0.844 . . . . 0.0 110.913 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.4 mtp180 -85.44 -33.65 21.86 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.217 -0.927 . . . . 0.0 111.304 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -140.26 8.97 2.27 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.17 -0.956 . . . . 0.0 112.192 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.72 24.95 75.38 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.482 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.14 144.41 43.22 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.208 -1.172 . . . . 0.0 110.714 -179.907 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 31.6 m 61.98 48.93 4.89 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 121.942 0.877 . . . . 0.0 109.395 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 18.2 m -89.08 -25.17 22.05 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.863 -0.523 . . . . 0.0 110.914 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -106.21 38.51 2.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.207 -0.933 . . . . 0.0 109.895 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.865 HG21 ' HB1' ' A' ' 44' ' ' ALA . 20.3 t . . . . . 0 N--CA 1.497 1.882 0 O-C-N 121.564 -0.71 . . . . 0.0 109.838 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo . . . . . 0 N--CA 1.489 1.214 0 N-CA-C 110.574 -0.587 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 69.9 t -62.09 -30.84 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.147 0 O-C-N 121.478 -0.764 . . . . 0.0 110.63 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.42 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 7.6 t -68.47 -10.23 54.07 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.446 -0.784 . . . . 0.0 111.307 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 35' ' ' SER . 73.4 m 59.36 27.49 16.59 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.355 -0.84 . . . . 0.0 110.996 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -108.59 150.63 27.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.394 -0.816 . . . . 0.0 110.028 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.55 24.09 71.3 Favored Glycine 0 N--CA 1.496 2.645 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.424 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 20.9 pt -134.06 157.41 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.049 -1.265 . . . . 0.0 110.278 179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.09 162.11 23.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.654 -0.654 . . . . 0.0 109.474 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 87.2 t80 -57.04 -49.74 74.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.399 -0.813 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -64.38 -33.12 75.11 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.589 -0.695 . . . . 0.0 110.146 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -65.6 -43.13 90.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.316 -0.865 . . . . 0.0 109.482 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.478 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -69.86 -36.26 75.37 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.636 . . . . 0.0 109.853 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.3 ttt180 -67.47 -40.16 85.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.67 -0.644 . . . . 0.0 110.149 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.3 t -66.07 -36.88 84.38 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.609 -0.682 . . . . 0.0 110.794 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 19.1 t -72.61 -31.32 65.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.25 -0.906 . . . . 0.0 111.325 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 29.9 t -58.9 -42.95 90.82 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.141 -0.974 . . . . 0.0 110.078 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.8 t -84.86 -24.45 28.54 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.396 -0.815 . . . . 0.0 110.948 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -83.29 -32.13 26.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.217 -0.927 . . . . 0.0 111.475 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.82 12.67 1.87 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.176 -0.952 . . . . 0.0 112.208 -179.063 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.29 31.05 79.42 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.7 mmt180 -118.42 139.88 50.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.389 -1.065 . . . . 0.0 110.458 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 10.5 m 62.46 55.14 2.33 Favored 'General case' 0 N--CA 1.498 1.951 0 CA-C-O 121.999 0.904 . . . . 0.0 109.327 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 19.1 m -96.3 -16.43 21.34 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.43 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -112.8 42.36 1.88 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.1 -1.0 . . . . 0.0 110.189 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.478 HG21 ' HB1' ' A' ' 44' ' ' ALA . 74.0 t . . . . . 0 N--CA 1.497 1.908 0 O-C-N 121.384 -0.823 . . . . 0.0 109.954 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 N--CA 1.49 1.295 0 N-CA-C 110.817 -0.493 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 t -61.39 -29.4 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.521 -0.737 . . . . 0.0 110.522 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.1 t -69.63 -8.05 44.22 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.434 -0.792 . . . . 0.0 111.147 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 35' ' ' SER . 81.6 m 59.14 25.22 13.68 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.353 -0.842 . . . . 0.0 111.255 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -112.39 158.05 20.29 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.288 -0.883 . . . . 0.0 110.012 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.16 22.08 76.95 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.1 pt -135.47 153.59 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.142 -1.211 . . . . 0.0 110.274 179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.2 t -80.3 169.25 18.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.632 -0.667 . . . . 0.0 109.952 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -60.31 -48.86 79.93 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.568 -0.708 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.2 t -61.83 -36.44 81.17 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.666 -0.647 . . . . 0.0 110.192 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -64.62 -44.8 89.39 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.565 -0.709 . . . . 0.0 109.886 179.51 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.6 -33.99 76.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.803 -0.561 . . . . 0.0 110.395 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.22 -39.57 78.49 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.466 -0.771 . . . . 0.0 110.122 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 3.6 t -64.95 -40.44 95.02 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.658 -0.652 . . . . 0.0 110.951 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.4 t -71.62 -32.03 67.54 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.282 -0.886 . . . . 0.0 111.443 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 33.1 t -58.64 -42.9 89.38 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.126 -0.984 . . . . 0.0 110.363 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 32.3 t -84.24 -25.98 29.02 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.352 -0.843 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.3 OUTLIER -84.26 -31.96 24.7 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.286 -0.884 . . . . 0.0 111.453 -179.394 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.4 mt -138.87 6.55 2.43 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 112.556 -178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.02 28.32 73.75 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 6.9 mmt-85 -115.6 139.92 49.65 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.213 -1.169 . . . . 0.0 110.638 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.486 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 80.5 m 62.46 57.27 1.92 Allowed 'General case' 0 N--CA 1.499 2.003 0 CA-C-O 121.939 0.876 . . . . 0.0 109.42 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 34.9 m -100.12 -6.21 26.63 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.749 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -128.18 46.43 2.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.065 . . . . 0.0 110.517 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 94.8 t . . . . . 0 N--CA 1.496 1.861 0 O-C-N 121.261 -0.9 . . . . 0.0 110.09 179.885 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo . . . . . 0 N--CA 1.488 1.197 0 N-CA-C 110.608 -0.574 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.35 -27.4 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.302 -0.874 . . . . 0.0 110.399 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.43 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -67.18 -18.39 65.25 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.429 -0.795 . . . . 0.0 110.78 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 35' ' ' SER . 95.5 m 58.99 26.27 14.86 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.549 -0.719 . . . . 0.0 111.178 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -108.95 144.57 36.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.261 -0.9 . . . . 0.0 110.046 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.27 34.27 64.23 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.3 pt -125.78 155.15 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.2 -1.176 . . . . 0.0 110.123 179.454 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.84 159.27 21.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.668 -0.645 . . . . 0.0 109.475 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -57.66 -42.47 83.57 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.424 -0.797 . . . . 0.0 109.641 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.2 t -67.32 -34.45 77.38 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.583 -0.698 . . . . 0.0 109.95 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.39 -41.35 89.5 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.473 -0.767 . . . . 0.0 109.69 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -74.23 -27.5 60.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.748 -0.595 . . . . 0.0 110.34 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -35.96 61.01 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.53 -0.731 . . . . 0.0 110.389 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -70.88 -40.62 72.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.448 -0.783 . . . . 0.0 111.09 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.7 t -73.55 -30.44 63.07 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.237 -0.914 . . . . 0.0 111.299 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.4 -42.63 92.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.126 -0.984 . . . . 0.0 110.579 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 33.1 t -82.92 -25.28 32.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.816 . . . . 0.0 111.587 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.9 mmm180 -92.28 -27.02 17.87 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.215 -0.928 . . . . 0.0 111.636 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 mt -137.31 2.95 2.56 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.071 -1.018 . . . . 0.0 112.509 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.64 28.28 73.46 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.422 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.8 OUTLIER -118.04 143.19 46.63 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.26 -1.141 . . . . 0.0 110.415 -179.647 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 1.3 m 62.39 52.87 2.91 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.001 0.905 . . . . 0.0 109.097 -179.252 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 50.4 m -97.85 -3.71 38.19 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.339 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 35.8 t-80 -122.67 45.35 2.4 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.167 -0.958 . . . . 0.0 109.88 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.456 HG21 ' HB1' ' A' ' 44' ' ' ALA . 17.0 t . . . . . 0 N--CA 1.497 1.885 0 O-C-N 121.373 -0.83 . . . . 0.0 110.194 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 N--CA 1.489 1.215 0 N-CA-C 110.839 -0.485 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.557 HG22 HH11 ' A' ' 53' ' ' ARG . 79.4 t -65.0 -28.79 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.535 -0.728 . . . . 0.0 110.429 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.432 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.2 t -67.12 -21.38 65.84 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.484 -0.76 . . . . 0.0 110.896 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' SER . 74.1 m 59.62 28.68 18.16 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.557 -0.715 . . . . 0.0 110.892 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -104.41 146.09 29.34 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.271 -0.893 . . . . 0.0 110.273 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.99 26.69 43.88 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.8 pt -137.01 160.0 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.221 -1.164 . . . . 0.0 110.259 179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.8 m -85.53 168.27 14.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.556 -0.715 . . . . 0.0 110.06 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.65 -45.27 94.73 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.598 -0.689 . . . . 0.0 109.376 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.1 t -65.42 -38.53 90.19 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.611 -0.681 . . . . 0.0 110.026 179.235 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -63.25 -43.04 99.12 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.809 . . . . 0.0 109.71 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -66.98 -38.48 86.12 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.685 -0.634 . . . . 0.0 109.846 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.96 -38.27 85.8 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-O 121.551 0.691 . . . . 0.0 109.69 178.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 t -62.79 -40.94 98.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.726 -0.609 . . . . 0.0 111.598 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.413 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 6.0 t -76.83 -28.42 55.51 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.997 -1.064 . . . . 0.0 111.599 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.4 t -59.28 -41.14 88.21 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.068 -1.02 . . . . 0.0 109.606 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.7 t -86.81 -24.32 25.06 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.413 ' HB3' ' HA ' ' A' ' 47' ' ' CYS . 3.1 tmm_? -77.94 -36.7 48.99 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.364 -0.835 . . . . 0.0 111.066 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.406 HD12 ' HD2' ' A' ' 50' ' ' ARG . 0.2 OUTLIER -144.07 16.97 1.74 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.231 -0.918 . . . . 0.0 111.946 -179.284 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.89 33.42 83.38 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.557 HH11 HG22 ' A' ' 34' ' ' VAL . 5.9 mmt-85 -119.6 144.27 47.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.418 -1.048 . . . . 0.0 110.598 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.7 m 60.2 54.7 3.93 Favored 'General case' 0 N--CA 1.498 1.965 0 CA-C-O 122.019 0.914 . . . . 0.0 109.095 -179.345 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.3 m -97.29 -17.15 19.96 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.399 -179.057 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -110.17 41.79 1.67 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.113 -0.992 . . . . 0.0 110.076 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.708 HG21 ' HB1' ' A' ' 44' ' ' ALA . 47.4 t . . . . . 0 N--CA 1.498 1.941 0 O-C-N 121.383 -0.823 . . . . 0.0 110.409 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo . . . . . 0 N--CA 1.494 1.505 0 CA-C-O 121.369 0.487 . . . . 0.0 111.621 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 54.3 t -79.85 -36.29 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.967 0 O-C-N 121.507 -0.746 . . . . 0.0 110.487 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -68.8 -15.02 63.39 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.541 -0.724 . . . . 0.0 111.383 -179.606 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 33.0 m 57.8 27.97 15.27 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.4 -0.812 . . . . 0.0 110.84 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 7.4 mtt-85 -111.09 149.94 30.1 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.354 -0.841 . . . . 0.0 109.982 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.01 34.18 43.03 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.6 pt -129.77 154.15 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.135 . . . . 0.0 110.177 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 m -83.83 161.47 20.9 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.599 -0.688 . . . . 0.0 109.741 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.92 -41.39 82.58 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.432 -0.793 . . . . 0.0 109.574 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -67.97 -36.44 80.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 0.0 110.093 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -67.43 -40.19 85.47 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.429 -0.794 . . . . 0.0 109.911 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.92 -34.52 73.6 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 0.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.6 ttp180 -70.12 -31.3 68.79 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.434 -0.791 . . . . 0.0 110.232 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 2.0 t -71.35 -44.24 65.41 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.542 -0.724 . . . . 0.0 111.314 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.7 t -75.41 -29.18 59.68 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.19 -0.944 . . . . 0.0 111.467 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.5 t -62.25 -42.67 99.54 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.165 -0.959 . . . . 0.0 110.078 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 10.2 t -84.97 -25.12 27.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.329 -0.857 . . . . 0.0 110.685 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 46' ' ' SER . 3.9 ttt180 -81.7 -33.71 31.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.414 -0.804 . . . . 0.0 111.312 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -142.12 9.57 1.9 Allowed 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.167 -0.958 . . . . 0.0 112.328 -179.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 66.99 27.72 73.53 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -115.73 144.82 43.42 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.172 -1.193 . . . . 0.0 110.812 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 44.9 m 62.08 51.78 3.5 Favored 'General case' 0 N--CA 1.499 1.985 0 CA-C-O 122.013 0.911 . . . . 0.0 109.438 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.36 -4.53 38.29 Favored 'General case' 0 N--CA 1.487 1.395 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.317 -179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.3 t-160 -126.02 47.74 2.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.048 -1.032 . . . . 0.0 109.944 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 64.2 t . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.511 -0.743 . . . . 0.0 110.379 -179.832 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 N--CA 1.487 1.104 0 N-CA-C 110.528 -0.605 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.2 t -79.83 -28.06 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.325 -0.859 . . . . 0.0 110.466 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -74.19 -11.8 60.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.228 -0.92 . . . . 0.0 111.179 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.8 m 58.27 25.69 12.99 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.399 -0.813 . . . . 0.0 111.006 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.8 mmt-85 -110.58 156.09 21.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.352 -0.843 . . . . 0.0 109.943 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.97 30.57 69.99 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.435 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.5 pt -131.69 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.266 -1.138 . . . . 0.0 109.981 179.62 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.408 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 1.6 m -82.27 158.52 23.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.715 -0.616 . . . . 0.0 109.446 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -56.62 -44.39 81.16 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.405 -0.809 . . . . 0.0 109.732 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.6 t -68.14 -35.74 78.58 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.598 -0.689 . . . . 0.0 109.971 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.0 OUTLIER -64.29 -41.92 96.63 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.638 -0.664 . . . . 0.0 109.925 179.548 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.435 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -66.98 -36.82 83.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.576 -0.703 . . . . 0.0 109.993 179.415 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.8 mtm180 -65.62 -40.77 92.94 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.656 -0.653 . . . . 0.0 110.062 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.04 -45.12 96.08 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.832 -0.543 . . . . 0.0 111.363 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.555 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 51.8 t -68.56 -33.37 73.96 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.163 -0.961 . . . . 0.0 111.11 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.9 t -60.29 -41.86 94.27 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.167 -0.958 . . . . 0.0 110.465 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 23.0 t -83.43 -22.47 32.65 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.372 -0.83 . . . . 0.0 111.538 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -95.55 -26.68 15.69 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.032 -1.043 . . . . 0.0 111.584 -179.291 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.1 mt -135.84 1.76 2.81 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.166 -0.959 . . . . 0.0 112.478 -178.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.79 26.94 73.7 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.555 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.78 146.31 42.93 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.304 -1.115 . . . . 0.0 110.418 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 92.6 m 60.76 53.52 3.9 Favored 'General case' 0 N--CA 1.499 1.978 0 CA-C-O 121.885 0.85 . . . . 0.0 109.136 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 53.6 m -100.15 -4.06 30.44 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.551 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -127.39 45.89 2.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.04 -1.038 . . . . 0.0 110.288 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 60.1 t . . . . . 0 N--CA 1.496 1.874 0 O-C-N 121.315 -0.866 . . . . 0.0 110.317 -179.934 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 N--CA 1.487 1.099 0 N-CA-C 110.577 -0.586 . . . . 0.0 110.577 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -69.14 -26.24 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 O-C-N 121.437 -0.789 . . . . 0.0 110.859 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.36 -11.13 59.99 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.15 -0.969 . . . . 0.0 111.411 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 79.7 m 57.44 26.79 13.02 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.391 -0.818 . . . . 0.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -108.45 150.32 27.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.304 -0.872 . . . . 0.0 110.565 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.86 28.23 65.28 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.9 pt -132.48 158.29 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.178 -1.189 . . . . 0.0 110.114 179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.32 161.08 25.25 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.636 . . . . 0.0 109.684 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.25 -48.46 78.8 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.439 -0.788 . . . . 0.0 109.8 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.01 -33.91 76.88 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.605 -0.685 . . . . 0.0 110.094 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -63.64 -43.87 95.54 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.486 -0.759 . . . . 0.0 109.678 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.875 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.01 -36.14 79.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.638 -0.664 . . . . 0.0 109.545 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -64.53 -40.01 94.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.701 -0.624 . . . . 0.0 110.225 179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.9 t -62.91 -44.91 94.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.627 -0.67 . . . . 0.0 111.041 -179.564 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.55 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 41.4 t -65.71 -34.05 77.3 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.231 -0.918 . . . . 0.0 110.945 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 40.3 t -59.54 -42.66 92.83 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.144 -0.973 . . . . 0.0 110.572 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -87.84 -26.77 22.63 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.335 -0.853 . . . . 0.0 111.164 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -85.62 -30.67 23.08 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.291 -0.881 . . . . 0.0 111.368 -179.289 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -134.52 4.58 3.39 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.29 -0.881 . . . . 0.0 112.21 -178.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.35 31.27 80.18 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.55 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 5.0 mmp_? -125.81 148.96 48.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.459 -1.024 . . . . 0.0 110.074 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.2 m 61.17 45.84 8.62 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.022 0.915 . . . . 0.0 108.611 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 9.0 m -90.12 -10.14 45.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.808 -0.557 . . . . 0.0 111.325 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -117.75 43.51 2.38 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.21 -0.931 . . . . 0.0 109.861 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.875 HG21 ' HB1' ' A' ' 44' ' ' ALA . 61.4 t . . . . . 0 N--CA 1.499 1.99 0 O-C-N 121.444 -0.785 . . . . 0.0 110.363 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo . . . . . 0 N--CA 1.488 1.193 0 N-CA-C 110.386 -0.659 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.2 t -78.2 -32.07 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.409 -0.807 . . . . 0.0 110.733 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.43 -16.61 60.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.172 -0.955 . . . . 0.0 110.952 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.1 m 57.99 30.39 19.12 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.372 -0.83 . . . . 0.0 110.239 -179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.5 mtp180 -113.01 154.07 27.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.508 -0.745 . . . . 0.0 110.128 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.55 34.69 59.91 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.9 pt -139.83 161.81 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.403 -1.057 . . . . 0.0 109.855 179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 7.8 m -80.44 161.08 25.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.534 -0.728 . . . . 0.0 109.963 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.9 t80 -58.54 -43.72 89.36 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.512 -0.743 . . . . 0.0 109.39 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.9 t -65.0 -38.63 91.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.641 -0.662 . . . . 0.0 109.827 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 28.5 tp60 -64.21 -44.76 90.94 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.611 -0.68 . . . . 0.0 109.593 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.93 79.2 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -65.69 -36.26 83.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.815 -0.553 . . . . 0.0 109.793 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -63.42 -47.77 80.57 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.797 -0.564 . . . . 0.0 111.197 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 53.1 t -66.45 -33.69 76.26 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.241 -0.912 . . . . 0.0 111.091 -179.543 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.0 t -57.81 -41.67 82.69 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.163 -0.961 . . . . 0.0 110.169 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -84.59 -25.59 28.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.272 -0.892 . . . . 0.0 110.367 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.8 ttm180 -79.39 -36.18 39.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.327 -0.858 . . . . 0.0 111.195 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.32 11.39 2.14 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.116 -0.99 . . . . 0.0 112.353 -178.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.04 26.93 73.29 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.461 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.74 141.61 47.61 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.243 -1.151 . . . . 0.0 110.571 -179.921 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 54.1 m 66.25 54.61 0.93 Allowed 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.799 0.809 . . . . 0.0 108.917 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 67.5 m -102.92 -0.62 30.82 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.845 -0.535 . . . . 0.0 111.75 -178.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -137.03 50.24 2.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.935 -1.103 . . . . 0.0 110.645 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.2 t . . . . . 0 N--CA 1.497 1.91 0 O-C-N 121.115 -0.99 . . . . 0.0 110.245 179.649 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.489 1.254 0 N-CA-C 110.719 -0.531 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.6 t -77.38 -29.93 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.475 -0.766 . . . . 0.0 110.861 -179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.419 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -73.33 -12.68 60.92 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.24 -0.912 . . . . 0.0 111.27 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 35' ' ' SER . 68.5 m 58.15 25.55 12.64 Favored 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.45 -0.781 . . . . 0.0 111.155 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.405 ' O ' HG23 ' A' ' 39' ' ' ILE . 2.0 mtt180 -115.9 158.55 22.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.317 -0.865 . . . . 0.0 110.032 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.83 28.74 73.91 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 37' ' ' ARG . 16.2 pt -125.71 152.0 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.325 -1.103 . . . . 0.0 109.937 179.538 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -77.32 160.17 29.01 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.77 -44.56 86.25 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.346 -0.846 . . . . 0.0 109.724 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.0 -35.57 80.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.513 -0.742 . . . . 0.0 109.914 179.143 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.4 -44.22 96.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.396 -0.815 . . . . 0.0 109.117 178.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.758 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.56 -34.83 72.67 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.814 -0.554 . . . . 0.0 109.571 178.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -34.96 77.0 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.696 -0.627 . . . . 0.0 110.283 179.388 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -69.65 -41.44 75.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.497 -0.752 . . . . 0.0 110.839 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 48.8 t -71.96 -32.83 67.66 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.408 -0.808 . . . . 0.0 111.061 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.5 t -65.36 -43.17 91.65 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.246 -0.909 . . . . 0.0 110.917 -179.471 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.6 t -80.94 -21.36 40.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.451 -0.781 . . . . 0.0 112.126 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -101.79 -23.24 14.22 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.009 -1.057 . . . . 0.0 111.724 -179.15 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -134.14 -8.73 2.64 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.967 -1.083 . . . . 0.0 112.541 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.02 26.51 66.45 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.42 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -120.23 148.72 43.33 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.246 -1.149 . . . . 0.0 110.689 -179.596 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 11.8 m 58.95 46.08 14.15 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 122.033 0.92 . . . . 0.0 108.885 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 20.7 m -88.76 -12.78 41.18 Favored 'General case' 0 N--CA 1.488 1.428 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.185 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -116.89 45.17 1.91 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.219 -0.926 . . . . 0.0 109.974 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.758 HG21 ' HB1' ' A' ' 44' ' ' ALA . 94.2 t . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.429 -0.795 . . . . 0.0 110.229 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 N-CA-C 110.455 -0.633 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.45 HG22 ' HD2' ' A' ' 53' ' ' ARG . 90.3 t -62.56 -32.07 54.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.474 -0.767 . . . . 0.0 110.438 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.9 -14.17 61.86 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.492 -0.755 . . . . 0.0 111.08 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.455 ' CB ' HG21 ' A' ' 57' ' ' VAL . 35.2 m 57.75 30.53 19.09 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.511 -0.743 . . . . 0.0 111.09 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.1 mtt85 -105.53 139.95 39.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.267 -0.895 . . . . 0.0 109.999 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.56 0.68 81.73 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 39' ' ' ILE . 27.0 pt -116.28 158.48 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.063 -1.257 . . . . 0.0 110.125 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -80.08 165.11 22.83 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.699 -0.626 . . . . 0.0 110.639 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -57.82 -48.81 78.66 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.61 -0.681 . . . . 0.0 109.288 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -61.45 -37.51 83.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.668 -0.645 . . . . 0.0 109.781 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -64.82 -44.0 91.3 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.425 -0.797 . . . . 0.0 109.56 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.49 78.42 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.69 -0.631 . . . . 0.0 109.66 179.112 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -36.89 80.57 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.716 -0.615 . . . . 0.0 109.76 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.6 t -64.45 -42.16 96.13 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.756 -0.59 . . . . 0.0 110.946 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 42.3 t -70.26 -34.99 73.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.113 -0.992 . . . . 0.0 111.176 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.3 t -58.15 -40.55 81.67 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.121 -0.987 . . . . 0.0 110.212 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.09 -14.32 50.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 111.297 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -101.62 -31.02 11.03 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.103 -0.998 . . . . 0.0 111.209 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -134.23 -1.69 2.89 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.207 -0.933 . . . . 0.0 112.306 -179.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.98 72.33 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HD2' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -113.49 152.0 30.73 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.07 -1.253 . . . . 0.0 110.521 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.5 m 59.79 53.55 4.79 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.887 0.851 . . . . 0.0 108.721 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 69.3 m -104.94 9.57 34.55 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.475 -178.61 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -146.01 46.04 1.25 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 110.523 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.455 HG21 ' CB ' ' A' ' 36' ' ' CYS . 70.8 t . . . . . 0 N--CA 1.496 1.87 0 O-C-N 121.17 -0.956 . . . . 0.0 110.35 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.42 ' HD2' HG21 ' A' ' 39' ' ' ILE . 41.4 Cg_endo . . . . . 0 N--CA 1.49 1.313 0 N-CA-C 110.758 -0.516 . . . . 0.0 110.758 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.646 HG13 ' NH1' ' A' ' 53' ' ' ARG . 87.4 t -60.03 -31.27 47.42 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.584 -0.697 . . . . 0.0 110.936 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 t -72.86 -4.49 32.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.234 -0.916 . . . . 0.0 111.767 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 55.6 28.58 12.14 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.291 -0.881 . . . . 0.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.3 mtt85 -123.63 161.47 24.97 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.307 -0.87 . . . . 0.0 110.213 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.59 30.81 65.99 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.42 HG21 ' HD2' ' A' ' 33' ' ' PRO . 16.0 pt -141.61 159.47 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.496 -1.002 . . . . 0.0 109.896 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 11.6 m -80.84 161.41 24.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.515 -0.74 . . . . 0.0 109.824 179.525 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -57.4 -45.68 84.29 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.553 -0.717 . . . . 0.0 109.389 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.1 t -64.04 -36.6 84.52 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.658 -0.651 . . . . 0.0 109.864 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.44 -44.87 89.81 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.649 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.1 -36.44 74.88 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.727 -0.608 . . . . 0.0 109.901 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.6 tpp85 -67.82 -38.0 82.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.675 -0.64 . . . . 0.0 109.508 179.088 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 16.3 t -64.05 -44.11 93.47 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.816 -0.552 . . . . 0.0 110.686 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.4 t -64.87 -30.18 71.16 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.935 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.8 t -70.3 -43.21 70.82 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.214 -0.929 . . . . 0.0 110.558 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -81.85 -21.05 37.76 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.272 -0.893 . . . . 0.0 112.016 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -105.59 -19.7 13.69 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.035 -1.04 . . . . 0.0 111.714 -179.493 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -6.33 2.87 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.108 -0.995 . . . . 0.0 112.446 -179.168 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.52 25.99 74.82 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.646 ' NH1' HG13 ' A' ' 34' ' ' VAL . 13.9 mmm180 -121.22 148.76 43.82 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.227 -1.161 . . . . 0.0 110.439 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 5.3 m 59.26 48.32 10.42 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-O 121.97 0.89 . . . . 0.0 108.824 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 14.8 m -91.43 -6.42 52.8 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.373 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -120.63 45.38 2.24 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.146 -0.971 . . . . 0.0 109.888 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.413 HG21 ' HB1' ' A' ' 44' ' ' ALA . 39.1 t . . . . . 0 N--CA 1.497 1.905 0 O-C-N 121.391 -0.818 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo . . . . . 0 N--CA 1.49 1.274 0 N-CA-C 110.832 -0.488 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.4 t -65.92 -27.86 42.31 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.384 -0.822 . . . . 0.0 110.31 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -65.38 -18.04 65.0 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.403 -0.811 . . . . 0.0 111.034 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 35' ' ' SER . 84.1 m 58.29 27.23 14.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.479 -0.763 . . . . 0.0 111.211 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -114.21 147.72 38.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.397 -0.814 . . . . 0.0 109.848 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.11 30.24 65.57 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.4 pt -124.67 155.77 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.381 -1.07 . . . . 0.0 109.854 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -82.13 157.32 24.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.647 . . . . 0.0 109.413 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.61 -39.95 78.03 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.419 -0.801 . . . . 0.0 109.69 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -69.91 -35.63 74.74 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.632 -0.668 . . . . 0.0 110.084 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -65.38 -40.16 93.17 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.714 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.59 -35.88 73.25 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.669 -0.644 . . . . 0.0 110.285 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.27 -32.36 70.14 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 179.428 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.524 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 8.5 t -71.44 -41.6 69.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.555 -0.716 . . . . 0.0 110.948 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.4 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 11.8 t -74.0 -29.07 61.76 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.242 -0.911 . . . . 0.0 111.743 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.7 t -59.48 -43.3 93.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.987 -1.07 . . . . 0.0 109.996 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 12.3 t -89.27 -25.21 21.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.381 -0.824 . . . . 0.0 110.629 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.524 ' HB2' ' O ' ' A' ' 46' ' ' SER . 2.3 ttp85 -79.72 -34.66 39.89 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.407 -0.808 . . . . 0.0 111.181 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -141.08 10.68 2.16 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.162 -0.961 . . . . 0.0 112.289 -179.026 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.81 33.38 82.82 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -123.68 142.52 50.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.584 -0.95 . . . . 0.0 110.097 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 1.8 m 59.76 56.29 3.6 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 121.985 0.898 . . . . 0.0 108.974 -179.038 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 4.4 m -94.98 -11.5 28.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.883 -0.511 . . . . 0.0 111.312 -178.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -122.69 44.14 2.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.149 -0.969 . . . . 0.0 110.078 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.714 HG21 ' HB1' ' A' ' 44' ' ' ALA . 38.1 t . . . . . 0 N--CA 1.5 2.026 0 O-C-N 121.494 -0.754 . . . . 0.0 110.363 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo . . . . . 0 N--CA 1.49 1.292 0 N-CA-C 110.692 -0.542 . . . . 0.0 110.692 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 96.2 t -66.22 -29.6 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.363 -0.836 . . . . 0.0 110.669 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.2 t -68.51 -19.31 64.52 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.353 -0.842 . . . . 0.0 111.092 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.3 m 60.69 30.18 19.53 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.495 -0.753 . . . . 0.0 110.627 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -107.41 146.47 31.63 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.27 -0.894 . . . . 0.0 110.373 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.83 29.22 55.23 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 28.4 pt -137.55 163.13 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.198 -1.178 . . . . 0.0 110.33 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.45 ' HB3' ' HB2' ' A' ' 43' ' ' GLN . 13.5 t -80.7 166.56 20.92 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.564 -0.71 . . . . 0.0 110.082 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -62.58 -49.34 75.64 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 46' ' ' SER . 2.7 t -63.57 -35.32 80.1 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.696 -0.627 . . . . 0.0 109.985 179.245 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.45 ' HB2' ' HB3' ' A' ' 40' ' ' SER . 8.6 tt0 -64.74 -43.39 93.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.45 -0.781 . . . . 0.0 109.645 179.356 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -70.73 -36.65 73.29 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.56 -0.713 . . . . 0.0 109.492 179.008 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 5.6 ttt-85 -68.36 -33.44 74.28 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.758 -0.589 . . . . 0.0 109.7 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 42' ' ' SER . 0.1 OUTLIER -66.33 -46.81 75.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.801 -0.562 . . . . 0.0 110.93 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.4 t -66.02 -30.13 70.61 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.321 -0.862 . . . . 0.0 111.248 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 35.4 t -58.84 -41.06 86.04 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.942 -1.099 . . . . 0.0 109.941 179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 19.4 t -87.26 -25.3 24.04 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.668 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.464 ' HD2' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -82.83 -34.41 26.9 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.314 -0.866 . . . . 0.0 111.316 -179.513 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' HD2' ' A' ' 50' ' ' ARG . 2.1 mt -137.56 6.79 2.76 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.178 -0.951 . . . . 0.0 112.374 -179.009 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.08 27.08 74.18 Favored Glycine 0 N--CA 1.497 2.749 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.498 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.4 OUTLIER -117.53 145.65 44.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.21 -1.17 . . . . 0.0 110.293 179.941 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 83.3 m 63.23 53.7 2.19 Favored 'General case' 0 N--CA 1.501 2.108 0 CA-C-O 121.903 0.858 . . . . 0.0 108.806 -178.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.2 m -101.27 8.56 42.4 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.904 -0.497 . . . . 0.0 111.689 -178.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.7 t60 -141.69 42.39 1.72 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 N--CA 1.495 1.809 0 O-C-N 121.276 -0.89 . . . . 0.0 110.061 179.871 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 CA-C-O 121.266 0.444 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 50.8 t -68.24 -31.1 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.409 -0.807 . . . . 0.0 110.348 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.8 t -68.48 -16.02 63.75 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.407 -0.808 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.492 ' CB ' HG21 ' A' ' 57' ' ' VAL . 75.5 m 57.42 30.33 18.43 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.358 -0.838 . . . . 0.0 110.775 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.3 mtt180 -102.14 152.65 20.76 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.337 -0.852 . . . . 0.0 110.444 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.38 17.22 76.58 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.3 pt -133.18 159.81 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.057 -1.26 . . . . 0.0 110.241 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.6 161.74 23.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.653 -0.655 . . . . 0.0 109.696 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 86.3 t80 -56.36 -50.12 72.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.498 -0.751 . . . . 0.0 109.567 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.5 t -63.07 -35.86 81.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.689 -0.632 . . . . 0.0 110.196 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -64.22 -42.47 96.58 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.43 -0.794 . . . . 0.0 109.801 179.39 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -36.06 77.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.552 -0.718 . . . . 0.0 109.9 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.38 -40.83 93.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.772 -0.58 . . . . 0.0 110.084 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.6 t -62.8 -43.47 98.73 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.558 -0.714 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.3 t -64.81 -34.26 77.95 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.253 -0.904 . . . . 0.0 110.776 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 37.3 t -61.28 -43.09 99.45 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.309 -0.869 . . . . 0.0 110.045 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.0 m -80.06 -13.07 59.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.51 -0.744 . . . . 0.0 111.265 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.92 -28.56 12.33 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.207 -0.933 . . . . 0.0 111.186 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.95 7.84 1.86 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.058 -1.026 . . . . 0.0 112.515 -179.129 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.76 27.17 74.06 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 120.857 -1.152 . . . . 0.0 110.312 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.4 mmp_? -114.83 143.5 45.01 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.078 -1.248 . . . . 0.0 110.562 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 27.5 m 61.7 56.02 2.56 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-O 121.879 0.847 . . . . 0.0 108.973 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 63.8 m -101.85 -3.14 28.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.925 -0.485 . . . . 0.0 112.01 -178.537 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -136.42 47.98 2.16 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.983 -1.073 . . . . 0.0 111.006 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.492 HG21 ' CB ' ' A' ' 36' ' ' CYS . 95.5 t . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.1 -1.0 . . . . 0.0 109.742 179.348 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HG3' HG21 ' A' ' 39' ' ' ILE . 46.3 Cg_endo . . . . . 0 N--CA 1.485 0.989 0 N-CA-C 109.879 -0.854 . . . . 0.0 109.879 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 43.5 t -73.82 -30.33 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.21 -0.931 . . . . 0.0 110.937 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.5 t -73.65 -10.88 60.15 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.275 -0.891 . . . . 0.0 111.825 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 74.8 m 57.43 29.28 16.72 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.232 -0.917 . . . . 0.0 110.878 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -128.51 158.94 36.99 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.306 -0.871 . . . . 0.0 110.636 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.24 37.25 71.45 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.54 HG21 ' HG3' ' A' ' 33' ' ' PRO . 14.1 pt -143.99 159.5 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.423 -1.045 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.5 m -76.06 160.28 29.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.642 -0.661 . . . . 0.0 109.701 179.369 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -58.17 -44.67 88.08 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 109.478 179.356 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -62.61 -37.86 87.92 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.619 -0.676 . . . . 0.0 109.903 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -64.51 -45.82 85.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.546 -0.721 . . . . 0.0 109.668 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.524 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -67.93 -36.7 80.59 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.813 -0.555 . . . . 0.0 109.932 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 33.4 ttp85 -69.95 -36.96 75.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.538 -0.726 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.1 t -63.27 -40.09 96.43 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.687 -0.633 . . . . 0.0 110.845 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 29.6 t -67.77 -40.05 84.05 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.352 -0.843 . . . . 0.0 110.745 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.5 t -59.07 -42.74 91.1 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.392 -0.817 . . . . 0.0 110.747 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.9 -18.89 49.45 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.427 -0.795 . . . . 0.0 111.902 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.83 -25.18 13.6 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.084 -1.01 . . . . 0.0 111.806 -179.229 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -135.1 -5.86 2.36 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.065 -1.022 . . . . 0.0 112.669 -178.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.5 22.92 71.75 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ARG . . . . . 0.5 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.74 148.01 41.51 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.238 -1.154 . . . . 0.0 110.548 -179.847 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 84.7 m 61.37 47.42 6.84 Favored 'General case' 0 N--CA 1.498 1.931 0 CA-C-O 121.974 0.892 . . . . 0.0 109.086 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 36.5 m -91.2 -7.96 49.88 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.904 -0.497 . . . . 0.0 111.228 -179.231 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.8 t60 -124.11 45.73 2.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.145 -0.972 . . . . 0.0 109.908 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.524 HG21 ' HB1' ' A' ' 44' ' ' ALA . 54.4 t . . . . . 0 N--CA 1.497 1.917 0 O-C-N 121.423 -0.798 . . . . 0.0 110.454 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 N--CA 1.497 1.917 0 CA-C-O 121.373 0.606 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.47 158.29 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.655 -0.653 . . . . 0.0 110.33 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.8 m-85 -82.76 118.75 23.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.361 -0.837 . . . . 0.0 110.496 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -105.92 99.51 9.1 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.404 -0.81 . . . . 0.0 110.208 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.29 58.67 3.1 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 174.09 56.59 0.05 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.596 ' O ' ' HB3' ' A' ' 8' ' ' ALA . 89.7 t80 -69.26 106.51 2.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.527 -0.984 . . . . 0.0 109.668 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.596 ' HB3' ' O ' ' A' ' 7' ' ' TYR . . . 70.16 -58.65 0.53 Allowed 'General case' 0 N--CA 1.504 2.245 0 O-C-N 122.043 -0.411 . . . . 0.0 110.61 -179.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -85.9 127.39 62.46 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.201 -0.937 . . . . 0.0 110.4 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HB2' HD12 ' A' ' 11' ' ' ILE . 45.8 Cg_endo -73.01 127.79 12.49 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.901 1.474 . . . . 0.0 110.226 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.4 HD12 ' HB2' ' A' ' 10' ' ' PRO . 2.7 mt 52.07 65.15 6.62 Favored Pre-proline 0 N--CA 1.503 2.215 0 O-C-N 121.751 -0.593 . . . . 0.0 110.153 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -79.68 71.88 6.81 Favored 'Trans proline' 0 C--N 1.314 -1.238 0 O-C-N 123.771 1.406 . . . . 0.0 110.551 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.48 123.28 82.44 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.33 -0.856 . . . . 0.0 110.203 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.93 148.8 58.29 Favored 'Trans proline' 0 C--N 1.315 -1.236 0 O-C-N 123.895 1.471 . . . . 0.0 110.681 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.05 160.6 47.09 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.908 1.478 . . . . 0.0 110.828 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -76.11 -173.21 1.6 Allowed 'Trans proline' 0 C--N 1.313 -1.299 0 O-C-N 123.967 1.509 . . . . 0.0 110.774 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -67.22 148.69 51.43 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.487 -0.758 . . . . 0.0 110.598 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.3 145.29 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.697 -0.627 . . . . 0.0 109.975 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -66.52 116.55 35.38 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.458 -0.776 . . . . 0.0 110.13 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -72.71 178.0 6.87 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.79 1.416 . . . . 0.0 110.792 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -134.37 101.89 11.99 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.621 -0.674 . . . . 0.0 110.112 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.05 138.24 27.84 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.759 1.399 . . . . 0.0 110.57 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.99 -61.91 0.98 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.33 169.21 43.07 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.69 152.1 64.25 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.876 1.461 . . . . 0.0 110.804 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.412 HD13 ' HA ' ' A' ' 26' ' ' ILE . 14.0 mm -85.37 152.57 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.43 -0.794 . . . . 0.0 110.306 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 62.02 72.97 0.56 Allowed Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -78.26 -34.51 1.55 Allowed 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.888 1.468 . . . . 0.0 110.998 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -82.67 67.78 8.87 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -0.884 . . . . 0.0 110.159 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -132.41 41.18 3.23 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.259 -0.901 . . . . 0.0 110.655 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.97 47.1 0.04 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.583 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.8 t -176.21 78.6 0.28 Allowed Pre-proline 0 N--CA 1.5 2.071 0 O-C-N 121.351 -1.088 . . . . 0.0 110.299 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.94 151.11 78.29 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 O-C-N 123.895 1.471 . . . . 0.0 110.966 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.4 t -62.84 -31.23 51.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.505 -0.747 . . . . 0.0 110.937 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.6 OUTLIER -69.22 -12.44 61.67 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.503 -0.748 . . . . 0.0 111.53 -179.677 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 35' ' ' SER . 78.8 m 61.78 27.75 16.99 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.409 -0.807 . . . . 0.0 110.575 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HG2' ' O ' ' A' ' 35' ' ' SER . 17.1 mmm180 -107.02 146.34 31.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.397 -0.814 . . . . 0.0 110.19 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.93 22.45 52.79 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.5 pt -138.87 154.96 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.154 -1.204 . . . . 0.0 110.281 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.486 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 55.0 m -74.51 165.75 24.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.607 -0.683 . . . . 0.0 110.043 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.49 ' CE2' ' HD2' ' A' ' 45' ' ' ARG . 84.2 t80 -60.02 -48.76 80.4 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.616 -0.677 . . . . 0.0 109.816 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -65.82 -33.75 76.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.583 -0.698 . . . . 0.0 110.122 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.486 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.3 OUTLIER -63.47 -46.38 86.47 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.143 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.81 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -63.47 -37.69 88.28 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.891 -0.505 . . . . 0.0 109.956 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.49 ' HD2' ' CE2' ' A' ' 41' ' ' PHE . 1.0 OUTLIER -64.54 -40.86 96.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.628 -0.67 . . . . 0.0 109.761 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -61.55 -43.95 97.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.774 -0.579 . . . . 0.0 110.971 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.1 t -67.04 -31.2 71.56 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.315 -0.865 . . . . 0.0 111.17 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 t -58.69 -42.5 88.7 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.077 -1.014 . . . . 0.0 109.86 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -84.53 -22.08 30.28 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.412 -0.805 . . . . 0.0 110.697 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -80.97 -36.01 31.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.239 -0.913 . . . . 0.0 111.01 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.49 18.29 1.69 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.187 -0.946 . . . . 0.0 111.97 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.28 31.74 78.22 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.524 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 3.6 mmp_? -117.57 137.75 52.38 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.43 -1.041 . . . . 0.0 110.68 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.524 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 21.5 m 64.35 52.51 1.86 Allowed 'General case' 0 N--CA 1.502 2.128 0 CA-C-O 121.84 0.828 . . . . 0.0 109.476 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 27.3 m -92.02 -20.39 21.38 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.955 -0.466 . . . . 0.0 111.262 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -112.81 42.55 1.84 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.167 -0.958 . . . . 0.0 110.002 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.81 HG21 ' HB1' ' A' ' 44' ' ' ALA . 75.8 t -71.22 125.49 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.529 -0.732 . . . . 0.0 110.199 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.17 125.49 3.28 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -160.97 141.81 11.5 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.592 -0.946 . . . . 0.0 110.324 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.73 -176.63 48.45 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 t80 -76.22 152.29 36.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.314 -1.109 . . . . 0.0 110.248 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -143.7 154.82 43.88 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.625 -0.672 . . . . 0.0 110.348 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.47 0 CA-C-O 118.118 -1.379 . . . . 0.0 109.679 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 . . . . . 0 N--CA 1.496 1.852 0 CA-C-O 121.316 0.579 . . . . 0.0 110.774 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 94.9 t -76.14 148.01 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.644 -0.66 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -90.4 153.88 20.09 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.507 -0.745 . . . . 0.0 110.239 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -108.3 117.69 34.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.443 -0.786 . . . . 0.0 110.284 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -147.82 -94.81 0.15 Allowed Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.1 138.25 6.01 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 5.0 m-85 -69.27 135.44 50.49 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.561 -0.964 . . . . 0.0 110.604 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -96.93 118.02 32.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.515 -0.741 . . . . 0.0 110.292 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.71 127.67 59.4 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.428 -0.795 . . . . 0.0 110.367 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.585 ' HB2' HD12 ' A' ' 11' ' ' ILE . 45.1 Cg_endo -70.86 152.82 63.95 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.921 1.485 . . . . 0.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.585 HD12 ' HB2' ' A' ' 10' ' ' PRO . 2.3 mp 54.74 75.92 0.56 Allowed Pre-proline 0 N--CA 1.502 2.144 0 O-C-N 121.763 -0.586 . . . . 0.0 110.0 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.32 85.17 1.08 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.851 1.448 . . . . 0.0 110.622 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.23 127.84 57.6 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.452 -0.78 . . . . 0.0 110.203 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.34 169.73 20.94 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.959 1.505 . . . . 0.0 110.688 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.56 119.89 6.55 Favored 'Trans proline' 0 C--N 1.315 -1.201 0 O-C-N 123.783 1.412 . . . . 0.0 110.483 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.57 91.56 0.78 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.935 1.492 . . . . 0.0 110.527 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -91.53 155.9 18.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.42 -0.8 . . . . 0.0 110.426 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t -125.62 146.65 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.618 -0.676 . . . . 0.0 110.159 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -76.57 129.73 78.72 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.387 -0.82 . . . . 0.0 110.077 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.69 -174.6 1.74 Allowed 'Trans proline' 0 C--N 1.314 -1.248 0 O-C-N 123.88 1.463 . . . . 0.0 110.777 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 2.2 tp -69.56 132.29 89.38 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.43 -0.794 . . . . 0.0 110.312 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.08 120.06 5.88 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 O-C-N 123.899 1.473 . . . . 0.0 110.764 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -76.68 85.28 0.97 Allowed Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.82 84.19 0.92 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.63 148.39 47.25 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.95 1.5 . . . . 0.0 110.756 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 13.0 mt -94.14 147.67 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.465 -0.772 . . . . 0.0 110.194 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.27 82.98 1.43 Allowed Glycine 0 N--CA 1.496 2.633 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -76.42 -174.69 2.21 Favored 'Trans proline' 0 C--N 1.315 -1.214 0 O-C-N 123.974 1.513 . . . . 0.0 110.764 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -79.33 69.32 5.54 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.397 -0.814 . . . . 0.0 110.207 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -151.09 41.36 0.74 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.378 -0.826 . . . . 0.0 110.669 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.21 43.02 0.25 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 52.8 t -175.03 89.08 0.31 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.587 -0.949 . . . . 0.0 110.023 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.86 141.95 60.98 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.756 1.398 . . . . 0.0 110.689 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.41 -30.64 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 121.485 -0.759 . . . . 0.0 110.811 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.55 -16.62 62.89 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.334 -0.854 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.484 ' CB ' HG21 ' A' ' 57' ' ' VAL . 38.8 m 59.31 25.56 14.24 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.512 -0.742 . . . . 0.0 111.169 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.4 mmt-85 -108.39 143.5 37.22 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.24 -0.913 . . . . 0.0 110.127 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.86 22.2 53.64 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.407 HD13 HG21 ' A' ' 39' ' ' ILE . 26.3 pt -134.93 156.3 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.135 -1.215 . . . . 0.0 110.098 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 m -74.48 166.02 24.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.637 -0.664 . . . . 0.0 110.515 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -60.18 -49.04 79.18 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.744 -0.597 . . . . 0.0 109.627 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -62.73 -35.36 79.49 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.624 -0.673 . . . . 0.0 110.059 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -63.36 -46.01 88.52 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.253 -0.904 . . . . 0.0 109.205 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.71 -33.04 68.43 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.714 -0.616 . . . . 0.0 109.552 179.023 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.1 mtp-105 -68.84 -38.2 79.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.831 -0.543 . . . . 0.0 110.495 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -67.4 -40.33 85.59 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.421 -0.799 . . . . 0.0 110.73 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 43.8 t -69.38 -31.82 70.45 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.351 -0.843 . . . . 0.0 111.207 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 30.5 t -58.41 -42.19 86.64 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.224 -0.923 . . . . 0.0 110.305 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -84.15 -23.66 30.54 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.385 -0.822 . . . . 0.0 111.0 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 4.6 mmt-85 -85.76 -32.9 21.6 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 111.309 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -139.35 9.29 2.48 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.121 -0.987 . . . . 0.0 112.283 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.06 27.79 72.73 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.513 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.08 140.1 48.76 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.271 -1.135 . . . . 0.0 110.382 -179.561 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 98.2 m 63.59 53.12 2.12 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.877 0.846 . . . . 0.0 109.181 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 25.8 m -97.13 -14.55 21.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.828 -0.545 . . . . 0.0 111.783 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -122.85 42.25 3.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.972 -1.08 . . . . 0.0 110.858 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.484 HG21 ' CB ' ' A' ' 36' ' ' CYS . 72.4 t -109.47 109.68 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.725 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.57 89.43 0.17 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 6.6 mmmt -64.92 109.72 2.2 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.578 -0.954 . . . . 0.0 110.094 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.52 -177.14 47.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 74.7 t80 -78.6 150.34 32.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.277 -1.131 . . . . 0.0 110.085 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p -145.06 156.51 43.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.644 -0.66 . . . . 0.0 110.275 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.527 0 CA-C-O 118.05 -1.417 . . . . 0.0 109.626 -179.95 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 121.322 0.582 . . . . 0.0 110.667 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.9 t -81.17 153.34 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.71 -0.619 . . . . 0.0 109.773 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -73.07 127.64 33.17 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.475 -0.766 . . . . 0.0 110.186 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.12 116.68 31.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.439 -0.788 . . . . 0.0 110.48 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.54 71.7 0.33 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 154.84 128.07 1.14 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 5.9 m-85 -69.88 147.71 49.95 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.499 -1.0 . . . . 0.0 110.348 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.46 -30.58 69.76 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.491 -0.756 . . . . 0.0 110.55 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.44 133.49 67.5 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.48 -0.762 . . . . 0.0 110.04 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.504 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.0 Cg_endo -72.95 136.91 25.81 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.933 1.491 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 44.8 mt 65.84 131.22 0.03 OUTLIER Pre-proline 0 N--CA 1.505 2.317 0 O-C-N 122.163 -0.335 . . . . 0.0 110.776 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.32 74.6 3.59 Favored 'Trans proline' 0 C--N 1.315 -1.186 0 O-C-N 123.683 1.36 . . . . 0.0 110.523 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.55 131.47 45.63 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.38 -0.825 . . . . 0.0 110.27 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -71.92 146.96 48.62 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 123.876 1.461 . . . . 0.0 110.84 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.71 147.24 39.7 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.875 1.461 . . . . 0.0 110.675 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.04 90.19 0.87 Allowed 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.866 1.456 . . . . 0.0 110.617 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -76.23 153.48 36.02 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.365 -0.835 . . . . 0.0 110.537 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.8 t -79.66 144.1 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.67 . . . . 0.0 110.154 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.1 tpm_? -110.83 99.54 42.62 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.515 -0.74 . . . . 0.0 110.012 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.07 -178.7 3.36 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 O-C-N 123.853 1.449 . . . . 0.0 110.904 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.434 HD22 ' HA ' ' A' ' 21' ' ' LEU . 0.2 OUTLIER -139.04 100.14 8.0 Favored Pre-proline 0 N--CA 1.495 1.779 0 O-C-N 121.388 -0.82 . . . . 0.0 110.187 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.34 158.79 40.7 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.841 1.443 . . . . 0.0 110.743 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.46 -91.03 1.58 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.33 99.35 1.15 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 148.15 47.98 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 O-C-N 123.889 1.468 . . . . 0.0 110.611 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 4.2 mt -106.74 135.57 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.392 -0.817 . . . . 0.0 110.23 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 81.48 83.36 0.79 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -72.91 -44.12 0.67 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.96 1.505 . . . . 0.0 110.654 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -93.36 49.3 1.38 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.25 38.62 2.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 110.428 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.35 41.47 0.89 Allowed Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 15.3 t -173.25 112.49 0.34 Allowed Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.414 -1.051 . . . . 0.0 110.092 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -72.5 129.52 14.85 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.599 1.315 . . . . 0.0 110.286 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.47 -28.44 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.457 -0.777 . . . . 0.0 110.845 -179.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -71.07 -12.66 61.64 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.257 -0.902 . . . . 0.0 111.353 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.2 m 55.32 29.19 12.51 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.333 -0.855 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -125.92 152.58 45.42 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.236 -0.915 . . . . 0.0 110.204 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.35 36.2 59.66 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -127.44 156.25 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.291 -1.123 . . . . 0.0 110.243 179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -82.38 160.24 22.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.507 -0.746 . . . . 0.0 109.38 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -58.15 -41.64 84.18 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.533 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -67.53 -36.72 81.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.633 -0.667 . . . . 0.0 110.156 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -65.61 -41.94 92.15 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.416 -0.803 . . . . 0.0 109.704 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.29 -34.12 75.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.757 -0.59 . . . . 0.0 110.361 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.16 -33.8 73.97 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.458 -0.776 . . . . 0.0 110.12 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -69.03 -46.0 69.03 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.538 -0.726 . . . . 0.0 111.059 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 42.4 t -69.52 -32.5 71.39 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.334 -0.854 . . . . 0.0 111.219 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.1 t -64.73 -42.04 95.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.222 -0.924 . . . . 0.0 110.775 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -82.46 -25.25 33.74 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.359 -0.838 . . . . 0.0 111.496 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.24 -29.51 18.14 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.189 -0.944 . . . . 0.0 111.526 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.2 mt -137.03 3.43 2.66 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.049 -1.032 . . . . 0.0 112.648 -178.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.49 28.45 73.61 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.453 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -118.16 146.81 43.92 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.296 -1.12 . . . . 0.0 110.606 -179.446 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.2 m 59.46 48.93 9.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 122.041 0.924 . . . . 0.0 109.027 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.5 m -92.53 -16.8 25.29 Favored 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.713 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -114.9 41.79 2.31 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.062 -1.023 . . . . 0.0 110.62 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.36 143.23 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.478 -0.764 . . . . 0.0 110.002 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.27 162.72 38.53 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -105.23 121.51 44.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.295 -1.121 . . . . 0.0 110.072 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.15 173.66 42.11 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.2 t80 -74.13 154.86 38.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.319 -1.107 . . . . 0.0 110.512 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.9 p -144.23 161.94 37.62 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.545 -0.722 . . . . 0.0 110.228 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.421 0 CA-C-O 118.178 -1.346 . . . . 0.0 109.823 -179.965 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLN . . . . . 0.458 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 3.4 mp0 . . . . . 0 N--CA 1.496 1.828 0 CA-C-O 121.04 0.447 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 39.2 t 63.79 161.49 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 CA-C-O 121.438 0.637 . . . . 0.0 110.825 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -82.93 141.1 32.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.227 -0.92 . . . . 0.0 110.134 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.37 149.66 44.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 110.639 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.59 -157.27 24.61 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.62 108.3 1.23 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -64.65 121.4 14.39 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.541 -0.976 . . . . 0.0 110.176 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 53.65 31.64 13.04 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.851 -0.531 . . . . 0.0 110.694 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.95 93.4 27.21 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.255 -0.903 . . . . 0.0 110.252 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.41 148.81 49.32 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 O-C-N 124.002 1.527 . . . . 0.0 110.974 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.6 pt -89.86 121.34 69.03 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.496 -0.752 . . . . 0.0 110.332 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.44 77.16 2.58 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.8 1.421 . . . . 0.0 110.697 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.61 142.0 73.42 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.296 -0.878 . . . . 0.0 110.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.61 113.37 3.72 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 124.026 1.54 . . . . 0.0 110.767 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.91 148.82 36.24 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.826 1.435 . . . . 0.0 110.653 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.0 76.46 3.77 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.963 1.507 . . . . 0.0 110.286 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -81.35 147.59 29.77 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.388 -0.82 . . . . 0.0 110.615 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -109.25 150.84 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.811 -0.556 . . . . 0.0 109.815 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 115.95 30.98 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.473 -0.767 . . . . 0.0 110.374 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -76.1 -173.23 1.6 Allowed 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.934 1.491 . . . . 0.0 110.793 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 1.9 pp -75.04 159.44 82.77 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 121.549 -0.719 . . . . 0.0 110.345 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.08 121.58 7.68 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.822 1.432 . . . . 0.0 110.615 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -131.75 97.86 0.36 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.82 91.03 1.32 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.77 145.93 41.95 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.912 1.48 . . . . 0.0 110.746 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.0 mt -115.46 158.23 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.502 -0.749 . . . . 0.0 110.08 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.52 136.05 7.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -76.28 -159.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.993 1.522 . . . . 0.0 110.615 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -69.36 79.36 0.38 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.414 -0.804 . . . . 0.0 110.228 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -159.49 42.94 0.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.393 -0.817 . . . . 0.0 110.49 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -160.23 42.31 0.44 Allowed Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 43.3 t -174.31 95.43 0.31 Allowed Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.478 -1.013 . . . . 0.0 110.091 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -67.34 153.06 78.09 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.579 1.305 . . . . 0.0 110.578 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.0 t -76.16 -33.04 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.356 -0.84 . . . . 0.0 110.719 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.423 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.5 OUTLIER -73.17 -13.87 61.25 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.449 -0.782 . . . . 0.0 111.355 -179.859 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.435 ' HB3' HG21 ' A' ' 57' ' ' VAL . 60.1 m 61.95 24.65 14.7 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.536 -0.728 . . . . 0.0 111.428 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -107.93 139.83 41.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.88 23.12 39.74 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.9 pt -135.35 160.32 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.08 -1.247 . . . . 0.0 110.246 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.9 m -81.47 164.54 21.95 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.58 -0.7 . . . . 0.0 110.388 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -58.38 -48.31 81.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.242 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.6 t -60.65 -37.86 82.94 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.692 -0.63 . . . . 0.0 110.181 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -65.92 -44.22 85.79 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.362 -0.836 . . . . 0.0 109.466 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.46 -35.52 70.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.775 -0.578 . . . . 0.0 109.899 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? -69.94 -37.51 75.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.563 -0.711 . . . . 0.0 109.931 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.0 t -64.59 -40.47 95.58 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.664 -0.647 . . . . 0.0 110.706 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.1 t -71.62 -33.38 68.92 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.456 -0.778 . . . . 0.0 111.596 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.5 t -57.63 -44.04 85.26 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 21.3 t -80.33 -24.42 39.91 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 111.087 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.65 -32.15 19.41 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.258 -0.901 . . . . 0.0 111.684 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.1 mt -137.37 2.11 2.46 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.067 -1.021 . . . . 0.0 112.671 -178.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 74.05 22.78 77.46 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.3 mmp_? -110.65 143.99 40.26 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.22 -1.165 . . . . 0.0 110.833 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 93.4 m 61.84 51.82 3.68 Favored 'General case' 0 N--CA 1.5 2.05 0 CA-C-O 121.949 0.88 . . . . 0.0 109.233 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 43.0 m -96.9 -14.28 21.89 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.882 -0.511 . . . . 0.0 111.872 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -124.97 42.68 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.978 -1.076 . . . . 0.0 111.025 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 36' ' ' CYS . 52.9 t -106.61 117.43 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.295 -0.878 . . . . 0.0 109.695 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.33 99.97 0.31 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.89 107.12 18.83 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.406 -1.055 . . . . 0.0 110.176 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.01 142.18 9.35 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -72.56 160.58 32.04 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.43 -1.041 . . . . 0.0 110.516 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.5 t -99.14 179.62 4.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.606 -0.684 . . . . 0.0 110.69 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 CA-C-O 117.937 -1.479 . . . . 0.0 109.549 179.891 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 . . . . . 0 N--CA 1.496 1.837 0 CA-C-O 121.289 0.566 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.41 HG22 ' H ' ' A' ' 2' ' ' VAL . 28.1 m -77.81 150.69 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.644 -0.66 . . . . 0.0 110.285 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -160.96 170.0 21.45 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.474 -0.766 . . . . 0.0 110.509 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 75.4 mttt -105.82 131.74 52.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.384 -0.823 . . . . 0.0 110.243 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.12 -131.33 1.42 Allowed Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -98.0 105.82 3.19 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -80.14 96.2 6.46 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.388 -1.066 . . . . 0.0 110.299 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 56.34 -90.23 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.855 -0.528 . . . . 0.0 110.851 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -96.01 122.92 57.06 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.004 -1.06 . . . . 0.0 110.131 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.25 127.7 12.98 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.831 1.438 . . . . 0.0 110.583 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.6 pt -134.95 119.53 13.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.507 -0.746 . . . . 0.0 110.423 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.06 90.49 0.97 Allowed 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.869 1.457 . . . . 0.0 110.425 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.51 135.59 90.69 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.419 -0.801 . . . . 0.0 110.471 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.31 130.95 15.77 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 124.083 1.57 . . . . 0.0 110.902 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.17 142.1 26.94 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 O-C-N 123.917 1.482 . . . . 0.0 110.751 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -73.65 82.9 1.62 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.862 1.454 . . . . 0.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -80.5 154.8 27.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.281 -0.887 . . . . 0.0 110.647 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -83.78 150.33 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.63 -0.669 . . . . 0.0 110.081 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.4 ttp85 -70.66 131.54 87.82 Favored Pre-proline 0 N--CA 1.497 1.904 0 O-C-N 121.539 -0.725 . . . . 0.0 110.027 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.68 126.93 12.52 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.869 1.457 . . . . 0.0 110.925 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.432 ' HG ' ' HD2' ' A' ' 22' ' ' PRO . 7.1 tt -91.63 131.31 36.25 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.674 -0.641 . . . . 0.0 110.373 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HG ' ' A' ' 21' ' ' LEU . 44.5 Cg_endo -72.24 105.43 1.85 Allowed 'Trans proline' 0 C--N 1.314 -1.253 0 O-C-N 123.911 1.479 . . . . 0.0 110.447 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -135.99 -50.82 0.07 OUTLIER Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.68 160.75 35.97 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.36 145.71 43.63 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.897 1.472 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.9 tt -147.06 160.67 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 110.471 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.33 166.14 41.01 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -74.8 -1.37 11.07 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.955 1.503 . . . . 0.0 111.792 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -70.84 80.1 0.63 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.088 -1.008 . . . . 0.0 110.708 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -147.43 46.75 1.13 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.461 -0.775 . . . . 0.0 110.442 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 32' ' ' CYS . . . 165.08 50.48 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 31' ' ' GLY . 51.9 t 178.91 81.01 0.16 Allowed Pre-proline 0 N--CA 1.501 2.078 0 O-C-N 121.566 -0.961 . . . . 0.0 109.978 179.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.46 159.98 49.95 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.761 1.4 . . . . 0.0 111.168 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.1 t -72.3 -29.28 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.41 -0.806 . . . . 0.0 110.748 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -74.09 -6.53 48.16 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.346 -0.846 . . . . 0.0 111.68 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 96.2 m 58.14 28.58 16.66 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.235 -0.916 . . . . 0.0 110.587 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -109.16 155.01 21.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 110.128 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.86 17.9 77.89 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.5 pt -136.47 162.13 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.188 -1.183 . . . . 0.0 110.066 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.6 t -87.92 169.11 12.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.404 -0.81 . . . . 0.0 110.023 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.421 ' O ' ' HB2' ' A' ' 45' ' ' ARG . 60.3 t80 -59.42 -44.66 92.82 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.655 -0.653 . . . . 0.0 109.455 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.0 t -65.47 -39.58 92.12 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.647 -0.658 . . . . 0.0 110.074 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -65.86 -42.24 90.68 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.388 -0.82 . . . . 0.0 109.697 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.865 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.59 -39.01 81.12 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.589 -0.695 . . . . 0.0 109.348 178.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -64.86 -40.02 94.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.792 -0.567 . . . . 0.0 109.533 178.874 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 t -62.04 -43.95 97.75 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.862 -0.524 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 27.2 t -67.26 -31.2 71.38 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.301 -0.874 . . . . 0.0 111.339 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.4 t -59.73 -41.95 92.07 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.968 -1.083 . . . . 0.0 109.855 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.9 t -84.84 -22.96 29.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.35 -0.844 . . . . 0.0 110.913 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.4 mtp180 -85.44 -33.65 21.86 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.217 -0.927 . . . . 0.0 111.304 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -140.26 8.97 2.27 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.17 -0.956 . . . . 0.0 112.192 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.72 24.95 75.38 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.482 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.14 144.41 43.22 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.208 -1.172 . . . . 0.0 110.714 -179.907 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 31.6 m 61.98 48.93 4.89 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 121.942 0.877 . . . . 0.0 109.395 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 18.2 m -89.08 -25.17 22.05 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.863 -0.523 . . . . 0.0 110.914 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -106.21 38.51 2.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.207 -0.933 . . . . 0.0 109.895 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.865 HG21 ' HB1' ' A' ' 44' ' ' ALA . 20.3 t -63.2 124.54 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.564 -0.71 . . . . 0.0 109.838 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.08 164.18 39.71 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 -179.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 5.0 mptt -85.54 76.77 9.99 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.252 -1.146 . . . . 0.0 110.396 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.69 141.09 3.88 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -72.85 153.97 40.81 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 110.159 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.1 t -154.33 -178.28 7.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.505 -0.747 . . . . 0.0 110.852 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.443 0 CA-C-O 117.963 -1.465 . . . . 0.0 109.567 179.928 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.498 1.932 0 CA-C-O 121.308 0.575 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.701 HG22 ' CD2' ' A' ' 3' ' ' TYR . 8.0 p -139.58 127.91 26.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.743 -0.598 . . . . 0.0 109.879 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TYR . . . . . 0.701 ' CD2' HG22 ' A' ' 2' ' ' VAL . 57.0 m-85 60.02 174.79 0.09 Allowed 'General case' 0 N--CA 1.505 2.287 0 CA-C-O 121.517 0.675 . . . . 0.0 111.013 -179.352 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.3 mmtt -109.24 90.62 3.35 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 109.895 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.14 157.2 23.87 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.02 40.22 88.72 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -101.15 125.23 47.75 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.48 -1.012 . . . . 0.0 110.46 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.22 71.06 1.37 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.611 -0.68 . . . . 0.0 110.119 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 18.8 ttp180 48.89 65.14 7.51 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.727 -0.608 . . . . 0.0 110.958 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -82.5 120.68 3.24 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.646 1.34 . . . . 0.0 110.733 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 11.6 mt -127.57 79.17 73.84 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.411 -0.805 . . . . 0.0 109.949 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.32 -164.96 0.3 Allowed 'Trans proline' 0 C--N 1.313 -1.299 0 O-C-N 123.773 1.407 . . . . 0.0 110.723 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.93 153.68 86.81 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.57 -0.706 . . . . 0.0 110.366 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.2 141.42 29.18 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 124.045 1.55 . . . . 0.0 110.67 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.68 137.05 21.97 Favored 'Trans proline' 0 C--N 1.316 -1.155 0 O-C-N 123.879 1.463 . . . . 0.0 110.878 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.33 149.64 31.68 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.862 1.454 . . . . 0.0 110.567 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CE2' HG23 ' A' ' 18' ' ' VAL . 79.0 t80 -77.71 147.02 35.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.572 -0.705 . . . . 0.0 110.155 179.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.448 HG23 ' CE2' ' A' ' 17' ' ' PHE . 2.0 t 60.37 165.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.119 0 CA-C-O 121.562 0.696 . . . . 0.0 110.846 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.6 90.57 8.98 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.154 -0.966 . . . . 0.0 109.939 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.77 177.97 6.95 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 O-C-N 123.802 1.422 . . . . 0.0 110.626 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.923 HD22 ' HA ' ' A' ' 25' ' ' PRO . 50.8 mt -122.83 101.57 39.22 Favored Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.601 -0.687 . . . . 0.0 110.105 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.35 111.53 3.31 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.858 1.452 . . . . 0.0 111.023 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.53 50.02 16.96 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.41 174.05 48.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.923 ' HA ' HD22 ' A' ' 21' ' ' LEU . 44.2 Cg_endo -70.25 129.15 16.6 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 O-C-N 123.973 1.512 . . . . 0.0 110.575 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mt -57.45 141.56 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.571 -0.705 . . . . 0.0 109.949 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.07 132.65 5.44 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.95 -26.93 18.08 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.874 1.46 . . . . 0.0 111.291 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -80.26 65.61 5.47 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.287 -0.883 . . . . 0.0 110.352 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -133.09 40.06 3.24 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.291 -0.881 . . . . 0.0 110.798 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.57 45.0 0.06 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 120.089 -1.053 . . . . 0.0 110.623 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 51.0 t -172.4 78.67 0.45 Allowed Pre-proline 0 N--CA 1.497 1.904 0 O-C-N 121.281 -1.129 . . . . 0.0 110.467 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -68.78 145.38 62.67 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.931 1.49 . . . . 0.0 110.574 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 69.9 t -62.09 -30.84 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.147 0 O-C-N 121.478 -0.764 . . . . 0.0 110.63 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.42 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 7.6 t -68.47 -10.23 54.07 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.446 -0.784 . . . . 0.0 111.307 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 35' ' ' SER . 73.4 m 59.36 27.49 16.59 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.355 -0.84 . . . . 0.0 110.996 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -108.59 150.63 27.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.394 -0.816 . . . . 0.0 110.028 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.55 24.09 71.3 Favored Glycine 0 N--CA 1.496 2.645 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.424 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 20.9 pt -134.06 157.41 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.049 -1.265 . . . . 0.0 110.278 179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.09 162.11 23.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.654 -0.654 . . . . 0.0 109.474 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 87.2 t80 -57.04 -49.74 74.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.399 -0.813 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -64.38 -33.12 75.11 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.589 -0.695 . . . . 0.0 110.146 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -65.6 -43.13 90.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.316 -0.865 . . . . 0.0 109.482 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.478 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -69.86 -36.26 75.37 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.636 . . . . 0.0 109.853 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.3 ttt180 -67.47 -40.16 85.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.67 -0.644 . . . . 0.0 110.149 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.3 t -66.07 -36.88 84.38 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.609 -0.682 . . . . 0.0 110.794 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 19.1 t -72.61 -31.32 65.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.25 -0.906 . . . . 0.0 111.325 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 29.9 t -58.9 -42.95 90.82 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.141 -0.974 . . . . 0.0 110.078 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.8 t -84.86 -24.45 28.54 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.396 -0.815 . . . . 0.0 110.948 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -83.29 -32.13 26.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.217 -0.927 . . . . 0.0 111.475 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.82 12.67 1.87 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.176 -0.952 . . . . 0.0 112.208 -179.063 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.29 31.05 79.42 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.7 mmt180 -118.42 139.88 50.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.389 -1.065 . . . . 0.0 110.458 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 10.5 m 62.46 55.14 2.33 Favored 'General case' 0 N--CA 1.498 1.951 0 CA-C-O 121.999 0.904 . . . . 0.0 109.327 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 19.1 m -96.3 -16.43 21.34 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.43 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -112.8 42.36 1.88 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.1 -1.0 . . . . 0.0 110.189 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.478 HG21 ' HB1' ' A' ' 44' ' ' ALA . 74.0 t -83.01 121.43 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.384 -0.823 . . . . 0.0 109.954 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.0 134.12 5.44 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 8.4 tttm 62.58 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 O-C-N 121.88 -0.776 . . . . 0.0 110.262 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.6 -176.12 41.15 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -76.43 160.9 29.12 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.4 -1.059 . . . . 0.0 110.516 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.4 m -64.78 154.2 37.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.514 -0.741 . . . . 0.0 110.619 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 117.905 -1.497 . . . . 0.0 109.478 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.4 mp0 . . . . . 0 N--CA 1.497 1.9 0 CA-C-O 121.18 0.514 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.8 t 52.68 73.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 CA-C-O 121.157 0.503 . . . . 0.0 110.222 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 2.3 t80 68.23 144.0 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.165 0 CA-C-O 121.238 0.542 . . . . 0.0 110.56 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 56.77 81.18 0.14 Allowed 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.57 -0.706 . . . . 0.0 110.707 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -161.98 124.98 1.36 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.09 77.45 2.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -136.24 107.15 6.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.474 -1.015 . . . . 0.0 110.053 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -71.44 -54.18 11.53 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.522 -0.736 . . . . 0.0 110.286 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.86 75.49 48.81 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 110.106 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.65 87.34 1.12 Allowed 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.846 1.445 . . . . 0.0 110.152 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.6 mm 57.04 75.94 0.53 Allowed Pre-proline 0 N--CA 1.501 2.085 0 O-C-N 121.719 -0.613 . . . . 0.0 110.119 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.07 80.18 1.9 Allowed 'Trans proline' 0 C--N 1.316 -1.17 0 O-C-N 123.771 1.406 . . . . 0.0 110.775 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.32 154.05 27.83 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.737 . . . . 0.0 109.982 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.29 132.7 21.37 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.845 1.445 . . . . 0.0 110.746 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.7 143.71 30.5 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 O-C-N 123.928 1.489 . . . . 0.0 110.762 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.66 175.71 10.94 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.864 1.455 . . . . 0.0 110.901 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -78.61 162.88 25.94 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.55 -0.719 . . . . 0.0 110.587 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -81.56 152.75 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.797 -0.564 . . . . 0.0 110.179 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -68.4 130.94 91.92 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.527 -0.733 . . . . 0.0 110.05 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -71.13 -178.67 2.99 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 O-C-N 123.97 1.511 . . . . 0.0 110.67 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.437 ' HB3' ' HD2' ' A' ' 22' ' ' PRO . 35.2 mt -125.86 165.79 25.08 Favored Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.516 -0.74 . . . . 0.0 110.258 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 21' ' ' LEU . 43.6 Cg_endo -69.94 118.97 5.99 Favored 'Trans proline' 0 C--N 1.315 -1.226 0 O-C-N 123.747 1.393 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.24 -96.97 1.84 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.83 88.11 0.39 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.28 129.39 13.91 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.96 1.505 . . . . 0.0 110.448 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 mm -127.82 158.02 39.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.462 -0.774 . . . . 0.0 110.372 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.99 84.84 1.35 Allowed Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.04 -169.74 0.61 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.967 1.509 . . . . 0.0 110.731 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -79.85 65.91 5.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.359 -0.838 . . . . 0.0 109.971 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 16.9 m-80 -133.06 40.72 3.19 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.519 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.18 44.58 0.06 OUTLIER Glycine 0 N--CA 1.493 2.485 0 C-N-CA 120.095 -1.05 . . . . 0.0 110.611 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.4 t -175.01 81.74 0.32 Allowed Pre-proline 0 N--CA 1.5 2.055 0 O-C-N 121.289 -1.124 . . . . 0.0 110.356 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.94 144.23 57.69 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 O-C-N 123.907 1.478 . . . . 0.0 110.817 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 t -61.39 -29.4 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.521 -0.737 . . . . 0.0 110.522 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.1 t -69.63 -8.05 44.22 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.434 -0.792 . . . . 0.0 111.147 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 35' ' ' SER . 81.6 m 59.14 25.22 13.68 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.353 -0.842 . . . . 0.0 111.255 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -112.39 158.05 20.29 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.288 -0.883 . . . . 0.0 110.012 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.16 22.08 76.95 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.1 pt -135.47 153.59 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.142 -1.211 . . . . 0.0 110.274 179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.2 t -80.3 169.25 18.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.632 -0.667 . . . . 0.0 109.952 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -60.31 -48.86 79.93 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.568 -0.708 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.2 t -61.83 -36.44 81.17 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.666 -0.647 . . . . 0.0 110.192 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -64.62 -44.8 89.39 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.565 -0.709 . . . . 0.0 109.886 179.51 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.6 -33.99 76.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.803 -0.561 . . . . 0.0 110.395 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.22 -39.57 78.49 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.466 -0.771 . . . . 0.0 110.122 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 3.6 t -64.95 -40.44 95.02 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.658 -0.652 . . . . 0.0 110.951 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.4 t -71.62 -32.03 67.54 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.282 -0.886 . . . . 0.0 111.443 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 33.1 t -58.64 -42.9 89.38 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.126 -0.984 . . . . 0.0 110.363 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 32.3 t -84.24 -25.98 29.02 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.352 -0.843 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.3 OUTLIER -84.26 -31.96 24.7 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.286 -0.884 . . . . 0.0 111.453 -179.394 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.4 mt -138.87 6.55 2.43 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 112.556 -178.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.02 28.32 73.75 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 6.9 mmt-85 -115.6 139.92 49.65 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.213 -1.169 . . . . 0.0 110.638 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.486 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 80.5 m 62.46 57.27 1.92 Allowed 'General case' 0 N--CA 1.499 2.003 0 CA-C-O 121.939 0.876 . . . . 0.0 109.42 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 34.9 m -100.12 -6.21 26.63 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.749 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -128.18 46.43 2.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.065 . . . . 0.0 110.517 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 94.8 t -92.68 115.85 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.261 -0.9 . . . . 0.0 110.09 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.32 118.04 1.91 Allowed Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.81 116.47 17.99 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.439 -1.036 . . . . 0.0 110.346 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.23 -178.05 43.03 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -77.26 163.47 26.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.391 -1.064 . . . . 0.0 110.465 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.8 m -76.44 163.58 26.81 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.498 -0.751 . . . . 0.0 110.444 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.925 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 . . . . . 0 N--CA 1.497 1.884 0 CA-C-O 121.336 0.589 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.97 104.06 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.614 -0.679 . . . . 0.0 109.79 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -147.67 143.41 27.63 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.512 -0.743 . . . . 0.0 110.357 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 23.8 tttm -156.82 134.88 11.13 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.464 -0.772 . . . . 0.0 110.406 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.1 -164.19 33.66 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -101.37 -73.13 1.0 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 3.5 t80 -105.0 127.49 52.89 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.532 -0.981 . . . . 0.0 110.247 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -159.1 79.65 0.76 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.469 -0.769 . . . . 0.0 110.367 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.43 105.49 47.12 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.348 -0.845 . . . . 0.0 110.029 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.412 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.2 Cg_endo -71.71 134.86 24.8 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 O-C-N 123.843 1.444 . . . . 0.0 110.759 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.412 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 51.3 mt 60.04 99.61 0.04 OUTLIER Pre-proline 0 N--CA 1.503 2.223 0 O-C-N 121.94 -0.475 . . . . 0.0 110.732 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.79 -160.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.659 1.347 . . . . 0.0 110.299 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.78 115.84 21.93 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.475 -0.766 . . . . 0.0 110.095 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.55 158.93 50.1 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.888 1.467 . . . . 0.0 110.624 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.32 150.04 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.93 1.49 . . . . 0.0 110.618 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.92 169.92 21.55 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 O-C-N 123.791 1.416 . . . . 0.0 110.591 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -160.41 160.06 31.77 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.62 -0.675 . . . . 0.0 110.489 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.6 t -74.39 140.15 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.566 -0.709 . . . . 0.0 110.045 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.54 100.21 52.71 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.414 -0.803 . . . . 0.0 110.096 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.05 177.05 8.26 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.774 1.408 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 2.0 pp -88.37 150.47 46.84 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.449 -0.782 . . . . 0.0 110.496 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.15 136.2 19.78 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.847 1.446 . . . . 0.0 110.472 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.64 -103.19 0.63 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.32 163.89 39.4 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.32 151.13 53.88 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.857 1.451 . . . . 0.0 110.69 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.411 ' HA ' HD13 ' A' ' 26' ' ' ILE . 18.5 mm -125.26 153.48 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.19 80.32 0.5 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -75.98 -42.16 0.44 Allowed 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.916 1.482 . . . . 0.0 111.071 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -82.61 70.4 9.57 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.24 -0.912 . . . . 0.0 110.234 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -144.98 43.44 1.33 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.374 -0.829 . . . . 0.0 110.565 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -177.85 46.37 0.1 OUTLIER Glycine 0 N--CA 1.494 2.539 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.1 t -168.87 91.01 0.6 Allowed Pre-proline 0 N--CA 1.498 1.941 0 O-C-N 121.326 -1.102 . . . . 0.0 110.331 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.33 139.77 32.51 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 O-C-N 123.762 1.401 . . . . 0.0 110.608 179.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.35 -27.4 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.302 -0.874 . . . . 0.0 110.399 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.43 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -67.18 -18.39 65.25 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.429 -0.795 . . . . 0.0 110.78 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 35' ' ' SER . 95.5 m 58.99 26.27 14.86 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.549 -0.719 . . . . 0.0 111.178 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -108.95 144.57 36.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.261 -0.9 . . . . 0.0 110.046 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.27 34.27 64.23 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.3 pt -125.78 155.15 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.2 -1.176 . . . . 0.0 110.123 179.454 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.84 159.27 21.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.668 -0.645 . . . . 0.0 109.475 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -57.66 -42.47 83.57 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.424 -0.797 . . . . 0.0 109.641 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.2 t -67.32 -34.45 77.38 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.583 -0.698 . . . . 0.0 109.95 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.39 -41.35 89.5 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.473 -0.767 . . . . 0.0 109.69 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -74.23 -27.5 60.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.748 -0.595 . . . . 0.0 110.34 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -35.96 61.01 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.53 -0.731 . . . . 0.0 110.389 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -70.88 -40.62 72.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.448 -0.783 . . . . 0.0 111.09 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.7 t -73.55 -30.44 63.07 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.237 -0.914 . . . . 0.0 111.299 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.4 -42.63 92.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.126 -0.984 . . . . 0.0 110.579 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 33.1 t -82.92 -25.28 32.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.816 . . . . 0.0 111.587 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.9 mmm180 -92.28 -27.02 17.87 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.215 -0.928 . . . . 0.0 111.636 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 mt -137.31 2.95 2.56 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.071 -1.018 . . . . 0.0 112.509 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.64 28.28 73.46 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.422 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.8 OUTLIER -118.04 143.19 46.63 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.26 -1.141 . . . . 0.0 110.415 -179.647 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 1.3 m 62.39 52.87 2.91 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.001 0.905 . . . . 0.0 109.097 -179.252 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 50.4 m -97.85 -3.71 38.19 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.339 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 35.8 t-80 -122.67 45.35 2.4 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.167 -0.958 . . . . 0.0 109.88 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.456 HG21 ' HB1' ' A' ' 44' ' ' ALA . 17.0 t -92.76 112.16 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.373 -0.83 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.39 88.72 0.54 Allowed Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -158.9 139.68 12.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.514 -0.992 . . . . 0.0 110.643 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.53 125.32 1.81 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 t80 -79.33 163.94 24.47 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.476 -1.014 . . . . 0.0 110.301 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.0 m -77.97 166.29 23.03 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.604 -0.685 . . . . 0.0 110.381 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 CA-C-O 117.985 -1.453 . . . . 0.0 109.535 179.906 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLN . . . . . 0.49 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 5.7 pm0 . . . . . 0 N--CA 1.497 1.904 0 CA-C-O 121.016 0.436 . . . . 0.0 110.648 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.49 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 46.9 t 65.8 144.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.308 0.575 . . . . 0.0 110.698 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 62.49 174.3 0.14 Allowed 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.473 -0.767 . . . . 0.0 110.75 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.4 pttm -86.09 129.06 34.96 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.317 -0.864 . . . . 0.0 110.312 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.42 -165.81 37.5 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -79.46 102.76 2.0 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -63.13 119.43 9.53 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.615 -0.932 . . . . 0.0 109.859 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 52.39 47.36 24.89 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.373 0.606 . . . . 0.0 110.178 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.7 ttt-85 -120.55 142.18 33.61 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.418 -0.801 . . . . 0.0 110.327 -179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -72.66 89.16 0.86 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 O-C-N 123.909 1.478 . . . . 0.0 110.309 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.1 pt -77.98 149.3 76.65 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.476 -0.765 . . . . 0.0 110.373 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.86 88.92 0.89 Allowed 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 124.063 1.559 . . . . 0.0 110.499 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 3.9 mtm105 -73.86 131.94 80.99 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.515 -0.74 . . . . 0.0 110.445 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.94 128.83 13.56 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 124.008 1.53 . . . . 0.0 110.755 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.2 129.22 11.97 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.794 1.418 . . . . 0.0 110.77 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -74.26 97.43 1.02 Allowed 'Trans proline' 0 C--N 1.316 -1.158 0 O-C-N 123.796 1.419 . . . . 0.0 110.52 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -154.11 152.71 30.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.325 -0.86 . . . . 0.0 110.545 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.4 t -82.55 145.27 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.676 -0.64 . . . . 0.0 109.701 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 -63.89 112.45 7.41 Favored Pre-proline 0 N--CA 1.497 1.896 0 O-C-N 121.575 -0.703 . . . . 0.0 110.417 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -78.01 -173.37 1.8 Allowed 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.836 1.44 . . . . 0.0 110.512 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.16 76.34 57.78 Favored Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.453 -0.779 . . . . 0.0 110.034 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.93 126.73 10.2 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 123.85 1.448 . . . . 0.0 110.74 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -127.18 -111.96 1.72 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.2 164.13 39.07 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.5 151.31 52.98 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.867 1.457 . . . . 0.0 110.684 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.6 tt -84.3 151.01 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.415 -0.803 . . . . 0.0 110.373 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.11 84.3 0.49 Allowed Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -74.48 -51.59 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.967 1.509 . . . . 0.0 111.042 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -110.97 45.05 1.2 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.171 -0.956 . . . . 0.0 110.095 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -131.08 34.81 3.99 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.519 -0.738 . . . . 0.0 110.569 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.83 38.7 0.75 Allowed Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.46 ' SG ' ' HB3' ' A' ' 53' ' ' ARG . 2.2 t -173.08 87.86 0.39 Allowed Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.597 -0.943 . . . . 0.0 110.183 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.89 139.83 44.39 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 124.007 1.53 . . . . 0.0 110.839 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.557 HG22 HH11 ' A' ' 53' ' ' ARG . 79.4 t -65.0 -28.79 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.535 -0.728 . . . . 0.0 110.429 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.432 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.2 t -67.12 -21.38 65.84 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.484 -0.76 . . . . 0.0 110.896 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' SER . 74.1 m 59.62 28.68 18.16 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.557 -0.715 . . . . 0.0 110.892 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -104.41 146.09 29.34 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.271 -0.893 . . . . 0.0 110.273 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.99 26.69 43.88 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.8 pt -137.01 160.0 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.221 -1.164 . . . . 0.0 110.259 179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.8 m -85.53 168.27 14.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.556 -0.715 . . . . 0.0 110.06 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.65 -45.27 94.73 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.598 -0.689 . . . . 0.0 109.376 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.1 t -65.42 -38.53 90.19 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.611 -0.681 . . . . 0.0 110.026 179.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -63.25 -43.04 99.12 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.809 . . . . 0.0 109.71 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -66.98 -38.48 86.12 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.685 -0.634 . . . . 0.0 109.846 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.96 -38.27 85.8 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-O 121.551 0.691 . . . . 0.0 109.69 178.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 t -62.79 -40.94 98.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.726 -0.609 . . . . 0.0 111.598 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.413 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 6.0 t -76.83 -28.42 55.51 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.997 -1.064 . . . . 0.0 111.599 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.4 t -59.28 -41.14 88.21 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.068 -1.02 . . . . 0.0 109.606 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.7 t -86.81 -24.32 25.06 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.413 ' HB3' ' HA ' ' A' ' 47' ' ' CYS . 3.1 tmm_? -77.94 -36.7 48.99 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.364 -0.835 . . . . 0.0 111.066 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.406 HD12 ' HD2' ' A' ' 50' ' ' ARG . 0.2 OUTLIER -144.07 16.97 1.74 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.231 -0.918 . . . . 0.0 111.946 -179.284 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.89 33.42 83.38 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.557 HH11 HG22 ' A' ' 34' ' ' VAL . 5.9 mmt-85 -119.6 144.27 47.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.418 -1.048 . . . . 0.0 110.598 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.7 m 60.2 54.7 3.93 Favored 'General case' 0 N--CA 1.498 1.965 0 CA-C-O 122.019 0.914 . . . . 0.0 109.095 -179.345 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.3 m -97.29 -17.15 19.96 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.399 -179.057 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -110.17 41.79 1.67 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.113 -0.992 . . . . 0.0 110.076 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.708 HG21 ' HB1' ' A' ' 44' ' ' ALA . 47.4 t -80.14 118.9 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.383 -0.823 . . . . 0.0 110.409 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.73 97.73 0.37 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -157.5 155.59 30.58 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.457 -1.025 . . . . 0.0 110.437 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.04 127.75 3.45 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.6 t80 -79.49 167.63 20.54 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.525 -0.985 . . . . 0.0 110.561 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 p -80.48 168.82 18.49 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.571 -0.706 . . . . 0.0 110.42 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.446 0 CA-C-O 118.034 -1.426 . . . . 0.0 109.732 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 35.4 mt-30 . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.301 0.572 . . . . 0.0 110.329 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.4 p -77.72 145.85 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.5 -0.75 . . . . 0.0 110.213 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -110.36 107.08 16.68 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.508 -0.745 . . . . 0.0 110.033 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.14 156.8 42.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.526 -0.734 . . . . 0.0 110.241 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.26 -73.65 0.05 OUTLIER Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 102.38 150.66 23.08 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -76.28 93.38 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.502 -0.999 . . . . 0.0 110.285 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -68.51 -32.82 73.05 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.522 -0.737 . . . . 0.0 110.796 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.98 118.14 55.53 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.387 -0.82 . . . . 0.0 110.267 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.92 128.56 11.65 Favored 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.855 1.45 . . . . 0.0 110.756 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.486 HG21 ' HB3' ' A' ' 14' ' ' PRO . 48.2 mt -86.23 115.0 60.34 Favored Pre-proline 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.824 . . . . 0.0 110.106 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.68 83.63 1.07 Allowed 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 123.924 1.486 . . . . 0.0 110.739 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.1 tpm_? 59.1 91.9 0.07 OUTLIER Pre-proline 0 N--CA 1.503 2.218 0 O-C-N 121.802 -0.561 . . . . 0.0 111.056 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.486 ' HB3' HG21 ' A' ' 11' ' ' ILE . 46.5 Cg_endo -74.45 127.96 11.53 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.857 1.451 . . . . 0.0 110.686 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.43 126.05 8.79 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.871 1.458 . . . . 0.0 110.595 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.508 ' O ' ' HB3' ' A' ' 17' ' ' PHE . 47.1 Cg_endo -73.1 95.77 0.85 Allowed 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.865 1.455 . . . . 0.0 110.707 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' HB3' ' O ' ' A' ' 16' ' ' PRO . 75.6 t80 63.22 151.04 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.256 0 CA-C-O 121.703 0.763 . . . . 0.0 111.433 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -114.65 136.16 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.346 -0.846 . . . . 0.0 109.955 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -111.09 121.43 40.65 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.499 -0.751 . . . . 0.0 110.417 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -73.17 -173.46 1.28 Allowed 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.916 1.482 . . . . 0.0 110.668 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 21' ' ' LEU . 1.3 mm? -108.95 94.88 15.63 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.429 -0.794 . . . . 0.0 110.259 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.66 95.76 0.97 Allowed 'Trans proline' 0 C--N 1.315 -1.22 0 O-C-N 123.846 1.445 . . . . 0.0 110.509 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.36 60.55 0.28 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 147.08 16.02 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -73.49 157.98 48.38 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.759 1.4 . . . . 0.0 110.542 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.3 mm -123.57 153.04 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.374 -0.829 . . . . 0.0 110.383 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.39 75.52 0.5 Allowed Glycine 0 N--CA 1.495 2.615 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -79.71 -38.26 0.39 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.862 1.453 . . . . 0.0 111.014 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -83.55 70.99 10.36 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.382 -0.824 . . . . 0.0 110.182 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -136.14 45.61 2.36 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 164.65 49.42 0.02 OUTLIER Glycine 0 N--CA 1.492 2.415 0 C-N-CA 119.866 -1.159 . . . . 0.0 110.662 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.3 t -172.79 96.7 0.36 Allowed Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 121.32 -1.106 . . . . 0.0 110.542 179.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -69.02 160.34 50.3 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 123.852 1.448 . . . . 0.0 111.621 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 54.3 t -79.85 -36.29 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.967 0 O-C-N 121.507 -0.746 . . . . 0.0 110.487 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -68.8 -15.02 63.39 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.541 -0.724 . . . . 0.0 111.383 -179.606 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 33.0 m 57.8 27.97 15.27 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.4 -0.812 . . . . 0.0 110.84 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 7.4 mtt-85 -111.09 149.94 30.1 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.354 -0.841 . . . . 0.0 109.982 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.01 34.18 43.03 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.6 pt -129.77 154.15 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.135 . . . . 0.0 110.177 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 m -83.83 161.47 20.9 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.599 -0.688 . . . . 0.0 109.741 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.92 -41.39 82.58 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.432 -0.793 . . . . 0.0 109.574 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -67.97 -36.44 80.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 0.0 110.093 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -67.43 -40.19 85.47 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.429 -0.794 . . . . 0.0 109.911 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.92 -34.52 73.6 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 0.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.6 ttp180 -70.12 -31.3 68.79 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.434 -0.791 . . . . 0.0 110.232 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 2.0 t -71.35 -44.24 65.41 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.542 -0.724 . . . . 0.0 111.314 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.7 t -75.41 -29.18 59.68 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.19 -0.944 . . . . 0.0 111.467 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.5 t -62.25 -42.67 99.54 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.165 -0.959 . . . . 0.0 110.078 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 10.2 t -84.97 -25.12 27.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.329 -0.857 . . . . 0.0 110.685 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 46' ' ' SER . 3.9 ttt180 -81.7 -33.71 31.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.414 -0.804 . . . . 0.0 111.312 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -142.12 9.57 1.9 Allowed 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.167 -0.958 . . . . 0.0 112.328 -179.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 66.99 27.72 73.53 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -115.73 144.82 43.42 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.172 -1.193 . . . . 0.0 110.812 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 44.9 m 62.08 51.78 3.5 Favored 'General case' 0 N--CA 1.499 1.985 0 CA-C-O 122.013 0.911 . . . . 0.0 109.438 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.36 -4.53 38.29 Favored 'General case' 0 N--CA 1.487 1.395 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.317 -179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.3 t-160 -126.02 47.74 2.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.048 -1.032 . . . . 0.0 109.944 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 64.2 t -90.68 144.7 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.511 -0.743 . . . . 0.0 110.379 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.33 139.01 7.6 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.971 -1.251 . . . . 0.0 109.971 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.6 106.86 3.64 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -1.043 . . . . 0.0 110.513 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.7 177.04 39.85 Favored Glycine 0 N--CA 1.494 2.554 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.417 ' O ' ' HB2' ' A' ' 62' ' ' SER . 39.6 t80 -74.69 153.16 39.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.378 -1.072 . . . . 0.0 110.331 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.417 ' HB2' ' O ' ' A' ' 61' ' ' TYR . 69.2 m 59.11 178.57 0.08 Allowed 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.554 0.693 . . . . 0.0 111.045 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.416 0 CA-C-O 118.003 -1.443 . . . . 0.0 109.528 -179.709 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.7 mm100 . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 121.35 0.595 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.0 t -84.89 130.86 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.543 -0.723 . . . . 0.0 109.877 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -110.23 108.73 18.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.372 -0.83 . . . . 0.0 110.329 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -132.85 81.38 1.94 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.501 -0.749 . . . . 0.0 109.935 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 74.15 -95.74 0.86 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 169.75 -77.82 0.1 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -94.71 94.06 7.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.546 -0.973 . . . . 0.0 109.796 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -155.32 -178.55 7.34 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.529 -0.732 . . . . 0.0 110.422 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.4 157.37 65.13 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.471 -0.768 . . . . 0.0 110.219 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 125.42 9.99 Favored 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.879 1.463 . . . . 0.0 110.659 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.533 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 tt -90.18 117.76 68.3 Favored Pre-proline 0 N--CA 1.494 1.773 0 O-C-N 121.379 -0.826 . . . . 0.0 110.513 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.55 74.29 3.81 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 123.85 1.447 . . . . 0.0 110.526 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.63 137.56 47.76 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.409 -0.807 . . . . 0.0 110.4 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.14 155.56 56.55 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 124.062 1.559 . . . . 0.0 110.776 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.6 120.9 6.99 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 O-C-N 123.878 1.462 . . . . 0.0 110.515 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -75.96 -171.88 1.19 Allowed 'Trans proline' 0 C--N 1.316 -1.18 0 O-C-N 123.858 1.452 . . . . 0.0 110.786 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -66.26 158.77 28.08 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.581 -0.699 . . . . 0.0 110.752 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -72.54 130.24 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.573 -0.704 . . . . 0.0 110.093 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.0 tpp180 -94.32 122.45 61.31 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.701 -0.624 . . . . 0.0 110.527 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.18 -172.38 1.13 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.96 1.505 . . . . 0.0 110.891 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.38 153.54 95.75 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.478 -0.764 . . . . 0.0 110.504 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.52 127.62 13.45 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.922 1.485 . . . . 0.0 110.58 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 154.79 -108.19 0.35 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.97 87.41 0.56 Allowed Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -73.49 140.03 29.41 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.879 1.463 . . . . 0.0 110.647 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.8 mp -121.24 163.06 19.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.487 -0.758 . . . . 0.0 110.173 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.29 171.33 39.74 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.89 -10.63 28.03 Favored 'Trans proline' 0 N--CA 1.491 1.372 0 O-C-N 124.12 1.59 . . . . 0.0 111.812 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.4 t80 -74.1 71.21 1.62 Allowed 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.117 -0.989 . . . . 0.0 110.371 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.96 43.72 0.15 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.312 -0.868 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.98 44.12 0.46 Allowed Glycine 0 N--CA 1.496 2.638 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 40.0 t -172.76 112.51 0.36 Allowed Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.423 -1.045 . . . . 0.0 110.227 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.54 150.01 50.62 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.579 1.305 . . . . 0.0 110.528 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.2 t -79.83 -28.06 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.325 -0.859 . . . . 0.0 110.466 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -74.19 -11.8 60.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.228 -0.92 . . . . 0.0 111.179 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.8 m 58.27 25.69 12.99 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.399 -0.813 . . . . 0.0 111.006 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.8 mmt-85 -110.58 156.09 21.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.352 -0.843 . . . . 0.0 109.943 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.97 30.57 69.99 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.435 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.5 pt -131.69 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.266 -1.138 . . . . 0.0 109.981 179.62 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.408 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 1.6 m -82.27 158.52 23.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.715 -0.616 . . . . 0.0 109.446 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -56.62 -44.39 81.16 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.405 -0.809 . . . . 0.0 109.732 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.6 t -68.14 -35.74 78.58 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.598 -0.689 . . . . 0.0 109.971 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.0 OUTLIER -64.29 -41.92 96.63 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.638 -0.664 . . . . 0.0 109.925 179.548 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.435 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -66.98 -36.82 83.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.576 -0.703 . . . . 0.0 109.993 179.415 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.8 mtm180 -65.62 -40.77 92.94 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.656 -0.653 . . . . 0.0 110.062 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.04 -45.12 96.08 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.832 -0.543 . . . . 0.0 111.363 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.555 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 51.8 t -68.56 -33.37 73.96 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.163 -0.961 . . . . 0.0 111.11 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.9 t -60.29 -41.86 94.27 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.167 -0.958 . . . . 0.0 110.465 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 23.0 t -83.43 -22.47 32.65 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.372 -0.83 . . . . 0.0 111.538 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -95.55 -26.68 15.69 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.032 -1.043 . . . . 0.0 111.584 -179.291 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.1 mt -135.84 1.76 2.81 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.166 -0.959 . . . . 0.0 112.478 -178.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.79 26.94 73.7 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.555 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.78 146.31 42.93 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.304 -1.115 . . . . 0.0 110.418 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 92.6 m 60.76 53.52 3.9 Favored 'General case' 0 N--CA 1.499 1.978 0 CA-C-O 121.885 0.85 . . . . 0.0 109.136 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 53.6 m -100.15 -4.06 30.44 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.551 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -127.39 45.89 2.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.04 -1.038 . . . . 0.0 110.288 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 60.1 t -90.09 145.02 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.315 -0.866 . . . . 0.0 110.317 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.38 81.91 1.09 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.3 tttp -166.8 120.84 1.05 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.706 -0.879 . . . . 0.0 110.293 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.7 135.22 6.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.5 t80 -70.52 155.29 40.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.311 -1.111 . . . . 0.0 110.362 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 p -130.26 164.24 25.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.578 -0.701 . . . . 0.0 110.682 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 CA-C-O 117.989 -1.45 . . . . 0.0 109.569 179.866 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.28 0.562 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.86 115.51 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.537 -0.727 . . . . 0.0 110.002 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -80.63 143.38 33.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.417 -0.802 . . . . 0.0 110.299 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.95 133.01 38.12 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.579 -0.701 . . . . 0.0 110.606 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.97 -56.7 1.0 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 7' ' ' TYR . . . 179.41 -63.93 0.08 OUTLIER Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.43 ' HB3' ' O ' ' A' ' 6' ' ' GLY . 70.1 t80 63.06 104.23 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 O-C-N 122.01 -0.7 . . . . 0.0 111.011 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -82.66 -171.71 3.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.266 -0.896 . . . . 0.0 110.197 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.0 126.33 89.43 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.347 -0.846 . . . . 0.0 110.409 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.19 121.75 7.48 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 O-C-N 123.907 1.477 . . . . 0.0 110.886 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.41 127.18 67.05 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.447 -0.783 . . . . 0.0 110.524 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -73.96 62.92 4.97 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.813 1.428 . . . . 0.0 110.549 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -163.9 72.74 1.76 Allowed Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.339 -0.851 . . . . 0.0 109.943 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.89 156.95 47.88 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.86 1.453 . . . . 0.0 110.867 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.18 143.08 28.08 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.993 1.522 . . . . 0.0 110.622 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -74.02 84.36 1.5 Allowed 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.868 1.457 . . . . 0.0 110.316 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -146.37 153.57 40.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.45 -0.781 . . . . 0.0 110.397 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.05 143.0 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.634 -0.666 . . . . 0.0 109.988 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -107.77 120.59 46.72 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 110.296 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.26 172.16 16.17 Favored 'Trans proline' 0 C--N 1.314 -1.241 0 O-C-N 123.876 1.461 . . . . 0.0 110.544 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.847 HD13 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -134.25 121.59 15.57 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.638 -0.664 . . . . 0.0 110.063 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.847 ' HD2' HD13 ' A' ' 21' ' ' LEU . 43.8 Cg_endo -70.51 116.39 4.62 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.808 1.425 . . . . 0.0 110.494 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.38 -68.57 0.3 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.651 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.57 158.66 34.58 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.58 144.46 35.84 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.575 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.437 ' HA ' HD13 ' A' ' 26' ' ' ILE . 13.4 mm -71.19 150.42 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.413 -0.805 . . . . 0.0 110.176 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.17 74.77 0.42 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -76.31 -47.85 0.15 Allowed 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.933 1.491 . . . . 0.0 110.622 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -84.49 64.52 8.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.85 . . . . 0.0 109.525 179.449 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -155.44 41.51 0.42 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.356 -0.84 . . . . 0.0 110.586 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.01 41.57 0.76 Allowed Glycine 0 N--CA 1.496 2.646 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.6 t -172.64 106.07 0.34 Allowed Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.456 -1.026 . . . . 0.0 110.048 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.1 139.8 36.4 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.609 1.321 . . . . 0.0 110.577 179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -69.14 -26.24 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 O-C-N 121.437 -0.789 . . . . 0.0 110.859 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.36 -11.13 59.99 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.15 -0.969 . . . . 0.0 111.411 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 79.7 m 57.44 26.79 13.02 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.391 -0.818 . . . . 0.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -108.45 150.32 27.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.304 -0.872 . . . . 0.0 110.565 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.86 28.23 65.28 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.9 pt -132.48 158.29 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.178 -1.189 . . . . 0.0 110.114 179.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.32 161.08 25.25 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.636 . . . . 0.0 109.684 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.25 -48.46 78.8 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.439 -0.788 . . . . 0.0 109.8 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.01 -33.91 76.88 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.605 -0.685 . . . . 0.0 110.094 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -63.64 -43.87 95.54 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.486 -0.759 . . . . 0.0 109.678 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.875 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.01 -36.14 79.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.638 -0.664 . . . . 0.0 109.545 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -64.53 -40.01 94.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.701 -0.624 . . . . 0.0 110.225 179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.9 t -62.91 -44.91 94.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.627 -0.67 . . . . 0.0 111.041 -179.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.55 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 41.4 t -65.71 -34.05 77.3 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.231 -0.918 . . . . 0.0 110.945 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 40.3 t -59.54 -42.66 92.83 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.144 -0.973 . . . . 0.0 110.572 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -87.84 -26.77 22.63 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.335 -0.853 . . . . 0.0 111.164 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -85.62 -30.67 23.08 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.291 -0.881 . . . . 0.0 111.368 -179.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -134.52 4.58 3.39 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.29 -0.881 . . . . 0.0 112.21 -178.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.35 31.27 80.18 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.55 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 5.0 mmp_? -125.81 148.96 48.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.459 -1.024 . . . . 0.0 110.074 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.2 m 61.17 45.84 8.62 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.022 0.915 . . . . 0.0 108.611 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 9.0 m -90.12 -10.14 45.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.808 -0.557 . . . . 0.0 111.325 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -117.75 43.51 2.38 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.21 -0.931 . . . . 0.0 109.861 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.875 HG21 ' HB1' ' A' ' 44' ' ' ALA . 61.4 t -79.63 117.57 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.444 -0.785 . . . . 0.0 110.363 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.34 143.25 10.5 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.79 124.15 2.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.51 -0.994 . . . . 0.0 110.352 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.65 -177.68 43.71 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 47.1 t80 -80.13 159.95 25.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.357 -1.084 . . . . 0.0 110.37 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 61.4 m -77.45 166.79 22.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.473 -0.767 . . . . 0.0 110.563 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.386 0 CA-C-O 118.031 -1.427 . . . . 0.0 109.662 -179.916 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.8 pm0 . . . . . 0 N--CA 1.497 1.907 0 CA-C-O 121.267 0.556 . . . . 0.0 110.646 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.9 p -132.42 149.73 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.704 -0.623 . . . . 0.0 110.329 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -108.95 79.76 1.25 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.442 -0.786 . . . . 0.0 109.826 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.0 107.91 3.55 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.459 -0.776 . . . . 0.0 110.168 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.45 -164.24 34.45 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -166.3 83.94 0.1 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -100.02 146.49 26.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.551 -0.97 . . . . 0.0 110.318 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 50.54 -134.12 1.59 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.735 -0.603 . . . . 0.0 110.486 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.3 122.0 7.3 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.098 -1.001 . . . . 0.0 110.06 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.64 ' HB2' HD12 ' A' ' 11' ' ' ILE . 44.3 Cg_endo -70.93 142.54 43.01 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.87 1.458 . . . . 0.0 110.349 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.64 HD12 ' HB2' ' A' ' 10' ' ' PRO . 2.5 mp 55.54 72.84 0.95 Allowed Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.866 -0.521 . . . . 0.0 110.084 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.95 -169.13 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.718 1.378 . . . . 0.0 110.63 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.468 ' HD2' ' HA ' ' A' ' 13' ' ' ARG . 4.4 mmm180 -68.67 114.85 25.08 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.794 -0.566 . . . . 0.0 110.295 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.89 145.11 44.76 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.86 1.453 . . . . 0.0 110.826 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.8 138.15 18.56 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.949 1.5 . . . . 0.0 110.656 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.02 95.61 0.84 Allowed 'Trans proline' 0 C--N 1.315 -1.192 0 O-C-N 123.916 1.482 . . . . 0.0 110.658 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -75.9 146.11 39.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.817 . . . . 0.0 110.39 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.2 t -85.3 156.66 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.649 -0.657 . . . . 0.0 110.132 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.13 117.28 20.36 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.645 -0.659 . . . . 0.0 110.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.11 169.89 19.48 Favored 'Trans proline' 0 C--N 1.315 -1.208 0 O-C-N 123.942 1.496 . . . . 0.0 110.633 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 52.32 64.13 7.95 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.844 -0.535 . . . . 0.0 110.727 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -81.88 144.58 13.74 Favored 'Trans proline' 0 C--N 1.314 -1.264 0 O-C-N 123.707 1.372 . . . . 0.0 110.726 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.07 54.85 2.36 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.385 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.67 139.8 4.01 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -76.8 178.75 7.21 Favored 'Trans proline' 0 N--CA 1.488 1.189 0 O-C-N 123.981 1.516 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.441 ' HA ' HD13 ' A' ' 26' ' ' ILE . 14.0 mm -63.21 156.33 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.63 -0.669 . . . . 0.0 110.459 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.08 85.03 1.43 Allowed Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.78 -20.95 19.38 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.97 1.51 . . . . 0.0 111.437 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -85.15 49.3 1.72 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.14 -0.975 . . . . 0.0 110.585 -179.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 m-80 -138.06 41.86 2.27 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.309 -0.87 . . . . 0.0 110.445 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.5 38.1 1.1 Allowed Glycine 0 N--CA 1.497 2.702 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 47.2 t -177.49 113.94 0.24 Allowed Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.632 -0.922 . . . . 0.0 110.006 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.93 149.63 66.08 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 O-C-N 123.55 1.289 . . . . 0.0 110.386 179.228 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.2 t -78.2 -32.07 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.409 -0.807 . . . . 0.0 110.733 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.43 -16.61 60.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.172 -0.955 . . . . 0.0 110.952 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.1 m 57.99 30.39 19.12 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.372 -0.83 . . . . 0.0 110.239 -179.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.5 mtp180 -113.01 154.07 27.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.508 -0.745 . . . . 0.0 110.128 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.55 34.69 59.91 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.9 pt -139.83 161.81 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.403 -1.057 . . . . 0.0 109.855 179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 7.8 m -80.44 161.08 25.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.534 -0.728 . . . . 0.0 109.963 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.9 t80 -58.54 -43.72 89.36 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.512 -0.743 . . . . 0.0 109.39 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.9 t -65.0 -38.63 91.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.641 -0.662 . . . . 0.0 109.827 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 28.5 tp60 -64.21 -44.76 90.94 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.611 -0.68 . . . . 0.0 109.593 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.93 79.2 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -65.69 -36.26 83.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.815 -0.553 . . . . 0.0 109.793 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -63.42 -47.77 80.57 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.797 -0.564 . . . . 0.0 111.197 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 53.1 t -66.45 -33.69 76.26 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.241 -0.912 . . . . 0.0 111.091 -179.543 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.0 t -57.81 -41.67 82.69 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.163 -0.961 . . . . 0.0 110.169 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -84.59 -25.59 28.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.272 -0.892 . . . . 0.0 110.367 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.8 ttm180 -79.39 -36.18 39.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.327 -0.858 . . . . 0.0 111.195 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.32 11.39 2.14 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.116 -0.99 . . . . 0.0 112.353 -178.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.04 26.93 73.29 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.461 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.74 141.61 47.61 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.243 -1.151 . . . . 0.0 110.571 -179.921 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 54.1 m 66.25 54.61 0.93 Allowed 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.799 0.809 . . . . 0.0 108.917 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 67.5 m -102.92 -0.62 30.82 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.845 -0.535 . . . . 0.0 111.75 -178.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -137.03 50.24 2.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.935 -1.103 . . . . 0.0 110.645 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.2 t -95.64 137.3 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.115 -0.99 . . . . 0.0 110.245 179.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.52 168.38 41.21 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.93 99.88 5.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.444 -1.033 . . . . 0.0 110.022 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 76.27 98.39 0.15 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -91.7 160.46 15.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.512 -0.993 . . . . 0.0 110.563 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.1 p -73.06 174.36 8.02 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.535 -0.728 . . . . 0.0 110.762 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 CA-C-O 118.021 -1.433 . . . . 0.0 109.608 179.967 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 121.354 0.597 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 94.3 t -104.49 134.66 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.661 -0.649 . . . . 0.0 109.897 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 60.51 101.2 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.197 0 CA-C-O 121.451 0.643 . . . . 0.0 110.619 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.31 101.66 1.96 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.292 -0.88 . . . . 0.0 110.421 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.45 -159.37 29.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -171.06 148.72 11.48 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 42.5 m-85 -87.41 84.67 7.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.433 -1.039 . . . . 0.0 110.141 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -158.94 160.38 35.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.433 -0.792 . . . . 0.0 110.305 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.6 mtt-85 -109.67 104.18 54.78 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.404 -0.81 . . . . 0.0 110.185 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.57 129.72 16.1 Favored 'Trans proline' 0 C--N 1.316 -1.165 0 O-C-N 123.824 1.434 . . . . 0.0 110.433 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 32.0 mt 53.46 69.62 2.18 Favored Pre-proline 0 N--CA 1.501 2.117 0 O-C-N 121.788 -0.57 . . . . 0.0 110.151 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -75.69 69.15 6.15 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.827 1.435 . . . . 0.0 110.372 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 15.4 tpp180 -153.2 112.14 2.65 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.38 -0.825 . . . . 0.0 110.031 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.1 141.13 29.09 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.918 1.483 . . . . 0.0 110.728 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.69 144.17 31.13 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.91 1.479 . . . . 0.0 110.655 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.69 72.67 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 O-C-N 123.832 1.438 . . . . 0.0 110.332 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -161.37 155.58 22.6 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.372 -0.83 . . . . 0.0 110.524 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -125.3 144.87 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.714 -0.616 . . . . 0.0 109.965 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -88.84 114.85 61.67 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.591 -0.693 . . . . 0.0 110.337 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.487 ' O ' ' HB2' ' A' ' 21' ' ' LEU . 51.4 Cg_endo -77.04 179.6 6.37 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.854 1.45 . . . . 0.0 110.745 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.487 ' HB2' ' O ' ' A' ' 20' ' ' PRO . 1.2 mt 63.63 157.61 0.12 Allowed Pre-proline 0 N--CA 1.506 2.361 0 O-C-N 122.028 -0.42 . . . . 0.0 111.456 179.597 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.48 105.66 2.12 Favored 'Trans proline' 0 C--N 1.314 -1.245 0 O-C-N 123.729 1.384 . . . . 0.0 110.517 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.28 90.01 0.62 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.52 89.6 1.32 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.33 156.0 55.27 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.89 1.468 . . . . 0.0 110.682 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.7 mp -105.84 143.78 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.404 -0.81 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.2 80.85 0.75 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.54 -171.09 1.01 Allowed 'Trans proline' 0 C--N 1.314 -1.272 0 O-C-N 123.887 1.467 . . . . 0.0 110.694 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.0 t80 -78.59 62.16 3.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.362 -0.836 . . . . 0.0 109.779 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -141.82 38.75 1.65 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.297 -0.877 . . . . 0.0 110.929 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -164.49 41.29 0.3 Allowed Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.955 -1.116 . . . . 0.0 110.418 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.1 t -170.31 98.71 0.45 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.367 -1.078 . . . . 0.0 110.372 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.79 152.9 69.26 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.833 1.438 . . . . 0.0 110.719 179.575 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.6 t -77.38 -29.93 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.475 -0.766 . . . . 0.0 110.861 -179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.419 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -73.33 -12.68 60.92 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.24 -0.912 . . . . 0.0 111.27 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 35' ' ' SER . 68.5 m 58.15 25.55 12.64 Favored 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.45 -0.781 . . . . 0.0 111.155 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.405 ' O ' HG23 ' A' ' 39' ' ' ILE . 2.0 mtt180 -115.9 158.55 22.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.317 -0.865 . . . . 0.0 110.032 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.83 28.74 73.91 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 37' ' ' ARG . 16.2 pt -125.71 152.0 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.325 -1.103 . . . . 0.0 109.937 179.538 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -77.32 160.17 29.01 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.77 -44.56 86.25 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.346 -0.846 . . . . 0.0 109.724 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.0 -35.57 80.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.513 -0.742 . . . . 0.0 109.914 179.143 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.4 -44.22 96.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.396 -0.815 . . . . 0.0 109.117 178.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.758 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.56 -34.83 72.67 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.814 -0.554 . . . . 0.0 109.571 178.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -34.96 77.0 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.696 -0.627 . . . . 0.0 110.283 179.388 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -69.65 -41.44 75.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.497 -0.752 . . . . 0.0 110.839 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 48.8 t -71.96 -32.83 67.66 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.408 -0.808 . . . . 0.0 111.061 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.5 t -65.36 -43.17 91.65 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.246 -0.909 . . . . 0.0 110.917 -179.471 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.6 t -80.94 -21.36 40.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.451 -0.781 . . . . 0.0 112.126 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -101.79 -23.24 14.22 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.009 -1.057 . . . . 0.0 111.724 -179.15 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -134.14 -8.73 2.64 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.967 -1.083 . . . . 0.0 112.541 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.02 26.51 66.45 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.42 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -120.23 148.72 43.33 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.246 -1.149 . . . . 0.0 110.689 -179.596 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 11.8 m 58.95 46.08 14.15 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 122.033 0.92 . . . . 0.0 108.885 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 20.7 m -88.76 -12.78 41.18 Favored 'General case' 0 N--CA 1.488 1.428 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.185 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -116.89 45.17 1.91 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.219 -0.926 . . . . 0.0 109.974 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.758 HG21 ' HB1' ' A' ' 44' ' ' ALA . 94.2 t -80.33 116.81 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.429 -0.795 . . . . 0.0 110.229 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.18 125.31 3.24 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -68.3 92.99 0.44 Allowed 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.452 -1.028 . . . . 0.0 109.838 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.32 -165.1 32.42 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -178.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 63.9 t80 -57.5 139.65 52.75 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.369 -1.077 . . . . 0.0 110.275 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -156.08 -179.87 8.56 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.625 -0.672 . . . . 0.0 110.595 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.484 0 CA-C-O 118.02 -1.433 . . . . 0.0 109.582 -179.974 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLN . . . . . 0.434 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 3.5 mp0 . . . . . 0 N--CA 1.496 1.856 0 CA-C-O 121.024 0.44 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.434 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 16.0 t 64.54 164.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.387 0 CA-C-O 121.414 0.626 . . . . 0.0 110.75 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -136.37 150.17 48.69 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.321 -0.862 . . . . 0.0 110.528 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.49 95.25 6.13 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.491 -0.755 . . . . 0.0 109.916 179.6 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.81 54.4 3.93 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -176.87 94.7 0.1 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -83.38 125.86 32.12 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.608 -0.936 . . . . 0.0 110.221 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -164.1 -57.16 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.505 -0.747 . . . . 0.0 110.402 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 5.7 mtp180 -76.08 157.91 82.74 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.413 -0.804 . . . . 0.0 110.456 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -71.87 138.03 30.69 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.821 1.432 . . . . 0.0 110.636 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.9 mt -92.3 134.2 28.7 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.469 -0.77 . . . . 0.0 110.008 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -71.26 73.16 2.14 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 124.045 1.55 . . . . 0.0 110.739 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 30.6 ttt85 -149.01 122.67 4.62 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.437 -0.79 . . . . 0.0 109.913 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.74 117.99 5.14 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.929 1.489 . . . . 0.0 110.557 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -76.09 143.92 26.24 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.825 1.434 . . . . 0.0 110.603 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.6 79.5 2.79 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.884 1.465 . . . . 0.0 110.388 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -91.31 149.48 21.72 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.26 -0.9 . . . . 0.0 110.468 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.65 145.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.742 -0.599 . . . . 0.0 109.892 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.14 112.33 54.51 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.564 -0.71 . . . . 0.0 110.199 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.18 179.3 5.93 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 O-C-N 123.802 1.422 . . . . 0.0 110.913 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 53.97 72.71 1.05 Allowed Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.913 -0.492 . . . . 0.0 110.905 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.86 142.84 28.84 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 123.76 1.4 . . . . 0.0 110.384 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.17 63.7 0.85 Allowed Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.1 166.0 41.71 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.92 153.19 58.28 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 O-C-N 123.851 1.448 . . . . 0.0 110.641 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 15.8 tt -83.1 150.13 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.418 -0.801 . . . . 0.0 110.466 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.69 83.84 0.59 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.33 -32.79 7.79 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 124.006 1.529 . . . . 0.0 110.867 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -79.98 63.59 4.55 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.356 -0.84 . . . . 0.0 110.102 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 -148.1 37.83 0.87 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.298 -0.876 . . . . 0.0 110.775 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.02 45.46 0.58 Allowed Glycine 0 N--CA 1.496 2.633 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 17.4 t -169.71 105.75 0.46 Allowed Pre-proline 0 N--CA 1.495 1.775 0 O-C-N 121.521 -0.988 . . . . 0.0 110.106 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.67 126.96 13.26 Favored 'Trans proline' 0 C--N 1.313 -1.315 0 O-C-N 123.624 1.328 . . . . 0.0 110.455 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.45 HG22 ' HD2' ' A' ' 53' ' ' ARG . 90.3 t -62.56 -32.07 54.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.474 -0.767 . . . . 0.0 110.438 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.9 -14.17 61.86 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.492 -0.755 . . . . 0.0 111.08 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.455 ' CB ' HG21 ' A' ' 57' ' ' VAL . 35.2 m 57.75 30.53 19.09 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.511 -0.743 . . . . 0.0 111.09 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.1 mtt85 -105.53 139.95 39.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.267 -0.895 . . . . 0.0 109.999 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.56 0.68 81.73 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 39' ' ' ILE . 27.0 pt -116.28 158.48 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.063 -1.257 . . . . 0.0 110.125 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -80.08 165.11 22.83 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.699 -0.626 . . . . 0.0 110.639 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -57.82 -48.81 78.66 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.61 -0.681 . . . . 0.0 109.288 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -61.45 -37.51 83.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.668 -0.645 . . . . 0.0 109.781 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -64.82 -44.0 91.3 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.425 -0.797 . . . . 0.0 109.56 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.49 78.42 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.69 -0.631 . . . . 0.0 109.66 179.112 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -36.89 80.57 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.716 -0.615 . . . . 0.0 109.76 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.6 t -64.45 -42.16 96.13 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.756 -0.59 . . . . 0.0 110.946 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 42.3 t -70.26 -34.99 73.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.113 -0.992 . . . . 0.0 111.176 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.3 t -58.15 -40.55 81.67 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.121 -0.987 . . . . 0.0 110.212 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.09 -14.32 50.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 111.297 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -101.62 -31.02 11.03 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.103 -0.998 . . . . 0.0 111.209 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -134.23 -1.69 2.89 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.207 -0.933 . . . . 0.0 112.306 -179.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.98 72.33 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HD2' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -113.49 152.0 30.73 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.07 -1.253 . . . . 0.0 110.521 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.5 m 59.79 53.55 4.79 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.887 0.851 . . . . 0.0 108.721 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 69.3 m -104.94 9.57 34.55 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.475 -178.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -146.01 46.04 1.25 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 110.523 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.455 HG21 ' CB ' ' A' ' 36' ' ' CYS . 70.8 t -106.26 126.24 61.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.17 -0.956 . . . . 0.0 110.35 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.63 157.52 33.75 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.86 136.75 3.02 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.513 -0.992 . . . . 0.0 110.462 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.2 -172.79 49.52 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.0 t80 -69.61 140.82 53.77 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.368 -1.077 . . . . 0.0 110.083 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.7 p -161.72 167.05 25.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.553 -0.717 . . . . 0.0 110.643 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 CA-C-O 118.015 -1.436 . . . . 0.0 109.533 179.9 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 . . . . . 0 N--CA 1.496 1.844 0 CA-C-O 121.311 0.577 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.5 p -132.1 147.69 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.657 -0.652 . . . . 0.0 110.113 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 56.62 79.79 0.17 Allowed 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.345 0.593 . . . . 0.0 110.574 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 26.7 tttm -89.65 141.7 28.36 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.364 -0.835 . . . . 0.0 110.42 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -161.8 -111.63 0.27 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 175.31 65.07 0.06 OUTLIER Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 51.3 m-85 -97.18 110.78 23.26 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.543 -0.975 . . . . 0.0 109.92 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 56.07 45.18 24.06 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.747 -0.596 . . . . 0.0 110.466 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -135.68 87.47 25.88 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.094 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.65 171.28 16.71 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.861 1.453 . . . . 0.0 110.609 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.527 HG23 ' O ' ' A' ' 11' ' ' ILE . 6.8 tt -57.71 115.57 11.41 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.532 -0.73 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 13' ' ' ARG . 50.6 Cg_endo -76.14 72.2 5.42 Favored 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.869 1.457 . . . . 0.0 110.573 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.436 ' HB3' ' O ' ' A' ' 12' ' ' PRO . 11.4 ttp-105 63.48 109.34 0.03 OUTLIER Pre-proline 0 N--CA 1.502 2.166 0 O-C-N 121.848 -0.533 . . . . 0.0 110.911 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.89 112.73 3.47 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.726 1.382 . . . . 0.0 110.27 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.95 162.01 42.11 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.777 1.409 . . . . 0.0 110.754 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.04 99.02 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.934 1.492 . . . . 0.0 110.631 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -73.69 161.54 30.15 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.509 -0.745 . . . . 0.0 110.639 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.92 151.16 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.74 -0.6 . . . . 0.0 110.248 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.446 ' HG3' ' HD2' ' A' ' 20' ' ' PRO . 3.7 tpp180 -72.92 132.46 82.88 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.454 -0.778 . . . . 0.0 110.367 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.446 ' HD2' ' HG3' ' A' ' 19' ' ' ARG . 49.2 Cg_endo -73.76 -171.08 0.78 Allowed 'Trans proline' 0 N--CA 1.488 1.177 0 O-C-N 123.906 1.477 . . . . 0.0 110.886 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 61.67 76.12 0.41 Allowed Pre-proline 0 N--CA 1.501 2.084 0 O-C-N 121.793 -0.567 . . . . 0.0 110.563 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.95 136.74 23.21 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.788 1.415 . . . . 0.0 110.727 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.71 110.2 3.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.6 92.08 1.28 Allowed Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.86 156.41 56.71 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 124.025 1.54 . . . . 0.0 110.892 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.7 tt -73.88 162.36 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.517 -0.739 . . . . 0.0 110.742 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.16 81.94 1.42 Allowed Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -77.23 -169.22 0.7 Allowed 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.894 1.47 . . . . 0.0 110.607 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -78.63 62.67 3.24 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.394 -0.816 . . . . 0.0 109.996 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -139.07 40.25 2.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 0.0 110.71 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -173.6 44.51 0.15 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 34.0 t -168.88 86.75 0.65 Allowed Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.364 -1.08 . . . . 0.0 110.327 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.42 ' HD2' HG21 ' A' ' 39' ' ' ILE . 41.4 Cg_endo -67.52 140.05 50.95 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.851 1.448 . . . . 0.0 110.758 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.646 HG13 ' NH1' ' A' ' 53' ' ' ARG . 87.4 t -60.03 -31.27 47.42 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.584 -0.697 . . . . 0.0 110.936 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 t -72.86 -4.49 32.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.234 -0.916 . . . . 0.0 111.767 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 55.6 28.58 12.14 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.291 -0.881 . . . . 0.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.3 mtt85 -123.63 161.47 24.97 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.307 -0.87 . . . . 0.0 110.213 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.59 30.81 65.99 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.42 HG21 ' HD2' ' A' ' 33' ' ' PRO . 16.0 pt -141.61 159.47 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.496 -1.002 . . . . 0.0 109.896 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 11.6 m -80.84 161.41 24.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.515 -0.74 . . . . 0.0 109.824 179.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -57.4 -45.68 84.29 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.553 -0.717 . . . . 0.0 109.389 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.1 t -64.04 -36.6 84.52 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.658 -0.651 . . . . 0.0 109.864 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.44 -44.87 89.81 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.649 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.1 -36.44 74.88 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.727 -0.608 . . . . 0.0 109.901 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.6 tpp85 -67.82 -38.0 82.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.675 -0.64 . . . . 0.0 109.508 179.088 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 16.3 t -64.05 -44.11 93.47 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.816 -0.552 . . . . 0.0 110.686 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.4 t -64.87 -30.18 71.16 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.935 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.8 t -70.3 -43.21 70.82 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.214 -0.929 . . . . 0.0 110.558 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -81.85 -21.05 37.76 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.272 -0.893 . . . . 0.0 112.016 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -105.59 -19.7 13.69 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.035 -1.04 . . . . 0.0 111.714 -179.493 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -6.33 2.87 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.108 -0.995 . . . . 0.0 112.446 -179.168 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.52 25.99 74.82 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.646 ' NH1' HG13 ' A' ' 34' ' ' VAL . 13.9 mmm180 -121.22 148.76 43.82 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.227 -1.161 . . . . 0.0 110.439 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 5.3 m 59.26 48.32 10.42 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-O 121.97 0.89 . . . . 0.0 108.824 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 14.8 m -91.43 -6.42 52.8 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.373 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -120.63 45.38 2.24 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.146 -0.971 . . . . 0.0 109.888 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.413 HG21 ' HB1' ' A' ' 44' ' ' ALA . 39.1 t -88.92 127.27 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.391 -0.818 . . . . 0.0 110.563 -179.585 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.98 116.99 1.98 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.1 mtmt -133.54 97.39 3.93 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.47 -1.017 . . . . 0.0 109.983 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.75 179.93 43.18 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -74.24 157.09 36.48 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.431 -1.041 . . . . 0.0 110.221 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.82 129.62 42.38 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.566 -0.709 . . . . 0.0 110.316 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 CA-C-O 117.918 -1.49 . . . . 0.0 109.636 -179.746 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 121.429 0.633 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 35.9 m -75.17 142.79 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.589 -0.695 . . . . 0.0 110.339 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -108.78 80.94 1.38 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.362 -0.836 . . . . 0.0 110.058 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 164.13 35.34 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.378 -0.826 . . . . 0.0 110.556 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -146.13 121.29 1.44 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -80.99 -76.52 1.04 Allowed Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.48 ' O ' ' HB3' ' A' ' 8' ' ' ALA . 32.1 m-85 -61.09 133.81 56.41 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.571 -0.958 . . . . 0.0 110.212 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 7' ' ' TYR . . . 62.05 87.56 0.1 Allowed 'General case' 0 N--CA 1.5 2.047 0 CA-C-O 121.438 0.637 . . . . 0.0 110.504 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.445 ' HG3' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -88.06 130.68 45.42 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.348 -0.845 . . . . 0.0 110.319 179.963 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' HD2' ' HG3' ' A' ' 9' ' ' ARG . 46.4 Cg_endo -73.07 146.32 41.09 Favored 'Trans proline' 0 C--N 1.315 -1.236 0 O-C-N 123.898 1.473 . . . . 0.0 110.761 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.0 mm -87.12 137.14 33.11 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.408 -0.807 . . . . 0.0 109.955 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.42 89.92 0.59 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 O-C-N 124.097 1.577 . . . . 0.0 110.4 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.459 ' HD3' ' HD2' ' A' ' 14' ' ' PRO . 0.1 OUTLIER -135.17 153.96 78.59 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.555 -0.715 . . . . 0.0 110.175 -179.846 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.459 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 44.3 Cg_endo -71.76 141.37 37.32 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.968 1.509 . . . . 0.0 110.559 179.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.44 124.09 9.14 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.841 1.443 . . . . 0.0 110.894 -179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -74.35 105.04 1.97 Allowed 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.915 1.482 . . . . 0.0 110.363 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -70.18 160.43 32.14 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.557 -0.715 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -77.01 143.28 13.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.603 -0.685 . . . . 0.0 110.232 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . 0.593 ' HG2' ' HD2' ' A' ' 20' ' ' PRO . 6.7 ttp85 -123.23 140.26 33.38 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.47 -0.769 . . . . 0.0 110.036 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HD2' ' HG2' ' A' ' 19' ' ' ARG . 43.5 Cg_endo -69.47 162.47 41.79 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.767 1.404 . . . . 0.0 110.92 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.6 mt -109.26 104.38 54.96 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.66 -0.65 . . . . 0.0 110.109 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.67 136.55 21.28 Favored 'Trans proline' 0 C--N 1.315 -1.206 0 O-C-N 123.894 1.471 . . . . 0.0 110.708 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.43 -128.72 2.73 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.44 146.49 16.04 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.03 98.92 1.04 Allowed 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.765 1.402 . . . . 0.0 110.601 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -124.13 148.67 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.673 -0.642 . . . . 0.0 110.086 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.83 129.38 5.04 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -78.02 1.72 8.64 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 123.953 1.502 . . . . 0.0 111.754 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -77.83 67.31 3.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.075 -1.016 . . . . 0.0 110.258 -179.625 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -134.04 42.2 2.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.325 -0.859 . . . . 0.0 110.55 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.4 45.19 0.06 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.982 -1.104 . . . . 0.0 110.655 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.4 t -173.83 86.46 0.37 Allowed Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.437 -1.037 . . . . 0.0 110.426 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.61 141.49 34.52 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.845 1.445 . . . . 0.0 110.832 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.4 t -65.92 -27.86 42.31 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.384 -0.822 . . . . 0.0 110.31 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -65.38 -18.04 65.0 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.403 -0.811 . . . . 0.0 111.034 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 35' ' ' SER . 84.1 m 58.29 27.23 14.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.479 -0.763 . . . . 0.0 111.211 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -114.21 147.72 38.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.397 -0.814 . . . . 0.0 109.848 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.11 30.24 65.57 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.4 pt -124.67 155.77 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.381 -1.07 . . . . 0.0 109.854 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -82.13 157.32 24.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.647 . . . . 0.0 109.413 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.61 -39.95 78.03 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.419 -0.801 . . . . 0.0 109.69 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -69.91 -35.63 74.74 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.632 -0.668 . . . . 0.0 110.084 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -65.38 -40.16 93.17 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.714 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.59 -35.88 73.25 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.669 -0.644 . . . . 0.0 110.285 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.27 -32.36 70.14 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 179.428 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.524 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 8.5 t -71.44 -41.6 69.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.555 -0.716 . . . . 0.0 110.948 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.4 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 11.8 t -74.0 -29.07 61.76 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.242 -0.911 . . . . 0.0 111.743 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.7 t -59.48 -43.3 93.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.987 -1.07 . . . . 0.0 109.996 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 12.3 t -89.27 -25.21 21.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.381 -0.824 . . . . 0.0 110.629 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.524 ' HB2' ' O ' ' A' ' 46' ' ' SER . 2.3 ttp85 -79.72 -34.66 39.89 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.407 -0.808 . . . . 0.0 111.181 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -141.08 10.68 2.16 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.162 -0.961 . . . . 0.0 112.289 -179.026 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.81 33.38 82.82 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -123.68 142.52 50.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.584 -0.95 . . . . 0.0 110.097 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 1.8 m 59.76 56.29 3.6 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 121.985 0.898 . . . . 0.0 108.974 -179.038 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 4.4 m -94.98 -11.5 28.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.883 -0.511 . . . . 0.0 111.312 -178.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -122.69 44.14 2.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.149 -0.969 . . . . 0.0 110.078 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.714 HG21 ' HB1' ' A' ' 44' ' ' ALA . 38.1 t -78.58 114.13 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.494 -0.754 . . . . 0.0 110.363 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.6 126.31 2.0 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -86.78 114.4 23.42 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.348 -1.09 . . . . 0.0 110.077 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.4 -179.82 43.59 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.69 163.05 24.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.47 -1.018 . . . . 0.0 110.473 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 m -79.07 167.55 20.9 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.573 -0.704 . . . . 0.0 110.444 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 CA-C-O 117.947 -1.474 . . . . 0.0 109.515 179.958 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 9.3 mm-40 . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.245 0.545 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 93.5 t -80.6 147.58 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.684 -0.635 . . . . 0.0 109.923 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -155.9 159.82 39.62 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.462 -0.773 . . . . 0.0 110.669 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.411 ' HA ' ' HB2' ' A' ' 8' ' ' ALA . 4.0 pttt -89.81 78.99 6.77 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.405 -0.809 . . . . 0.0 110.462 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.5 83.89 0.33 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.49 -74.43 1.77 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.8 118.61 37.05 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.44 -1.035 . . . . 0.0 110.278 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.411 ' HB2' ' HA ' ' A' ' 4' ' ' LYS . . . -146.64 63.14 1.2 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.344 -0.847 . . . . 0.0 110.408 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.44 78.35 72.01 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.85 118.74 5.7 Favored 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.891 1.469 . . . . 0.0 110.43 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 46.0 mm 56.08 80.45 0.29 Allowed Pre-proline 0 N--CA 1.502 2.139 0 O-C-N 121.785 -0.572 . . . . 0.0 110.178 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.14 78.01 1.92 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 123.794 1.418 . . . . 0.0 110.81 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.78 78.48 5.51 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.317 -0.864 . . . . 0.0 109.926 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.55 147.57 46.2 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.814 1.429 . . . . 0.0 111.013 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -74.78 148.3 36.18 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 124.045 1.55 . . . . 0.0 110.62 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -74.12 71.81 4.23 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.882 1.464 . . . . 0.0 110.447 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -153.65 151.12 29.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.324 -0.86 . . . . 0.0 110.394 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -86.42 145.82 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.339 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.8 106.89 52.49 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.637 -0.664 . . . . 0.0 110.052 179.749 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.96 178.22 6.75 Favored 'Trans proline' 0 C--N 1.315 -1.187 0 O-C-N 123.746 1.393 . . . . 0.0 110.839 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.23 99.75 19.25 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.486 -0.759 . . . . 0.0 110.186 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.29 92.99 0.98 Allowed 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.845 1.445 . . . . 0.0 110.701 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -163.79 78.04 0.15 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.74 86.84 0.84 Allowed Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.89 145.04 35.52 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.805 1.424 . . . . 0.0 110.78 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 57.4 mt -127.72 145.45 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.452 -0.78 . . . . 0.0 110.042 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.1 87.85 1.32 Allowed Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.08 -32.82 10.38 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.861 1.453 . . . . 0.0 110.996 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 33.4 t80 -76.59 69.89 3.06 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.333 -0.854 . . . . 0.0 110.15 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -149.92 36.72 0.7 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.376 -0.828 . . . . 0.0 110.75 -179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.34 43.45 0.51 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 52.5 t -177.37 88.29 0.24 Allowed Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.609 -0.936 . . . . 0.0 109.828 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.24 143.35 58.51 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 O-C-N 123.775 1.408 . . . . 0.0 110.692 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 96.2 t -66.22 -29.6 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.363 -0.836 . . . . 0.0 110.669 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.2 t -68.51 -19.31 64.52 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.353 -0.842 . . . . 0.0 111.092 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.3 m 60.69 30.18 19.53 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.495 -0.753 . . . . 0.0 110.627 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -107.41 146.47 31.63 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.27 -0.894 . . . . 0.0 110.373 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.83 29.22 55.23 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 28.4 pt -137.55 163.13 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.198 -1.178 . . . . 0.0 110.33 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.45 ' HB3' ' HB2' ' A' ' 43' ' ' GLN . 13.5 t -80.7 166.56 20.92 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.564 -0.71 . . . . 0.0 110.082 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -62.58 -49.34 75.64 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 46' ' ' SER . 2.7 t -63.57 -35.32 80.1 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.696 -0.627 . . . . 0.0 109.985 179.245 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.45 ' HB2' ' HB3' ' A' ' 40' ' ' SER . 8.6 tt0 -64.74 -43.39 93.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.45 -0.781 . . . . 0.0 109.645 179.356 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -70.73 -36.65 73.29 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.56 -0.713 . . . . 0.0 109.492 179.008 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 5.6 ttt-85 -68.36 -33.44 74.28 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.758 -0.589 . . . . 0.0 109.7 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 42' ' ' SER . 0.1 OUTLIER -66.33 -46.81 75.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.801 -0.562 . . . . 0.0 110.93 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.4 t -66.02 -30.13 70.61 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.321 -0.862 . . . . 0.0 111.248 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 35.4 t -58.84 -41.06 86.04 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.942 -1.099 . . . . 0.0 109.941 179.715 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 19.4 t -87.26 -25.3 24.04 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.668 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.464 ' HD2' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -82.83 -34.41 26.9 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.314 -0.866 . . . . 0.0 111.316 -179.513 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' HD2' ' A' ' 50' ' ' ARG . 2.1 mt -137.56 6.79 2.76 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.178 -0.951 . . . . 0.0 112.374 -179.009 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.08 27.08 74.18 Favored Glycine 0 N--CA 1.497 2.749 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.498 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.4 OUTLIER -117.53 145.65 44.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.21 -1.17 . . . . 0.0 110.293 179.941 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 83.3 m 63.23 53.7 2.19 Favored 'General case' 0 N--CA 1.501 2.108 0 CA-C-O 121.903 0.858 . . . . 0.0 108.806 -178.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.2 m -101.27 8.56 42.4 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.904 -0.497 . . . . 0.0 111.689 -178.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.7 t60 -141.69 42.39 1.72 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 96.4 t -98.49 117.27 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.276 -0.89 . . . . 0.0 110.061 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.75 54.41 2.79 Favored Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -91.08 78.47 5.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.708 -0.878 . . . . 0.0 110.154 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.14 133.74 5.37 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 72.6 t80 -79.0 155.25 28.95 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.383 -1.069 . . . . 0.0 110.234 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.09 131.71 37.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.518 -0.739 . . . . 0.0 110.18 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 CA-C-O 117.968 -1.462 . . . . 0.0 109.593 -179.959 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 CA-C-O 121.317 0.579 . . . . 0.0 110.72 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.5 p -161.43 149.67 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.73 -0.606 . . . . 0.0 110.381 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -123.37 167.66 13.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.445 -0.784 . . . . 0.0 110.354 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 20.7 tttm 56.67 73.61 0.44 Allowed 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.404 0.621 . . . . 0.0 110.089 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 139.28 102.11 0.53 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.71 146.11 15.66 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -105.79 114.6 28.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.4 -1.059 . . . . 0.0 110.172 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -138.82 135.62 34.78 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.384 -0.823 . . . . 0.0 110.416 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -86.02 132.9 42.32 Favored Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 110.135 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.78 157.0 52.56 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 124.002 1.527 . . . . 0.0 111.086 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.419 HG23 ' HD2' ' A' ' 12' ' ' PRO . 6.1 mt -70.24 140.23 87.78 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 121.515 -0.741 . . . . 0.0 110.154 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 11' ' ' ILE . 46.4 Cg_endo -72.31 79.0 1.84 Allowed 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.996 1.524 . . . . 0.0 110.305 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.495 ' HG3' ' HD2' ' A' ' 14' ' ' PRO . 19.5 ttt-85 -135.56 144.36 48.91 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.533 -0.729 . . . . 0.0 109.96 -179.772 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.495 ' HD2' ' HG3' ' A' ' 13' ' ' ARG . 44.1 Cg_endo -70.07 144.35 52.13 Favored 'Trans proline' 0 C--N 1.313 -1.318 0 O-C-N 123.836 1.44 . . . . 0.0 110.501 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.9 147.17 43.48 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.885 1.466 . . . . 0.0 110.873 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -77.14 -169.5 0.75 Allowed 'Trans proline' 0 C--N 1.315 -1.22 0 O-C-N 123.979 1.515 . . . . 0.0 110.809 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -68.05 167.6 13.62 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.539 -0.726 . . . . 0.0 110.596 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.79 144.87 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.687 -0.633 . . . . 0.0 110.525 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -99.08 123.27 49.58 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.586 -0.696 . . . . 0.0 110.14 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.55 159.22 51.84 Favored 'Trans proline' 0 C--N 1.314 -1.289 0 O-C-N 123.757 1.398 . . . . 0.0 110.475 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -107.98 106.64 58.99 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.616 -0.678 . . . . 0.0 110.239 -179.902 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.96 140.87 32.27 Favored 'Trans proline' 0 C--N 1.315 -1.2 0 O-C-N 123.851 1.448 . . . . 0.0 110.528 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -77.08 -41.47 22.12 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.67 102.47 0.98 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.33 115.01 4.16 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.89 1.468 . . . . 0.0 110.691 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 15.9 tt -73.14 165.67 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.592 -0.693 . . . . 0.0 110.145 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.24 -172.82 35.29 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -67.56 -11.13 31.07 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 O-C-N 124.101 1.579 . . . . 0.0 111.741 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -82.11 63.41 6.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.148 -0.97 . . . . 0.0 110.262 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -130.02 36.74 3.99 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.103 -0.998 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 172.89 46.59 0.04 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.54 179.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 5.0 t -168.93 81.95 0.7 Allowed Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.235 -1.156 . . . . 0.0 110.208 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -65.81 152.83 80.46 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 124.027 1.541 . . . . 0.0 111.074 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 50.8 t -68.24 -31.1 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.409 -0.807 . . . . 0.0 110.348 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.8 t -68.48 -16.02 63.75 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.407 -0.808 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.492 ' CB ' HG21 ' A' ' 57' ' ' VAL . 75.5 m 57.42 30.33 18.43 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.358 -0.838 . . . . 0.0 110.775 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.3 mtt180 -102.14 152.65 20.76 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.337 -0.852 . . . . 0.0 110.444 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.38 17.22 76.58 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.3 pt -133.18 159.81 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.057 -1.26 . . . . 0.0 110.241 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.6 161.74 23.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.653 -0.655 . . . . 0.0 109.696 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 86.3 t80 -56.36 -50.12 72.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.498 -0.751 . . . . 0.0 109.567 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.5 t -63.07 -35.86 81.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.689 -0.632 . . . . 0.0 110.196 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -64.22 -42.47 96.58 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.43 -0.794 . . . . 0.0 109.801 179.39 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -36.06 77.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.552 -0.718 . . . . 0.0 109.9 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.38 -40.83 93.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.772 -0.58 . . . . 0.0 110.084 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.6 t -62.8 -43.47 98.73 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.558 -0.714 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.3 t -64.81 -34.26 77.95 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.253 -0.904 . . . . 0.0 110.776 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 37.3 t -61.28 -43.09 99.45 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.309 -0.869 . . . . 0.0 110.045 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.0 m -80.06 -13.07 59.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.51 -0.744 . . . . 0.0 111.265 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.92 -28.56 12.33 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.207 -0.933 . . . . 0.0 111.186 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.95 7.84 1.86 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.058 -1.026 . . . . 0.0 112.515 -179.129 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.76 27.17 74.06 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 120.857 -1.152 . . . . 0.0 110.312 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.4 mmp_? -114.83 143.5 45.01 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.078 -1.248 . . . . 0.0 110.562 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 27.5 m 61.7 56.02 2.56 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-O 121.879 0.847 . . . . 0.0 108.973 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 63.8 m -101.85 -3.14 28.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.925 -0.485 . . . . 0.0 112.01 -178.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -136.42 47.98 2.16 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.983 -1.073 . . . . 0.0 111.006 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.492 HG21 ' CB ' ' A' ' 36' ' ' CYS . 95.5 t -106.35 109.49 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.1 -1.0 . . . . 0.0 109.742 179.348 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.7 93.62 0.3 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 6.6 tttm -99.9 102.16 13.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -1.007 . . . . 0.0 110.206 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.52 -176.68 40.13 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.9 t80 -73.46 157.15 37.36 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.468 -1.019 . . . . 0.0 110.521 -179.804 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.8 p -154.84 166.44 33.48 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.593 -0.692 . . . . 0.0 110.514 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 CA-C-O 118.011 -1.439 . . . . 0.0 109.59 179.974 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 . . . . . 0 N--CA 1.498 1.957 0 CA-C-O 121.365 0.602 . . . . 0.0 110.657 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 66.7 t -113.26 139.98 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.654 -0.654 . . . . 0.0 109.846 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER 65.96 166.54 0.2 Allowed 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.31 149.62 49.8 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.413 -0.804 . . . . 0.0 110.324 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.04 -86.85 0.23 Allowed Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.55 152.8 11.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 t80 -145.05 79.58 1.59 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.47 -1.018 . . . . 0.0 110.227 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -157.63 125.34 5.3 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.393 -0.817 . . . . 0.0 110.191 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 1.1 ttm-85 -139.65 86.84 13.54 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.238 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.49 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.5 Cg_endo -73.28 130.1 14.77 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.955 1.502 . . . . 0.0 110.343 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.49 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 48.5 mt 65.0 118.21 0.02 OUTLIER Pre-proline 0 N--CA 1.505 2.314 0 O-C-N 122.073 -0.392 . . . . 0.0 110.606 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -76.7 65.68 7.5 Favored 'Trans proline' 0 C--N 1.315 -1.201 0 O-C-N 123.571 1.3 . . . . 0.0 110.469 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.5 ttm-85 -164.01 140.04 5.1 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.399 -0.813 . . . . 0.0 109.95 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.23 136.88 25.11 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.88 1.463 . . . . 0.0 110.68 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.82 140.66 26.26 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.937 1.493 . . . . 0.0 110.737 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.69 80.87 2.24 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.842 1.443 . . . . 0.0 110.4 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -80.56 153.54 28.0 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.316 -0.865 . . . . 0.0 110.489 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -85.74 141.78 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.657 -0.652 . . . . 0.0 110.045 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.8 ttt-85 -110.61 126.53 28.62 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.448 -0.783 . . . . 0.0 110.159 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -72.86 177.91 7.08 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 O-C-N 123.868 1.457 . . . . 0.0 110.669 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.5 tp -148.88 74.85 10.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.47 -0.769 . . . . 0.0 110.18 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -73.79 115.58 4.38 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.792 1.417 . . . . 0.0 110.379 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 118.48 -66.81 0.37 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.73 95.84 0.54 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.84 142.41 35.22 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.875 1.461 . . . . 0.0 110.839 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 mt -97.75 141.82 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.491 -0.755 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.73 84.22 1.33 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.73 -33.11 8.57 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 124.049 1.552 . . . . 0.0 111.018 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.593 ' CE1' ' HB3' ' A' ' 32' ' ' CYS . 3.2 t80 -81.66 77.2 8.53 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.311 -0.868 . . . . 0.0 109.357 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -114.83 42.03 2.25 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.26 -0.9 . . . . 0.0 111.073 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.452 ' O ' ' HB2' ' A' ' 32' ' ' CYS . . . -156.32 32.64 0.59 Allowed Glycine 0 N--CA 1.494 2.519 0 C-N-CA 119.959 -1.115 . . . . 0.0 110.541 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.593 ' HB3' ' CE1' ' A' ' 29' ' ' TYR . 40.7 t 177.79 119.51 0.18 Allowed Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.6 -0.941 . . . . 0.0 110.569 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HG3' HG21 ' A' ' 39' ' ' ILE . 46.3 Cg_endo -75.96 142.78 25.4 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.311 1.164 . . . . 0.0 109.879 178.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 43.5 t -73.82 -30.33 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.21 -0.931 . . . . 0.0 110.937 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.5 t -73.65 -10.88 60.15 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.275 -0.891 . . . . 0.0 111.825 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 74.8 m 57.43 29.28 16.72 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.232 -0.917 . . . . 0.0 110.878 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -128.51 158.94 36.99 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.306 -0.871 . . . . 0.0 110.636 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.24 37.25 71.45 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.54 HG21 ' HG3' ' A' ' 33' ' ' PRO . 14.1 pt -143.99 159.5 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.423 -1.045 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.5 m -76.06 160.28 29.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.642 -0.661 . . . . 0.0 109.701 179.369 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -58.17 -44.67 88.08 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 109.478 179.356 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -62.61 -37.86 87.92 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.619 -0.676 . . . . 0.0 109.903 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -64.51 -45.82 85.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.546 -0.721 . . . . 0.0 109.668 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.524 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -67.93 -36.7 80.59 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.813 -0.555 . . . . 0.0 109.932 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 33.4 ttp85 -69.95 -36.96 75.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.538 -0.726 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.1 t -63.27 -40.09 96.43 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.687 -0.633 . . . . 0.0 110.845 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 29.6 t -67.77 -40.05 84.05 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.352 -0.843 . . . . 0.0 110.745 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.5 t -59.07 -42.74 91.1 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.392 -0.817 . . . . 0.0 110.747 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.9 -18.89 49.45 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.427 -0.795 . . . . 0.0 111.902 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.83 -25.18 13.6 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.084 -1.01 . . . . 0.0 111.806 -179.229 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.473 HD22 ' CE2' ' A' ' 29' ' ' TYR . 8.5 mt -135.1 -5.86 2.36 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.065 -1.022 . . . . 0.0 112.669 -178.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.5 22.92 71.75 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.5 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.74 148.01 41.51 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.238 -1.154 . . . . 0.0 110.548 -179.847 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 84.7 m 61.37 47.42 6.84 Favored 'General case' 0 N--CA 1.498 1.931 0 CA-C-O 121.974 0.892 . . . . 0.0 109.086 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 36.5 m -91.2 -7.96 49.88 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.904 -0.497 . . . . 0.0 111.228 -179.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.8 t60 -124.11 45.73 2.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.145 -0.972 . . . . 0.0 109.908 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.524 HG21 ' HB1' ' A' ' 44' ' ' ALA . 54.4 t -81.79 137.33 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.423 -0.798 . . . . 0.0 110.454 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.8 112.54 0.49 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.1 mtmt -114.23 98.76 7.14 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.419 -1.048 . . . . 0.0 110.081 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.85 126.52 3.42 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -70.42 157.01 38.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.458 -1.025 . . . . 0.0 110.331 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.2 p -131.32 164.1 26.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.526 -0.734 . . . . 0.0 110.685 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.906 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 N-CA-C 110.966 -0.436 . . . . 0.0 110.966 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.4 t -62.84 -31.23 51.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.505 -0.747 . . . . 0.0 110.937 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.6 OUTLIER -69.22 -12.44 61.67 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.503 -0.748 . . . . 0.0 111.53 -179.677 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 35' ' ' SER . 78.8 m 61.78 27.75 16.99 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.409 -0.807 . . . . 0.0 110.575 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HG2' ' O ' ' A' ' 35' ' ' SER . 17.1 mmm180 -107.02 146.34 31.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.397 -0.814 . . . . 0.0 110.19 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.93 22.45 52.79 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.5 pt -138.87 154.96 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.154 -1.204 . . . . 0.0 110.281 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.486 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 55.0 m -74.51 165.75 24.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.607 -0.683 . . . . 0.0 110.043 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.49 ' CE2' ' HD2' ' A' ' 45' ' ' ARG . 84.2 t80 -60.02 -48.76 80.4 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.616 -0.677 . . . . 0.0 109.816 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -65.82 -33.75 76.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.583 -0.698 . . . . 0.0 110.122 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.486 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.3 OUTLIER -63.47 -46.38 86.47 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.143 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.81 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -63.47 -37.69 88.28 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.891 -0.505 . . . . 0.0 109.956 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.49 ' HD2' ' CE2' ' A' ' 41' ' ' PHE . 1.0 OUTLIER -64.54 -40.86 96.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.628 -0.67 . . . . 0.0 109.761 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -61.55 -43.95 97.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.774 -0.579 . . . . 0.0 110.971 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.1 t -67.04 -31.2 71.56 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.315 -0.865 . . . . 0.0 111.17 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 t -58.69 -42.5 88.7 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.077 -1.014 . . . . 0.0 109.86 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -84.53 -22.08 30.28 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.412 -0.805 . . . . 0.0 110.697 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -80.97 -36.01 31.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.239 -0.913 . . . . 0.0 111.01 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.49 18.29 1.69 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.187 -0.946 . . . . 0.0 111.97 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.28 31.74 78.22 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.524 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 3.6 mmp_? -117.57 137.75 52.38 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.43 -1.041 . . . . 0.0 110.68 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.524 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 21.5 m 64.35 52.51 1.86 Allowed 'General case' 0 N--CA 1.502 2.128 0 CA-C-O 121.84 0.828 . . . . 0.0 109.476 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 27.3 m -92.02 -20.39 21.38 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.955 -0.466 . . . . 0.0 111.262 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -112.81 42.55 1.84 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.167 -0.958 . . . . 0.0 110.002 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.81 HG21 ' HB1' ' A' ' 44' ' ' ALA . 75.8 t . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.529 -0.732 . . . . 0.0 110.199 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo . . . . . 0 N--CA 1.489 1.244 0 N-CA-C 110.689 -0.543 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.41 -30.64 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 121.485 -0.759 . . . . 0.0 110.811 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.55 -16.62 62.89 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.334 -0.854 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.484 ' CB ' HG21 ' A' ' 57' ' ' VAL . 38.8 m 59.31 25.56 14.24 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.512 -0.742 . . . . 0.0 111.169 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.4 mmt-85 -108.39 143.5 37.22 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.24 -0.913 . . . . 0.0 110.127 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.86 22.2 53.64 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.407 HD13 HG21 ' A' ' 39' ' ' ILE . 26.3 pt -134.93 156.3 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.135 -1.215 . . . . 0.0 110.098 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 m -74.48 166.02 24.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.637 -0.664 . . . . 0.0 110.515 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -60.18 -49.04 79.18 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.744 -0.597 . . . . 0.0 109.627 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -62.73 -35.36 79.49 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.624 -0.673 . . . . 0.0 110.059 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -63.36 -46.01 88.52 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.253 -0.904 . . . . 0.0 109.205 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.71 -33.04 68.43 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.714 -0.616 . . . . 0.0 109.552 179.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.1 mtp-105 -68.84 -38.2 79.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.831 -0.543 . . . . 0.0 110.495 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -67.4 -40.33 85.59 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.421 -0.799 . . . . 0.0 110.73 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 43.8 t -69.38 -31.82 70.45 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.351 -0.843 . . . . 0.0 111.207 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 30.5 t -58.41 -42.19 86.64 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.224 -0.923 . . . . 0.0 110.305 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -84.15 -23.66 30.54 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.385 -0.822 . . . . 0.0 111.0 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 4.6 mmt-85 -85.76 -32.9 21.6 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 111.309 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -139.35 9.29 2.48 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.121 -0.987 . . . . 0.0 112.283 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.06 27.79 72.73 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.513 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.08 140.1 48.76 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.271 -1.135 . . . . 0.0 110.382 -179.561 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 98.2 m 63.59 53.12 2.12 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.877 0.846 . . . . 0.0 109.181 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 25.8 m -97.13 -14.55 21.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.828 -0.545 . . . . 0.0 111.783 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -122.85 42.25 3.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.972 -1.08 . . . . 0.0 110.858 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.484 HG21 ' CB ' ' A' ' 36' ' ' CYS . 72.4 t . . . . . 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.725 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo . . . . . 0 N--CA 1.485 1.018 0 N-CA-C 110.286 -0.698 . . . . 0.0 110.286 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.47 -28.44 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.457 -0.777 . . . . 0.0 110.845 -179.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -71.07 -12.66 61.64 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.257 -0.902 . . . . 0.0 111.353 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.2 m 55.32 29.19 12.51 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.333 -0.855 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -125.92 152.58 45.42 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.236 -0.915 . . . . 0.0 110.204 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.35 36.2 59.66 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -127.44 156.25 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.291 -1.123 . . . . 0.0 110.243 179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -82.38 160.24 22.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.507 -0.746 . . . . 0.0 109.38 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -58.15 -41.64 84.18 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.533 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -67.53 -36.72 81.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.633 -0.667 . . . . 0.0 110.156 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -65.61 -41.94 92.15 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.416 -0.803 . . . . 0.0 109.704 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.29 -34.12 75.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.757 -0.59 . . . . 0.0 110.361 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.16 -33.8 73.97 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.458 -0.776 . . . . 0.0 110.12 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -69.03 -46.0 69.03 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.538 -0.726 . . . . 0.0 111.059 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 42.4 t -69.52 -32.5 71.39 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.334 -0.854 . . . . 0.0 111.219 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.1 t -64.73 -42.04 95.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.222 -0.924 . . . . 0.0 110.775 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -82.46 -25.25 33.74 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.359 -0.838 . . . . 0.0 111.496 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.24 -29.51 18.14 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.189 -0.944 . . . . 0.0 111.526 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.2 mt -137.03 3.43 2.66 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.049 -1.032 . . . . 0.0 112.648 -178.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.49 28.45 73.61 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.453 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -118.16 146.81 43.92 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.296 -1.12 . . . . 0.0 110.606 -179.446 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.2 m 59.46 48.93 9.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 122.041 0.924 . . . . 0.0 109.027 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.5 m -92.53 -16.8 25.29 Favored 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.713 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -114.9 41.79 2.31 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.062 -1.023 . . . . 0.0 110.62 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 95.5 t . . . . . 0 N--CA 1.499 2.003 0 O-C-N 121.478 -0.764 . . . . 0.0 110.002 179.804 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo . . . . . 0 N--CA 1.488 1.166 0 N-CA-C 110.578 -0.585 . . . . 0.0 110.578 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.0 t -76.16 -33.04 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.356 -0.84 . . . . 0.0 110.719 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.423 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.5 OUTLIER -73.17 -13.87 61.25 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.449 -0.782 . . . . 0.0 111.355 -179.859 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.435 ' HB3' HG21 ' A' ' 57' ' ' VAL . 60.1 m 61.95 24.65 14.7 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.536 -0.728 . . . . 0.0 111.428 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -107.93 139.83 41.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.88 23.12 39.74 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.9 pt -135.35 160.32 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.08 -1.247 . . . . 0.0 110.246 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.9 m -81.47 164.54 21.95 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.58 -0.7 . . . . 0.0 110.388 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -58.38 -48.31 81.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.242 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.6 t -60.65 -37.86 82.94 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.692 -0.63 . . . . 0.0 110.181 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -65.92 -44.22 85.79 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.362 -0.836 . . . . 0.0 109.466 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.46 -35.52 70.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.775 -0.578 . . . . 0.0 109.899 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? -69.94 -37.51 75.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.563 -0.711 . . . . 0.0 109.931 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.0 t -64.59 -40.47 95.58 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.664 -0.647 . . . . 0.0 110.706 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.1 t -71.62 -33.38 68.92 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.456 -0.778 . . . . 0.0 111.596 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.5 t -57.63 -44.04 85.26 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 21.3 t -80.33 -24.42 39.91 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 111.087 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.65 -32.15 19.41 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.258 -0.901 . . . . 0.0 111.684 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.1 mt -137.37 2.11 2.46 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.067 -1.021 . . . . 0.0 112.671 -178.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 74.05 22.78 77.46 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.3 mmp_? -110.65 143.99 40.26 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.22 -1.165 . . . . 0.0 110.833 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 93.4 m 61.84 51.82 3.68 Favored 'General case' 0 N--CA 1.5 2.05 0 CA-C-O 121.949 0.88 . . . . 0.0 109.233 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 43.0 m -96.9 -14.28 21.89 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.882 -0.511 . . . . 0.0 111.872 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -124.97 42.68 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.978 -1.076 . . . . 0.0 111.025 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 36' ' ' CYS . 52.9 t . . . . . 0 N--CA 1.494 1.741 0 O-C-N 121.295 -0.878 . . . . 0.0 109.695 179.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 CA-C-O 121.313 0.464 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.1 t -72.3 -29.28 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.41 -0.806 . . . . 0.0 110.748 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -74.09 -6.53 48.16 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.346 -0.846 . . . . 0.0 111.68 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 96.2 m 58.14 28.58 16.66 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.235 -0.916 . . . . 0.0 110.587 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -109.16 155.01 21.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 110.128 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.86 17.9 77.89 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.5 pt -136.47 162.13 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.188 -1.183 . . . . 0.0 110.066 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.6 t -87.92 169.11 12.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.404 -0.81 . . . . 0.0 110.023 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.421 ' O ' ' HB2' ' A' ' 45' ' ' ARG . 60.3 t80 -59.42 -44.66 92.82 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.655 -0.653 . . . . 0.0 109.455 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.0 t -65.47 -39.58 92.12 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.647 -0.658 . . . . 0.0 110.074 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -65.86 -42.24 90.68 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.388 -0.82 . . . . 0.0 109.697 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.865 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.59 -39.01 81.12 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.589 -0.695 . . . . 0.0 109.348 178.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -64.86 -40.02 94.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.792 -0.567 . . . . 0.0 109.533 178.874 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 t -62.04 -43.95 97.75 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.862 -0.524 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 27.2 t -67.26 -31.2 71.38 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.301 -0.874 . . . . 0.0 111.339 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.4 t -59.73 -41.95 92.07 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.968 -1.083 . . . . 0.0 109.855 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.9 t -84.84 -22.96 29.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.35 -0.844 . . . . 0.0 110.913 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.4 mtp180 -85.44 -33.65 21.86 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.217 -0.927 . . . . 0.0 111.304 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -140.26 8.97 2.27 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.17 -0.956 . . . . 0.0 112.192 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.72 24.95 75.38 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.482 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.14 144.41 43.22 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.208 -1.172 . . . . 0.0 110.714 -179.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 31.6 m 61.98 48.93 4.89 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 121.942 0.877 . . . . 0.0 109.395 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 18.2 m -89.08 -25.17 22.05 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.863 -0.523 . . . . 0.0 110.914 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -106.21 38.51 2.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.207 -0.933 . . . . 0.0 109.895 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.865 HG21 ' HB1' ' A' ' 44' ' ' ALA . 20.3 t . . . . . 0 N--CA 1.497 1.882 0 O-C-N 121.564 -0.71 . . . . 0.0 109.838 179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo . . . . . 0 N--CA 1.489 1.214 0 N-CA-C 110.574 -0.587 . . . . 0.0 110.574 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 69.9 t -62.09 -30.84 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.147 0 O-C-N 121.478 -0.764 . . . . 0.0 110.63 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.42 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 7.6 t -68.47 -10.23 54.07 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.446 -0.784 . . . . 0.0 111.307 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 35' ' ' SER . 73.4 m 59.36 27.49 16.59 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.355 -0.84 . . . . 0.0 110.996 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -108.59 150.63 27.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.394 -0.816 . . . . 0.0 110.028 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.55 24.09 71.3 Favored Glycine 0 N--CA 1.496 2.645 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.424 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 20.9 pt -134.06 157.41 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.049 -1.265 . . . . 0.0 110.278 179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.09 162.11 23.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.654 -0.654 . . . . 0.0 109.474 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 87.2 t80 -57.04 -49.74 74.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.399 -0.813 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -64.38 -33.12 75.11 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.589 -0.695 . . . . 0.0 110.146 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -65.6 -43.13 90.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.316 -0.865 . . . . 0.0 109.482 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.478 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -69.86 -36.26 75.37 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.636 . . . . 0.0 109.853 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.3 ttt180 -67.47 -40.16 85.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.67 -0.644 . . . . 0.0 110.149 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.3 t -66.07 -36.88 84.38 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.609 -0.682 . . . . 0.0 110.794 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 19.1 t -72.61 -31.32 65.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.25 -0.906 . . . . 0.0 111.325 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 29.9 t -58.9 -42.95 90.82 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.141 -0.974 . . . . 0.0 110.078 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.8 t -84.86 -24.45 28.54 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.396 -0.815 . . . . 0.0 110.948 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -83.29 -32.13 26.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.217 -0.927 . . . . 0.0 111.475 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.82 12.67 1.87 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.176 -0.952 . . . . 0.0 112.208 -179.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.29 31.05 79.42 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.7 mmt180 -118.42 139.88 50.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.389 -1.065 . . . . 0.0 110.458 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 10.5 m 62.46 55.14 2.33 Favored 'General case' 0 N--CA 1.498 1.951 0 CA-C-O 121.999 0.904 . . . . 0.0 109.327 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 19.1 m -96.3 -16.43 21.34 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.43 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -112.8 42.36 1.88 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.1 -1.0 . . . . 0.0 110.189 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.478 HG21 ' HB1' ' A' ' 44' ' ' ALA . 74.0 t . . . . . 0 N--CA 1.497 1.908 0 O-C-N 121.384 -0.823 . . . . 0.0 109.954 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo . . . . . 0 N--CA 1.49 1.295 0 N-CA-C 110.817 -0.493 . . . . 0.0 110.817 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 t -61.39 -29.4 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.521 -0.737 . . . . 0.0 110.522 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.1 t -69.63 -8.05 44.22 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.434 -0.792 . . . . 0.0 111.147 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 35' ' ' SER . 81.6 m 59.14 25.22 13.68 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.353 -0.842 . . . . 0.0 111.255 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -112.39 158.05 20.29 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.288 -0.883 . . . . 0.0 110.012 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.16 22.08 76.95 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.1 pt -135.47 153.59 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.142 -1.211 . . . . 0.0 110.274 179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.2 t -80.3 169.25 18.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.632 -0.667 . . . . 0.0 109.952 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -60.31 -48.86 79.93 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.568 -0.708 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.2 t -61.83 -36.44 81.17 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.666 -0.647 . . . . 0.0 110.192 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -64.62 -44.8 89.39 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.565 -0.709 . . . . 0.0 109.886 179.51 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.6 -33.99 76.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.803 -0.561 . . . . 0.0 110.395 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.22 -39.57 78.49 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.466 -0.771 . . . . 0.0 110.122 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 3.6 t -64.95 -40.44 95.02 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.658 -0.652 . . . . 0.0 110.951 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.4 t -71.62 -32.03 67.54 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.282 -0.886 . . . . 0.0 111.443 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 33.1 t -58.64 -42.9 89.38 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.126 -0.984 . . . . 0.0 110.363 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 32.3 t -84.24 -25.98 29.02 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.352 -0.843 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.3 OUTLIER -84.26 -31.96 24.7 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.286 -0.884 . . . . 0.0 111.453 -179.394 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.4 mt -138.87 6.55 2.43 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 112.556 -178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.02 28.32 73.75 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 6.9 mmt-85 -115.6 139.92 49.65 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.213 -1.169 . . . . 0.0 110.638 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.486 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 80.5 m 62.46 57.27 1.92 Allowed 'General case' 0 N--CA 1.499 2.003 0 CA-C-O 121.939 0.876 . . . . 0.0 109.42 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 34.9 m -100.12 -6.21 26.63 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.749 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -128.18 46.43 2.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.065 . . . . 0.0 110.517 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 94.8 t . . . . . 0 N--CA 1.496 1.861 0 O-C-N 121.261 -0.9 . . . . 0.0 110.09 179.885 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo . . . . . 0 N--CA 1.488 1.197 0 N-CA-C 110.608 -0.574 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.35 -27.4 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.302 -0.874 . . . . 0.0 110.399 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.43 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -67.18 -18.39 65.25 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.429 -0.795 . . . . 0.0 110.78 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 35' ' ' SER . 95.5 m 58.99 26.27 14.86 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.549 -0.719 . . . . 0.0 111.178 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -108.95 144.57 36.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.261 -0.9 . . . . 0.0 110.046 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.27 34.27 64.23 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.3 pt -125.78 155.15 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.2 -1.176 . . . . 0.0 110.123 179.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.84 159.27 21.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.668 -0.645 . . . . 0.0 109.475 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -57.66 -42.47 83.57 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.424 -0.797 . . . . 0.0 109.641 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.2 t -67.32 -34.45 77.38 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.583 -0.698 . . . . 0.0 109.95 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.39 -41.35 89.5 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.473 -0.767 . . . . 0.0 109.69 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -74.23 -27.5 60.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.748 -0.595 . . . . 0.0 110.34 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -35.96 61.01 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.53 -0.731 . . . . 0.0 110.389 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -70.88 -40.62 72.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.448 -0.783 . . . . 0.0 111.09 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.7 t -73.55 -30.44 63.07 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.237 -0.914 . . . . 0.0 111.299 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.4 -42.63 92.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.126 -0.984 . . . . 0.0 110.579 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 33.1 t -82.92 -25.28 32.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.816 . . . . 0.0 111.587 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.9 mmm180 -92.28 -27.02 17.87 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.215 -0.928 . . . . 0.0 111.636 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 mt -137.31 2.95 2.56 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.071 -1.018 . . . . 0.0 112.509 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.64 28.28 73.46 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.422 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.8 OUTLIER -118.04 143.19 46.63 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.26 -1.141 . . . . 0.0 110.415 -179.647 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 1.3 m 62.39 52.87 2.91 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.001 0.905 . . . . 0.0 109.097 -179.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 50.4 m -97.85 -3.71 38.19 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.339 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 35.8 t-80 -122.67 45.35 2.4 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.167 -0.958 . . . . 0.0 109.88 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.456 HG21 ' HB1' ' A' ' 44' ' ' ALA . 17.0 t . . . . . 0 N--CA 1.497 1.885 0 O-C-N 121.373 -0.83 . . . . 0.0 110.194 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo . . . . . 0 N--CA 1.489 1.215 0 N-CA-C 110.839 -0.485 . . . . 0.0 110.839 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.557 HG22 HH11 ' A' ' 53' ' ' ARG . 79.4 t -65.0 -28.79 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.535 -0.728 . . . . 0.0 110.429 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.432 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.2 t -67.12 -21.38 65.84 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.484 -0.76 . . . . 0.0 110.896 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' SER . 74.1 m 59.62 28.68 18.16 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.557 -0.715 . . . . 0.0 110.892 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -104.41 146.09 29.34 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.271 -0.893 . . . . 0.0 110.273 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.99 26.69 43.88 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.8 pt -137.01 160.0 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.221 -1.164 . . . . 0.0 110.259 179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.8 m -85.53 168.27 14.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.556 -0.715 . . . . 0.0 110.06 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.65 -45.27 94.73 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.598 -0.689 . . . . 0.0 109.376 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.1 t -65.42 -38.53 90.19 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.611 -0.681 . . . . 0.0 110.026 179.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -63.25 -43.04 99.12 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.809 . . . . 0.0 109.71 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -66.98 -38.48 86.12 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.685 -0.634 . . . . 0.0 109.846 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.96 -38.27 85.8 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-O 121.551 0.691 . . . . 0.0 109.69 178.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 t -62.79 -40.94 98.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.726 -0.609 . . . . 0.0 111.598 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.413 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 6.0 t -76.83 -28.42 55.51 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.997 -1.064 . . . . 0.0 111.599 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.4 t -59.28 -41.14 88.21 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.068 -1.02 . . . . 0.0 109.606 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.7 t -86.81 -24.32 25.06 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.413 ' HB3' ' HA ' ' A' ' 47' ' ' CYS . 3.1 tmm_? -77.94 -36.7 48.99 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.364 -0.835 . . . . 0.0 111.066 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.406 HD12 ' HD2' ' A' ' 50' ' ' ARG . 0.2 OUTLIER -144.07 16.97 1.74 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.231 -0.918 . . . . 0.0 111.946 -179.284 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.89 33.42 83.38 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.557 HH11 HG22 ' A' ' 34' ' ' VAL . 5.9 mmt-85 -119.6 144.27 47.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.418 -1.048 . . . . 0.0 110.598 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.7 m 60.2 54.7 3.93 Favored 'General case' 0 N--CA 1.498 1.965 0 CA-C-O 122.019 0.914 . . . . 0.0 109.095 -179.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.3 m -97.29 -17.15 19.96 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.399 -179.057 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -110.17 41.79 1.67 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.113 -0.992 . . . . 0.0 110.076 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.708 HG21 ' HB1' ' A' ' 44' ' ' ALA . 47.4 t . . . . . 0 N--CA 1.498 1.941 0 O-C-N 121.383 -0.823 . . . . 0.0 110.409 -179.663 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo . . . . . 0 N--CA 1.494 1.505 0 CA-C-O 121.369 0.487 . . . . 0.0 111.621 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 54.3 t -79.85 -36.29 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.967 0 O-C-N 121.507 -0.746 . . . . 0.0 110.487 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -68.8 -15.02 63.39 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.541 -0.724 . . . . 0.0 111.383 -179.606 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 33.0 m 57.8 27.97 15.27 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.4 -0.812 . . . . 0.0 110.84 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 7.4 mtt-85 -111.09 149.94 30.1 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.354 -0.841 . . . . 0.0 109.982 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.01 34.18 43.03 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.6 pt -129.77 154.15 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.135 . . . . 0.0 110.177 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 m -83.83 161.47 20.9 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.599 -0.688 . . . . 0.0 109.741 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.92 -41.39 82.58 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.432 -0.793 . . . . 0.0 109.574 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -67.97 -36.44 80.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 0.0 110.093 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -67.43 -40.19 85.47 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.429 -0.794 . . . . 0.0 109.911 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.92 -34.52 73.6 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 0.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.6 ttp180 -70.12 -31.3 68.79 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.434 -0.791 . . . . 0.0 110.232 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 2.0 t -71.35 -44.24 65.41 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.542 -0.724 . . . . 0.0 111.314 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.7 t -75.41 -29.18 59.68 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.19 -0.944 . . . . 0.0 111.467 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.5 t -62.25 -42.67 99.54 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.165 -0.959 . . . . 0.0 110.078 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 10.2 t -84.97 -25.12 27.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.329 -0.857 . . . . 0.0 110.685 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 46' ' ' SER . 3.9 ttt180 -81.7 -33.71 31.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.414 -0.804 . . . . 0.0 111.312 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -142.12 9.57 1.9 Allowed 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.167 -0.958 . . . . 0.0 112.328 -179.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 66.99 27.72 73.53 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -115.73 144.82 43.42 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.172 -1.193 . . . . 0.0 110.812 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 44.9 m 62.08 51.78 3.5 Favored 'General case' 0 N--CA 1.499 1.985 0 CA-C-O 122.013 0.911 . . . . 0.0 109.438 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.36 -4.53 38.29 Favored 'General case' 0 N--CA 1.487 1.395 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.317 -179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.3 t-160 -126.02 47.74 2.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.048 -1.032 . . . . 0.0 109.944 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 64.2 t . . . . . 0 N--CA 1.496 1.862 0 O-C-N 121.511 -0.743 . . . . 0.0 110.379 -179.832 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo . . . . . 0 N--CA 1.487 1.104 0 N-CA-C 110.528 -0.605 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.2 t -79.83 -28.06 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.325 -0.859 . . . . 0.0 110.466 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -74.19 -11.8 60.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.228 -0.92 . . . . 0.0 111.179 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.8 m 58.27 25.69 12.99 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.399 -0.813 . . . . 0.0 111.006 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.8 mmt-85 -110.58 156.09 21.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.352 -0.843 . . . . 0.0 109.943 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.97 30.57 69.99 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.435 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.5 pt -131.69 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.266 -1.138 . . . . 0.0 109.981 179.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.408 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 1.6 m -82.27 158.52 23.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.715 -0.616 . . . . 0.0 109.446 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -56.62 -44.39 81.16 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.405 -0.809 . . . . 0.0 109.732 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.6 t -68.14 -35.74 78.58 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.598 -0.689 . . . . 0.0 109.971 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.0 OUTLIER -64.29 -41.92 96.63 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.638 -0.664 . . . . 0.0 109.925 179.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.435 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -66.98 -36.82 83.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.576 -0.703 . . . . 0.0 109.993 179.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.8 mtm180 -65.62 -40.77 92.94 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.656 -0.653 . . . . 0.0 110.062 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.04 -45.12 96.08 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.832 -0.543 . . . . 0.0 111.363 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.555 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 51.8 t -68.56 -33.37 73.96 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.163 -0.961 . . . . 0.0 111.11 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.9 t -60.29 -41.86 94.27 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.167 -0.958 . . . . 0.0 110.465 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 23.0 t -83.43 -22.47 32.65 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.372 -0.83 . . . . 0.0 111.538 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -95.55 -26.68 15.69 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.032 -1.043 . . . . 0.0 111.584 -179.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.1 mt -135.84 1.76 2.81 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.166 -0.959 . . . . 0.0 112.478 -178.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.79 26.94 73.7 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.555 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.78 146.31 42.93 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.304 -1.115 . . . . 0.0 110.418 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 92.6 m 60.76 53.52 3.9 Favored 'General case' 0 N--CA 1.499 1.978 0 CA-C-O 121.885 0.85 . . . . 0.0 109.136 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 53.6 m -100.15 -4.06 30.44 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.551 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -127.39 45.89 2.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.04 -1.038 . . . . 0.0 110.288 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 60.1 t . . . . . 0 N--CA 1.496 1.874 0 O-C-N 121.315 -0.866 . . . . 0.0 110.317 -179.934 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 N--CA 1.487 1.099 0 N-CA-C 110.577 -0.586 . . . . 0.0 110.577 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -69.14 -26.24 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 O-C-N 121.437 -0.789 . . . . 0.0 110.859 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.36 -11.13 59.99 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.15 -0.969 . . . . 0.0 111.411 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 79.7 m 57.44 26.79 13.02 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.391 -0.818 . . . . 0.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -108.45 150.32 27.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.304 -0.872 . . . . 0.0 110.565 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.86 28.23 65.28 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.9 pt -132.48 158.29 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.178 -1.189 . . . . 0.0 110.114 179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.32 161.08 25.25 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.636 . . . . 0.0 109.684 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.25 -48.46 78.8 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.439 -0.788 . . . . 0.0 109.8 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.01 -33.91 76.88 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.605 -0.685 . . . . 0.0 110.094 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -63.64 -43.87 95.54 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.486 -0.759 . . . . 0.0 109.678 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.875 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.01 -36.14 79.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.638 -0.664 . . . . 0.0 109.545 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -64.53 -40.01 94.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.701 -0.624 . . . . 0.0 110.225 179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.9 t -62.91 -44.91 94.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.627 -0.67 . . . . 0.0 111.041 -179.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.55 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 41.4 t -65.71 -34.05 77.3 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.231 -0.918 . . . . 0.0 110.945 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 40.3 t -59.54 -42.66 92.83 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.144 -0.973 . . . . 0.0 110.572 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -87.84 -26.77 22.63 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.335 -0.853 . . . . 0.0 111.164 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -85.62 -30.67 23.08 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.291 -0.881 . . . . 0.0 111.368 -179.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -134.52 4.58 3.39 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.29 -0.881 . . . . 0.0 112.21 -178.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.35 31.27 80.18 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.55 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 5.0 mmp_? -125.81 148.96 48.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.459 -1.024 . . . . 0.0 110.074 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.2 m 61.17 45.84 8.62 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.022 0.915 . . . . 0.0 108.611 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 9.0 m -90.12 -10.14 45.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.808 -0.557 . . . . 0.0 111.325 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -117.75 43.51 2.38 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.21 -0.931 . . . . 0.0 109.861 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.875 HG21 ' HB1' ' A' ' 44' ' ' ALA . 61.4 t . . . . . 0 N--CA 1.499 1.99 0 O-C-N 121.444 -0.785 . . . . 0.0 110.363 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo . . . . . 0 N--CA 1.488 1.193 0 N-CA-C 110.386 -0.659 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.2 t -78.2 -32.07 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.409 -0.807 . . . . 0.0 110.733 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.43 -16.61 60.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.172 -0.955 . . . . 0.0 110.952 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.1 m 57.99 30.39 19.12 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.372 -0.83 . . . . 0.0 110.239 -179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.5 mtp180 -113.01 154.07 27.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.508 -0.745 . . . . 0.0 110.128 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.55 34.69 59.91 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.9 pt -139.83 161.81 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.403 -1.057 . . . . 0.0 109.855 179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 7.8 m -80.44 161.08 25.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.534 -0.728 . . . . 0.0 109.963 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.9 t80 -58.54 -43.72 89.36 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.512 -0.743 . . . . 0.0 109.39 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.9 t -65.0 -38.63 91.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.641 -0.662 . . . . 0.0 109.827 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 28.5 tp60 -64.21 -44.76 90.94 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.611 -0.68 . . . . 0.0 109.593 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.93 79.2 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -65.69 -36.26 83.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.815 -0.553 . . . . 0.0 109.793 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -63.42 -47.77 80.57 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.797 -0.564 . . . . 0.0 111.197 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 53.1 t -66.45 -33.69 76.26 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.241 -0.912 . . . . 0.0 111.091 -179.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.0 t -57.81 -41.67 82.69 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.163 -0.961 . . . . 0.0 110.169 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -84.59 -25.59 28.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.272 -0.892 . . . . 0.0 110.367 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.8 ttm180 -79.39 -36.18 39.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.327 -0.858 . . . . 0.0 111.195 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.32 11.39 2.14 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.116 -0.99 . . . . 0.0 112.353 -178.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.04 26.93 73.29 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.461 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.74 141.61 47.61 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.243 -1.151 . . . . 0.0 110.571 -179.921 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 54.1 m 66.25 54.61 0.93 Allowed 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.799 0.809 . . . . 0.0 108.917 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 67.5 m -102.92 -0.62 30.82 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.845 -0.535 . . . . 0.0 111.75 -178.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -137.03 50.24 2.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.935 -1.103 . . . . 0.0 110.645 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.2 t . . . . . 0 N--CA 1.497 1.91 0 O-C-N 121.115 -0.99 . . . . 0.0 110.245 179.649 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo . . . . . 0 N--CA 1.489 1.254 0 N-CA-C 110.719 -0.531 . . . . 0.0 110.719 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.6 t -77.38 -29.93 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.475 -0.766 . . . . 0.0 110.861 -179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.419 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -73.33 -12.68 60.92 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.24 -0.912 . . . . 0.0 111.27 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 35' ' ' SER . 68.5 m 58.15 25.55 12.64 Favored 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.45 -0.781 . . . . 0.0 111.155 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.405 ' O ' HG23 ' A' ' 39' ' ' ILE . 2.0 mtt180 -115.9 158.55 22.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.317 -0.865 . . . . 0.0 110.032 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.83 28.74 73.91 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 37' ' ' ARG . 16.2 pt -125.71 152.0 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.325 -1.103 . . . . 0.0 109.937 179.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -77.32 160.17 29.01 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.77 -44.56 86.25 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.346 -0.846 . . . . 0.0 109.724 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.0 -35.57 80.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.513 -0.742 . . . . 0.0 109.914 179.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.4 -44.22 96.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.396 -0.815 . . . . 0.0 109.117 178.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.758 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.56 -34.83 72.67 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.814 -0.554 . . . . 0.0 109.571 178.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -34.96 77.0 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.696 -0.627 . . . . 0.0 110.283 179.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -69.65 -41.44 75.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.497 -0.752 . . . . 0.0 110.839 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 48.8 t -71.96 -32.83 67.66 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.408 -0.808 . . . . 0.0 111.061 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.5 t -65.36 -43.17 91.65 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.246 -0.909 . . . . 0.0 110.917 -179.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.6 t -80.94 -21.36 40.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.451 -0.781 . . . . 0.0 112.126 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -101.79 -23.24 14.22 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.009 -1.057 . . . . 0.0 111.724 -179.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -134.14 -8.73 2.64 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.967 -1.083 . . . . 0.0 112.541 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.02 26.51 66.45 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.42 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -120.23 148.72 43.33 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.246 -1.149 . . . . 0.0 110.689 -179.596 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 11.8 m 58.95 46.08 14.15 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 122.033 0.92 . . . . 0.0 108.885 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 20.7 m -88.76 -12.78 41.18 Favored 'General case' 0 N--CA 1.488 1.428 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.185 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -116.89 45.17 1.91 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.219 -0.926 . . . . 0.0 109.974 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.758 HG21 ' HB1' ' A' ' 44' ' ' ALA . 94.2 t . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.429 -0.795 . . . . 0.0 110.229 -179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 N-CA-C 110.455 -0.633 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.45 HG22 ' HD2' ' A' ' 53' ' ' ARG . 90.3 t -62.56 -32.07 54.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.474 -0.767 . . . . 0.0 110.438 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.9 -14.17 61.86 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.492 -0.755 . . . . 0.0 111.08 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.455 ' CB ' HG21 ' A' ' 57' ' ' VAL . 35.2 m 57.75 30.53 19.09 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.511 -0.743 . . . . 0.0 111.09 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.1 mtt85 -105.53 139.95 39.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.267 -0.895 . . . . 0.0 109.999 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.56 0.68 81.73 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 39' ' ' ILE . 27.0 pt -116.28 158.48 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.063 -1.257 . . . . 0.0 110.125 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -80.08 165.11 22.83 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.699 -0.626 . . . . 0.0 110.639 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -57.82 -48.81 78.66 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.61 -0.681 . . . . 0.0 109.288 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -61.45 -37.51 83.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.668 -0.645 . . . . 0.0 109.781 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -64.82 -44.0 91.3 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.425 -0.797 . . . . 0.0 109.56 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.49 78.42 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.69 -0.631 . . . . 0.0 109.66 179.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -36.89 80.57 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.716 -0.615 . . . . 0.0 109.76 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.6 t -64.45 -42.16 96.13 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.756 -0.59 . . . . 0.0 110.946 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 42.3 t -70.26 -34.99 73.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.113 -0.992 . . . . 0.0 111.176 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.3 t -58.15 -40.55 81.67 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.121 -0.987 . . . . 0.0 110.212 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.09 -14.32 50.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 111.297 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -101.62 -31.02 11.03 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.103 -0.998 . . . . 0.0 111.209 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -134.23 -1.69 2.89 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.207 -0.933 . . . . 0.0 112.306 -179.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.98 72.33 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HD2' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -113.49 152.0 30.73 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.07 -1.253 . . . . 0.0 110.521 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.5 m 59.79 53.55 4.79 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.887 0.851 . . . . 0.0 108.721 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 69.3 m -104.94 9.57 34.55 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.475 -178.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -146.01 46.04 1.25 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 110.523 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.455 HG21 ' CB ' ' A' ' 36' ' ' CYS . 70.8 t . . . . . 0 N--CA 1.496 1.87 0 O-C-N 121.17 -0.956 . . . . 0.0 110.35 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.42 ' HD2' HG21 ' A' ' 39' ' ' ILE . 41.4 Cg_endo . . . . . 0 N--CA 1.49 1.313 0 N-CA-C 110.758 -0.516 . . . . 0.0 110.758 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.646 HG13 ' NH1' ' A' ' 53' ' ' ARG . 87.4 t -60.03 -31.27 47.42 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.584 -0.697 . . . . 0.0 110.936 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 t -72.86 -4.49 32.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.234 -0.916 . . . . 0.0 111.767 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 55.6 28.58 12.14 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.291 -0.881 . . . . 0.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.3 mtt85 -123.63 161.47 24.97 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.307 -0.87 . . . . 0.0 110.213 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.59 30.81 65.99 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.42 HG21 ' HD2' ' A' ' 33' ' ' PRO . 16.0 pt -141.61 159.47 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.496 -1.002 . . . . 0.0 109.896 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 11.6 m -80.84 161.41 24.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.515 -0.74 . . . . 0.0 109.824 179.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -57.4 -45.68 84.29 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.553 -0.717 . . . . 0.0 109.389 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.1 t -64.04 -36.6 84.52 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.658 -0.651 . . . . 0.0 109.864 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.44 -44.87 89.81 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.649 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.1 -36.44 74.88 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.727 -0.608 . . . . 0.0 109.901 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.6 tpp85 -67.82 -38.0 82.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.675 -0.64 . . . . 0.0 109.508 179.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 16.3 t -64.05 -44.11 93.47 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.816 -0.552 . . . . 0.0 110.686 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.4 t -64.87 -30.18 71.16 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.935 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.8 t -70.3 -43.21 70.82 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.214 -0.929 . . . . 0.0 110.558 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -81.85 -21.05 37.76 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.272 -0.893 . . . . 0.0 112.016 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -105.59 -19.7 13.69 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.035 -1.04 . . . . 0.0 111.714 -179.493 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -6.33 2.87 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.108 -0.995 . . . . 0.0 112.446 -179.168 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.52 25.99 74.82 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.646 ' NH1' HG13 ' A' ' 34' ' ' VAL . 13.9 mmm180 -121.22 148.76 43.82 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.227 -1.161 . . . . 0.0 110.439 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 5.3 m 59.26 48.32 10.42 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-O 121.97 0.89 . . . . 0.0 108.824 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 14.8 m -91.43 -6.42 52.8 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.373 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -120.63 45.38 2.24 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.146 -0.971 . . . . 0.0 109.888 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.413 HG21 ' HB1' ' A' ' 44' ' ' ALA . 39.1 t . . . . . 0 N--CA 1.497 1.905 0 O-C-N 121.391 -0.818 . . . . 0.0 110.563 -179.585 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo . . . . . 0 N--CA 1.49 1.274 0 N-CA-C 110.832 -0.488 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.4 t -65.92 -27.86 42.31 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.384 -0.822 . . . . 0.0 110.31 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -65.38 -18.04 65.0 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.403 -0.811 . . . . 0.0 111.034 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 35' ' ' SER . 84.1 m 58.29 27.23 14.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.479 -0.763 . . . . 0.0 111.211 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -114.21 147.72 38.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.397 -0.814 . . . . 0.0 109.848 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.11 30.24 65.57 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.4 pt -124.67 155.77 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.381 -1.07 . . . . 0.0 109.854 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -82.13 157.32 24.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.647 . . . . 0.0 109.413 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.61 -39.95 78.03 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.419 -0.801 . . . . 0.0 109.69 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -69.91 -35.63 74.74 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.632 -0.668 . . . . 0.0 110.084 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -65.38 -40.16 93.17 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.714 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.59 -35.88 73.25 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.669 -0.644 . . . . 0.0 110.285 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.27 -32.36 70.14 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 179.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.524 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 8.5 t -71.44 -41.6 69.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.555 -0.716 . . . . 0.0 110.948 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.4 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 11.8 t -74.0 -29.07 61.76 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.242 -0.911 . . . . 0.0 111.743 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.7 t -59.48 -43.3 93.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.987 -1.07 . . . . 0.0 109.996 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 12.3 t -89.27 -25.21 21.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.381 -0.824 . . . . 0.0 110.629 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.524 ' HB2' ' O ' ' A' ' 46' ' ' SER . 2.3 ttp85 -79.72 -34.66 39.89 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.407 -0.808 . . . . 0.0 111.181 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -141.08 10.68 2.16 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.162 -0.961 . . . . 0.0 112.289 -179.026 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.81 33.38 82.82 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -123.68 142.52 50.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.584 -0.95 . . . . 0.0 110.097 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 1.8 m 59.76 56.29 3.6 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 121.985 0.898 . . . . 0.0 108.974 -179.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 4.4 m -94.98 -11.5 28.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.883 -0.511 . . . . 0.0 111.312 -178.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -122.69 44.14 2.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.149 -0.969 . . . . 0.0 110.078 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.714 HG21 ' HB1' ' A' ' 44' ' ' ALA . 38.1 t . . . . . 0 N--CA 1.5 2.026 0 O-C-N 121.494 -0.754 . . . . 0.0 110.363 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo . . . . . 0 N--CA 1.49 1.292 0 N-CA-C 110.692 -0.542 . . . . 0.0 110.692 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 96.2 t -66.22 -29.6 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.363 -0.836 . . . . 0.0 110.669 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.2 t -68.51 -19.31 64.52 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.353 -0.842 . . . . 0.0 111.092 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.3 m 60.69 30.18 19.53 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.495 -0.753 . . . . 0.0 110.627 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -107.41 146.47 31.63 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.27 -0.894 . . . . 0.0 110.373 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.83 29.22 55.23 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 28.4 pt -137.55 163.13 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.198 -1.178 . . . . 0.0 110.33 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.45 ' HB3' ' HB2' ' A' ' 43' ' ' GLN . 13.5 t -80.7 166.56 20.92 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.564 -0.71 . . . . 0.0 110.082 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -62.58 -49.34 75.64 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 46' ' ' SER . 2.7 t -63.57 -35.32 80.1 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.696 -0.627 . . . . 0.0 109.985 179.245 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.45 ' HB2' ' HB3' ' A' ' 40' ' ' SER . 4.8 tt0 -64.74 -43.39 93.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.45 -0.781 . . . . 0.0 109.645 179.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -70.73 -36.65 73.29 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.56 -0.713 . . . . 0.0 109.492 179.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 5.6 ttt-85 -68.36 -33.44 74.28 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.758 -0.589 . . . . 0.0 109.7 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 42' ' ' SER . 0.1 OUTLIER -66.33 -46.81 75.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.801 -0.562 . . . . 0.0 110.93 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.4 t -66.02 -30.13 70.61 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.321 -0.862 . . . . 0.0 111.248 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 35.4 t -58.84 -41.06 86.04 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.942 -1.099 . . . . 0.0 109.941 179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 19.4 t -87.26 -25.3 24.04 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.668 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.464 ' HD2' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -82.83 -34.41 26.9 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.314 -0.866 . . . . 0.0 111.316 -179.513 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' HD2' ' A' ' 50' ' ' ARG . 2.1 mt -137.56 6.79 2.76 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.178 -0.951 . . . . 0.0 112.374 -179.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.08 27.08 74.18 Favored Glycine 0 N--CA 1.497 2.749 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.498 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.4 OUTLIER -117.53 145.65 44.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.21 -1.17 . . . . 0.0 110.293 179.941 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 83.3 m 63.23 53.7 2.19 Favored 'General case' 0 N--CA 1.501 2.108 0 CA-C-O 121.903 0.858 . . . . 0.0 108.806 -178.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.2 m -101.27 8.56 42.4 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.904 -0.497 . . . . 0.0 111.689 -178.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.7 t60 -141.69 42.39 1.72 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 96.4 t . . . . . 0 N--CA 1.495 1.809 0 O-C-N 121.276 -0.89 . . . . 0.0 110.061 179.871 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo . . . . . 0 N--CA 1.491 1.349 0 CA-C-O 121.266 0.444 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 50.8 t -68.24 -31.1 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.409 -0.807 . . . . 0.0 110.348 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.8 t -68.48 -16.02 63.75 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.407 -0.808 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.492 ' CB ' HG21 ' A' ' 57' ' ' VAL . 75.5 m 57.42 30.33 18.43 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.358 -0.838 . . . . 0.0 110.775 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.3 mtt180 -102.14 152.65 20.76 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.337 -0.852 . . . . 0.0 110.444 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.38 17.22 76.58 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.3 pt -133.18 159.81 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.057 -1.26 . . . . 0.0 110.241 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.6 161.74 23.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.653 -0.655 . . . . 0.0 109.696 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 86.3 t80 -56.36 -50.12 72.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.498 -0.751 . . . . 0.0 109.567 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.5 t -63.07 -35.86 81.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.689 -0.632 . . . . 0.0 110.196 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -64.22 -42.47 96.58 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.43 -0.794 . . . . 0.0 109.801 179.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -36.06 77.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.552 -0.718 . . . . 0.0 109.9 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.38 -40.83 93.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.772 -0.58 . . . . 0.0 110.084 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.6 t -62.8 -43.47 98.73 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.558 -0.714 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.3 t -64.81 -34.26 77.95 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.253 -0.904 . . . . 0.0 110.776 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 37.3 t -61.28 -43.09 99.45 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.309 -0.869 . . . . 0.0 110.045 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.0 m -80.06 -13.07 59.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.51 -0.744 . . . . 0.0 111.265 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.92 -28.56 12.33 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.207 -0.933 . . . . 0.0 111.186 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.95 7.84 1.86 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.058 -1.026 . . . . 0.0 112.515 -179.129 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.76 27.17 74.06 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 120.857 -1.152 . . . . 0.0 110.312 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.4 mmp_? -114.83 143.5 45.01 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.078 -1.248 . . . . 0.0 110.562 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 27.5 m 61.7 56.02 2.56 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-O 121.879 0.847 . . . . 0.0 108.973 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 63.8 m -101.85 -3.14 28.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.925 -0.485 . . . . 0.0 112.01 -178.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -136.42 47.98 2.16 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.983 -1.073 . . . . 0.0 111.006 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.492 HG21 ' CB ' ' A' ' 36' ' ' CYS . 95.5 t . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.1 -1.0 . . . . 0.0 109.742 179.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HG3' HG21 ' A' ' 39' ' ' ILE . 46.3 Cg_endo . . . . . 0 N--CA 1.485 0.989 0 N-CA-C 109.879 -0.854 . . . . 0.0 109.879 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 43.5 t -73.82 -30.33 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.21 -0.931 . . . . 0.0 110.937 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.5 t -73.65 -10.88 60.15 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.275 -0.891 . . . . 0.0 111.825 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 74.8 m 57.43 29.28 16.72 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.232 -0.917 . . . . 0.0 110.878 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -128.51 158.94 36.99 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.306 -0.871 . . . . 0.0 110.636 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.24 37.25 71.45 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.54 HG21 ' HG3' ' A' ' 33' ' ' PRO . 14.1 pt -143.99 159.5 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.423 -1.045 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.5 m -76.06 160.28 29.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.642 -0.661 . . . . 0.0 109.701 179.369 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -58.17 -44.67 88.08 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 109.478 179.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -62.61 -37.86 87.92 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.619 -0.676 . . . . 0.0 109.903 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -64.51 -45.82 85.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.546 -0.721 . . . . 0.0 109.668 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.524 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -67.93 -36.7 80.59 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.813 -0.555 . . . . 0.0 109.932 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 33.4 ttp85 -69.95 -36.96 75.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.538 -0.726 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.1 t -63.27 -40.09 96.43 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.687 -0.633 . . . . 0.0 110.845 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 29.6 t -67.77 -40.05 84.05 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.352 -0.843 . . . . 0.0 110.745 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.5 t -59.07 -42.74 91.1 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.392 -0.817 . . . . 0.0 110.747 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.9 -18.89 49.45 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.427 -0.795 . . . . 0.0 111.902 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.83 -25.18 13.6 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.084 -1.01 . . . . 0.0 111.806 -179.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -135.1 -5.86 2.36 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.065 -1.022 . . . . 0.0 112.669 -178.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.5 22.92 71.75 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ARG . . . . . 0.5 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.74 148.01 41.51 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.238 -1.154 . . . . 0.0 110.548 -179.847 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 84.7 m 61.37 47.42 6.84 Favored 'General case' 0 N--CA 1.498 1.931 0 CA-C-O 121.974 0.892 . . . . 0.0 109.086 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 36.5 m -91.2 -7.96 49.88 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.904 -0.497 . . . . 0.0 111.228 -179.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.8 t60 -124.11 45.73 2.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.145 -0.972 . . . . 0.0 109.908 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.524 HG21 ' HB1' ' A' ' 44' ' ' ALA . 54.4 t . . . . . 0 N--CA 1.497 1.917 0 O-C-N 121.423 -0.798 . . . . 0.0 110.454 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 . . . . . 0 N--CA 1.497 1.917 0 CA-C-O 121.373 0.606 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.8 p -73.47 158.29 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 121.655 -0.653 . . . . 0.0 110.33 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 15.8 m-85 -82.76 118.75 23.6 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.361 -0.837 . . . . 0.0 110.496 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 17.5 mtpt -105.92 99.51 9.1 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.404 -0.81 . . . . 0.0 110.208 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -91.29 58.67 3.1 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 174.09 56.59 0.05 OUTLIER Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.596 ' O ' ' HB3' ' A' ' 8' ' ' ALA . 89.7 t80 -69.26 106.51 2.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.527 -0.984 . . . . 0.0 109.668 179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.596 ' HB3' ' O ' ' A' ' 7' ' ' TYR . . . 70.16 -58.65 0.53 Allowed 'General case' 0 N--CA 1.504 2.245 0 O-C-N 122.043 -0.411 . . . . 0.0 110.61 -179.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 17.5 ttt180 -85.9 127.39 62.46 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.201 -0.937 . . . . 0.0 110.4 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' HB2' HD12 ' A' ' 11' ' ' ILE . 45.8 Cg_endo -73.01 127.79 12.49 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.901 1.474 . . . . 0.0 110.226 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.4 HD12 ' HB2' ' A' ' 10' ' ' PRO . 2.7 mt 52.07 65.15 6.62 Favored Pre-proline 0 N--CA 1.503 2.215 0 O-C-N 121.751 -0.593 . . . . 0.0 110.153 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -79.68 71.88 6.81 Favored 'Trans proline' 0 C--N 1.314 -1.238 0 O-C-N 123.771 1.406 . . . . 0.0 110.551 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.48 123.28 82.44 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.33 -0.856 . . . . 0.0 110.203 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.93 148.8 58.29 Favored 'Trans proline' 0 C--N 1.315 -1.236 0 O-C-N 123.895 1.471 . . . . 0.0 110.681 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.05 160.6 47.09 Favored 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.908 1.478 . . . . 0.0 110.828 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -76.11 -173.21 1.6 Allowed 'Trans proline' 0 C--N 1.313 -1.299 0 O-C-N 123.967 1.509 . . . . 0.0 110.774 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -67.22 148.69 51.43 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.487 -0.758 . . . . 0.0 110.598 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -124.3 145.29 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.697 -0.627 . . . . 0.0 109.975 179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -66.52 116.55 35.38 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.458 -0.776 . . . . 0.0 110.13 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -72.71 178.0 6.87 Favored 'Trans proline' 0 C--N 1.315 -1.221 0 O-C-N 123.79 1.416 . . . . 0.0 110.792 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -134.37 101.89 11.99 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.621 -0.674 . . . . 0.0 110.112 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.05 138.24 27.84 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 O-C-N 123.759 1.399 . . . . 0.0 110.57 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -95.99 -61.91 0.98 Allowed Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.33 169.21 43.07 Favored Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.69 152.1 64.25 Favored 'Trans proline' 0 C--N 1.313 -1.319 0 O-C-N 123.876 1.461 . . . . 0.0 110.804 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.412 HD13 ' HA ' ' A' ' 26' ' ' ILE . 14.0 mm -85.37 152.57 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.43 -0.794 . . . . 0.0 110.306 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 62.02 72.97 0.56 Allowed Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -78.26 -34.51 1.55 Allowed 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.888 1.468 . . . . 0.0 110.998 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -82.67 67.78 8.87 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.286 -0.884 . . . . 0.0 110.159 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 7.9 m-80 -132.41 41.18 3.23 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.259 -0.901 . . . . 0.0 110.655 -179.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 170.97 47.1 0.04 OUTLIER Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.996 -1.097 . . . . 0.0 110.583 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.8 t -176.21 78.6 0.28 Allowed Pre-proline 0 N--CA 1.5 2.071 0 O-C-N 121.351 -1.088 . . . . 0.0 110.299 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.94 151.11 78.29 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 O-C-N 123.895 1.471 . . . . 0.0 110.966 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.4 t -62.84 -31.23 51.63 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.11 0 O-C-N 121.505 -0.747 . . . . 0.0 110.937 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.6 OUTLIER -69.22 -12.44 61.67 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.503 -0.748 . . . . 0.0 111.53 -179.677 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 35' ' ' SER . 78.8 m 61.78 27.75 16.99 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.409 -0.807 . . . . 0.0 110.575 -179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HG2' ' O ' ' A' ' 35' ' ' SER . 17.1 mmm180 -107.02 146.34 31.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.397 -0.814 . . . . 0.0 110.19 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.93 22.45 52.79 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 16.5 pt -138.87 154.96 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.154 -1.204 . . . . 0.0 110.281 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.486 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 55.0 m -74.51 165.75 24.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.607 -0.683 . . . . 0.0 110.043 179.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.49 ' CE2' ' HD2' ' A' ' 45' ' ' ARG . 84.2 t80 -60.02 -48.76 80.4 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.616 -0.677 . . . . 0.0 109.816 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -65.82 -33.75 76.58 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.583 -0.698 . . . . 0.0 110.122 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.486 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.3 OUTLIER -63.47 -46.38 86.47 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.143 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.81 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -63.47 -37.69 88.28 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.891 -0.505 . . . . 0.0 109.956 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.49 ' HD2' ' CE2' ' A' ' 41' ' ' PHE . 1.0 OUTLIER -64.54 -40.86 96.37 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.628 -0.67 . . . . 0.0 109.761 179.038 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -61.55 -43.95 97.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.774 -0.579 . . . . 0.0 110.971 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.1 t -67.04 -31.2 71.56 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.315 -0.865 . . . . 0.0 111.17 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 t -58.69 -42.5 88.7 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.077 -1.014 . . . . 0.0 109.86 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -84.53 -22.08 30.28 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.412 -0.805 . . . . 0.0 110.697 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.5 mpp_? -80.97 -36.01 31.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.239 -0.913 . . . . 0.0 111.01 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.49 18.29 1.69 Allowed 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.187 -0.946 . . . . 0.0 111.97 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 61.28 31.74 78.22 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.524 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 3.6 mmp_? -117.57 137.75 52.38 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.43 -1.041 . . . . 0.0 110.68 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.524 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 21.5 m 64.35 52.51 1.86 Allowed 'General case' 0 N--CA 1.502 2.128 0 CA-C-O 121.84 0.828 . . . . 0.0 109.476 -179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 27.3 m -92.02 -20.39 21.38 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.955 -0.466 . . . . 0.0 111.262 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -112.81 42.55 1.84 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.167 -0.958 . . . . 0.0 110.002 179.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.81 HG21 ' HB1' ' A' ' 44' ' ' ALA . 75.8 t -71.22 125.49 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.529 -0.732 . . . . 0.0 110.199 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.17 125.49 3.28 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 2.6 ttmm -160.97 141.81 11.5 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.592 -0.946 . . . . 0.0 110.324 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.73 -176.63 48.45 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 t80 -76.22 152.29 36.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.314 -1.109 . . . . 0.0 110.248 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.7 p -143.7 154.82 43.88 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.625 -0.672 . . . . 0.0 110.348 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.47 0 CA-C-O 118.118 -1.379 . . . . 0.0 109.679 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 . . . . . 0 N--CA 1.496 1.852 0 CA-C-O 121.316 0.579 . . . . 0.0 110.774 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 94.9 t -76.14 148.01 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.644 -0.66 . . . . 0.0 110.1 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -90.4 153.88 20.09 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.507 -0.745 . . . . 0.0 110.239 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 tttp -108.3 117.69 34.81 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.443 -0.786 . . . . 0.0 110.284 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -147.82 -94.81 0.15 Allowed Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.1 138.25 6.01 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 5.0 m-85 -69.27 135.44 50.49 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.561 -0.964 . . . . 0.0 110.604 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -96.93 118.02 32.43 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.515 -0.741 . . . . 0.0 110.292 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.71 127.67 59.4 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.428 -0.795 . . . . 0.0 110.367 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.585 ' HB2' HD12 ' A' ' 11' ' ' ILE . 45.1 Cg_endo -70.86 152.82 63.95 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.921 1.485 . . . . 0.0 110.482 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.585 HD12 ' HB2' ' A' ' 10' ' ' PRO . 2.3 mp 54.74 75.92 0.56 Allowed Pre-proline 0 N--CA 1.502 2.144 0 O-C-N 121.763 -0.586 . . . . 0.0 110.0 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.32 85.17 1.08 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.851 1.448 . . . . 0.0 110.622 -179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.23 127.84 57.6 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.452 -0.78 . . . . 0.0 110.203 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -72.34 169.73 20.94 Favored 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.959 1.505 . . . . 0.0 110.688 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.56 119.89 6.55 Favored 'Trans proline' 0 C--N 1.315 -1.201 0 O-C-N 123.783 1.412 . . . . 0.0 110.483 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.57 91.56 0.78 Allowed 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.935 1.492 . . . . 0.0 110.527 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -91.53 155.9 18.06 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.42 -0.8 . . . . 0.0 110.426 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.9 t -125.62 146.65 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.618 -0.676 . . . . 0.0 110.159 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -76.57 129.73 78.72 Favored Pre-proline 0 N--CA 1.496 1.867 0 O-C-N 121.387 -0.82 . . . . 0.0 110.077 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.69 -174.6 1.74 Allowed 'Trans proline' 0 C--N 1.314 -1.248 0 O-C-N 123.88 1.463 . . . . 0.0 110.777 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 2.2 tp -69.56 132.29 89.38 Favored Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.43 -0.794 . . . . 0.0 110.312 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -75.08 120.06 5.88 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 O-C-N 123.899 1.473 . . . . 0.0 110.764 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -76.68 85.28 0.97 Allowed Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.82 84.19 0.92 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.63 148.39 47.25 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.95 1.5 . . . . 0.0 110.756 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 13.0 mt -94.14 147.67 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.465 -0.772 . . . . 0.0 110.194 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.27 82.98 1.43 Allowed Glycine 0 N--CA 1.496 2.633 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -76.42 -174.69 2.21 Favored 'Trans proline' 0 C--N 1.315 -1.214 0 O-C-N 123.974 1.513 . . . . 0.0 110.764 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.4 t80 -79.33 69.32 5.54 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.397 -0.814 . . . . 0.0 110.207 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -151.09 41.36 0.74 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.378 -0.826 . . . . 0.0 110.669 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.21 43.02 0.25 Allowed Glycine 0 N--CA 1.495 2.572 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 52.8 t -175.03 89.08 0.31 Allowed Pre-proline 0 N--CA 1.497 1.885 0 O-C-N 121.587 -0.949 . . . . 0.0 110.023 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -66.86 141.95 60.98 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.756 1.398 . . . . 0.0 110.689 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.41 -30.64 50.72 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 121.485 -0.759 . . . . 0.0 110.811 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.55 -16.62 62.89 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.334 -0.854 . . . . 0.0 111.091 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.484 ' CB ' HG21 ' A' ' 57' ' ' VAL . 38.8 m 59.31 25.56 14.24 Favored 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.512 -0.742 . . . . 0.0 111.169 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.4 mmt-85 -108.39 143.5 37.22 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.24 -0.913 . . . . 0.0 110.127 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.86 22.2 53.64 Favored Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.407 HD13 HG21 ' A' ' 39' ' ' ILE . 26.3 pt -134.93 156.3 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.135 -1.215 . . . . 0.0 110.098 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 59.8 m -74.48 166.02 24.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.637 -0.664 . . . . 0.0 110.515 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -60.18 -49.04 79.18 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.744 -0.597 . . . . 0.0 109.627 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -62.73 -35.36 79.49 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.624 -0.673 . . . . 0.0 110.059 179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -63.36 -46.01 88.52 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.253 -0.904 . . . . 0.0 109.205 178.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.71 -33.04 68.43 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.714 -0.616 . . . . 0.0 109.552 179.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 3.1 mtp-105 -68.84 -38.2 79.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.831 -0.543 . . . . 0.0 110.495 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -67.4 -40.33 85.59 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.421 -0.799 . . . . 0.0 110.73 -179.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 43.8 t -69.38 -31.82 70.45 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.351 -0.843 . . . . 0.0 111.207 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 30.5 t -58.41 -42.19 86.64 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.224 -0.923 . . . . 0.0 110.305 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -84.15 -23.66 30.54 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.385 -0.822 . . . . 0.0 111.0 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 4.6 mmt-85 -85.76 -32.9 21.6 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.234 -0.916 . . . . 0.0 111.309 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -139.35 9.29 2.48 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.121 -0.987 . . . . 0.0 112.283 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.06 27.79 72.73 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.513 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.08 140.1 48.76 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.271 -1.135 . . . . 0.0 110.382 -179.561 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.49 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 98.2 m 63.59 53.12 2.12 Favored 'General case' 0 N--CA 1.5 2.072 0 CA-C-O 121.877 0.846 . . . . 0.0 109.181 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 25.8 m -97.13 -14.55 21.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.828 -0.545 . . . . 0.0 111.783 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -122.85 42.25 3.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.972 -1.08 . . . . 0.0 110.858 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.484 HG21 ' CB ' ' A' ' 36' ' ' CYS . 72.4 t -109.47 109.68 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.295 -0.878 . . . . 0.0 109.725 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.57 89.43 0.17 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 6.6 mmmt -64.92 109.72 2.2 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.578 -0.954 . . . . 0.0 110.094 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 74.52 -177.14 47.14 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 74.7 t80 -78.6 150.34 32.75 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.277 -1.131 . . . . 0.0 110.085 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.3 p -145.06 156.51 43.96 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.644 -0.66 . . . . 0.0 110.275 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.527 0 CA-C-O 118.05 -1.417 . . . . 0.0 109.626 -179.95 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 . . . . . 0 N--CA 1.497 1.886 0 CA-C-O 121.322 0.582 . . . . 0.0 110.667 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.9 t -81.17 153.34 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.71 -0.619 . . . . 0.0 109.773 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -73.07 127.64 33.17 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.475 -0.766 . . . . 0.0 110.186 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.12 116.68 31.9 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.439 -0.788 . . . . 0.0 110.48 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -119.54 71.7 0.33 Allowed Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 154.84 128.07 1.14 Allowed Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 5.9 m-85 -69.88 147.71 49.95 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.499 -1.0 . . . . 0.0 110.348 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.46 -30.58 69.76 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.491 -0.756 . . . . 0.0 110.55 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.44 133.49 67.5 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.48 -0.762 . . . . 0.0 110.04 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.504 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.0 Cg_endo -72.95 136.91 25.81 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.933 1.491 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.504 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 44.8 mt 65.84 131.22 0.03 OUTLIER Pre-proline 0 N--CA 1.505 2.317 0 O-C-N 122.163 -0.335 . . . . 0.0 110.776 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -74.32 74.6 3.59 Favored 'Trans proline' 0 C--N 1.315 -1.186 0 O-C-N 123.683 1.36 . . . . 0.0 110.523 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.55 131.47 45.63 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.38 -0.825 . . . . 0.0 110.27 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -71.92 146.96 48.62 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 123.876 1.461 . . . . 0.0 110.84 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.71 147.24 39.7 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.875 1.461 . . . . 0.0 110.675 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.04 90.19 0.87 Allowed 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.866 1.456 . . . . 0.0 110.617 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -76.23 153.48 36.02 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.365 -0.835 . . . . 0.0 110.537 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 86.8 t -79.66 144.1 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.67 . . . . 0.0 110.154 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.1 tpm_? -110.83 99.54 42.62 Favored Pre-proline 0 N--CA 1.494 1.761 0 O-C-N 121.515 -0.74 . . . . 0.0 110.012 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.07 -178.7 3.36 Favored 'Trans proline' 0 C--N 1.316 -1.183 0 O-C-N 123.853 1.449 . . . . 0.0 110.904 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.434 HD22 ' HA ' ' A' ' 21' ' ' LEU . 0.2 OUTLIER -139.04 100.14 8.0 Favored Pre-proline 0 N--CA 1.495 1.779 0 O-C-N 121.388 -0.82 . . . . 0.0 110.187 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.34 158.79 40.7 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.841 1.443 . . . . 0.0 110.743 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -93.46 -91.03 1.58 Allowed Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.328 -1.509 . . . . 0.0 109.328 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.33 99.35 1.15 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 148.15 47.98 Favored 'Trans proline' 0 C--N 1.314 -1.267 0 O-C-N 123.889 1.468 . . . . 0.0 110.611 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 4.2 mt -106.74 135.57 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.392 -0.817 . . . . 0.0 110.23 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 81.48 83.36 0.79 Allowed Glycine 0 N--CA 1.495 2.627 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -72.91 -44.12 0.67 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.96 1.505 . . . . 0.0 110.654 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.6 t80 -93.36 49.3 1.38 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.358 -0.839 . . . . 0.0 109.542 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -137.25 38.62 2.51 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 110.428 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -148.35 41.47 0.89 Allowed Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 15.3 t -173.25 112.49 0.34 Allowed Pre-proline 0 N--CA 1.495 1.818 0 O-C-N 121.414 -1.051 . . . . 0.0 110.092 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -72.5 129.52 14.85 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.599 1.315 . . . . 0.0 110.286 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 71.1 t -62.47 -28.44 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.089 0 O-C-N 121.457 -0.777 . . . . 0.0 110.845 -179.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -71.07 -12.66 61.64 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.257 -0.902 . . . . 0.0 111.353 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 19.2 m 55.32 29.19 12.51 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.333 -0.855 . . . . 0.0 110.88 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -125.92 152.58 45.42 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.236 -0.915 . . . . 0.0 110.204 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.35 36.2 59.66 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 14.0 pt -127.44 156.25 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.291 -1.123 . . . . 0.0 110.243 179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.8 m -82.38 160.24 22.84 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.507 -0.746 . . . . 0.0 109.38 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -58.15 -41.64 84.18 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.338 -0.851 . . . . 0.0 109.533 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -67.53 -36.72 81.56 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.633 -0.667 . . . . 0.0 110.156 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 20.6 tt0 -65.61 -41.94 92.15 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.416 -0.803 . . . . 0.0 109.704 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -68.29 -34.12 75.58 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.757 -0.59 . . . . 0.0 110.361 179.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.16 -33.8 73.97 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.458 -0.776 . . . . 0.0 110.12 179.44 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -69.03 -46.0 69.03 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.538 -0.726 . . . . 0.0 111.059 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 42.4 t -69.52 -32.5 71.39 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.334 -0.854 . . . . 0.0 111.219 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.1 t -64.73 -42.04 95.5 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.222 -0.924 . . . . 0.0 110.775 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 31.5 t -82.46 -25.25 33.74 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.359 -0.838 . . . . 0.0 111.496 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.24 -29.51 18.14 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.189 -0.944 . . . . 0.0 111.526 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.2 mt -137.03 3.43 2.66 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.049 -1.032 . . . . 0.0 112.648 -178.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.49 28.45 73.61 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.453 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.4 OUTLIER -118.16 146.81 43.92 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.296 -1.12 . . . . 0.0 110.606 -179.446 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.2 m 59.46 48.93 9.23 Favored 'General case' 0 N--CA 1.501 2.09 0 CA-C-O 122.041 0.924 . . . . 0.0 109.027 -179.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.5 m -92.53 -16.8 25.29 Favored 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.713 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -114.9 41.79 2.31 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.062 -1.023 . . . . 0.0 110.62 -179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 95.5 t -76.36 143.23 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.003 0 O-C-N 121.478 -0.764 . . . . 0.0 110.002 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.27 162.72 38.53 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -105.23 121.51 44.0 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.295 -1.121 . . . . 0.0 110.072 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.15 173.66 42.11 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.2 t80 -74.13 154.86 38.95 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.319 -1.107 . . . . 0.0 110.512 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.9 p -144.23 161.94 37.62 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.545 -0.722 . . . . 0.0 110.228 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.421 0 CA-C-O 118.178 -1.346 . . . . 0.0 109.823 -179.965 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . 0.458 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 3.4 mp0 . . . . . 0 N--CA 1.496 1.828 0 CA-C-O 121.04 0.447 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 39.2 t 63.79 161.49 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.325 0 CA-C-O 121.438 0.637 . . . . 0.0 110.825 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -82.93 141.1 32.42 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.227 -0.92 . . . . 0.0 110.134 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.37 149.66 44.14 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.499 -0.751 . . . . 0.0 110.639 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -103.59 -157.27 24.61 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.62 108.3 1.23 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -64.65 121.4 14.39 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.541 -0.976 . . . . 0.0 110.176 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 53.65 31.64 13.04 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.851 -0.531 . . . . 0.0 110.694 -179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.95 93.4 27.21 Favored Pre-proline 0 N--CA 1.486 1.339 0 O-C-N 121.255 -0.903 . . . . 0.0 110.252 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.41 148.81 49.32 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 O-C-N 124.002 1.527 . . . . 0.0 110.974 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.6 pt -89.86 121.34 69.03 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.496 -0.752 . . . . 0.0 110.332 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.44 77.16 2.58 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.8 1.421 . . . . 0.0 110.697 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.61 142.0 73.42 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.296 -0.878 . . . . 0.0 110.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.61 113.37 3.72 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 124.026 1.54 . . . . 0.0 110.767 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.91 148.82 36.24 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.826 1.435 . . . . 0.0 110.653 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.0 76.46 3.77 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.963 1.507 . . . . 0.0 110.286 179.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -81.35 147.59 29.77 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.388 -0.82 . . . . 0.0 110.615 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -109.25 150.84 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.811 -0.556 . . . . 0.0 109.815 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.12 115.95 30.98 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.473 -0.767 . . . . 0.0 110.374 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -76.1 -173.23 1.6 Allowed 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.934 1.491 . . . . 0.0 110.793 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 1.9 pp -75.04 159.44 82.77 Favored Pre-proline 0 N--CA 1.497 1.902 0 O-C-N 121.549 -0.719 . . . . 0.0 110.345 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -72.08 121.58 7.68 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.822 1.432 . . . . 0.0 110.615 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -131.75 97.86 0.36 Allowed Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.82 91.03 1.32 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -72.77 145.93 41.95 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.912 1.48 . . . . 0.0 110.746 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.0 mt -115.46 158.23 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.502 -0.749 . . . . 0.0 110.08 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.52 136.05 7.77 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.021 -1.232 . . . . 0.0 110.021 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -76.28 -159.7 0.1 OUTLIER 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.993 1.522 . . . . 0.0 110.615 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -69.36 79.36 0.38 Allowed 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.414 -0.804 . . . . 0.0 110.228 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -159.49 42.94 0.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.393 -0.817 . . . . 0.0 110.49 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -160.23 42.31 0.44 Allowed Glycine 0 N--CA 1.494 2.52 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 43.3 t -174.31 95.43 0.31 Allowed Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.478 -1.013 . . . . 0.0 110.091 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -67.34 153.06 78.09 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 123.579 1.305 . . . . 0.0 110.578 179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.0 t -76.16 -33.04 23.5 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.356 -0.84 . . . . 0.0 110.719 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.423 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.5 OUTLIER -73.17 -13.87 61.25 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.449 -0.782 . . . . 0.0 111.355 -179.859 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.435 ' HB3' HG21 ' A' ' 57' ' ' VAL . 60.1 m 61.95 24.65 14.7 Favored 'General case' 0 N--CA 1.503 2.195 0 O-C-N 121.536 -0.728 . . . . 0.0 111.428 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.4 mmt180 -107.93 139.83 41.97 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.204 -0.935 . . . . 0.0 109.868 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.88 23.12 39.74 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.9 pt -135.35 160.32 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.08 -1.247 . . . . 0.0 110.246 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.9 m -81.47 164.54 21.95 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.58 -0.7 . . . . 0.0 110.388 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -58.38 -48.31 81.03 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.563 -0.711 . . . . 0.0 109.242 178.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.6 t -60.65 -37.86 82.94 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.692 -0.63 . . . . 0.0 110.181 179.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -65.92 -44.22 85.79 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.362 -0.836 . . . . 0.0 109.466 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.46 -35.52 70.88 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.775 -0.578 . . . . 0.0 109.899 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? -69.94 -37.51 75.88 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.563 -0.711 . . . . 0.0 109.931 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.0 t -64.59 -40.47 95.58 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.664 -0.647 . . . . 0.0 110.706 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.1 t -71.62 -33.38 68.92 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.456 -0.778 . . . . 0.0 111.596 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.5 t -57.63 -44.04 85.26 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 21.3 t -80.33 -24.42 39.91 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 111.087 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.65 -32.15 19.41 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.258 -0.901 . . . . 0.0 111.684 -179.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.1 mt -137.37 2.11 2.46 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.067 -1.021 . . . . 0.0 112.671 -178.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 74.05 22.78 77.46 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.105 -1.198 . . . . 0.0 110.105 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.456 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.3 mmp_? -110.65 143.99 40.26 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.22 -1.165 . . . . 0.0 110.833 -179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 93.4 m 61.84 51.82 3.68 Favored 'General case' 0 N--CA 1.5 2.05 0 CA-C-O 121.949 0.88 . . . . 0.0 109.233 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 43.0 m -96.9 -14.28 21.89 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.882 -0.511 . . . . 0.0 111.872 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -124.97 42.68 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.978 -1.076 . . . . 0.0 111.025 -179.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 36' ' ' CYS . 52.9 t -106.61 117.43 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.295 -0.878 . . . . 0.0 109.695 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.33 99.97 0.31 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.89 107.12 18.83 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.406 -1.055 . . . . 0.0 110.176 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.01 142.18 9.35 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -72.56 160.58 32.04 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.43 -1.041 . . . . 0.0 110.516 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 21.5 t -99.14 179.62 4.55 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.606 -0.684 . . . . 0.0 110.69 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 CA-C-O 117.937 -1.479 . . . . 0.0 109.549 179.891 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 . . . . . 0 N--CA 1.496 1.837 0 CA-C-O 121.289 0.566 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.41 ' H ' HG22 ' A' ' 2' ' ' VAL . 28.1 m -77.81 150.69 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.644 -0.66 . . . . 0.0 110.285 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -160.96 170.0 21.45 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.474 -0.766 . . . . 0.0 110.509 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 75.4 mttt -105.82 131.74 52.78 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.384 -0.823 . . . . 0.0 110.243 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.12 -131.33 1.42 Allowed Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -98.0 105.82 3.19 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 17.5 t80 -80.14 96.2 6.46 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.388 -1.066 . . . . 0.0 110.299 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 56.34 -90.23 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.855 -0.528 . . . . 0.0 110.851 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -96.01 122.92 57.06 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.004 -1.06 . . . . 0.0 110.131 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.25 127.7 12.98 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.831 1.438 . . . . 0.0 110.583 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 3.6 pt -134.95 119.53 13.67 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.507 -0.746 . . . . 0.0 110.423 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -74.06 90.49 0.97 Allowed 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.869 1.457 . . . . 0.0 110.425 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.51 135.59 90.69 Favored Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.419 -0.801 . . . . 0.0 110.471 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.31 130.95 15.77 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 124.083 1.57 . . . . 0.0 110.902 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.17 142.1 26.94 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 O-C-N 123.917 1.482 . . . . 0.0 110.751 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -73.65 82.9 1.62 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.862 1.454 . . . . 0.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -80.5 154.8 27.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.281 -0.887 . . . . 0.0 110.647 -179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.7 t -83.78 150.33 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.63 -0.669 . . . . 0.0 110.081 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.4 ttp85 -70.66 131.54 87.82 Favored Pre-proline 0 N--CA 1.497 1.904 0 O-C-N 121.539 -0.725 . . . . 0.0 110.027 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.68 126.93 12.52 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 O-C-N 123.869 1.457 . . . . 0.0 110.925 -179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.432 ' HG ' ' HD2' ' A' ' 22' ' ' PRO . 7.1 tt -91.63 131.31 36.25 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.674 -0.641 . . . . 0.0 110.373 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HG ' ' A' ' 21' ' ' LEU . 44.5 Cg_endo -72.24 105.43 1.85 Allowed 'Trans proline' 0 C--N 1.314 -1.253 0 O-C-N 123.911 1.479 . . . . 0.0 110.447 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -135.99 -50.82 0.07 OUTLIER Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.68 160.75 35.97 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.36 145.71 43.63 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.897 1.472 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.9 tt -147.06 160.67 8.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.501 -0.749 . . . . 0.0 110.471 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.33 166.14 41.01 Favored Glycine 0 N--CA 1.495 2.608 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -74.8 -1.37 11.07 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.955 1.503 . . . . 0.0 111.792 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.7 t80 -70.84 80.1 0.63 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.088 -1.008 . . . . 0.0 110.708 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -147.43 46.75 1.13 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.461 -0.775 . . . . 0.0 110.442 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 32' ' ' CYS . . . 165.08 50.48 0.02 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.091 -1.204 . . . . 0.0 110.091 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 31' ' ' GLY . 51.9 t 178.91 81.01 0.16 Allowed Pre-proline 0 N--CA 1.501 2.078 0 O-C-N 121.566 -0.961 . . . . 0.0 109.978 179.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.46 159.98 49.95 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.761 1.4 . . . . 0.0 111.168 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.1 t -72.3 -29.28 31.26 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.087 0 O-C-N 121.41 -0.806 . . . . 0.0 110.748 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -74.09 -6.53 48.16 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.346 -0.846 . . . . 0.0 111.68 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 96.2 m 58.14 28.58 16.66 Favored 'General case' 0 N--CA 1.502 2.137 0 O-C-N 121.235 -0.916 . . . . 0.0 110.587 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -109.16 155.01 21.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.405 -0.809 . . . . 0.0 110.128 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.86 17.9 77.89 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.5 pt -136.47 162.13 35.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.188 -1.183 . . . . 0.0 110.066 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.6 t -87.92 169.11 12.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.404 -0.81 . . . . 0.0 110.023 179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.421 ' O ' ' HB2' ' A' ' 45' ' ' ARG . 60.3 t80 -59.42 -44.66 92.82 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.655 -0.653 . . . . 0.0 109.455 179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.0 t -65.47 -39.58 92.12 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.647 -0.658 . . . . 0.0 110.074 179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -65.86 -42.24 90.68 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.388 -0.82 . . . . 0.0 109.697 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.865 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.59 -39.01 81.12 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.589 -0.695 . . . . 0.0 109.348 178.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 41' ' ' PHE . 0.1 OUTLIER -64.86 -40.02 94.47 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.792 -0.567 . . . . 0.0 109.533 178.874 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 t -62.04 -43.95 97.75 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.862 -0.524 . . . . 0.0 110.871 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 27.2 t -67.26 -31.2 71.38 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.301 -0.874 . . . . 0.0 111.339 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.4 t -59.73 -41.95 92.07 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 120.968 -1.083 . . . . 0.0 109.855 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.9 t -84.84 -22.96 29.24 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.35 -0.844 . . . . 0.0 110.913 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 31.4 mtp180 -85.44 -33.65 21.86 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.217 -0.927 . . . . 0.0 111.304 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -140.26 8.97 2.27 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.17 -0.956 . . . . 0.0 112.192 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.72 24.95 75.38 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.482 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -114.14 144.41 43.22 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.208 -1.172 . . . . 0.0 110.714 -179.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.482 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 31.6 m 61.98 48.93 4.89 Favored 'General case' 0 N--CA 1.501 2.088 0 CA-C-O 121.942 0.877 . . . . 0.0 109.395 -179.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 18.2 m -89.08 -25.17 22.05 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.863 -0.523 . . . . 0.0 110.914 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -106.21 38.51 2.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.207 -0.933 . . . . 0.0 109.895 179.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.865 HG21 ' HB1' ' A' ' 44' ' ' ALA . 20.3 t -63.2 124.54 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.564 -0.71 . . . . 0.0 109.838 179.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.08 164.18 39.71 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 -179.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 5.0 mptt -85.54 76.77 9.99 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.252 -1.146 . . . . 0.0 110.396 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.69 141.09 3.88 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 45.6 t80 -72.85 153.97 40.81 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.343 -1.092 . . . . 0.0 110.159 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.1 t -154.33 -178.28 7.02 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.505 -0.747 . . . . 0.0 110.852 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.443 0 CA-C-O 117.963 -1.465 . . . . 0.0 109.567 179.928 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.498 1.932 0 CA-C-O 121.308 0.575 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.701 HG22 ' CD2' ' A' ' 3' ' ' TYR . 8.0 p -139.58 127.91 26.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.743 -0.598 . . . . 0.0 109.879 179.459 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . 0.701 ' CD2' HG22 ' A' ' 2' ' ' VAL . 57.0 m-85 60.02 174.79 0.09 Allowed 'General case' 0 N--CA 1.505 2.287 0 CA-C-O 121.517 0.675 . . . . 0.0 111.013 -179.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.3 mmtt -109.24 90.62 3.35 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 109.895 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.14 157.2 23.87 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.02 40.22 88.72 Favored Glycine 0 N--CA 1.494 2.548 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -101.15 125.23 47.75 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.48 -1.012 . . . . 0.0 110.46 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -139.22 71.06 1.37 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.611 -0.68 . . . . 0.0 110.119 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 18.8 ttp180 48.89 65.14 7.51 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.727 -0.608 . . . . 0.0 110.958 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -82.5 120.68 3.24 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.646 1.34 . . . . 0.0 110.733 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 11.6 mt -127.57 79.17 73.84 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.411 -0.805 . . . . 0.0 109.949 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.32 -164.96 0.3 Allowed 'Trans proline' 0 C--N 1.313 -1.299 0 O-C-N 123.773 1.407 . . . . 0.0 110.723 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -74.93 153.68 86.81 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.57 -0.706 . . . . 0.0 110.366 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.2 141.42 29.18 Favored 'Trans proline' 0 C--N 1.311 -1.437 0 O-C-N 124.045 1.55 . . . . 0.0 110.67 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.68 137.05 21.97 Favored 'Trans proline' 0 C--N 1.316 -1.155 0 O-C-N 123.879 1.463 . . . . 0.0 110.878 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -76.33 149.64 31.68 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.862 1.454 . . . . 0.0 110.567 179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CE2' HG23 ' A' ' 18' ' ' VAL . 79.0 t80 -77.71 147.02 35.63 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.572 -0.705 . . . . 0.0 110.155 179.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.448 HG23 ' CE2' ' A' ' 17' ' ' PHE . 2.0 t 60.37 165.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.119 0 CA-C-O 121.562 0.696 . . . . 0.0 110.846 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.6 90.57 8.98 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.154 -0.966 . . . . 0.0 109.939 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.77 177.97 6.95 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 O-C-N 123.802 1.422 . . . . 0.0 110.626 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.923 HD22 ' HA ' ' A' ' 25' ' ' PRO . 50.8 mt -122.83 101.57 39.22 Favored Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.601 -0.687 . . . . 0.0 110.105 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.35 111.53 3.31 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.858 1.452 . . . . 0.0 111.023 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.53 50.02 16.96 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.41 174.05 48.69 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.923 ' HA ' HD22 ' A' ' 21' ' ' LEU . 44.2 Cg_endo -70.25 129.15 16.6 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 O-C-N 123.973 1.512 . . . . 0.0 110.575 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.5 mt -57.45 141.56 14.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.571 -0.705 . . . . 0.0 109.949 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.07 132.65 5.44 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.33 -1.508 . . . . 0.0 109.33 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.95 -26.93 18.08 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.874 1.46 . . . . 0.0 111.291 -179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -80.26 65.61 5.47 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.287 -0.883 . . . . 0.0 110.352 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -133.09 40.06 3.24 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.291 -0.881 . . . . 0.0 110.798 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.57 45.0 0.06 OUTLIER Glycine 0 N--CA 1.492 2.409 0 C-N-CA 120.089 -1.053 . . . . 0.0 110.623 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 51.0 t -172.4 78.67 0.45 Allowed Pre-proline 0 N--CA 1.497 1.904 0 O-C-N 121.281 -1.129 . . . . 0.0 110.467 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -68.78 145.38 62.67 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.931 1.49 . . . . 0.0 110.574 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 69.9 t -62.09 -30.84 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.147 0 O-C-N 121.478 -0.764 . . . . 0.0 110.63 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.42 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 7.6 t -68.47 -10.23 54.07 Favored 'General case' 0 N--CA 1.5 2.065 0 O-C-N 121.446 -0.784 . . . . 0.0 111.307 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 35' ' ' SER . 73.4 m 59.36 27.49 16.59 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.355 -0.84 . . . . 0.0 110.996 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -108.59 150.63 27.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.394 -0.816 . . . . 0.0 110.028 179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.55 24.09 71.3 Favored Glycine 0 N--CA 1.496 2.645 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.424 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 20.9 pt -134.06 157.41 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.049 -1.265 . . . . 0.0 110.278 179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.09 162.11 23.86 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.654 -0.654 . . . . 0.0 109.474 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 87.2 t80 -57.04 -49.74 74.89 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.399 -0.813 . . . . 0.0 109.795 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.4 t -64.38 -33.12 75.11 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.589 -0.695 . . . . 0.0 110.146 179.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -65.6 -43.13 90.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.316 -0.865 . . . . 0.0 109.482 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.478 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -69.86 -36.26 75.37 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.683 -0.636 . . . . 0.0 109.853 179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 19.3 ttt180 -67.47 -40.16 85.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.67 -0.644 . . . . 0.0 110.149 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.3 t -66.07 -36.88 84.38 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.609 -0.682 . . . . 0.0 110.794 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 19.1 t -72.61 -31.32 65.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.25 -0.906 . . . . 0.0 111.325 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 29.9 t -58.9 -42.95 90.82 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.141 -0.974 . . . . 0.0 110.078 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 22.8 t -84.86 -24.45 28.54 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.396 -0.815 . . . . 0.0 110.948 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -83.29 -32.13 26.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.217 -0.927 . . . . 0.0 111.475 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -142.82 12.67 1.87 Allowed 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.176 -0.952 . . . . 0.0 112.208 -179.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.29 31.05 79.42 Favored Glycine 0 N--CA 1.497 2.746 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 1.7 mmt180 -118.42 139.88 50.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.389 -1.065 . . . . 0.0 110.458 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 10.5 m 62.46 55.14 2.33 Favored 'General case' 0 N--CA 1.498 1.951 0 CA-C-O 121.999 0.904 . . . . 0.0 109.327 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 19.1 m -96.3 -16.43 21.34 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.43 -179.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -112.8 42.36 1.88 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.1 -1.0 . . . . 0.0 110.189 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.478 HG21 ' HB1' ' A' ' 44' ' ' ALA . 74.0 t -83.01 121.43 36.02 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.384 -0.823 . . . . 0.0 109.954 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.0 134.12 5.44 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 8.4 tttm 62.58 103.21 0.03 OUTLIER 'General case' 0 N--CA 1.505 2.284 0 O-C-N 121.88 -0.776 . . . . 0.0 110.262 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.6 -176.12 41.15 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -76.43 160.9 29.12 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.4 -1.059 . . . . 0.0 110.516 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.4 m -64.78 154.2 37.64 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.514 -0.741 . . . . 0.0 110.619 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.367 0 CA-C-O 117.905 -1.497 . . . . 0.0 109.478 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.4 mp0 . . . . . 0 N--CA 1.497 1.9 0 CA-C-O 121.18 0.514 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.8 t 52.68 73.11 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.502 2.141 0 CA-C-O 121.157 0.503 . . . . 0.0 110.222 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 2.3 t80 68.23 144.0 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.165 0 CA-C-O 121.238 0.542 . . . . 0.0 110.56 -179.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 56.77 81.18 0.14 Allowed 'General case' 0 N--CA 1.501 2.105 0 O-C-N 121.57 -0.706 . . . . 0.0 110.707 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -161.98 124.98 1.36 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.09 77.45 2.03 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -136.24 107.15 6.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.474 -1.015 . . . . 0.0 110.053 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -71.44 -54.18 11.53 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.522 -0.736 . . . . 0.0 110.286 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.86 75.49 48.81 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 110.106 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -73.65 87.34 1.12 Allowed 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.846 1.445 . . . . 0.0 110.152 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 43.6 mm 57.04 75.94 0.53 Allowed Pre-proline 0 N--CA 1.501 2.085 0 O-C-N 121.719 -0.613 . . . . 0.0 110.119 -179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -73.07 80.18 1.9 Allowed 'Trans proline' 0 C--N 1.316 -1.17 0 O-C-N 123.771 1.406 . . . . 0.0 110.775 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.32 154.05 27.83 Favored Pre-proline 0 N--CA 1.493 1.701 0 O-C-N 121.521 -0.737 . . . . 0.0 109.982 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -71.29 132.7 21.37 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.845 1.445 . . . . 0.0 110.746 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.7 143.71 30.5 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 O-C-N 123.928 1.489 . . . . 0.0 110.762 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.66 175.71 10.94 Favored 'Trans proline' 0 C--N 1.313 -1.298 0 O-C-N 123.864 1.455 . . . . 0.0 110.901 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -78.61 162.88 25.94 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.55 -0.719 . . . . 0.0 110.587 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -81.56 152.75 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.797 -0.564 . . . . 0.0 110.179 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -68.4 130.94 91.92 Favored Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.527 -0.733 . . . . 0.0 110.05 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -71.13 -178.67 2.99 Favored 'Trans proline' 0 C--N 1.314 -1.256 0 O-C-N 123.97 1.511 . . . . 0.0 110.67 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.437 ' HB3' ' HD2' ' A' ' 22' ' ' PRO . 35.2 mt -125.86 165.79 25.08 Favored Pre-proline 0 N--CA 1.496 1.849 0 O-C-N 121.516 -0.74 . . . . 0.0 110.258 -179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 21' ' ' LEU . 43.6 Cg_endo -69.94 118.97 5.99 Favored 'Trans proline' 0 C--N 1.315 -1.226 0 O-C-N 123.747 1.393 . . . . 0.0 110.486 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.24 -96.97 1.84 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.83 88.11 0.39 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.28 129.39 13.91 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.96 1.505 . . . . 0.0 110.448 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 23.1 mm -127.82 158.02 39.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.462 -0.774 . . . . 0.0 110.372 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.99 84.84 1.35 Allowed Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.04 -169.74 0.61 Allowed 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.967 1.509 . . . . 0.0 110.731 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -79.85 65.91 5.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.359 -0.838 . . . . 0.0 109.971 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 16.9 m-80 -133.06 40.72 3.19 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.397 -0.814 . . . . 0.0 110.519 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.18 44.58 0.06 OUTLIER Glycine 0 N--CA 1.493 2.485 0 C-N-CA 120.095 -1.05 . . . . 0.0 110.611 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.4 t -175.01 81.74 0.32 Allowed Pre-proline 0 N--CA 1.5 2.055 0 O-C-N 121.289 -1.124 . . . . 0.0 110.356 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.94 144.23 57.69 Favored 'Trans proline' 0 C--N 1.311 -1.423 0 O-C-N 123.907 1.478 . . . . 0.0 110.817 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 t -61.39 -29.4 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.161 0 O-C-N 121.521 -0.737 . . . . 0.0 110.522 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.436 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.1 t -69.63 -8.05 44.22 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.434 -0.792 . . . . 0.0 111.147 179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 35' ' ' SER . 81.6 m 59.14 25.22 13.68 Favored 'General case' 0 N--CA 1.501 2.092 0 O-C-N 121.353 -0.842 . . . . 0.0 111.255 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -112.39 158.05 20.29 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.288 -0.883 . . . . 0.0 110.012 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.16 22.08 76.95 Favored Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.1 pt -135.47 153.59 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.846 0 O-C-N 121.142 -1.211 . . . . 0.0 110.274 179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.2 t -80.3 169.25 18.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.632 -0.667 . . . . 0.0 109.952 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 72.0 t80 -60.31 -48.86 79.93 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.568 -0.708 . . . . 0.0 109.484 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 8.2 t -61.83 -36.44 81.17 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.666 -0.647 . . . . 0.0 110.192 179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -64.62 -44.8 89.39 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.565 -0.709 . . . . 0.0 109.886 179.51 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.6 -33.99 76.9 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.803 -0.561 . . . . 0.0 110.395 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.22 -39.57 78.49 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.466 -0.771 . . . . 0.0 110.122 179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 3.6 t -64.95 -40.44 95.02 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.658 -0.652 . . . . 0.0 110.951 -179.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.4 t -71.62 -32.03 67.54 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.282 -0.886 . . . . 0.0 111.443 -179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 33.1 t -58.64 -42.9 89.38 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.126 -0.984 . . . . 0.0 110.363 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 32.3 t -84.24 -25.98 29.02 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.352 -0.843 . . . . 0.0 110.904 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.406 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.3 OUTLIER -84.26 -31.96 24.7 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.286 -0.884 . . . . 0.0 111.453 -179.394 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.4 mt -138.87 6.55 2.43 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.217 -0.927 . . . . 0.0 112.556 -178.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.02 28.32 73.75 Favored Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 6.9 mmt-85 -115.6 139.92 49.65 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.213 -1.169 . . . . 0.0 110.638 -179.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.486 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 80.5 m 62.46 57.27 1.92 Allowed 'General case' 0 N--CA 1.499 2.003 0 CA-C-O 121.939 0.876 . . . . 0.0 109.42 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 34.9 m -100.12 -6.21 26.63 Favored 'General case' 0 N--CA 1.488 1.464 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.749 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -128.18 46.43 2.58 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.995 -1.065 . . . . 0.0 110.517 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 94.8 t -92.68 115.85 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.261 -0.9 . . . . 0.0 110.09 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.32 118.04 1.91 Allowed Glycine 0 N--CA 1.493 2.485 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -130.81 116.47 17.99 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.439 -1.036 . . . . 0.0 110.346 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.23 -178.05 43.03 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -77.26 163.47 26.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.391 -1.064 . . . . 0.0 110.465 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.8 m -76.44 163.58 26.81 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.498 -0.751 . . . . 0.0 110.444 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.925 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.6 mp0 . . . . . 0 N--CA 1.497 1.884 0 CA-C-O 121.336 0.589 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 59.2 t -110.97 104.06 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.614 -0.679 . . . . 0.0 109.79 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -147.67 143.41 27.63 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.512 -0.743 . . . . 0.0 110.357 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 23.8 tttm -156.82 134.88 11.13 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.464 -0.772 . . . . 0.0 110.406 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -96.1 -164.19 33.66 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -101.37 -73.13 1.0 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 3.5 t80 -105.0 127.49 52.89 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.532 -0.981 . . . . 0.0 110.247 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -159.1 79.65 0.76 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.469 -0.769 . . . . 0.0 110.367 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.43 105.49 47.12 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.348 -0.845 . . . . 0.0 110.029 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.412 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.2 Cg_endo -71.71 134.86 24.8 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 O-C-N 123.843 1.444 . . . . 0.0 110.759 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.412 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 51.3 mt 60.04 99.61 0.04 OUTLIER Pre-proline 0 N--CA 1.503 2.223 0 O-C-N 121.94 -0.475 . . . . 0.0 110.732 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -72.79 -160.88 0.1 OUTLIER 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.659 1.347 . . . . 0.0 110.299 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.78 115.84 21.93 Favored Pre-proline 0 N--CA 1.495 1.807 0 O-C-N 121.475 -0.766 . . . . 0.0 110.095 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.55 158.93 50.1 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 123.888 1.467 . . . . 0.0 110.624 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.32 150.04 46.28 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 O-C-N 123.93 1.49 . . . . 0.0 110.618 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -74.92 169.92 21.55 Favored 'Trans proline' 0 C--N 1.313 -1.29 0 O-C-N 123.791 1.416 . . . . 0.0 110.591 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -160.41 160.06 31.77 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.62 -0.675 . . . . 0.0 110.489 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.6 t -74.39 140.15 18.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.896 0 O-C-N 121.566 -0.709 . . . . 0.0 110.045 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.54 100.21 52.71 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.414 -0.803 . . . . 0.0 110.096 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -73.05 177.05 8.26 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.774 1.408 . . . . 0.0 110.88 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 2.0 pp -88.37 150.47 46.84 Favored Pre-proline 0 N--CA 1.496 1.864 0 O-C-N 121.449 -0.782 . . . . 0.0 110.496 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -75.15 136.2 19.78 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.847 1.446 . . . . 0.0 110.472 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -137.64 -103.19 0.63 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.32 163.89 39.4 Favored Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.32 151.13 53.88 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.857 1.451 . . . . 0.0 110.69 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.411 ' HA ' HD13 ' A' ' 26' ' ' ILE . 18.5 mm -125.26 153.48 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.19 80.32 0.5 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -75.98 -42.16 0.44 Allowed 'Trans proline' 0 C--N 1.313 -1.301 0 O-C-N 123.916 1.482 . . . . 0.0 111.071 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -82.61 70.4 9.57 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.24 -0.912 . . . . 0.0 110.234 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.1 m120 -144.98 43.44 1.33 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.374 -0.829 . . . . 0.0 110.565 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -177.85 46.37 0.1 OUTLIER Glycine 0 N--CA 1.494 2.539 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 49.1 t -168.87 91.01 0.6 Allowed Pre-proline 0 N--CA 1.498 1.941 0 O-C-N 121.326 -1.102 . . . . 0.0 110.331 179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.33 139.77 32.51 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 O-C-N 123.762 1.401 . . . . 0.0 110.608 179.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.35 -27.4 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 O-C-N 121.302 -0.874 . . . . 0.0 110.399 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.43 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -67.18 -18.39 65.25 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.429 -0.795 . . . . 0.0 110.78 179.45 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 35' ' ' SER . 95.5 m 58.99 26.27 14.86 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.549 -0.719 . . . . 0.0 111.178 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 14.8 mtt180 -108.95 144.57 36.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.261 -0.9 . . . . 0.0 110.046 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.27 34.27 64.23 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.234 -1.147 . . . . 0.0 110.234 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.503 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.3 pt -125.78 155.15 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.2 -1.176 . . . . 0.0 110.123 179.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.84 159.27 21.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.668 -0.645 . . . . 0.0 109.475 179.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -57.66 -42.47 83.57 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.424 -0.797 . . . . 0.0 109.641 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.2 t -67.32 -34.45 77.38 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.583 -0.698 . . . . 0.0 109.95 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.39 -41.35 89.5 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.473 -0.767 . . . . 0.0 109.69 179.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.503 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -74.23 -27.5 60.81 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.748 -0.595 . . . . 0.0 110.34 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -35.96 61.01 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.53 -0.731 . . . . 0.0 110.389 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.0 t -70.88 -40.62 72.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.448 -0.783 . . . . 0.0 111.09 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 18.7 t -73.55 -30.44 63.07 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.237 -0.914 . . . . 0.0 111.299 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.4 -42.63 92.38 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.126 -0.984 . . . . 0.0 110.579 -179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 33.1 t -82.92 -25.28 32.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.816 . . . . 0.0 111.587 -179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 8.9 mmm180 -92.28 -27.02 17.87 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.215 -0.928 . . . . 0.0 111.636 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 mt -137.31 2.95 2.56 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.071 -1.018 . . . . 0.0 112.509 -179.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 65.64 28.28 73.46 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.422 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.8 OUTLIER -118.04 143.19 46.63 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.26 -1.141 . . . . 0.0 110.415 -179.647 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 1.3 m 62.39 52.87 2.91 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.001 0.905 . . . . 0.0 109.097 -179.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 50.4 m -97.85 -3.71 38.19 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.339 -179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 35.8 t-80 -122.67 45.35 2.4 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.167 -0.958 . . . . 0.0 109.88 179.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.456 HG21 ' HB1' ' A' ' 44' ' ' ALA . 17.0 t -92.76 112.16 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.373 -0.83 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.39 88.72 0.54 Allowed Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -158.9 139.68 12.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.514 -0.992 . . . . 0.0 110.643 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 86.53 125.32 1.81 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.4 t80 -79.33 163.94 24.47 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.476 -1.014 . . . . 0.0 110.301 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.0 m -77.97 166.29 23.03 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.604 -0.685 . . . . 0.0 110.381 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 CA-C-O 117.985 -1.453 . . . . 0.0 109.535 179.906 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . 0.49 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 5.7 pm0 . . . . . 0 N--CA 1.497 1.904 0 CA-C-O 121.016 0.436 . . . . 0.0 110.648 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.49 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 46.9 t 65.8 144.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.308 0.575 . . . . 0.0 110.698 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 62.49 174.3 0.14 Allowed 'General case' 0 N--CA 1.502 2.167 0 O-C-N 121.473 -0.767 . . . . 0.0 110.75 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.4 pttm -86.09 129.06 34.96 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.317 -0.864 . . . . 0.0 110.312 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.42 -165.81 37.5 Favored Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -79.46 102.76 2.0 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 67.7 m-85 -63.13 119.43 9.53 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.615 -0.932 . . . . 0.0 109.859 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 52.39 47.36 24.89 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.373 0.606 . . . . 0.0 110.178 -179.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.7 ttt-85 -120.55 142.18 33.61 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.418 -0.801 . . . . 0.0 110.327 -179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -72.66 89.16 0.86 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 O-C-N 123.909 1.478 . . . . 0.0 110.309 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.1 pt -77.98 149.3 76.65 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.476 -0.765 . . . . 0.0 110.373 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.86 88.92 0.89 Allowed 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 124.063 1.559 . . . . 0.0 110.499 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 3.9 mtm105 -73.86 131.94 80.99 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.515 -0.74 . . . . 0.0 110.445 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.94 128.83 13.56 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 124.008 1.53 . . . . 0.0 110.755 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.2 129.22 11.97 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.794 1.418 . . . . 0.0 110.77 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -74.26 97.43 1.02 Allowed 'Trans proline' 0 C--N 1.316 -1.158 0 O-C-N 123.796 1.419 . . . . 0.0 110.52 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 36.5 t80 -154.11 152.71 30.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.325 -0.86 . . . . 0.0 110.545 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 95.4 t -82.55 145.27 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.676 -0.64 . . . . 0.0 109.701 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.1 ttp180 -63.89 112.45 7.41 Favored Pre-proline 0 N--CA 1.497 1.896 0 O-C-N 121.575 -0.703 . . . . 0.0 110.417 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -78.01 -173.37 1.8 Allowed 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.836 1.44 . . . . 0.0 110.512 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -135.16 76.34 57.78 Favored Pre-proline 0 N--CA 1.495 1.8 0 O-C-N 121.453 -0.779 . . . . 0.0 110.034 179.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.93 126.73 10.2 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 123.85 1.448 . . . . 0.0 110.74 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -127.18 -111.96 1.72 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 86.2 164.13 39.07 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.5 151.31 52.98 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.867 1.457 . . . . 0.0 110.684 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.6 tt -84.3 151.01 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.415 -0.803 . . . . 0.0 110.373 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.11 84.3 0.49 Allowed Glycine 0 N--CA 1.496 2.642 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -74.48 -51.59 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.967 1.509 . . . . 0.0 111.042 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -110.97 45.05 1.2 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.171 -0.956 . . . . 0.0 110.095 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -131.08 34.81 3.99 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.519 -0.738 . . . . 0.0 110.569 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.83 38.7 0.75 Allowed Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.46 ' SG ' ' HB3' ' A' ' 53' ' ' ARG . 2.2 t -173.08 87.86 0.39 Allowed Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.597 -0.943 . . . . 0.0 110.183 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -68.89 139.83 44.39 Favored 'Trans proline' 0 C--N 1.313 -1.328 0 O-C-N 124.007 1.53 . . . . 0.0 110.839 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.557 HG22 HH11 ' A' ' 53' ' ' ARG . 79.4 t -65.0 -28.79 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.535 -0.728 . . . . 0.0 110.429 179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.432 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 2.2 t -67.12 -21.38 65.84 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.484 -0.76 . . . . 0.0 110.896 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' SER . 74.1 m 59.62 28.68 18.16 Favored 'General case' 0 N--CA 1.503 2.209 0 O-C-N 121.557 -0.715 . . . . 0.0 110.892 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 6.5 mmt85 -104.41 146.09 29.34 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.271 -0.893 . . . . 0.0 110.273 179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.99 26.69 43.88 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 22.8 pt -137.01 160.0 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.221 -1.164 . . . . 0.0 110.259 179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.8 m -85.53 168.27 14.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.556 -0.715 . . . . 0.0 110.06 179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.65 -45.27 94.73 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.598 -0.689 . . . . 0.0 109.376 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 4.1 t -65.42 -38.53 90.19 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.611 -0.681 . . . . 0.0 110.026 179.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -63.25 -43.04 99.12 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.405 -0.809 . . . . 0.0 109.71 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -66.98 -38.48 86.12 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.685 -0.634 . . . . 0.0 109.846 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.96 -38.27 85.8 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-O 121.551 0.691 . . . . 0.0 109.69 178.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.8 t -62.79 -40.94 98.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.726 -0.609 . . . . 0.0 111.598 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.413 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 6.0 t -76.83 -28.42 55.51 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.997 -1.064 . . . . 0.0 111.599 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.4 t -59.28 -41.14 88.21 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.068 -1.02 . . . . 0.0 109.606 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.7 t -86.81 -24.32 25.06 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.33 -0.856 . . . . 0.0 110.377 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.413 ' HB3' ' HA ' ' A' ' 47' ' ' CYS . 3.1 tmm_? -77.94 -36.7 48.99 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.364 -0.835 . . . . 0.0 111.066 -179.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.406 HD12 ' HD2' ' A' ' 50' ' ' ARG . 0.2 OUTLIER -144.07 16.97 1.74 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.231 -0.918 . . . . 0.0 111.946 -179.284 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.89 33.42 83.38 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.557 HH11 HG22 ' A' ' 34' ' ' VAL . 5.9 mmt-85 -119.6 144.27 47.2 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.418 -1.048 . . . . 0.0 110.598 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.7 m 60.2 54.7 3.93 Favored 'General case' 0 N--CA 1.498 1.965 0 CA-C-O 122.019 0.914 . . . . 0.0 109.095 -179.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.3 m -97.29 -17.15 19.96 Favored 'General case' 0 N--CA 1.489 1.506 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.399 -179.057 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -110.17 41.79 1.67 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.113 -0.992 . . . . 0.0 110.076 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.708 HG21 ' HB1' ' A' ' 44' ' ' ALA . 47.4 t -80.14 118.9 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.383 -0.823 . . . . 0.0 110.409 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 80.73 97.73 0.37 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -157.5 155.59 30.58 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.457 -1.025 . . . . 0.0 110.437 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.04 127.75 3.45 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 4.6 t80 -79.49 167.63 20.54 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.525 -0.985 . . . . 0.0 110.561 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.5 p -80.48 168.82 18.49 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.571 -0.706 . . . . 0.0 110.42 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.446 0 CA-C-O 118.034 -1.426 . . . . 0.0 109.732 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 35.4 mt-30 . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.301 0.572 . . . . 0.0 110.329 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.4 p -77.72 145.85 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.5 -0.75 . . . . 0.0 110.213 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -110.36 107.08 16.68 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.508 -0.745 . . . . 0.0 110.033 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.14 156.8 42.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.526 -0.734 . . . . 0.0 110.241 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -175.26 -73.65 0.05 OUTLIER Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 102.38 150.66 23.08 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -76.28 93.38 3.41 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.502 -0.999 . . . . 0.0 110.285 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -68.51 -32.82 73.05 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.522 -0.737 . . . . 0.0 110.796 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.98 118.14 55.53 Favored Pre-proline 0 N--CA 1.496 1.872 0 O-C-N 121.387 -0.82 . . . . 0.0 110.267 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.92 128.56 11.65 Favored 'Trans proline' 0 C--N 1.315 -1.218 0 O-C-N 123.855 1.45 . . . . 0.0 110.756 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.486 HG21 ' HB3' ' A' ' 14' ' ' PRO . 48.2 mt -86.23 115.0 60.34 Favored Pre-proline 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.824 . . . . 0.0 110.106 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -71.68 83.63 1.07 Allowed 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 123.924 1.486 . . . . 0.0 110.739 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.1 tpm_? 59.1 91.9 0.07 OUTLIER Pre-proline 0 N--CA 1.503 2.218 0 O-C-N 121.802 -0.561 . . . . 0.0 111.056 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.486 ' HB3' HG21 ' A' ' 11' ' ' ILE . 46.5 Cg_endo -74.45 127.96 11.53 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.857 1.451 . . . . 0.0 110.686 179.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -76.43 126.05 8.79 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.871 1.458 . . . . 0.0 110.595 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.508 ' O ' ' HB3' ' A' ' 17' ' ' PHE . 47.1 Cg_endo -73.1 95.77 0.85 Allowed 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.865 1.455 . . . . 0.0 110.707 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.508 ' HB3' ' O ' ' A' ' 16' ' ' PRO . 75.6 t80 63.22 151.04 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.256 0 CA-C-O 121.703 0.763 . . . . 0.0 111.433 179.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -114.65 136.16 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.346 -0.846 . . . . 0.0 109.955 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 41.8 ttp180 -111.09 121.43 40.65 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.499 -0.751 . . . . 0.0 110.417 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -73.17 -173.46 1.28 Allowed 'Trans proline' 0 C--N 1.314 -1.25 0 O-C-N 123.916 1.482 . . . . 0.0 110.668 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.43 HD13 ' HA ' ' A' ' 21' ' ' LEU . 1.3 mm? -108.95 94.88 15.63 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.429 -0.794 . . . . 0.0 110.259 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.66 95.76 0.97 Allowed 'Trans proline' 0 C--N 1.315 -1.22 0 O-C-N 123.846 1.445 . . . . 0.0 110.509 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -162.36 60.55 0.28 Allowed Glycine 0 N--CA 1.495 2.608 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.82 147.08 16.02 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -73.49 157.98 48.38 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.759 1.4 . . . . 0.0 110.542 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.3 mm -123.57 153.04 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.374 -0.829 . . . . 0.0 110.383 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.39 75.52 0.5 Allowed Glycine 0 N--CA 1.495 2.615 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -79.71 -38.26 0.39 Allowed 'Trans proline' 0 C--N 1.314 -1.249 0 O-C-N 123.862 1.453 . . . . 0.0 111.014 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -83.55 70.99 10.36 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.382 -0.824 . . . . 0.0 110.182 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -136.14 45.61 2.36 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 164.65 49.42 0.02 OUTLIER Glycine 0 N--CA 1.492 2.415 0 C-N-CA 119.866 -1.159 . . . . 0.0 110.662 179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.3 t -172.79 96.7 0.36 Allowed Pre-proline 0 N--CA 1.499 1.987 0 O-C-N 121.32 -1.106 . . . . 0.0 110.542 179.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -69.02 160.34 50.3 Favored 'Trans proline' 0 N--CA 1.494 1.505 0 O-C-N 123.852 1.448 . . . . 0.0 111.621 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 54.3 t -79.85 -36.29 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.967 0 O-C-N 121.507 -0.746 . . . . 0.0 110.487 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.8 OUTLIER -68.8 -15.02 63.39 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.541 -0.724 . . . . 0.0 111.383 -179.606 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' SER . 33.0 m 57.8 27.97 15.27 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.4 -0.812 . . . . 0.0 110.84 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 7.4 mtt-85 -111.09 149.94 30.1 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.354 -0.841 . . . . 0.0 109.982 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.01 34.18 43.03 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.159 -1.177 . . . . 0.0 110.159 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 15.6 pt -129.77 154.15 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.271 -1.135 . . . . 0.0 110.177 179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 m -83.83 161.47 20.9 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.599 -0.688 . . . . 0.0 109.741 179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.92 -41.39 82.58 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.432 -0.793 . . . . 0.0 109.574 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -67.97 -36.44 80.07 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.535 -0.728 . . . . 0.0 110.093 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -67.43 -40.19 85.47 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.429 -0.794 . . . . 0.0 109.911 179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.92 -34.52 73.6 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 0.0 110.252 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 2.6 ttp180 -70.12 -31.3 68.79 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.434 -0.791 . . . . 0.0 110.232 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 2.0 t -71.35 -44.24 65.41 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.542 -0.724 . . . . 0.0 111.314 -179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 11.7 t -75.41 -29.18 59.68 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.19 -0.944 . . . . 0.0 111.467 -179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.5 t -62.25 -42.67 99.54 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.165 -0.959 . . . . 0.0 110.078 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 10.2 t -84.97 -25.12 27.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.329 -0.857 . . . . 0.0 110.685 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 46' ' ' SER . 3.9 ttt180 -81.7 -33.71 31.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.414 -0.804 . . . . 0.0 111.312 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -142.12 9.57 1.9 Allowed 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.167 -0.958 . . . . 0.0 112.328 -179.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 66.99 27.72 73.53 Favored Glycine 0 N--CA 1.497 2.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.0 OUTLIER -115.73 144.82 43.42 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.172 -1.193 . . . . 0.0 110.812 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 44.9 m 62.08 51.78 3.5 Favored 'General case' 0 N--CA 1.499 1.985 0 CA-C-O 122.013 0.911 . . . . 0.0 109.438 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.36 -4.53 38.29 Favored 'General case' 0 N--CA 1.487 1.395 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.317 -179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.3 t-160 -126.02 47.74 2.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.048 -1.032 . . . . 0.0 109.944 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 64.2 t -90.68 144.7 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.511 -0.743 . . . . 0.0 110.379 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.33 139.01 7.6 Favored Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.971 -1.251 . . . . 0.0 109.971 179.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -70.6 106.86 3.64 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.426 -1.043 . . . . 0.0 110.513 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.7 177.04 39.85 Favored Glycine 0 N--CA 1.494 2.554 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.417 ' O ' ' HB2' ' A' ' 62' ' ' SER . 39.6 t80 -74.69 153.16 39.01 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.378 -1.072 . . . . 0.0 110.331 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.417 ' HB2' ' O ' ' A' ' 61' ' ' TYR . 69.2 m 59.11 178.57 0.08 Allowed 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.554 0.693 . . . . 0.0 111.045 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.416 0 CA-C-O 118.003 -1.443 . . . . 0.0 109.528 -179.709 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.7 mm100 . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 121.35 0.595 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 87.0 t -84.89 130.86 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.543 -0.723 . . . . 0.0 109.877 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -110.23 108.73 18.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.372 -0.83 . . . . 0.0 110.329 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -132.85 81.38 1.94 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.501 -0.749 . . . . 0.0 109.935 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 74.15 -95.74 0.86 Allowed Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 169.75 -77.82 0.1 Allowed Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -94.71 94.06 7.89 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.546 -0.973 . . . . 0.0 109.796 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -155.32 -178.55 7.34 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.529 -0.732 . . . . 0.0 110.422 -179.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.4 157.37 65.13 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.471 -0.768 . . . . 0.0 110.219 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.71 125.42 9.99 Favored 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.879 1.463 . . . . 0.0 110.659 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 11' ' ' ILE . 13.7 tt -90.18 117.76 68.3 Favored Pre-proline 0 N--CA 1.494 1.773 0 O-C-N 121.379 -0.826 . . . . 0.0 110.513 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.55 74.29 3.81 Favored 'Trans proline' 0 N--CA 1.489 1.218 0 O-C-N 123.85 1.447 . . . . 0.0 110.526 179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.63 137.56 47.76 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.409 -0.807 . . . . 0.0 110.4 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.14 155.56 56.55 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 124.062 1.559 . . . . 0.0 110.776 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.6 120.9 6.99 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 O-C-N 123.878 1.462 . . . . 0.0 110.515 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -75.96 -171.88 1.19 Allowed 'Trans proline' 0 C--N 1.316 -1.18 0 O-C-N 123.858 1.452 . . . . 0.0 110.786 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -66.26 158.77 28.08 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.581 -0.699 . . . . 0.0 110.752 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 47.8 t -72.54 130.24 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.97 0 O-C-N 121.573 -0.704 . . . . 0.0 110.093 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.0 tpp180 -94.32 122.45 61.31 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.701 -0.624 . . . . 0.0 110.527 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.18 -172.38 1.13 Allowed 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.96 1.505 . . . . 0.0 110.891 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -69.38 153.54 95.75 Favored Pre-proline 0 N--CA 1.498 1.955 0 O-C-N 121.478 -0.764 . . . . 0.0 110.504 -179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -71.52 127.62 13.45 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.922 1.485 . . . . 0.0 110.58 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 154.79 -108.19 0.35 Allowed Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.97 87.41 0.56 Allowed Glycine 0 N--CA 1.494 2.558 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -73.49 140.03 29.41 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.879 1.463 . . . . 0.0 110.647 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.8 mp -121.24 163.06 19.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.487 -0.758 . . . . 0.0 110.173 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.29 171.33 39.74 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -70.89 -10.63 28.03 Favored 'Trans proline' 0 N--CA 1.491 1.372 0 O-C-N 124.12 1.59 . . . . 0.0 111.812 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 32.4 t80 -74.1 71.21 1.62 Allowed 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.117 -0.989 . . . . 0.0 110.371 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.96 43.72 0.15 Allowed 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.312 -0.868 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.98 44.12 0.46 Allowed Glycine 0 N--CA 1.496 2.638 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 40.0 t -172.76 112.51 0.36 Allowed Pre-proline 0 N--CA 1.497 1.912 0 O-C-N 121.423 -1.045 . . . . 0.0 110.227 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.54 150.01 50.62 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.579 1.305 . . . . 0.0 110.528 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 97.2 t -79.83 -28.06 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 121.325 -0.859 . . . . 0.0 110.466 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 t -74.19 -11.8 60.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.228 -0.92 . . . . 0.0 111.179 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.8 m 58.27 25.69 12.99 Favored 'General case' 0 N--CA 1.504 2.237 0 O-C-N 121.399 -0.813 . . . . 0.0 111.006 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.8 mmt-85 -110.58 156.09 21.41 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.352 -0.843 . . . . 0.0 109.943 179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.97 30.57 69.99 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.435 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.5 pt -131.69 158.89 43.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.266 -1.138 . . . . 0.0 109.981 179.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.408 ' HB2' ' HB2' ' A' ' 43' ' ' GLN . 1.6 m -82.27 158.52 23.45 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.715 -0.616 . . . . 0.0 109.446 179.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -56.62 -44.39 81.16 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.405 -0.809 . . . . 0.0 109.732 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.6 t -68.14 -35.74 78.58 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.598 -0.689 . . . . 0.0 109.971 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' SER . 0.0 OUTLIER -64.29 -41.92 96.63 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.638 -0.664 . . . . 0.0 109.925 179.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.435 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -66.98 -36.82 83.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.576 -0.703 . . . . 0.0 109.993 179.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 27.8 mtm180 -65.62 -40.77 92.94 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.656 -0.653 . . . . 0.0 110.062 179.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.04 -45.12 96.08 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.832 -0.543 . . . . 0.0 111.363 -179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.555 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 51.8 t -68.56 -33.37 73.96 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.163 -0.961 . . . . 0.0 111.11 -179.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.9 t -60.29 -41.86 94.27 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.167 -0.958 . . . . 0.0 110.465 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 23.0 t -83.43 -22.47 32.65 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.372 -0.83 . . . . 0.0 111.538 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -95.55 -26.68 15.69 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.032 -1.043 . . . . 0.0 111.584 -179.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.1 mt -135.84 1.76 2.81 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.166 -0.959 . . . . 0.0 112.478 -178.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.79 26.94 73.7 Favored Glycine 0 N--CA 1.497 2.731 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.555 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.78 146.31 42.93 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.304 -1.115 . . . . 0.0 110.418 -179.819 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 92.6 m 60.76 53.52 3.9 Favored 'General case' 0 N--CA 1.499 1.978 0 CA-C-O 121.885 0.85 . . . . 0.0 109.136 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 53.6 m -100.15 -4.06 30.44 Favored 'General case' 0 N--CA 1.487 1.42 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.551 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -127.39 45.89 2.64 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.04 -1.038 . . . . 0.0 110.288 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 60.1 t -90.09 145.02 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.874 0 O-C-N 121.315 -0.866 . . . . 0.0 110.317 -179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.38 81.91 1.09 Allowed Glycine 0 N--CA 1.494 2.523 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.3 tttp -166.8 120.84 1.05 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.706 -0.879 . . . . 0.0 110.293 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.7 135.22 6.16 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.5 t80 -70.52 155.29 40.91 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.311 -1.111 . . . . 0.0 110.362 179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 p -130.26 164.24 25.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.578 -0.701 . . . . 0.0 110.682 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 CA-C-O 117.989 -1.45 . . . . 0.0 109.569 179.866 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 . . . . . 0 N--CA 1.496 1.835 0 CA-C-O 121.28 0.562 . . . . 0.0 110.335 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 99.2 t -121.86 115.51 46.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.537 -0.727 . . . . 0.0 110.002 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -80.63 143.38 33.15 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.417 -0.802 . . . . 0.0 110.299 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.95 133.01 38.12 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.579 -0.701 . . . . 0.0 110.606 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -98.97 -56.7 1.0 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 7' ' ' TYR . . . 179.41 -63.93 0.08 OUTLIER Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.43 ' HB3' ' O ' ' A' ' 6' ' ' GLY . 70.1 t80 63.06 104.23 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.172 0 O-C-N 122.01 -0.7 . . . . 0.0 111.011 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -82.66 -171.71 3.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.266 -0.896 . . . . 0.0 110.197 179.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.0 126.33 89.43 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.347 -0.846 . . . . 0.0 110.409 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.19 121.75 7.48 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 O-C-N 123.907 1.477 . . . . 0.0 110.886 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 1.2 pp -84.41 127.18 67.05 Favored Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.447 -0.783 . . . . 0.0 110.524 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -73.96 62.92 4.97 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.813 1.428 . . . . 0.0 110.549 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -163.9 72.74 1.76 Allowed Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.339 -0.851 . . . . 0.0 109.943 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -73.89 156.95 47.88 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 O-C-N 123.86 1.453 . . . . 0.0 110.867 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.18 143.08 28.08 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.993 1.522 . . . . 0.0 110.622 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -74.02 84.36 1.5 Allowed 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.868 1.457 . . . . 0.0 110.316 179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -146.37 153.57 40.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.45 -0.781 . . . . 0.0 110.397 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -90.05 143.0 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.634 -0.666 . . . . 0.0 109.988 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -107.77 120.59 46.72 Favored Pre-proline 0 N--CA 1.494 1.727 0 O-C-N 121.461 -0.774 . . . . 0.0 110.296 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.26 172.16 16.17 Favored 'Trans proline' 0 C--N 1.314 -1.241 0 O-C-N 123.876 1.461 . . . . 0.0 110.544 179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.847 HD13 ' HD2' ' A' ' 22' ' ' PRO . 0.2 OUTLIER -134.25 121.59 15.57 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.638 -0.664 . . . . 0.0 110.063 179.969 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.847 ' HD2' HD13 ' A' ' 21' ' ' LEU . 43.8 Cg_endo -70.51 116.39 4.62 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.808 1.425 . . . . 0.0 110.494 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.38 -68.57 0.3 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.57 158.66 34.58 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.58 144.46 35.84 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.575 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.437 ' HA ' HD13 ' A' ' 26' ' ' ILE . 13.4 mm -71.19 150.42 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.413 -0.805 . . . . 0.0 110.176 179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 64.17 74.77 0.42 Allowed Glycine 0 N--CA 1.495 2.633 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -76.31 -47.85 0.15 Allowed 'Trans proline' 0 C--N 1.314 -1.274 0 O-C-N 123.933 1.491 . . . . 0.0 110.622 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 57.7 t80 -84.49 64.52 8.47 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.85 . . . . 0.0 109.525 179.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -155.44 41.51 0.42 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.356 -0.84 . . . . 0.0 110.586 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -151.01 41.57 0.76 Allowed Glycine 0 N--CA 1.496 2.646 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.6 t -172.64 106.07 0.34 Allowed Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.456 -1.026 . . . . 0.0 110.048 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.1 139.8 36.4 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.609 1.321 . . . . 0.0 110.577 179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 78.4 t -69.14 -26.24 31.55 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 O-C-N 121.437 -0.789 . . . . 0.0 110.859 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.36 -11.13 59.99 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.15 -0.969 . . . . 0.0 111.411 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 79.7 m 57.44 26.79 13.02 Favored 'General case' 0 N--CA 1.503 2.204 0 O-C-N 121.391 -0.818 . . . . 0.0 111.009 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -108.45 150.32 27.58 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.304 -0.872 . . . . 0.0 110.565 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.86 28.23 65.28 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.465 -1.054 . . . . 0.0 110.465 179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.9 pt -132.48 158.29 43.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.178 -1.189 . . . . 0.0 110.114 179.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -80.32 161.08 25.25 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.682 -0.636 . . . . 0.0 109.684 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 50.8 t80 -57.25 -48.46 78.8 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.439 -0.788 . . . . 0.0 109.8 179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.01 -33.91 76.88 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.605 -0.685 . . . . 0.0 110.094 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 4.9 tt0 -63.64 -43.87 95.54 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.486 -0.759 . . . . 0.0 109.678 179.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.875 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -68.01 -36.14 79.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.638 -0.664 . . . . 0.0 109.545 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 9.9 mtt180 -64.53 -40.01 94.82 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.701 -0.624 . . . . 0.0 110.225 179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.9 t -62.91 -44.91 94.8 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.627 -0.67 . . . . 0.0 111.041 -179.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.55 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 41.4 t -65.71 -34.05 77.3 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.231 -0.918 . . . . 0.0 110.945 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 40.3 t -59.54 -42.66 92.83 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.144 -0.973 . . . . 0.0 110.572 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -87.84 -26.77 22.63 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.335 -0.853 . . . . 0.0 111.164 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -85.62 -30.67 23.08 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.291 -0.881 . . . . 0.0 111.368 -179.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.1 mt -134.52 4.58 3.39 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.29 -0.881 . . . . 0.0 112.21 -178.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 63.35 31.27 80.18 Favored Glycine 0 N--CA 1.497 2.713 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -179.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.55 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 5.0 mmp_? -125.81 148.96 48.97 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.459 -1.024 . . . . 0.0 110.074 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 3.2 m 61.17 45.84 8.62 Favored 'General case' 0 N--CA 1.5 2.06 0 CA-C-O 122.022 0.915 . . . . 0.0 108.611 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 9.0 m -90.12 -10.14 45.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.808 -0.557 . . . . 0.0 111.325 -179.231 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -117.75 43.51 2.38 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.21 -0.931 . . . . 0.0 109.861 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.875 HG21 ' HB1' ' A' ' 44' ' ' ALA . 61.4 t -79.63 117.57 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 121.444 -0.785 . . . . 0.0 110.363 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.34 143.25 10.5 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -162.79 124.15 2.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.51 -0.994 . . . . 0.0 110.352 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.65 -177.68 43.71 Favored Glycine 0 N--CA 1.495 2.615 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 47.1 t80 -80.13 159.95 25.88 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.357 -1.084 . . . . 0.0 110.37 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 61.4 m -77.45 166.79 22.65 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.473 -0.767 . . . . 0.0 110.563 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.386 0 CA-C-O 118.031 -1.427 . . . . 0.0 109.662 -179.916 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.8 pm0 . . . . . 0 N--CA 1.497 1.907 0 CA-C-O 121.267 0.556 . . . . 0.0 110.646 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.9 p -132.42 149.73 32.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.704 -0.623 . . . . 0.0 110.329 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -108.95 79.76 1.25 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.442 -0.786 . . . . 0.0 109.826 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.0 107.91 3.55 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.459 -0.776 . . . . 0.0 110.168 -179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -82.45 -164.24 34.45 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -166.3 83.94 0.1 Allowed Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.2 p90 -100.02 146.49 26.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.551 -0.97 . . . . 0.0 110.318 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 50.54 -134.12 1.59 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.735 -0.603 . . . . 0.0 110.486 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.3 122.0 7.3 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.098 -1.001 . . . . 0.0 110.06 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.64 ' HB2' HD12 ' A' ' 11' ' ' ILE . 44.3 Cg_endo -70.93 142.54 43.01 Favored 'Trans proline' 0 C--N 1.315 -1.223 0 O-C-N 123.87 1.458 . . . . 0.0 110.349 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.64 HD12 ' HB2' ' A' ' 10' ' ' PRO . 2.5 mp 55.54 72.84 0.95 Allowed Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.866 -0.521 . . . . 0.0 110.084 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -75.95 -169.13 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.718 1.378 . . . . 0.0 110.63 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.468 ' HA ' ' HD2' ' A' ' 13' ' ' ARG . 4.4 mmm180 -68.67 114.85 25.08 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.794 -0.566 . . . . 0.0 110.295 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -71.89 145.11 44.76 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.86 1.453 . . . . 0.0 110.826 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.8 138.15 18.56 Favored 'Trans proline' 0 C--N 1.315 -1.216 0 O-C-N 123.949 1.5 . . . . 0.0 110.656 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.02 95.61 0.84 Allowed 'Trans proline' 0 C--N 1.315 -1.192 0 O-C-N 123.916 1.482 . . . . 0.0 110.658 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -75.9 146.11 39.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.394 -0.817 . . . . 0.0 110.39 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 92.2 t -85.3 156.66 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.934 0 O-C-N 121.649 -0.657 . . . . 0.0 110.132 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.13 117.28 20.36 Favored Pre-proline 0 N--CA 1.497 1.9 0 O-C-N 121.645 -0.659 . . . . 0.0 110.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.11 169.89 19.48 Favored 'Trans proline' 0 C--N 1.315 -1.208 0 O-C-N 123.942 1.496 . . . . 0.0 110.633 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 52.32 64.13 7.95 Favored Pre-proline 0 N--CA 1.499 2.013 0 O-C-N 121.844 -0.535 . . . . 0.0 110.727 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -81.88 144.58 13.74 Favored 'Trans proline' 0 C--N 1.314 -1.264 0 O-C-N 123.707 1.372 . . . . 0.0 110.726 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.07 54.85 2.36 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.67 139.8 4.01 Favored Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -76.8 178.75 7.21 Favored 'Trans proline' 0 N--CA 1.488 1.189 0 O-C-N 123.981 1.516 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.441 ' HA ' HD13 ' A' ' 26' ' ' ILE . 14.0 mm -63.21 156.33 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.013 0 O-C-N 121.63 -0.669 . . . . 0.0 110.459 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.08 85.03 1.43 Allowed Glycine 0 N--CA 1.496 2.634 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -73.78 -20.95 19.38 Favored 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.97 1.51 . . . . 0.0 111.437 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -85.15 49.3 1.72 Allowed 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.14 -0.975 . . . . 0.0 110.585 -179.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 m-80 -138.06 41.86 2.27 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.309 -0.87 . . . . 0.0 110.445 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.5 38.1 1.1 Allowed Glycine 0 N--CA 1.497 2.702 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 47.2 t -177.49 113.94 0.24 Allowed Pre-proline 0 N--CA 1.497 1.918 0 O-C-N 121.632 -0.922 . . . . 0.0 110.006 179.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.93 149.63 66.08 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 O-C-N 123.55 1.289 . . . . 0.0 110.386 179.228 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 79.2 t -78.2 -32.07 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.993 0 O-C-N 121.409 -0.807 . . . . 0.0 110.733 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -74.43 -16.61 60.87 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.172 -0.955 . . . . 0.0 110.952 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 34.1 m 57.99 30.39 19.12 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.372 -0.83 . . . . 0.0 110.239 -179.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.5 mtp180 -113.01 154.07 27.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.508 -0.745 . . . . 0.0 110.128 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.55 34.69 59.91 Favored Glycine 0 N--CA 1.495 2.585 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 26.9 pt -139.83 161.81 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.403 -1.057 . . . . 0.0 109.855 179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 7.8 m -80.44 161.08 25.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.534 -0.728 . . . . 0.0 109.963 179.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.9 t80 -58.54 -43.72 89.36 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.512 -0.743 . . . . 0.0 109.39 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.9 t -65.0 -38.63 91.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.641 -0.662 . . . . 0.0 109.827 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 28.5 tp60 -64.21 -44.76 90.94 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.611 -0.68 . . . . 0.0 109.593 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.93 79.2 Favored 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 11.3 mtp180 -65.69 -36.26 83.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.815 -0.553 . . . . 0.0 109.793 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.3 t -63.42 -47.77 80.57 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.797 -0.564 . . . . 0.0 111.197 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 53.1 t -66.45 -33.69 76.26 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.241 -0.912 . . . . 0.0 111.091 -179.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.0 t -57.81 -41.67 82.69 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 121.163 -0.961 . . . . 0.0 110.169 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 8.9 t -84.59 -25.59 28.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.272 -0.892 . . . . 0.0 110.367 179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 7.8 ttm180 -79.39 -36.18 39.59 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.327 -0.858 . . . . 0.0 111.195 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -141.32 11.39 2.14 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.116 -0.99 . . . . 0.0 112.353 -178.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 67.04 26.93 73.29 Favored Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.461 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -114.74 141.61 47.61 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.243 -1.151 . . . . 0.0 110.571 -179.921 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 54.1 m 66.25 54.61 0.93 Allowed 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.799 0.809 . . . . 0.0 108.917 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 67.5 m -102.92 -0.62 30.82 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.845 -0.535 . . . . 0.0 111.75 -178.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -137.03 50.24 2.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.935 -1.103 . . . . 0.0 110.645 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 92.2 t -95.64 137.3 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 O-C-N 121.115 -0.99 . . . . 0.0 110.245 179.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.52 168.38 41.21 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.93 99.88 5.06 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.444 -1.033 . . . . 0.0 110.022 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 76.27 98.39 0.15 Allowed Glycine 0 N--CA 1.494 2.533 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -91.7 160.46 15.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.512 -0.993 . . . . 0.0 110.563 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.1 p -73.06 174.36 8.02 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.535 -0.728 . . . . 0.0 110.762 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 CA-C-O 118.021 -1.433 . . . . 0.0 109.608 179.967 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 . . . . . 0 N--CA 1.496 1.849 0 CA-C-O 121.354 0.597 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 94.3 t -104.49 134.66 45.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.661 -0.649 . . . . 0.0 109.897 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 60.51 101.2 0.02 OUTLIER 'General case' 0 N--CA 1.503 2.197 0 CA-C-O 121.451 0.643 . . . . 0.0 110.619 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.31 101.66 1.96 Allowed 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.292 -0.88 . . . . 0.0 110.421 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -84.45 -159.37 29.86 Favored Glycine 0 N--CA 1.493 2.461 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -171.06 148.72 11.48 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.659 -1.377 . . . . 0.0 109.659 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 42.5 m-85 -87.41 84.67 7.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.433 -1.039 . . . . 0.0 110.141 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -158.94 160.38 35.98 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.433 -0.792 . . . . 0.0 110.305 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 3.6 mtt-85 -109.67 104.18 54.78 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.404 -0.81 . . . . 0.0 110.185 179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.57 129.72 16.1 Favored 'Trans proline' 0 C--N 1.316 -1.165 0 O-C-N 123.824 1.434 . . . . 0.0 110.433 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 32.0 mt 53.46 69.62 2.18 Favored Pre-proline 0 N--CA 1.501 2.117 0 O-C-N 121.788 -0.57 . . . . 0.0 110.151 -179.715 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -75.69 69.15 6.15 Favored 'Trans proline' 0 C--N 1.315 -1.219 0 O-C-N 123.827 1.435 . . . . 0.0 110.372 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 15.4 tpp180 -153.2 112.14 2.65 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.38 -0.825 . . . . 0.0 110.031 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.1 141.13 29.09 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.918 1.483 . . . . 0.0 110.728 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.69 144.17 31.13 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.91 1.479 . . . . 0.0 110.655 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.69 72.67 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 O-C-N 123.832 1.438 . . . . 0.0 110.332 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -161.37 155.58 22.6 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.372 -0.83 . . . . 0.0 110.524 -179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -125.3 144.87 33.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.714 -0.616 . . . . 0.0 109.965 179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -88.84 114.85 61.67 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.591 -0.693 . . . . 0.0 110.337 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.487 ' O ' ' HB2' ' A' ' 21' ' ' LEU . 51.4 Cg_endo -77.04 179.6 6.37 Favored 'Trans proline' 0 C--N 1.315 -1.204 0 O-C-N 123.854 1.45 . . . . 0.0 110.745 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.487 ' HB2' ' O ' ' A' ' 20' ' ' PRO . 1.2 mt 63.63 157.61 0.12 Allowed Pre-proline 0 N--CA 1.506 2.361 0 O-C-N 122.028 -0.42 . . . . 0.0 111.456 179.597 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -76.48 105.66 2.12 Favored 'Trans proline' 0 C--N 1.314 -1.245 0 O-C-N 123.729 1.384 . . . . 0.0 110.517 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.28 90.01 0.62 Allowed Glycine 0 N--CA 1.494 2.557 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.52 89.6 1.32 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.33 156.0 55.27 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 O-C-N 123.89 1.468 . . . . 0.0 110.682 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.7 mp -105.84 143.78 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.404 -0.81 . . . . 0.0 110.144 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.2 80.85 0.75 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -76.54 -171.09 1.01 Allowed 'Trans proline' 0 C--N 1.314 -1.272 0 O-C-N 123.887 1.467 . . . . 0.0 110.694 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.0 t80 -78.59 62.16 3.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.362 -0.836 . . . . 0.0 109.779 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 -141.82 38.75 1.65 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.297 -0.877 . . . . 0.0 110.929 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -164.49 41.29 0.3 Allowed Glycine 0 N--CA 1.494 2.518 0 C-N-CA 119.955 -1.116 . . . . 0.0 110.418 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 39.1 t -170.31 98.71 0.45 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 121.367 -1.078 . . . . 0.0 110.372 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.79 152.9 69.26 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.833 1.438 . . . . 0.0 110.719 179.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 91.6 t -77.38 -29.93 17.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 121.475 -0.766 . . . . 0.0 110.861 -179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.419 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -73.33 -12.68 60.92 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.24 -0.912 . . . . 0.0 111.27 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 35' ' ' SER . 68.5 m 58.15 25.55 12.64 Favored 'General case' 0 N--CA 1.503 2.192 0 O-C-N 121.45 -0.781 . . . . 0.0 111.155 -179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.405 ' O ' HG23 ' A' ' 39' ' ' ILE . 2.0 mtt180 -115.9 158.55 22.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.317 -0.865 . . . . 0.0 110.032 179.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.83 28.74 73.91 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 37' ' ' ARG . 16.2 pt -125.71 152.0 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.325 -1.103 . . . . 0.0 109.937 179.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -77.32 160.17 29.01 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.77 -44.56 86.25 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.346 -0.846 . . . . 0.0 109.724 179.627 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.7 t -66.0 -35.57 80.92 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.513 -0.742 . . . . 0.0 109.914 179.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.4 -44.22 96.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.396 -0.815 . . . . 0.0 109.117 178.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.758 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.56 -34.83 72.67 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.814 -0.554 . . . . 0.0 109.571 178.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.37 -34.96 77.0 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.696 -0.627 . . . . 0.0 110.283 179.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -69.65 -41.44 75.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.497 -0.752 . . . . 0.0 110.839 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.42 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 48.8 t -71.96 -32.83 67.66 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.408 -0.808 . . . . 0.0 111.061 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 53.5 t -65.36 -43.17 91.65 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.246 -0.909 . . . . 0.0 110.917 -179.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 9.6 t -80.94 -21.36 40.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.451 -0.781 . . . . 0.0 112.126 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 17.2 mtt180 -101.79 -23.24 14.22 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.009 -1.057 . . . . 0.0 111.724 -179.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.2 mt -134.14 -8.73 2.64 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 120.967 -1.083 . . . . 0.0 112.541 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 75.02 26.51 66.45 Favored Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.42 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -120.23 148.72 43.33 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.246 -1.149 . . . . 0.0 110.689 -179.596 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 11.8 m 58.95 46.08 14.15 Favored 'General case' 0 N--CA 1.499 2.02 0 CA-C-O 122.033 0.92 . . . . 0.0 108.885 -179.252 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 20.7 m -88.76 -12.78 41.18 Favored 'General case' 0 N--CA 1.488 1.428 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.185 -179.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -116.89 45.17 1.91 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.219 -0.926 . . . . 0.0 109.974 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.758 HG21 ' HB1' ' A' ' 44' ' ' ALA . 94.2 t -80.33 116.81 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.429 -0.795 . . . . 0.0 110.229 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.18 125.31 3.24 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -68.3 92.99 0.44 Allowed 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.452 -1.028 . . . . 0.0 109.838 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.32 -165.1 32.42 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -178.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 63.9 t80 -57.5 139.65 52.75 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.369 -1.077 . . . . 0.0 110.275 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -156.08 -179.87 8.56 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.625 -0.672 . . . . 0.0 110.595 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.484 0 CA-C-O 118.02 -1.433 . . . . 0.0 109.582 -179.974 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . 0.434 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 3.5 mp0 . . . . . 0 N--CA 1.496 1.856 0 CA-C-O 121.024 0.44 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.434 ' HB ' ' O ' ' A' ' 1' ' ' GLN . 16.0 t 64.54 164.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.507 2.387 0 CA-C-O 121.414 0.626 . . . . 0.0 110.75 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 2.2 t80 -136.37 150.17 48.69 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.321 -0.862 . . . . 0.0 110.528 -179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.49 95.25 6.13 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.491 -0.755 . . . . 0.0 109.916 179.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 79.81 54.4 3.93 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -176.87 94.7 0.1 OUTLIER Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -83.38 125.86 32.12 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.608 -0.936 . . . . 0.0 110.221 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -164.1 -57.16 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.505 -0.747 . . . . 0.0 110.402 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 5.7 mtp180 -76.08 157.91 82.74 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.413 -0.804 . . . . 0.0 110.456 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -71.87 138.03 30.69 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.821 1.432 . . . . 0.0 110.636 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 29.9 mt -92.3 134.2 28.7 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.469 -0.77 . . . . 0.0 110.008 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -71.26 73.16 2.14 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 124.045 1.55 . . . . 0.0 110.739 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 30.6 ttt85 -149.01 122.67 4.62 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.437 -0.79 . . . . 0.0 109.913 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -74.74 117.99 5.14 Favored 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.929 1.489 . . . . 0.0 110.557 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -76.09 143.92 26.24 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.825 1.434 . . . . 0.0 110.603 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -75.6 79.5 2.79 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.884 1.465 . . . . 0.0 110.388 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 88.3 t80 -91.31 149.48 21.72 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.26 -0.9 . . . . 0.0 110.468 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.65 145.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.742 -0.599 . . . . 0.0 109.892 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -92.14 112.33 54.51 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.564 -0.71 . . . . 0.0 110.199 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -74.18 179.3 5.93 Favored 'Trans proline' 0 N--CA 1.488 1.203 0 O-C-N 123.802 1.422 . . . . 0.0 110.913 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 53.97 72.71 1.05 Allowed Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.913 -0.492 . . . . 0.0 110.905 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.86 142.84 28.84 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 O-C-N 123.76 1.4 . . . . 0.0 110.384 179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -98.17 63.7 0.85 Allowed Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 89.1 166.0 41.71 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -71.92 153.19 58.28 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 O-C-N 123.851 1.448 . . . . 0.0 110.641 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 15.8 tt -83.1 150.13 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.418 -0.801 . . . . 0.0 110.466 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.69 83.84 0.59 Allowed Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.33 -32.79 7.79 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 O-C-N 124.006 1.529 . . . . 0.0 110.867 179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 27.9 t80 -79.98 63.59 4.55 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.356 -0.84 . . . . 0.0 110.102 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 -148.1 37.83 0.87 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.298 -0.876 . . . . 0.0 110.775 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -153.02 45.46 0.58 Allowed Glycine 0 N--CA 1.496 2.633 0 N-CA-C 109.977 -1.249 . . . . 0.0 109.977 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 17.4 t -169.71 105.75 0.46 Allowed Pre-proline 0 N--CA 1.495 1.775 0 O-C-N 121.521 -0.988 . . . . 0.0 110.106 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -70.67 126.96 13.26 Favored 'Trans proline' 0 C--N 1.313 -1.315 0 O-C-N 123.624 1.328 . . . . 0.0 110.455 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.45 HG22 ' HD2' ' A' ' 53' ' ' ARG . 90.3 t -62.56 -32.07 54.11 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.091 0 O-C-N 121.474 -0.767 . . . . 0.0 110.438 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.9 -14.17 61.86 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.492 -0.755 . . . . 0.0 111.08 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.455 ' CB ' HG21 ' A' ' 57' ' ' VAL . 35.2 m 57.75 30.53 19.09 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.511 -0.743 . . . . 0.0 111.09 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 27.1 mtt85 -105.53 139.95 39.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.267 -0.895 . . . . 0.0 109.999 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.56 0.68 81.73 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.821 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.402 HD13 HG21 ' A' ' 39' ' ' ILE . 27.0 pt -116.28 158.48 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.063 -1.257 . . . . 0.0 110.125 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.9 m -80.08 165.11 22.83 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.699 -0.626 . . . . 0.0 110.639 -179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -57.82 -48.81 78.66 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.61 -0.681 . . . . 0.0 109.288 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.3 t -61.45 -37.51 83.83 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.668 -0.645 . . . . 0.0 109.781 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -64.82 -44.0 91.3 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.425 -0.797 . . . . 0.0 109.56 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.1 -37.49 78.42 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.69 -0.631 . . . . 0.0 109.66 179.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -36.89 80.57 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.716 -0.615 . . . . 0.0 109.76 179.058 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.6 t -64.45 -42.16 96.13 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.756 -0.59 . . . . 0.0 110.946 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 42.3 t -70.26 -34.99 73.48 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.113 -0.992 . . . . 0.0 111.176 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.3 t -58.15 -40.55 81.67 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.121 -0.987 . . . . 0.0 110.212 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -84.09 -14.32 50.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.495 -0.753 . . . . 0.0 111.297 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -101.62 -31.02 11.03 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.103 -0.998 . . . . 0.0 111.209 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 mt -134.23 -1.69 2.89 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.207 -0.933 . . . . 0.0 112.306 -179.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.98 72.33 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.45 ' HD2' HG22 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -113.49 152.0 30.73 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.07 -1.253 . . . . 0.0 110.521 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 34.5 m 59.79 53.55 4.79 Favored 'General case' 0 N--CA 1.499 2.01 0 CA-C-O 121.887 0.851 . . . . 0.0 108.721 -179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 69.3 m -104.94 9.57 34.55 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.475 -178.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -146.01 46.04 1.25 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.165 -0.959 . . . . 0.0 110.523 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.455 HG21 ' CB ' ' A' ' 36' ' ' CYS . 70.8 t -106.26 126.24 61.89 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.17 -0.956 . . . . 0.0 110.35 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.63 157.52 33.75 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.86 136.75 3.02 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.513 -0.992 . . . . 0.0 110.462 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.2 -172.79 49.52 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.0 t80 -69.61 140.82 53.77 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.368 -1.077 . . . . 0.0 110.083 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 2.7 p -161.72 167.05 25.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.553 -0.717 . . . . 0.0 110.643 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 CA-C-O 118.015 -1.436 . . . . 0.0 109.533 179.9 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.1 mt-30 . . . . . 0 N--CA 1.496 1.844 0 CA-C-O 121.311 0.577 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.5 p -132.1 147.69 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.657 -0.652 . . . . 0.0 110.113 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 56.62 79.79 0.17 Allowed 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.345 0.593 . . . . 0.0 110.574 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 26.7 tttm -89.65 141.7 28.36 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.364 -0.835 . . . . 0.0 110.42 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -161.8 -111.63 0.27 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 175.31 65.07 0.06 OUTLIER Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 51.3 m-85 -97.18 110.78 23.26 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.543 -0.975 . . . . 0.0 109.92 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . 56.07 45.18 24.06 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.747 -0.596 . . . . 0.0 110.466 -179.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -135.68 87.47 25.88 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.353 -0.842 . . . . 0.0 110.094 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.65 171.28 16.71 Favored 'Trans proline' 0 C--N 1.313 -1.309 0 O-C-N 123.861 1.453 . . . . 0.0 110.609 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.527 ' O ' HG23 ' A' ' 11' ' ' ILE . 6.8 tt -57.71 115.57 11.41 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.532 -0.73 . . . . 0.0 110.572 -179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 13' ' ' ARG . 50.6 Cg_endo -76.14 72.2 5.42 Favored 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.869 1.457 . . . . 0.0 110.573 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.436 ' HB3' ' O ' ' A' ' 12' ' ' PRO . 11.4 ttp-105 63.48 109.34 0.03 OUTLIER Pre-proline 0 N--CA 1.502 2.166 0 O-C-N 121.848 -0.533 . . . . 0.0 110.911 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.89 112.73 3.47 Favored 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.726 1.382 . . . . 0.0 110.27 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.95 162.01 42.11 Favored 'Trans proline' 0 C--N 1.315 -1.207 0 O-C-N 123.777 1.409 . . . . 0.0 110.754 -179.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -72.04 99.02 0.95 Allowed 'Trans proline' 0 C--N 1.314 -1.277 0 O-C-N 123.934 1.492 . . . . 0.0 110.631 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -73.69 161.54 30.15 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.509 -0.745 . . . . 0.0 110.639 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 99.0 t -70.92 151.16 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.916 0 O-C-N 121.74 -0.6 . . . . 0.0 110.248 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.446 ' HG3' ' HD2' ' A' ' 20' ' ' PRO . 3.7 tpp180 -72.92 132.46 82.88 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.454 -0.778 . . . . 0.0 110.367 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.446 ' HD2' ' HG3' ' A' ' 19' ' ' ARG . 49.2 Cg_endo -73.76 -171.08 0.78 Allowed 'Trans proline' 0 N--CA 1.488 1.177 0 O-C-N 123.906 1.477 . . . . 0.0 110.886 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 61.67 76.12 0.41 Allowed Pre-proline 0 N--CA 1.501 2.084 0 O-C-N 121.793 -0.567 . . . . 0.0 110.563 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.95 136.74 23.21 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.788 1.415 . . . . 0.0 110.727 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.71 110.2 3.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.6 92.08 1.28 Allowed Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.86 156.41 56.71 Favored 'Trans proline' 0 C--N 1.314 -1.279 0 O-C-N 124.025 1.54 . . . . 0.0 110.892 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 14.7 tt -73.88 162.36 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.517 -0.739 . . . . 0.0 110.742 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.16 81.94 1.42 Allowed Glycine 0 N--CA 1.496 2.671 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -77.23 -169.22 0.7 Allowed 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.894 1.47 . . . . 0.0 110.607 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -78.63 62.67 3.24 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.394 -0.816 . . . . 0.0 109.996 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -139.07 40.25 2.12 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.293 -0.879 . . . . 0.0 110.71 -179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -173.6 44.51 0.15 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 34.0 t -168.88 86.75 0.65 Allowed Pre-proline 0 N--CA 1.498 1.928 0 O-C-N 121.364 -1.08 . . . . 0.0 110.327 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.42 ' HD2' HG21 ' A' ' 39' ' ' ILE . 41.4 Cg_endo -67.52 140.05 50.95 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.851 1.448 . . . . 0.0 110.758 179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.646 HG13 ' NH1' ' A' ' 53' ' ' ARG . 87.4 t -60.03 -31.27 47.42 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.187 0 O-C-N 121.584 -0.697 . . . . 0.0 110.936 -179.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.6 t -72.86 -4.49 32.14 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.234 -0.916 . . . . 0.0 111.767 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m 55.6 28.58 12.14 Favored 'General case' 0 N--CA 1.503 2.188 0 O-C-N 121.291 -0.881 . . . . 0.0 110.908 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 13.3 mtt85 -123.63 161.47 24.97 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.307 -0.87 . . . . 0.0 110.213 179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.59 30.81 65.99 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.42 HG21 ' HD2' ' A' ' 33' ' ' PRO . 16.0 pt -141.61 159.47 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.496 -1.002 . . . . 0.0 109.896 179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 11.6 m -80.84 161.41 24.45 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.515 -0.74 . . . . 0.0 109.824 179.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 66.6 t80 -57.4 -45.68 84.29 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.553 -0.717 . . . . 0.0 109.389 179.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.1 t -64.04 -36.6 84.52 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.658 -0.651 . . . . 0.0 109.864 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.44 -44.87 89.81 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.649 179.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.1 -36.44 74.88 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.727 -0.608 . . . . 0.0 109.901 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 6.6 tpp85 -67.82 -38.0 82.7 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.675 -0.64 . . . . 0.0 109.508 179.088 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.407 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 16.3 t -64.05 -44.11 93.47 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.816 -0.552 . . . . 0.0 110.686 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.4 t -64.87 -30.18 71.16 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.441 -0.787 . . . . 0.0 110.935 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 43.8 t -70.3 -43.21 70.82 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.214 -0.929 . . . . 0.0 110.558 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -81.85 -21.05 37.76 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.272 -0.893 . . . . 0.0 112.016 -178.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.407 ' HB2' ' O ' ' A' ' 46' ' ' SER . 0.0 OUTLIER -105.59 -19.7 13.69 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.035 -1.04 . . . . 0.0 111.714 -179.493 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -6.33 2.87 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.108 -0.995 . . . . 0.0 112.446 -179.168 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.52 25.99 74.82 Favored Glycine 0 N--CA 1.496 2.67 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.646 ' NH1' HG13 ' A' ' 34' ' ' VAL . 13.9 mmm180 -121.22 148.76 43.82 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.227 -1.161 . . . . 0.0 110.439 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 5.3 m 59.26 48.32 10.42 Favored 'General case' 0 N--CA 1.5 2.039 0 CA-C-O 121.97 0.89 . . . . 0.0 108.824 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 14.8 m -91.43 -6.42 52.8 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.373 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -120.63 45.38 2.24 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.146 -0.971 . . . . 0.0 109.888 179.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.413 HG21 ' HB1' ' A' ' 44' ' ' ALA . 39.1 t -88.92 127.27 41.79 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.391 -0.818 . . . . 0.0 110.563 -179.585 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.98 116.99 1.98 Allowed Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.1 mtmt -133.54 97.39 3.93 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.47 -1.017 . . . . 0.0 109.983 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.75 179.93 43.18 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -74.24 157.09 36.48 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.431 -1.041 . . . . 0.0 110.221 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.82 129.62 42.38 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.566 -0.709 . . . . 0.0 110.316 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 CA-C-O 117.918 -1.49 . . . . 0.0 109.636 -179.746 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 . . . . . 0 N--CA 1.497 1.921 0 CA-C-O 121.429 0.633 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 35.9 m -75.17 142.79 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.981 0 O-C-N 121.589 -0.695 . . . . 0.0 110.339 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -108.78 80.94 1.38 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.362 -0.836 . . . . 0.0 110.058 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.8 164.13 35.34 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.378 -0.826 . . . . 0.0 110.556 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -146.13 121.29 1.44 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -80.99 -76.52 1.04 Allowed Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.48 ' O ' ' HB3' ' A' ' 8' ' ' ALA . 32.1 m-85 -61.09 133.81 56.41 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.571 -0.958 . . . . 0.0 110.212 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' A' ' 7' ' ' TYR . . . 62.05 87.56 0.1 Allowed 'General case' 0 N--CA 1.5 2.047 0 CA-C-O 121.438 0.637 . . . . 0.0 110.504 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.445 ' HG3' ' HD2' ' A' ' 10' ' ' PRO . 0.0 OUTLIER -88.06 130.68 45.42 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.348 -0.845 . . . . 0.0 110.319 179.963 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.445 ' HD2' ' HG3' ' A' ' 9' ' ' ARG . 46.4 Cg_endo -73.07 146.32 41.09 Favored 'Trans proline' 0 C--N 1.315 -1.236 0 O-C-N 123.898 1.473 . . . . 0.0 110.761 179.81 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 42.0 mm -87.12 137.14 33.11 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.408 -0.807 . . . . 0.0 109.955 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -70.42 89.92 0.59 Allowed 'Trans proline' 0 C--N 1.312 -1.362 0 O-C-N 124.097 1.577 . . . . 0.0 110.4 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.459 ' HD3' ' HD2' ' A' ' 14' ' ' PRO . 0.1 OUTLIER -135.17 153.96 78.59 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.555 -0.715 . . . . 0.0 110.175 -179.846 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.459 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 44.3 Cg_endo -71.76 141.37 37.32 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 O-C-N 123.968 1.509 . . . . 0.0 110.559 179.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.44 124.09 9.14 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.841 1.443 . . . . 0.0 110.894 -179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -74.35 105.04 1.97 Allowed 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.915 1.482 . . . . 0.0 110.363 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -70.18 160.43 32.14 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.557 -0.715 . . . . 0.0 110.719 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -77.01 143.28 13.15 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.603 -0.685 . . . . 0.0 110.232 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . 0.593 ' HG2' ' HD2' ' A' ' 20' ' ' PRO . 6.7 ttp85 -123.23 140.26 33.38 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.47 -0.769 . . . . 0.0 110.036 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HD2' ' HG2' ' A' ' 19' ' ' ARG . 43.5 Cg_endo -69.47 162.47 41.79 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.767 1.404 . . . . 0.0 110.92 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 6.6 mt -109.26 104.38 54.96 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.66 -0.65 . . . . 0.0 110.109 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.67 136.55 21.28 Favored 'Trans proline' 0 C--N 1.315 -1.206 0 O-C-N 123.894 1.471 . . . . 0.0 110.708 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.43 -128.72 2.73 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 90.44 146.49 16.04 Favored Glycine 0 N--CA 1.495 2.63 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.03 98.92 1.04 Allowed 'Trans proline' 0 C--N 1.316 -1.156 0 O-C-N 123.765 1.402 . . . . 0.0 110.601 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.7 mt -124.13 148.67 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.673 -0.642 . . . . 0.0 110.086 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.83 129.38 5.04 Favored Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -78.02 1.72 8.64 Favored 'Trans proline' 0 N--CA 1.489 1.236 0 O-C-N 123.953 1.502 . . . . 0.0 111.754 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 4.0 t80 -77.83 67.31 3.67 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.075 -1.016 . . . . 0.0 110.258 -179.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -134.04 42.2 2.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.325 -0.859 . . . . 0.0 110.55 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 176.4 45.19 0.06 OUTLIER Glycine 0 N--CA 1.492 2.427 0 C-N-CA 119.982 -1.104 . . . . 0.0 110.655 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.4 t -173.83 86.46 0.37 Allowed Pre-proline 0 N--CA 1.5 2.035 0 O-C-N 121.437 -1.037 . . . . 0.0 110.426 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.61 141.49 34.52 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 O-C-N 123.845 1.445 . . . . 0.0 110.832 179.624 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 12.4 t -65.92 -27.86 42.31 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.111 0 O-C-N 121.384 -0.822 . . . . 0.0 110.31 179.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 36' ' ' CYS . 0.4 OUTLIER -65.38 -18.04 65.0 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.403 -0.811 . . . . 0.0 111.034 179.85 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 35' ' ' SER . 84.1 m 58.29 27.23 14.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.479 -0.763 . . . . 0.0 111.211 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -114.21 147.72 38.48 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.397 -0.814 . . . . 0.0 109.848 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.11 30.24 65.57 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.893 -1.283 . . . . 0.0 109.893 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.407 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 23.4 pt -124.67 155.77 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.381 -1.07 . . . . 0.0 109.854 179.576 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -82.13 157.32 24.1 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.647 . . . . 0.0 109.413 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.61 -39.95 78.03 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.419 -0.801 . . . . 0.0 109.69 179.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 3.0 t -69.91 -35.63 74.74 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.632 -0.668 . . . . 0.0 110.084 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -65.38 -40.16 93.17 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.426 -0.796 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.714 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -70.59 -35.88 73.25 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.669 -0.644 . . . . 0.0 110.285 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.27 -32.36 70.14 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.563 -0.711 . . . . 0.0 110.226 179.428 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.524 ' O ' ' HB2' ' A' ' 50' ' ' ARG . 8.5 t -71.44 -41.6 69.28 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.555 -0.716 . . . . 0.0 110.948 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.4 ' HA ' ' HB3' ' A' ' 50' ' ' ARG . 11.8 t -74.0 -29.07 61.76 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.242 -0.911 . . . . 0.0 111.743 -179.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.7 t -59.48 -43.3 93.3 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 120.987 -1.07 . . . . 0.0 109.996 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 12.3 t -89.27 -25.21 21.82 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.381 -0.824 . . . . 0.0 110.629 179.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.524 ' HB2' ' O ' ' A' ' 46' ' ' SER . 2.3 ttp85 -79.72 -34.66 39.89 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.407 -0.808 . . . . 0.0 111.181 -179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -141.08 10.68 2.16 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.162 -0.961 . . . . 0.0 112.289 -179.026 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 60.81 33.38 82.82 Favored Glycine 0 N--CA 1.497 2.737 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -179.298 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -123.68 142.52 50.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.584 -0.95 . . . . 0.0 110.097 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . . . . . . . . . 1.8 m 59.76 56.29 3.6 Favored 'General case' 0 N--CA 1.499 1.99 0 CA-C-O 121.985 0.898 . . . . 0.0 108.974 -179.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 4.4 m -94.98 -11.5 28.41 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.883 -0.511 . . . . 0.0 111.312 -178.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -122.69 44.14 2.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.149 -0.969 . . . . 0.0 110.078 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.714 HG21 ' HB1' ' A' ' 44' ' ' ALA . 38.1 t -78.58 114.13 18.82 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.026 0 O-C-N 121.494 -0.754 . . . . 0.0 110.363 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.6 126.31 2.0 Allowed Glycine 0 N--CA 1.496 2.643 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 31.8 tptt -86.78 114.4 23.42 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.348 -1.09 . . . . 0.0 110.077 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.4 -179.82 43.59 Favored Glycine 0 N--CA 1.494 2.54 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -79.69 163.05 24.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.47 -1.018 . . . . 0.0 110.473 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.6 m -79.07 167.55 20.9 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.573 -0.704 . . . . 0.0 110.444 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 CA-C-O 117.947 -1.474 . . . . 0.0 109.515 179.958 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 9.3 mm-40 . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.245 0.545 . . . . 0.0 110.422 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 93.5 t -80.6 147.58 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.92 0 O-C-N 121.684 -0.635 . . . . 0.0 109.923 179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -155.9 159.82 39.62 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.462 -0.773 . . . . 0.0 110.669 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.411 ' HA ' ' HB2' ' A' ' 8' ' ' ALA . 4.0 pttt -89.81 78.99 6.77 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.405 -0.809 . . . . 0.0 110.462 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.5 83.89 0.33 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.49 -74.43 1.77 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.8 118.61 37.05 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.44 -1.035 . . . . 0.0 110.278 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.411 ' HB2' ' HA ' ' A' ' 4' ' ' LYS . . . -146.64 63.14 1.2 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.344 -0.847 . . . . 0.0 110.408 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.44 78.35 72.01 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.85 118.74 5.7 Favored 'Trans proline' 0 C--N 1.314 -1.268 0 O-C-N 123.891 1.469 . . . . 0.0 110.43 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 46.0 mm 56.08 80.45 0.29 Allowed Pre-proline 0 N--CA 1.502 2.139 0 O-C-N 121.785 -0.572 . . . . 0.0 110.178 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.14 78.01 1.92 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 O-C-N 123.794 1.418 . . . . 0.0 110.81 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.78 78.48 5.51 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.317 -0.864 . . . . 0.0 109.926 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.55 147.57 46.2 Favored 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.814 1.429 . . . . 0.0 111.013 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -74.78 148.3 36.18 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 O-C-N 124.045 1.55 . . . . 0.0 110.62 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -74.12 71.81 4.23 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.882 1.464 . . . . 0.0 110.447 179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -153.65 151.12 29.33 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.324 -0.86 . . . . 0.0 110.394 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -86.42 145.82 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.339 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.8 106.89 52.49 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 121.637 -0.664 . . . . 0.0 110.052 179.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.96 178.22 6.75 Favored 'Trans proline' 0 C--N 1.315 -1.187 0 O-C-N 123.746 1.393 . . . . 0.0 110.839 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -130.23 99.75 19.25 Favored Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.486 -0.759 . . . . 0.0 110.186 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -75.29 92.99 0.98 Allowed 'Trans proline' 0 C--N 1.314 -1.246 0 O-C-N 123.845 1.445 . . . . 0.0 110.701 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -163.79 78.04 0.15 Allowed Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 83.74 86.84 0.84 Allowed Glycine 0 N--CA 1.494 2.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -73.89 145.04 35.52 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.805 1.424 . . . . 0.0 110.78 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 57.4 mt -127.72 145.45 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.452 -0.78 . . . . 0.0 110.042 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.1 87.85 1.32 Allowed Glycine 0 N--CA 1.495 2.603 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.08 -32.82 10.38 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.861 1.453 . . . . 0.0 110.996 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 33.4 t80 -76.59 69.89 3.06 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.333 -0.854 . . . . 0.0 110.15 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -149.92 36.72 0.7 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.376 -0.828 . . . . 0.0 110.75 -179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -157.34 43.45 0.51 Allowed Glycine 0 N--CA 1.494 2.553 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 52.5 t -177.37 88.29 0.24 Allowed Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.609 -0.936 . . . . 0.0 109.828 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.24 143.35 58.51 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 O-C-N 123.775 1.408 . . . . 0.0 110.692 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 96.2 t -66.22 -29.6 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.363 -0.836 . . . . 0.0 110.669 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 7.2 t -68.51 -19.31 64.52 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.353 -0.842 . . . . 0.0 111.092 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 35.3 m 60.69 30.18 19.53 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.495 -0.753 . . . . 0.0 110.627 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -107.41 146.47 31.63 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.27 -0.894 . . . . 0.0 110.373 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.83 29.22 55.23 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 44' ' ' ALA . 28.4 pt -137.55 163.13 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.198 -1.178 . . . . 0.0 110.33 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.45 ' HB3' ' HB2' ' A' ' 43' ' ' GLN . 13.5 t -80.7 166.56 20.92 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.564 -0.71 . . . . 0.0 110.082 179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -62.58 -49.34 75.64 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . 0.418 ' O ' ' HB2' ' A' ' 46' ' ' SER . 2.7 t -63.57 -35.32 80.1 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.696 -0.627 . . . . 0.0 109.985 179.245 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.45 ' HB2' ' HB3' ' A' ' 40' ' ' SER . 4.8 tt0 -64.74 -43.39 93.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.45 -0.781 . . . . 0.0 109.645 179.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.445 ' HB2' ' CD1' ' A' ' 39' ' ' ILE . . . -70.73 -36.65 73.29 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.56 -0.713 . . . . 0.0 109.492 179.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 5.6 ttt-85 -68.36 -33.44 74.28 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.758 -0.589 . . . . 0.0 109.7 178.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 42' ' ' SER . 0.1 OUTLIER -66.33 -46.81 75.57 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.801 -0.562 . . . . 0.0 110.93 179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 32.4 t -66.02 -30.13 70.61 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.321 -0.862 . . . . 0.0 111.248 -179.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 35.4 t -58.84 -41.06 86.04 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.942 -1.099 . . . . 0.0 109.941 179.715 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 19.4 t -87.26 -25.3 24.04 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.421 -0.799 . . . . 0.0 110.668 179.469 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.464 ' HD2' HD12 ' A' ' 51' ' ' LEU . 0.0 OUTLIER -82.83 -34.41 26.9 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.314 -0.866 . . . . 0.0 111.316 -179.513 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.464 HD12 ' HD2' ' A' ' 50' ' ' ARG . 2.1 mt -137.56 6.79 2.76 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.178 -0.951 . . . . 0.0 112.374 -179.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 69.08 27.08 74.18 Favored Glycine 0 N--CA 1.497 2.749 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.498 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 0.4 OUTLIER -117.53 145.65 44.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.21 -1.17 . . . . 0.0 110.293 179.941 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 83.3 m 63.23 53.7 2.19 Favored 'General case' 0 N--CA 1.501 2.108 0 CA-C-O 121.903 0.858 . . . . 0.0 108.806 -178.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 35.2 m -101.27 8.56 42.4 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.904 -0.497 . . . . 0.0 111.689 -178.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.7 t60 -141.69 42.39 1.72 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.048 -1.032 . . . . 0.0 110.52 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . . . . . . . . . 96.4 t -98.49 117.27 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.276 -0.89 . . . . 0.0 110.061 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.75 54.41 2.79 Favored Glycine 0 N--CA 1.494 2.5 0 N-CA-C 109.396 -1.481 . . . . 0.0 109.396 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -91.08 78.47 5.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.708 -0.878 . . . . 0.0 110.154 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.14 133.74 5.37 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 72.6 t80 -79.0 155.25 28.95 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.383 -1.069 . . . . 0.0 110.234 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -78.09 131.71 37.4 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.518 -0.739 . . . . 0.0 110.18 -179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 CA-C-O 117.968 -1.462 . . . . 0.0 109.593 -179.959 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 CA-C-O 121.317 0.579 . . . . 0.0 110.72 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.5 p -161.43 149.67 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.73 -0.606 . . . . 0.0 110.381 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -123.37 167.66 13.52 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.445 -0.784 . . . . 0.0 110.354 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 20.7 tttm 56.67 73.61 0.44 Allowed 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.404 0.621 . . . . 0.0 110.089 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 139.28 102.11 0.53 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.71 146.11 15.66 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 179.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -105.79 114.6 28.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.4 -1.059 . . . . 0.0 110.172 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -138.82 135.62 34.78 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.384 -0.823 . . . . 0.0 110.416 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 24.3 ttp180 -86.02 132.9 42.32 Favored Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 121.383 -0.823 . . . . 0.0 110.135 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.78 157.0 52.56 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 124.002 1.527 . . . . 0.0 111.086 179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.419 HG23 ' HD2' ' A' ' 12' ' ' PRO . 6.1 mt -70.24 140.23 87.78 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 121.515 -0.741 . . . . 0.0 110.154 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . 0.419 ' HD2' HG23 ' A' ' 11' ' ' ILE . 46.4 Cg_endo -72.31 79.0 1.84 Allowed 'Trans proline' 0 C--N 1.313 -1.307 0 O-C-N 123.996 1.524 . . . . 0.0 110.305 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.495 ' HG3' ' HD2' ' A' ' 14' ' ' PRO . 19.5 ttt-85 -135.56 144.36 48.91 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.533 -0.729 . . . . 0.0 109.96 -179.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.495 ' HD2' ' HG3' ' A' ' 13' ' ' ARG . 44.1 Cg_endo -70.07 144.35 52.13 Favored 'Trans proline' 0 C--N 1.313 -1.318 0 O-C-N 123.836 1.44 . . . . 0.0 110.501 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.9 147.17 43.48 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.885 1.466 . . . . 0.0 110.873 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -77.14 -169.5 0.75 Allowed 'Trans proline' 0 C--N 1.315 -1.22 0 O-C-N 123.979 1.515 . . . . 0.0 110.809 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -68.05 167.6 13.62 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.539 -0.726 . . . . 0.0 110.596 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.79 144.87 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.042 0 O-C-N 121.687 -0.633 . . . . 0.0 110.525 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.2 tpt180 -99.08 123.27 49.58 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.586 -0.696 . . . . 0.0 110.14 179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.55 159.22 51.84 Favored 'Trans proline' 0 C--N 1.314 -1.289 0 O-C-N 123.757 1.398 . . . . 0.0 110.475 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.444 HD22 ' HA ' ' A' ' 21' ' ' LEU . 0.3 OUTLIER -107.98 106.64 58.99 Favored Pre-proline 0 N--CA 1.493 1.711 0 O-C-N 121.616 -0.678 . . . . 0.0 110.239 -179.902 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.96 140.87 32.27 Favored 'Trans proline' 0 C--N 1.315 -1.2 0 O-C-N 123.851 1.448 . . . . 0.0 110.528 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -77.08 -41.47 22.12 Favored Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 88.67 102.47 0.98 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.33 115.01 4.16 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.89 1.468 . . . . 0.0 110.691 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 15.9 tt -73.14 165.67 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.592 -0.693 . . . . 0.0 110.145 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.24 -172.82 35.29 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -67.56 -11.13 31.07 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 O-C-N 124.101 1.579 . . . . 0.0 111.741 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -82.11 63.41 6.31 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.148 -0.97 . . . . 0.0 110.262 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -130.02 36.74 3.99 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.103 -0.998 . . . . 0.0 111.279 -179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 172.89 46.59 0.04 OUTLIER Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.03 -1.081 . . . . 0.0 110.54 179.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 5.0 t -168.93 81.95 0.7 Allowed Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.235 -1.156 . . . . 0.0 110.208 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -65.81 152.83 80.46 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 O-C-N 124.027 1.541 . . . . 0.0 111.074 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 50.8 t -68.24 -31.1 50.15 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.409 -0.807 . . . . 0.0 110.348 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.8 t -68.48 -16.02 63.75 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.407 -0.808 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.492 ' CB ' HG21 ' A' ' 57' ' ' VAL . 75.5 m 57.42 30.33 18.43 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.358 -0.838 . . . . 0.0 110.775 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 31.3 mtt180 -102.14 152.65 20.76 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.337 -0.852 . . . . 0.0 110.444 179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 79.38 17.22 76.58 Favored Glycine 0 N--CA 1.497 2.715 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.3 pt -133.18 159.81 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.057 -1.26 . . . . 0.0 110.241 179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.6 161.74 23.39 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.653 -0.655 . . . . 0.0 109.696 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 86.3 t80 -56.36 -50.12 72.44 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.498 -0.751 . . . . 0.0 109.567 179.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 1.5 t -63.07 -35.86 81.65 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.689 -0.632 . . . . 0.0 110.196 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -64.22 -42.47 96.58 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.43 -0.794 . . . . 0.0 109.801 179.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -69.03 -36.06 77.3 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.552 -0.718 . . . . 0.0 109.9 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.38 -40.83 93.99 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.772 -0.58 . . . . 0.0 110.084 179.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.6 t -62.8 -43.47 98.73 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.558 -0.714 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.3 t -64.81 -34.26 77.95 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.253 -0.904 . . . . 0.0 110.776 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 37.3 t -61.28 -43.09 99.45 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.309 -0.869 . . . . 0.0 110.045 179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.0 m -80.06 -13.07 59.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.51 -0.744 . . . . 0.0 111.265 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.92 -28.56 12.33 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.207 -0.933 . . . . 0.0 111.186 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.95 7.84 1.86 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.058 -1.026 . . . . 0.0 112.515 -179.129 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 68.76 27.17 74.06 Favored Glycine 0 N--CA 1.498 2.829 0 O-C-N 120.857 -1.152 . . . . 0.0 110.312 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 54' ' ' CYS . 5.4 mmp_? -114.83 143.5 45.01 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.078 -1.248 . . . . 0.0 110.562 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 27.5 m 61.7 56.02 2.56 Favored 'General case' 0 N--CA 1.501 2.079 0 CA-C-O 121.879 0.847 . . . . 0.0 108.973 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 63.8 m -101.85 -3.14 28.47 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.925 -0.485 . . . . 0.0 112.01 -178.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 27.8 t-80 -136.42 47.98 2.16 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.983 -1.073 . . . . 0.0 111.006 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.492 HG21 ' CB ' ' A' ' 36' ' ' CYS . 95.5 t -106.35 109.49 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 O-C-N 121.1 -1.0 . . . . 0.0 109.742 179.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.7 93.62 0.3 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.346 -1.501 . . . . 0.0 109.346 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 6.6 tttm -99.9 102.16 13.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.487 -1.007 . . . . 0.0 110.206 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.52 -176.68 40.13 Favored Glycine 0 N--CA 1.495 2.576 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 37.9 t80 -73.46 157.15 37.36 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.468 -1.019 . . . . 0.0 110.521 -179.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.8 p -154.84 166.44 33.48 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.593 -0.692 . . . . 0.0 110.514 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 CA-C-O 118.011 -1.439 . . . . 0.0 109.59 179.974 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 9.3 pm0 . . . . . 0 N--CA 1.498 1.957 0 CA-C-O 121.365 0.602 . . . . 0.0 110.657 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 66.7 t -113.26 139.98 35.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.654 -0.654 . . . . 0.0 109.846 179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER 65.96 166.54 0.2 Allowed 'General case' 0 N--CA 1.502 2.161 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -135.31 149.62 49.8 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.413 -0.804 . . . . 0.0 110.324 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.04 -86.85 0.23 Allowed Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 82.55 152.8 11.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.811 -1.316 . . . . 0.0 109.811 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 18.9 t80 -145.05 79.58 1.59 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.47 -1.018 . . . . 0.0 110.227 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -157.63 125.34 5.3 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.393 -0.817 . . . . 0.0 110.191 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 1.1 ttm-85 -139.65 86.84 13.54 Favored Pre-proline 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.238 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.49 ' O ' ' HB ' ' A' ' 11' ' ' ILE . 46.5 Cg_endo -73.28 130.1 14.77 Favored 'Trans proline' 0 C--N 1.313 -1.329 0 O-C-N 123.955 1.502 . . . . 0.0 110.343 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.49 ' HB ' ' O ' ' A' ' 10' ' ' PRO . 48.5 mt 65.0 118.21 0.02 OUTLIER Pre-proline 0 N--CA 1.505 2.314 0 O-C-N 122.073 -0.392 . . . . 0.0 110.606 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -76.7 65.68 7.5 Favored 'Trans proline' 0 C--N 1.315 -1.201 0 O-C-N 123.571 1.3 . . . . 0.0 110.469 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.5 ttm-85 -164.01 140.04 5.1 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.399 -0.813 . . . . 0.0 109.95 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.23 136.88 25.11 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.88 1.463 . . . . 0.0 110.68 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -74.82 140.66 26.26 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.937 1.493 . . . . 0.0 110.737 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -74.69 80.87 2.24 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 O-C-N 123.842 1.443 . . . . 0.0 110.4 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -80.56 153.54 28.0 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.316 -0.865 . . . . 0.0 110.489 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -85.74 141.78 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.657 -0.652 . . . . 0.0 110.045 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.8 ttt-85 -110.61 126.53 28.62 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.448 -0.783 . . . . 0.0 110.159 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -72.86 177.91 7.08 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 O-C-N 123.868 1.457 . . . . 0.0 110.669 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 4.5 tp -148.88 74.85 10.11 Favored Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.47 -0.769 . . . . 0.0 110.18 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -73.79 115.58 4.38 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.792 1.417 . . . . 0.0 110.379 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 118.48 -66.81 0.37 Allowed Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.73 95.84 0.54 Allowed Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.84 142.41 35.22 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.875 1.461 . . . . 0.0 110.839 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 mt -97.75 141.82 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.491 -0.755 . . . . 0.0 110.035 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.73 84.22 1.33 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.73 -33.11 8.57 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 124.049 1.552 . . . . 0.0 111.018 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.593 ' CE1' ' HB3' ' A' ' 32' ' ' CYS . 3.2 t80 -81.66 77.2 8.53 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.311 -0.868 . . . . 0.0 109.357 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -114.83 42.03 2.25 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.26 -0.9 . . . . 0.0 111.073 -179.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.452 ' O ' ' HB2' ' A' ' 32' ' ' CYS . . . -156.32 32.64 0.59 Allowed Glycine 0 N--CA 1.494 2.519 0 C-N-CA 119.959 -1.115 . . . . 0.0 110.541 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.593 ' HB3' ' CE1' ' A' ' 29' ' ' TYR . 40.7 t 177.79 119.51 0.18 Allowed Pre-proline 0 N--CA 1.499 1.989 0 O-C-N 121.6 -0.941 . . . . 0.0 110.569 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.54 ' HG3' HG21 ' A' ' 39' ' ' ILE . 46.3 Cg_endo -75.96 142.78 25.4 Favored 'Trans proline' 0 C--N 1.315 -1.225 0 O-C-N 123.311 1.164 . . . . 0.0 109.879 178.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 43.5 t -73.82 -30.33 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 O-C-N 121.21 -0.931 . . . . 0.0 110.937 -179.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.5 t -73.65 -10.88 60.15 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.275 -0.891 . . . . 0.0 111.825 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 74.8 m 57.43 29.28 16.72 Favored 'General case' 0 N--CA 1.505 2.293 0 O-C-N 121.232 -0.917 . . . . 0.0 110.878 -179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -128.51 158.94 36.99 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.306 -0.871 . . . . 0.0 110.636 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.24 37.25 71.45 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.54 HG21 ' HG3' ' A' ' 33' ' ' PRO . 14.1 pt -143.99 159.5 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.423 -1.045 . . . . 0.0 110.332 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 5.5 m -76.06 160.28 29.95 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.642 -0.661 . . . . 0.0 109.701 179.369 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -58.17 -44.67 88.08 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.45 -0.781 . . . . 0.0 109.478 179.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 2.5 t -62.61 -37.86 87.92 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.619 -0.676 . . . . 0.0 109.903 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -64.51 -45.82 85.61 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.546 -0.721 . . . . 0.0 109.668 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.524 ' HB1' HG21 ' A' ' 57' ' ' VAL . . . -67.93 -36.7 80.59 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.813 -0.555 . . . . 0.0 109.932 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 33.4 ttp85 -69.95 -36.96 75.67 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.538 -0.726 . . . . 0.0 109.732 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.1 t -63.27 -40.09 96.43 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.687 -0.633 . . . . 0.0 110.845 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' HB2' ' A' ' 53' ' ' ARG . 29.6 t -67.77 -40.05 84.05 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.352 -0.843 . . . . 0.0 110.745 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 42.5 t -59.07 -42.74 91.1 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.392 -0.817 . . . . 0.0 110.747 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.9 -18.89 49.45 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.427 -0.795 . . . . 0.0 111.902 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.83 -25.18 13.6 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.084 -1.01 . . . . 0.0 111.806 -179.229 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.473 HD22 ' CE2' ' A' ' 29' ' ' TYR . 8.5 mt -135.1 -5.86 2.36 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.065 -1.022 . . . . 0.0 112.669 -178.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 76.5 22.92 71.75 Favored Glycine 0 N--CA 1.497 2.7 0 N-CA-C 110.005 -1.238 . . . . 0.0 110.005 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.5 ' HB2' ' SG ' ' A' ' 47' ' ' CYS . 0.0 OUTLIER -116.74 148.01 41.51 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.238 -1.154 . . . . 0.0 110.548 -179.847 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 53' ' ' ARG . 84.7 m 61.37 47.42 6.84 Favored 'General case' 0 N--CA 1.498 1.931 0 CA-C-O 121.974 0.892 . . . . 0.0 109.086 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' CYS . . . . . . . . . . . . . 36.5 m -91.2 -7.96 49.88 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.904 -0.497 . . . . 0.0 111.228 -179.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 5.8 t60 -124.11 45.73 2.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.145 -0.972 . . . . 0.0 109.908 179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.524 HG21 ' HB1' ' A' ' 44' ' ' ALA . 54.4 t -81.79 137.33 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.423 -0.798 . . . . 0.0 110.454 -179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.8 112.54 0.49 Allowed Glycine 0 N--CA 1.494 2.502 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.1 mtmt -114.23 98.76 7.14 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.419 -1.048 . . . . 0.0 110.081 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.85 126.52 3.42 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -70.42 157.01 38.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.458 -1.025 . . . . 0.0 110.331 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.2 p -131.32 164.1 26.39 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.526 -0.734 . . . . 0.0 110.685 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.465 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.906 . . . . . . . . 0 0 . 1 stop_ save_